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ABSTRACT 
Nonoxido and Oxido Vanadium Complexes Featuring O- and N- donor Ligands in Relation 
to Biological and Catalytic Activities 
Subhashree Priyadarsini Dash 
Department of chemistry, National Institute of Technology, Rourkela-769008, Odisha, India 
 
Chapter 1: In this chapter the scope of the present investigation is delineated briefly along with 
the aim of the work. 
 
Chapter 2: Synthesis, X-ray structure and characterization of three highly stable, 
hexacoordinated nonoxido vanadium(IV), V
IV
(L)2, complexes with tridentate aroylhydrazonates 
containing ONO- donor atoms have been reported. All the complexes are stable in open air in the 
solid state as well as in solution, a phenomenon rarely observed in nonoxido vanadium(IV) 
complexes. The complexes have good solubility in organic solvents, permitting electrochemical 
and various spectroscopic investigations. The existence of nonoxido vanadium(IV) complexes 
was confirmed by elemental analysis, ESI mass spectroscopy, cyclic voltammetry, EPR and 
magnetic susceptibility measurements. X-ray crystallography showed the N2O4 donor set to 
define a trigonal prismatic geometry in each case. All the complexes show in vitro insulin 
mimetic activity against insulin responsive L6 myoblast cells. In addition, the in vitro 
antiproliferative activity of all the complexes against HeLa cell line was assayed, where the 
complexes found to show good cytotoxic activity.  
 
Chapter 3: Some new oxido vanadium(V) complexes [VOL
1-3
(OEt)(EtOH)] (1-3) have been 
reported which were obtained from the reaction of the Schiff bases (H2L
1-3 
) (Where H2L
1
= 
salicylhydrazone of diacetyl monoxime; H2L
2
= 4-methoxy salicylhydrazone of diacetyl 
monoxime and H2L
3 
= 4-hydroxy salicylhydrazone of diacetyl monoxime) with VO(acac)2 in 1:1 
molar ratio. Three 4-R- aroylhydrazoneoximes have been used as ligands in the present study, 
differing in the inductive effect of the substituent R (R = H, OCH3 and OH), in order to observe 
their influence, if any, on the redox potentials and biological activity of the complexes. All the 
synthesized ligands and the metal complexes were successfully characterized by elemental 
vi 
 
analysis, IR, UV-Vis and NMR spectroscopy. X-ray diffraction study of [VOL
1
(OEt)(EtOH)], 1 
reveals that the metal centre is in distorted octahedral O5N coordination spheres where the ONO- 
donor ligand and the ethoxido group constitute a satisfactory O3N basal plane. Cyclic 
voltammetry of the complexes show a quasi-reversible cyclic voltammetric response in the 
potential range of 0.29−0.36 V involving single electron V(V)−V(IV) reduction. The complexes 
have also been screened for their antibacterial activity against Escherichia coli, Bacillus, Proteus 
and Klebsiella. Minimum inhibitory concentration of these complexes and antibacterial activity 
indicates the compound 1 as the potential lead molecule for drug designing.  
 
Chapter 4: Four oxidoalkoxido vanadium(V) [V
V
O(L
1-4
)OEt] (1–4) and one dinuclear 
oxidoethoxido mixed-ligand vanadium(V) [{VO(L
2
)OEt}2(Q)]{Q = 4,4'-bipyridine}(5), 
complexes, taking potentially tridentate binegative aroylhydrazone ligands are reported [where 
H2L
1 
= anthranylhydrazone of 2-hydroxy-1-napthaldehyde, H2L
2 
= salicylhydrazone of 2-
hydroxy-1-napthaldehyde, H2L
3 
= benzoylhydrazone of 2-hydroxy-1-acetonaphthone, H2L
4 
= 
anthranylhydrazone of 2-hydroxy-1-acetonaphthone]. All the complexes were characterized by 
various physicochemical techniques. Single crystal X-ray crystallography of 1–4 reveals that the 
metal centre is in distorted square pyramidal geometry with O4N coordination spheres, whereas 5 
exhibits a distorted octahedral geometry around the metal center. The solution behavior of the 
oxidoethoxido vanadium(V) species was studied, which indicates the existence of two species 
(1:1 ratio) in solution. Catalytic potential of these complexes was tested for the oxidative 
bromination of styrene, salicylaldehyde and oxidation of methyl phenyl sulphide. All the 
complexes (1–5) showed good DNA binding and photo-nuclease propensity. Among these, 3 and 
4 show high binding affinity towards CT-DNA than others.  
 
Chapter 5: Eight alkali metal ion-mediated dioxido vanadium(V), [{V
V
O2L
1-6
}A(H2O)n](1-8), 
complexes for A = Li
+
, Na
+
, K
+
 and Cs
+
, containing tridentate ONO- donor aroylhydrazonate 
ligands are described. All the synthesised ligands and the metal complexes were successfully 
characterised by elemental analysis, IR, UV-Vis and NMR spectroscopy. X-ray crystallographic 
investigation of 3, 5−7 shows the presence of distorted NO4 coordination geometry. The dioxido 
vanadium(V) complexes were found to exhibit DNA binding activity due to their interaction 
with CT-DNA by the groove binding mode, with binding constants ranging from 10
3 −104 M-1. 
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Complexes 1−8 were also tested for DNA nuclease activity against pUC19 plasmid DNA which 
showed that 6 and 7 had the best DNA binding and photonuclease activity; these results support 
their good protein binding and cleavage activity with binding constants ranging from 10
4 −105  
M
-1
. Finally, the in vitro antiproliferative activity of all complexes was assayed against the HeLa 
cell line. Some of the complexes (2, 5, 6 and 7) show considerable activity compared to 
commonly use chemotherapeutic drugs.  
 
Chapter 6: In this chapter, four neutral oxido vanadium(V) complexes [VO2L
1
](1), [VO2L
2
](2), 
[VOL
3
(OEt)](3), [VOL
4
(OEt)EtOH](4) [where HL
1 
= 2-thiophenoylhydrazone of 2-
acetylpyridine, HL
2 
= 2-amino benzoylhydrazone of 2-benzoyl pyridine, H2L
3 
= 
isonicotinoylhydrazone of 2-hydroxy acetophenone, H2L
4 
= 2-furoylhydrazone of 2-hydroxy-1-
napthaldehyde] with a bioactive hydrazone scaffold containing furan, thiophene and pyridine-
residues have been synthesized. All complexes were thoroughly characterized by various 
spectroscopic (IR, UV-Vis, NMR and ESI-MS) and single crystal X-ray diffraction techniques. 
Biological studies reveal that, 1–4 show good DNA binding propensity and interact with CT-
DNA by a minor groove binding mode, with binding constants ranging from 10
3−105 M-1. All 
complexes show good photo-induced cleavage of pUC19 supercoiled plasmid DNA with 3 
showing the highest photo-induced DNA cleavage activity of ~ 65%. Additionally, 1–4 show 
satisfactory cytotoxic activity against the human cervical cancer cell line (HeLa) following the 
order 4 > 2 > 3 > 1 with IC50 values ranging from 10 to 20 µM. 
 
Chapter 7: A series of  nonoxido vanadium(IV) [V
IV
(L
1-4
)2] (1–4), oxidoethoxido vanadium(V)    
[V
V
O(L
1-4
)OEt] (5–8), and μ-oxido divanadium(V) [VV2O3(L
1
)2]
 
(9) complexes, taking 
potentially tridentate dibasic aroylhydrazone ligands are reported [where H2L
1 
= 2-furoyl 
hydrazone of 2-hydroxy-1-acetonaphthone, H2L
2 
=2-thiophenoylhydrazone hydrazone of 2-
hydroxy-1-acetonaphthone, H2L
3 
=1-napthoyl hydrazone of 2-hydroxy-1-acetonaphthone, H2L
4 
=3-hydroxy-2-napthoyl hydrazone of 2-hydroxy-1-acetonaphthone]. All the complexes were 
characterized by elemental analysis as well as various spectroscopic techniques. Most of the 
complexes (2, 3, 5, 6 and 8) were also characterized by single crystal X-ray crystallography. The 
nonoxido vanadium(IV) complexes are quite stable in open air as well as in solution. The 
solution chemistry of the oxidoethoxido vanadium(V) complexes were reported. This indicates 
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the existence of two different species in solution. The new species, a μ-oxido divanadium(V) 
complex, [V2O3(L
1
)2]
 
(9), is successfully isolated in solid state and fully characterized by several 
physicochemical techniques & single crystal X-ray crystallography.  
______________________________________________________________________________ 
Keywords: Aroylhydrazones / Nonoxido vanadium(IV) and oxido vanadium(V) Complexes / 
Solution chemistry / X-ray crystal structure / Pharmacological (Cytotoxic, Antibacterial, Insulin 
mimetic, DNA and BSA binding and cleaving) activity / Catalytic oxidation & oxidative 
bromination.  
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Preface 
 
The present dissertation describes the design, synthesis, full characterization and the exploration 
of solution chemistry, chemical, electrochemical properties and the study of catalytic and 
pharmacological activity of a series of mono- and binuclear variable- valence nonoxido and 
oxido vanadium complexes of some selected multidentate ONO- and ONN- donor ligands. 
Structures of nineteen important nonoxido and oxido vanadium complexes are determined by 
single crystal X-ray analysis. Structure-reactivity relations are discussed and implications of 
structure determination on the design of new complexes using the structurally characterized 
compounds as precursors are elaborated. All the complexes described in this dissertation are 
characterized by various physicochemical techniques such as elemental analysis, measurement of 
magnetic susceptibility at room temperature in solid state, measurement of conductivity in 
solution and by various spectroscopic techniques (UV-Vis, IR, NMR, EPR and ESI-MS). 
Electrochemical characteristics of the complexes were studied by cyclic voltammetry and, as 
pointed out before, single crystal X-ray crystallography were used to find out crystal and 
molecular structure of all the compounds of mononuclear nonoxido vanadium(IV) and mono- 
and binuclear oxido vanadium(V) complexes. Biological activities particularly antimicrobial, 
antiproliferative, insulin mimetic, DNA and BSA binding and cleavage activity and catalytic 
activities of some of the above complexes particularly oxidation of sulphides and oxidative 
bromination of aromatic aldehydes were also studied. The subject matter of this dissertation is 
divided into seven chapters containing the chemistry of nonoxido vanadium(IV) and oxido 
vanadium(V) ligated to selected O- and N- donor ligands and a brief resume of the work 
embodied in this dissertation and concluding remarks.  
   Chapter 1 is a general introduction to the entire work described in the present dissertation and 
spells out the objectives of the thesis. The objectives of the works are placed at the end of the 
general introduction. The entire subject matter of this dissertation is organized as follows: 
    Chapter 2 deals with the synthesis, X-ray structure and characterization of three highly stable, 
hexacoordinated nonoxido vanadium(IV), V
IV
(L)2, complexes with tridentate aroylhydrazonates 
containing ONO- donor ligands. All the complexes are stable in open air in the solid state as well 
as in solution, a phenomenon rarely observed in nonoxido vanadium(IV) complexes. The 
complexes have good solubility in organic solvents, permitting electrochemical and various 
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spectroscopic investigations. The existence of nonoxido vanadium(IV) complexes was confirmed 
by elemental analysis, ESI mass spectroscopy, cyclic voltammetry, EPR and magnetic 
susceptibility measurements. X-ray crystallography showed the N2O4 donor set to define a 
trigonal prismatic geometry in each case. All the complexes show in vitro insulin mimetic 
activity against insulin responsive L6 myoblast cells. In addition, the in vitro antiproliferative 
activity of all the complexes against HeLa cell line was assayed, where the complexes found to 
show good cytotoxic activity.  
   In Chapter 3 the chemistry of some new oxido vanadium(V) complexes [VOL1-3(OEt)(EtOH)] 
(1-3) have been reported which were obtained from the reaction of the Schiff bases (H2L
1-3 
) 
(Where H2L
1
= salicylhydrazone of diacetyl monoxime; H2L
2
= 4-methoxy salicylhydrazone of 
diacetyl monoxime and H2L
3 
= 4-hydroxy salicylhydrazone of diacetyl monoxime) with 
VO(acac)2 in 1:1 molar ratio. Three 4-R- aroylhydrazoneoximes have been used as ligands in the 
present study, differing in the inductive effect of the substituent R (R = H, OCH3 and OH), in 
order to observe their influence, if any, on the redox potentials and biological activity of the 
complexes. All the synthesized ligands and the metal complexes were successfully characterized 
by elemental analysis, IR, UV-Vis and NMR spectroscopy. X-ray diffraction study of 
[VOL
1
(OEt)(EtOH)], 1 reveals that the metal centre is in distorted octahedral O5N coordination 
spheres where the ONO- donor ligand and the ethoxo group constitute a satisfactory O3N basal 
plane. Cyclic voltammetry of the complexes show a quasi-reversible cyclic voltammetric 
response in the potential range of 0.29−0.36 V involving single electron V(V)−V(IV) reduction. 
The complexes have also been screened for their antibacterial activity against Escherichia coli, 
Bacillus, Proteus and Klebsiella. Minimum inhibitory concentration of these complexes and 
antibacterial activity indicates the compound 1 as the potential lead molecule for drug designing.  
   Chapter 4 describes the report of four oxidoethoxido vanadium(V) [V
V
O(L
1-4
)OEt] (1–4) and 
one dinuclear oxidoalkoxido mixed-ligand vanadium(V) [{VO(L
2
)OEt}2(Q)]{Q = 4,4'-
bipyridine}(5), complexes, taking potentially tridentate binegative aroylhydrazone ligands 
[where H2L
1 
= anthranylhydrazone of 2-hydroxy-1-napthaldehyde, H2L
2 
= salicylhydrazone of   
2-hydroxy-1-napthaldehyde, H2L
3 
= benzoylhydrazone of 2-hydroxy-1-acetonaphthone, H2L
4 
= 
anthranylhydrazone of 2-hydroxy-1-acetonaphthone]. All the complexes were characterized by 
various physicochemical techniques. Single crystal X-ray crystallography of 1–4 reveals that the 
metal centre is in distorted square pyramidal geometry with O4N coordination spheres, where as 
3 
 
5 exhibits a distorted octahedral geometry around the metal center. The solution behavior of the 
oxidoethoxido vanadium(V) species was studied, which indicates the existence of two species 
(1:1 ratio ) in solution. Catalytic potential of these complexes was tested for the oxidative 
bromination of styrene, salicylaldehyde and oxidation of methyl phenyl sulphide. All the 
complexes (1–5) showed good DNA binding and photo-nuclease propensity. Among these, 3 and 
4 show high binding affinity towards CT-DNA than others.  
   In chapter 5 eight alkali metal ion-mediated dioxido vanadium(V), [{V
V
O2L
1-6
}A(H2O)n]     
(1–8), complexes for A = Li+, Na+, K+ and Cs+, containing tridentate ONO- donor 
aroylhydrazonate ligands are described. All the synthesised ligands and the metal complexes 
were successfully characterised by elemental analysis, IR, UV-Vis and NMR spectroscopy.       
X-ray crystallographic investigation of 3, 5−7 shows the presence of distorted NO4 coordination 
geometry. The dioxido vanadium(V) complexes were found to exhibit DNA binding activity due 
to their interaction with CT-DNA by the groove binding mode, with binding constants ranging 
from 10
3 −104 M–1. Complexes 1−8 were also tested for DNA nuclease activity against pUC19 
plasmid DNA which showed that 6 and 7 had the best DNA binding and photonuclease activity; 
these results support their good protein binding and cleavage activity with binding constants 
ranging from 10
4 −105 M–1. Finally, the in vitro antiproliferative activity of all complexes was 
assayed against the HeLa cell line. Some of the complexes (2, 5, 6 and 7) show considerable 
activity compared to commonly use chemotherapeutic drugs.  
   In this chapter (6), four neutral oxido vanadium(V) complexes [VO2L
1
](1), [VO2L
2
](2), 
[VOL
3
(OEt)](3), [VOL
4
(OEt)EtOH](4) [where HL
1 
= 2-thiophenoylhydrazone of                       
2-acetylpyridine, HL
2 
= 2-amino benzoylhydrazone of 2-benzoyl pyridine, H2L
3 
= 
isonicotinoylhydrazone of 2-hydroxy acetophenone, H2L
4 
= 2-furoylhydrazone of 2-hydroxy-1-
napthaldehyde] with a bioactive hydrazone scaffold containing furan, thiophene and pyridine-
residues have been synthesized. All complexes were thoroughly characterized by various 
spectroscopic (IR, UV-Vis, NMR and ESI-MS) and single crystal X-ray diffraction techniques. 
Biological studies reveal that, 1–4 show good DNA binding propensity and interact with CT-
DNA by a minor groove binding mode, with binding constants ranging from 10
3−105 M–1. All 
complexes show good photo-induced cleavage of pUC19 supercoiled plasmid DNA with 3 
showing the highest photo-induced DNA cleavage activity of ~ 65%. Additionally, 1–4 show 
4 
 
satisfactory cytotoxic activity against the human cervical cancer cell line (HeLa) following the 
order 4 > 2 > 3 > 1 with IC50 values ranging from 10 to 20 µM. 
   The essence of the work presented in chapter 7 is the detailed account of a series of  nonoxido 
vanadium(IV) [V
IV
(L
1-4
)2] (1–4), oxidoethoxido vanadium(V) [V
V
O(L
1-4
)OEt] (5–8), and           
μ-oxido divanadium(V) [VV2O3(L
1
)2]
 
(9) complexes, taking potentially tridentate dibasic 
aroylhydrazone ligands [where H2L
1 
= 2-furoyl hydrazone of 2-hydroxy-1-acetonaphthone, H2L
2 
=2-thiophenoylhydrazone hydrazone of 2-hydroxy-1-acetonaphthone, H2L
3 
=1-napthoyl 
hydrazone of 2-hydroxy-1-acetonaphthone, H2L
4 
=3-hydroxy-2-napthoyl hydrazone of                
2-hydroxy-1-acetonaphthone]. All the complexes were characterized by elemental analysis as 
well as various spectroscopic techniques. Most of the complexes (2, 3, 5, 6 and 8) were also 
characterized by single crystal X-ray crystallography. The nonoxido vanadium(IV) complexes 
are quite stable in open air as well as in solution. The solution chemistry of the oxidoethoxido 
vanadium(V) complexes were reported. This indicates the existence of two different species in 
solution. The new species, a μ-oxido divanadium(V) complex, [V2O3(L
1
)2]
 
(9), is successfully 
isolated in solid state and fully characterized by several physicochemical techniques & single 
crystal X-ray crystallography. 
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Chapter 1 
Scope of the present investigation 
Abstract: In this chapter the scope of the present investigation is delineated briefly along with 
the aim of the work. 
1.1. REVIEW ON NONOXIDO VANADIUM(IV) AND OXIDO VANADIUM(V) 
COMPLEXES WITH O- AND N- DONOR LIGANDS 
The studies described in the present dissertation involve coordination complexes of variable- 
valence vanadium featuring O- and N- donor ligands in relation to their biological and catalytic 
activities. The coordination chemistry of metal complexes with aroylhydrazone ligands has 
attracted continuing attention for the synthetic chemist due to their ease of synthesis and stability 
under a variety of oxidative and reductive conditions. Hydrazone moieties are the most important 
pharmacophoric cores of several anticancer, antiinflammatory, antinociceptive, and antiplatelet 
drugs.
1
 Vanadium plays  number of roles in the biological systems and has been found in many 
naturally occurring compounds.
2
 In humans, V compounds exhibit a wide variety of 
pharmacological properties, and many complexes have been tested as antiparasitic, spermicidal, 
antiviral, anti-HIV, antituberculosis, and antitumor agents.
3
 Particularly, vanadium has been 
proved to be one of the most efficient metal ions with potential antidiabetic activity.
4
 Vanadium 
complexes show varied stereochemistry. It can form compounds with inorganic and organic 
ligands, with particular preference for oxygen, nitrogen and sulphur donor atoms.  
Again, coordination chemistry of variable valence vanadium assumed special importance due to 
the following reasons: 
 
1. Vanadium in higher oxidation states (+5 and +4) is oxidophilic. It forms various types of 
oxido species depending on the charge and denticity of the coordinating ligand attached to 
the metal centers.
5 
Among these compounds, those containing the VO
n+
 (n = 2-3) and  
[V2O3]
n+
 (n = 2−4) cores belong to the largest family. 
 
2. Although the chemistry of oxido vanadium(IV) and (V) complexes is well developed, the 
number of nonoxido vanadium(IV) complexes in the electronic Cambridge Structural 
Database remains scarce. Formation of nonoxido or ‗bare‘ hexacoordinated vanadium(IV) 
7 
 
complexes is rather difficult because the strong V=O bond must be broken and the oxido 
ligand must leave the complex as a good leaving group.   
 
3. Many oxidation states of vanadium are relevant for biological systems like +III, +IV, and 
+V.
6,7
 However, V
III
 is very susceptible to oxidation and appears to be of less importance 
than V
IV
 and V
V
.  
 
4. Vanadium is a ubiquitous trace element6 and  is present in two families of enzymes, i.e., 
vanadium-dependent haloperoxidases
8
 and nitrogenases.
9
 It is accumulated in several marine 
organisms such as ascidians
10
 and polychaete fan worms,
11
 and it is also found in very high 
concentrations in amavadin, the complex isolated from Amanita muscaria.
12
 
 
5. Moreover, a number of vanadium(IV) and (V) complexes, were found to show their profound 
catalytic activity to carry out a variety of oxidation reactions, including alkene epoxidation 
and hydroxylation, aromatic alkane and alcohol oxidation, sulfide and halide oxidation, and 
also in oxidative bromination reaction.
13 
 
In this context, role of the coordination environment around the central metal (vanadium) ion is 
most important. Variation in the coordination environment can only bring about corresponding 
variation in the properties of the complexes. Chemistry of non oxidovanadium(IV) and mono- 
and binuclear oxido vanadium(V) with ligands of various types has been of significant 
importance in this regard. Review on some of the recent reports of the nonoxido vanadium(IV) 
and mono- and binuclear oxido vanadium(V) complexes with O- and N- donor environments, 
which are drawing much current attention, are highlighted below. 
 
 
 
 
 
 
8 
 
1.1.1. Nonoxido vanadium(IV) complexes. Vanadium is an oxidophilic metal and has the 
tendency to form oxido-species in its +5 and +4 oxidation states. But there are certain vanadium 
complexes which contain no oxido group, and are known to be nonoxido or ‗bare‘ complex. In 
recent time such species attract special attention to inorganic chemist due to the structural 
similarities with amavadin. Amavadin is the first octacoordinated vanadium(IV) complex 
isolated from Amanita mushrooms.
14,15
 It is a nonoxido vanadium(IV) complex but this character 
was established after a long time.
16,17
 Three types of nonoxido vanadium(IV) compounds, viz. 
hexa-, hepta- and octacoordinate, are reported. A characteristic feature of all nonoxido 
vanadium(IV) complexes is the absence of the (V=O) band in the 935–1035 cm−1 region in the 
IR spectra, which, in contrast, is a signature for all oxido vanadium(IV) and (V) compounds. 
 
P. Chaudhuri
18
 and group has contributed a lot in the field of nonoxido vanadium chemistry. In 
2011 they have reported the structural and magnetochemical characterization of two nonoxido 
vanadium(IV) complexes [LV
IV
(OCH3)] (1) (Figure 1.1) and [LV
IV
(acac)] (2) using tris(2-
hydroxy-3,5-di-tert butylbenzyl) amine as ligand (H3L). The transformation of 5-coordinated 
TBP nonoxido vanadium complex 1 to the 6-coordinated octahedral complex 2 was observed in 
presence of a bidentate chelate acetylacetone ligand. 
 
 
 
Figure 1.1. 
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In 2004, the same group has reported, another series of nonoxido vanadium(IV) complexes 
taking potentially tridentate bisphenol ligands (H2L) (Figure 1.2) containing [O, X, O] donor 
atoms (X = S (3), Se (4), P (5), or P=O (6)).
19
 The ligands with different hetero donor atoms 
yielded different nonoxido vanadium(IV) complexes, V
IV
L2, having six-coordinated V
IV
, VO4X2, 
core which was confirmed by X-ray diffraction methods. The paramagnetic and nonoxido nature 
of 3–6 were supported by variable-temperature (2–295 K) magnetic susceptibility measurements, 
X-band electron paramagnetic resonanace (EPR) (2–60 K) spectroscopy, electrochemical 
methods, and magnetic circular dichroism (MCD) (5 K) measurements. 
 
  
                            H2L
S             
H2L
Se 
  
 
                          H2L
P                                                                                   
H2L
PO 
 
                       V
IV
L
S
2 (3), V
IV
L
Se
2 (4), V
IV
L
P
2 (5), V
IV
L
PO
2 (6) 
 
Figure. 1.2 
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In 2003, Chaudhuri et al.
20
 have also reported two mononuclear nonoxido vanadium(IV) 
complexes, [V
IV
LMe2] (7) (Figure 1.3) and [V
IV
LtBu2] (8), with a tridentate bis(phenol) ligand 
(H2L) bearing the O2N donor atoms and with either dimethyl or ditert-butyl substituents. Both 
the complexes 7 and 8 were structurally characterized and were found to show distorted 
octahedral geometry. For complex 7, isomerization of the meridional form to the facial form was 
observed in solution. 
 
 
Figure 1.3 
 
Ghosh et al.
21
 have reported a very general route for the synthesis of a series of stable 
octacoordinated nonoxido vanadium(IV) complexes of the general formula VL2 (where H2L is a 
ONNO donor tetradentate hydrazone ligand). These compounds were found to be highly stable 
in open air, in the solid state as well as in solution and don‘t require any inert condition for 
synthesis, which is an unusual phenomenon for such type of complexes. One of these compounds 
VL
1
2 (9) has been structurally characterized (Figure 1.4) {where H2L
1
 = benzildihydrazone of 2-
aminobenzoylhydrazine} and was found to exhibit a dodecahedral structure existing in a 
tetragonal space group P4
‾
n2. 
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Figure 1.4 
Garribba et al.
22
 have reported the synthesis and characterization of two nonoxido vanadium(IV) 
complexes, [V(H–3ino)2][K2(ino)2].4H2O (10) and [Na6V(H–3ino)2](SO4)2.6H2O (11) {where, ino 
= cis-inositol}. Structures of both the complexes were determined by single-crystal X-ray 
analysis. Crystal structure of the 10 (Figure 1.5) represents an unusual 1:1 packing of            
[V(H–3ino)2]
2-
 dianions and [K2(ino)2]
2+
 dications, in which both K
+
 ions have a coordination 
number of nine and are bonded simultaneously to a 1,3,5-triaxial and an 1,2,3-axial-equatorial-
axial site of ino. 
 
Figure 1.5 
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1.1.2. Oxidoalkoxido vanadium(V) complexes. Monooxidoalkoxido vanadium(V) complexes, 
[V
V
O(OR)] have been known for a long time
23 
and their chemistry has got increased importance 
in recent years
24-31
. Such species constitute useful oxidants
32
 and are bioinorganically relevant in 
the context of haloperoxidation
33
, phosphorylation
34
 and insulin mimicking
35
. 
 
Recently, M. R. Maurya and coworkers
36
 have reported  synthesis, characterisation and study of 
catalytic three alkoxido vanadium(V) complexes [V
V
O(OMe)(MeOH){Hdfmp(inh)2}] (12), 
[V
V
O(OMe)(MeOH){Hdfmp(nah)2}] (13) and [V
V
O(OMe)(MeOH){Hdfmp(bhz)2}] (14) 
(Figure 1.6) [where, H3dfmp(L)2 are obtained by the condensation of 2,6-diformyl-4-
methylphenol and hydrazones (L), L = isonicotinoylhydrazide (inh), nicotinoylhydrazide (nah) 
and benzoylhydrazide (bhz)]. The results of catalytic study suggest that these complexes have the 
potential to be considered as a functional models of VHPOs. 
 
 
Figure 1.6 
 
S. K. Kar and group
37
 has highlighted the structural behavior of two mononuclear oxidoalkoxido 
vanadium(V) complexes [{VO(L1)(OCH3)(CH3OH)}{VO(L1)(OCH3)}] (15) and              
[VO(L2) (OCH3)(CH3OH)] (16) {HL1 = [N′-(2-hydroxybenzylidene)-5-methyl-1-(pyridin-2-yl)-
1H-pyrazole-3-carbohydrazide] and HL2 = [1- (4, 6-dimethylpyrimidin-2-yl)-N′-(2-
hydroxybenzylidene)-5-methyl-1H-pyrazole-3-carbohydrazide]} where two different 
coordination geometry around two V(V) centres in the asymmetric unit of complex 15 with 
ligand HL1 is observed (Figure 1.7). In other compound 16, the vanadium(V) atom sits in the 
13 
 
distorted octahedral coordination pocket formed by one tridentate ONO binegative ligand 
molecule (HL2), one oxido group, one methoxido group and one methanol moiety.  
 
Figure 1.7 
 
Monfared et al.
38
 have reported the catalytic potential of three monooxido alkoxido vanadium(V) 
complexes, [VO(OMe)L
1
] (20), [VO(OMe)L
2
] (21) and [VO(OMe)L
3
] (22), {(H2L
1
 = (E)-3-
hydroxy-N′-(2-hydroxy-3-methoxybenzylidene)-2-naphthohydrazide, H2L
2
 = (E)-3-hydroxy-N′-
(2-hydroxybenzylidene)-2-naphthohydrazide and H2L
3
 = (E)-N′-(5-bromo-2-
hydroxybenzylidene)-3-hydroxy-2-naphthohydrazide} for the oxidation of cyclooctene using 
H2O2 as terminal oxidant. The complex, 21 (Figure 1.8) showed the most potent catalytic 
activity in oxidation of various terminal, cyclic and phenyl substituted olefins.  
.  
Figure 1.8 
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There is a report by M. Sutradhar and coworkers,
39
 where a mononuclear oxido alkoxido 
vanadium(V) complex, [VO(OEt)L] (23) (Figure 1.9) was isolated from the corresponding 
binuclear precursor (V2O3L2) { H2L = 2-hydroxyacetophenone-2-aminobenzoylhydrazone} with 
the reaction of excess triphenylphosphine in refluxing ethanol. The reaction proceeds through the 
oxido bridge splitting of the binuclear species. 
 
Figure 1.9 
 
Kurup et al.
40
 have reported the synthesis, spectral and structural study of some oxidoalkoxido 
vanadium(IV/V) complexes by taking 2-hydroxyacetophenone-3-hydroxy-2-naphthoylhydrazone 
(H2L). Among these complexes, [VOL(OCH3)] (24) was found to exist in two polymorphic 
forms denoted by 24a (Figure 1.10) and 24b (Figure 1.11), with space groups Pn21a and Pī, 
respectively. 
 
 
 
Figure 1.10                                                                                Figure 1.11 
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Chen et al.
41
 and Zhou et al.
42
 have structurally characterized alkoxido vanadium(V) complexes, 
[V(C15H12N2O4)(CH3O)O] (25) and [VO(C13H10N2O4)(OCH3)] (26) where the V
V
 ion exhibits a 
distorted square-pyramidal coordination geometry. Similarly, L. Liu
43
 and F.-M. Wang
44
 have 
reported the crystal structure of [V(C15H10I2N2O2)(CH3O)O(CH3OH)] (27) and 
[V(C14H8BrClN2O2)-(CH3O)O(CH3OH)] (28) respectively, where a distorted octahedral 
geometry was observed around the central metal atom.  
 
M. S. Lah and group
45
 has reported the solution behavior along with the synthesis and structural 
characterization of a five-coordinated square pyramidal vanadium(V) complex, 
[VO(Hacshz)(OEt)] (29) (Figure 1.12), (Hacshz
2-
 = acetylacetosalicylhydrazone). Here the 
reported complex was found to exist in two forms. Among these two forms, the major one is a 
monomeric species, as isolated in the solid-state, and the minor species was found to get 
converted to the monomeric form in the presence of a small amount of ethanol.  
 
Figure 1.12 
In the context of solution behavior, an interesting observation was reported by Dinda et al.
46
 
where monooxido alkoxido vanadium(V) complex [VO(OEt)L], (30) {H2L= 2-
hydroxybenzaldehydehydrazone of 2-hydroxybenzoylhydrazine} gets transformed to 
corresponding monooxidobridged divanadium(V,V) complex [(VOL)2O] in solution. It was 
observed that, by controlled potential electrolysis it leads to the generation of a mixed valence 
vanadium(IV,V) species. This mixed valence species is identified and studied by EPR technique 
(at room temperature (Figure 1.13a) as well as in liquid nitrogen temperature (Figure 1.13b) 
and also by UV-Vis spectroscopy (Figure 1.14). 
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                        Figure 1.13                                                             Figure 1.14  
 
 
1.1.3. Dioxido vanadium(V) complexes. The dioxido vanadium(V) complexes constitute a large 
class of vanadium(V) complex like that of monooxido vanadium(V) complexes. The formation 
of the dioxido vanadium(V) complexes largely depends on the basic character of the ligands and 
sometimes addition of base to the reaction medium promotes their formation from the 
corresponding oxido vanadium(V) complexes.  
 
Plass and coworkers
47
 have reported the first supramolecular inclusion compound, a cis-dioxido 
vanadium(V) complex K[VO2(salhybiph)@ β-CD] (31) (Figure 1.15) by the reaction of 
potassium vanadate and the hydrazone ligand derived from Schiff base condensation of 
salicylaldehyde and biphenyl-4-carboxylic acid hydrazide (H2salhybiph) in the presence of β-
cyclodextrin (β-CD) in water. It is expected that, through modification of the CD-host, it may be 
possible to utilize this concept for the generation of novel systems in oxidation catalysis, 
including the potential influence of the sugar backbone on chiral induction of vanadium-
catalyzed oxidation reactions. 
17 
 
 
Figure 1.15 
This group has also reported
48
 the synthesis, characterization and crystal structure of a dioxido 
vanadium(V) complex NH4[VO2(salhyph)] (32) with the tridentate Schiff base ligand derived 
from salicylaldehyde and benzoic acid hydrazide (H2salhyph), where the vanadium atom of the 
dioxido vanadium(V) moiety has a distorted square-pyramidal geometry. Extensive hydrogen 
bonding was observed between the ammonium cation and the oxygen atoms coordinated to the 
vanadium atom yielding a two-dimensional network (Figure 1.16), where the complex anions 
were arranged in a bilayer manner. Additional crystal packing within the bilayer appears to be 
controlled mostly by π stacking between the aromatic rings of the ligand.  
 
Figure 1.16 
M. R. Maurya and group
49
 has reported the synthesisis and characterization of           
[V
V
O2(acac-ambmz)] (33), [V
V
O2(sal-ambmz)] (34) and [V
V
O2(sal-aebmz)] (35)              
(Figure 1.17) {Hacac-ambmz = Schiff base derived from acetylacetone and                                               
18 
 
2-aminomethylbenzimidazole, Hsal-ambmz = Schiff base obtained by the condensation of 
salicylaldehyde and 2-aminomethylbenzimidazole, Hsal-aebmz = derived from salicylaldehyde 
and 2-aminoethylbenzimidazole}, among which, 33 and 35 can be considered to be structural 
models of VHPO due to their structural similaries. Moreover, all the complexes, 33–35 are found 
to catalyze the oxidation of methyl phenyl sulfide to methyl phenyl sulfoxide and methyl phenyl 
sulfone . 
 
 
               33                                                                  34                                                        35 
Figure 1.17 
In 2004, Gambino et al.
50
 have reported three new dioxido(semicarbazone) vanadium(V) 
complexes cis-VO2L
1–3
(36–38) {where L1 = salicylaldehyde semicarbazone, L2 = salicylaldehyde 
4-n-butylsemicarbazone, L
3 
= salicylaldehyde 4-(2-naphthyl) semicarbazone} which were tested 
for  their insulin-mimetic activity. The observation suggested that all dioxido vanadium(V) 
complexes exhibited essentially no in vitro insulin-mimetic activity, except VO2L
2 
(37), that 
developed activity in the presence of ascorbic acid, similar to that of vanadyl sulfate. 
The same group in 2005, has reported
51
 the synthesis of five dioxido vanadium(V) 
semicarbazone complexes with the formula cis-VO2L, where L = 5-bromosalicylaldehyde 
semicarbazone and 2-hydroxynaphtalen-1-carboxaldehyde semicarbazone. All the complexes 
were tested in three different human tumor cell lines where they showed selective cytotoxicity on 
TK-10 cell line. Results suggested that structural modifications on the semicarbazone moiety 
could have a significant effect on the anti-tumor activity of the vanadium complexes. The 
molecular structure of the novel [V
V
O2(5-bromosalicylaldehyde semicarbazone)] (39) (Figure 
1.18) complex was solved by X-ray diffraction methods, where vanadium atom was surrounded 
by distorted square pyramidal coordination sphere. 
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Figure 1.18 
Dinda et al.
52
 have reported the syntheses and characterization of two alkali metal complexes 
[{VO2L}M(H2O}n] [M = Na
+
 (40), K
+
 (41)] of anionic cis-dioxido vanadium(V) species (LVO2
-
) 
{L = 2-hydroxybenzoylhydrazone of 2-hydroxybenzaldehyde}. These compounds represent a 
class of metal-mediated supramolecular assembly [{VO2L}M(H2O}n] with an infinite polymeric 
structure containing an alternating array of cis-dioxido vanadium(V), [VO2L]
-
, units and aquated 
metal ion centres which was confirmed by X-ray crystallographic investigation of both the 
complexes. Staircase like arrangement of complex 41 along the a axis is shown in Figure 1.19. 
 
Figure 1.19 
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S. K. Kar and group
53
 has reported the anionic cis-dioxido vanadium(V) complexes, LVO2
-
 and 
L1VO2
-
 of two tridentate ONO ligands that bind alkali metal ions in a bis-monodentate fashion 
like a bridging carboxylate group. Where the complementary units are held together by hydrogen 
bonding and coulombic interactions. Among these complexes [L1VO2Li(H2O)2]∞ (42), 
[LVO2Na(H2O)2]∞ (43) and [LVO2K(H2O)2]∞ (44) were crystallographically characterized. {H2L 
= (N′-[(E)-(2-hydroxyphenyl) methylidene]-3-methyl-1H-pyrazole-5-carbohydrazide) and H2L1 
= (N′-[(1E)-1-(2-hydroxyphenyl) ethylidene]-3-methyl-1H-pyrazole-5-carbohydrazide)}. A 3D 
polymeric cluster of 44 is shown in Figure 1.20. 
 
Figure 1.20 
 
1.1.4. Binuclear dioxido vanadium(V) complexes. Binuclear complexes of oxido vanadium(V) 
usually display a bridging ligand, connecting the two oxido vanadium(V) centers, of the types, μ-
oxido, di-μ-oxido or di-μ-alkoxido. Binuclear metal complexes connected by a sole μ-oxido 
bridge continue to attract increasing attention in contemporary coordination chemistry. Such 
species, often supported by ancillary bridging ligand(s) (viz. carboxylates, etc.) are known to 
play pivotal roles in biology during dioxygen activation by a host of metalloenzymes, namely, 
methane monooxygenase, Δ9-desaturase, ribonucleotide reductase, cytochrome c oxidase, and so 
forth.
54-56 
 
Kurup and group
57
 has reported the crystal structure of [VO(BPB)(µ2-O)]2 (45) (Figure1.21) and 
[VO(DKN)(µ2-O)]2 .½H2O (46) {HBPB = 2-benzoylpyridine benzoyl hydrazone, HDKN = di-2-
pyridyl ketone nicotinoyl hydrazone}. Each of the complexes exhibits a binuclear structure 
where two vanadium(V) centres are bridged by two oxygen atoms to form distorted octahedral 
structures within cis-N2O4 donor sets.
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Figure 1.21 
H. H. Monfared and group
58
 has reported the structure and characterization of the 
methoxidobridged divanadium(V) complex [V
V
O(µ2-OCH3)(L
1
)]2 (47) (Figure 1.22) (H2L
1
 = 
benzoylhydrazone of acetylacetone). The complex was found to show a distorted octahedral 
geometry around the vanadium(V) centre. The catalytic activity of 47 was examined for the 
oxidation of various hydrocarbons (alkanes, alkenes and aromatic hydrocarbons) with H2O2 in 
acetonitrile under mild condition. 
 
Figure 1.22 
M. Chaudhury and group
59
 has reported for the first time a general protocol for the synthesis of  
mixed ligand oxido bridged binuclear oxido vanadium(V) complexes, [LOV(μ-O)VO(Salen)] 
(48-50). L2
-
 is tridentate biprotic ONO donor Schiff-base ligands (Figure 1.23) and H2Salen = N, 
22 
 
N′-bis(salicylidene)-1,2-diaminoethane. Molecular structure and atom-numbering scheme for 49 
is shown in Figure 1.24. Where one of the vanadium centers in these compounds has an 
octahedral environment, completed by tetradentate Salen ligand, whereas the remaining center 
has a square pyramidal geometry, made up of tridentate biprotic type donor combinations. The 
existence of two different vanadium(V) centers was confirmed by 
51
V NMR spectroscopy. 
 
 
 
 
 
 
X = H,       LiHL
1 
(48) 
     
= Br,      LiHL
2
 (49) 
    
= NO2,     LiHL
3
 (50) 
 
      Figure 1.23                                                                                         Figure 1.24 
 
M. Chaudhury
60
 and group has also reported a new class of divanadium(V) compounds 
connected by an unsupported hydroxido bridge. Dinuclear oxido vanadium(V) compounds of 
general formula [LV
V
O(μ-OH)OVVL](PF6) [H2L = N,N′-tert-ethylene bis(salicylideneimine) 
(H2Salen) and its derivatives] (51–53) were obtained by aerial oxidation of V
IV
OL precursors in 
THF in the presence of NH4PF6. The observation was explained with the possibility that, 
probably, the oxidized vanadium(V) extracts an OH- ligand from the residual moisture in the 
solvent and retained as an unsupported hydroxido-bridge between the metal centers of these 
compounds as confirmed by single-crystal X-ray diffraction analyses. The molecules of 51–53 
have centrosymmetric structures with each vanadium center having a distorted octahedral 
geometry. One of the hydroxido bridged compounds (51) is shown in Figure 1.25. 
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Figure 1.25 
 
1.2. AIM OF THE PRESENT WORK 
The primary aim of the present work has been to study the chemistry of vanadium(IV/V) 
complexes with -ONO / -ONN donor ligand systems. The different ligands that has been used for 
this purpose are shown below, along with their observed coordination modes. 
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1.3. THE MAIN OBJECTIVES OF THE PRESENT STUDY    
1. To develop some O- and N- donor mono- and binucleating ligand systems, (especially 
aroylhydrazones and oximes) inspired by the paradigm of biologically and catalytically 
important vanadium complexes.  
2. To develop versatile, new-generation nonoxido vanadium(IV) and mono- and binuclear 
oxido vanadium(V) systems, for use as reagents in some bio- and catalytic reactions and as 
model complex of few metalloenzymes. This work uses synthetic and analytical approaches 
to generate and study vanadium-(IV), and -(V) complexes complexes, relying upon current 
mechanistic understanding of their mode of action.  
3. Study the properties of these metal complexes, such as spectral, magnetic and redox 
behavior. Solve the X-ray structure of these complexes and develop the structure-reactivity 
correlation.  
4. Exploration of pharmacological studies such as antimicrobial, DNA & protein binding, 
cleavage, insulin mimetic and antiproliferative activity. Study of catalytic activities 
particularly oxidation of methyl phenyl sulphide and oxidative bromination of styrene and 
salicylaldehyde using synthesised metal complexes. 
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Chapter 2 
 
Highly stable hexacoordinated nonoxido vanadium(IV) complexes of sterically constrained 
ligands: Syntheses, structure and study of antiproliferative and insulin mimetic activity 
 
ABSTRACT 
__________________________________________________________________________________ 
Three highly stable, hexacoordinated nonoxido vanadium(IV), V
IV
(L)2, complexes (1−3) have 
been isolated and structurally characterized with tridentate aroylhydrazonates containing ONO 
donor atoms. All the complexes are stable in the open air in the solid state as well as in solution, 
a phenomenon rarely observed in nonoxido vanadium(IV) complexes. The complexes have good 
solubility in organic solvents, permitting electrochemical and various spectroscopic 
investigations. The existence of nonoxido vanadium(IV) complexes was confirmed by elemental 
analysis, ESI mass spectroscopy, cyclic voltammetry, EPR and magnetic susceptibility 
measurements. X-ray crystallography showed the N2O4 donor set to define a trigonal prismatic 
geometry in each case. All the complexes show in vitro insulin mimetic activity against insulin 
responsive L6 myoblast cells, with complex 3 being the most potent which is comparable to 
insulin at the complex concentration of 4 M, while the others have moderate insulin mimetic 
activity. In addition, the in vitro antiproliferative activity of complexes 1–3 against HeLa cell 
line was assayed. The cytotoxicity of the complexes is affected by the various functional groups 
attached to the bezoylhydrazone derivative and 2 showed considerable antiproliferative activity 
compared to most commonly use chemotherapeutic drugs. 
______________________________________________________________________________ 
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2.1. INTRODUCTION 
 
Vanadium attracts increasing interest in biochemistry.
1,2
 Of the numerous reported effects of 
vanadium on organisms, its stimulatory effect on the growth of algae and plants,
3
 the inhibitory 
action of vanadate(V) on Na, K-ATPase,
4
 the presence of vanadium at the active site of certain 
enzymes, including haloperoxidases in sea algae and lichens
5
 and some nitrogenases in nitrogen-
fixing Azotobacter
6 
are especially worth mentioning. Moreover, inorganic vanadyl and vanadate, 
as well as some vanadium(IV) and (V) complexes, are potent insulin mimics and as such may 
find use as alternatives to insulin in the treatment of diabetes.
7
 The discovery of the in vivo 
insulin mimesis per os of oxido vanadates(V)
8
, the oxido vanadium(IV) precursor, vanadyl 
sulfate,
9
 and the much more potent bis(maltolato)-oxido vanadium(IV) (BMOV)
10
 stimulates the 
search for vanadium complexes which may have application in the treatment of type II 
diabetes.
11,12
 Different approaches have been attempted to develop more potent and orally active 
vanadium-containing insulin enhancing agents.
13
 Although the said complexes have shown 
pharmacological advantages compared to the uncomplexed VOSO4, further improvement in 
ligand design is needed, focusing on identifying new vanadium complexes with increased 
potency and decreased toxicity.
14 
 
 In the past few years new metal complexes have been identified as a very promising class of 
anticancer active compounds.
15–22
 Some vanadium complexes, particularly, peroxido 
vanadates(V) and bis(cyclopentadienyl)vanadium(IV) complexes
23
 have been found to possess 
antitumor activity. Recently, some new type of oxido vanadium(IV) complexes, 
mono(phenanthroline)oxido vanadium(IV) [VO(phen)(H2O)2]
2+ 24
 and bis(1,10-
phenanthroline)sulfatooxido vanadium(IV) [VO(SO4)(phen)2]
25
 were reported to exhibit potent 
antitumor activity against the human nasopharyngeal carcinoma-KB cells line and clonogenic 
NALM-6 cells line, respectively. Dong et al. have reported the cytotoxic activity of some 
bis(phenanthroline)oxido vanadium(IV) complexes against the human leukemic NALM-6 cell 
line.
25
 Noleto and co-workers described the cytotoxic activity of some GALMAN-A:VO
2+/
VO
3+
 
and GALMAN-B:VO
2+/
VO
3+
 complexes against HeLa cells.
26
 Very recently, Sasmal et al. have 
reported the photocytotoxicity of the oxido vanadium(IV) complex [VO(L)(B)]Cl2, where L is 
bis(2-benzimidazolylmethyl)amine and B is dipyrido[3,2-a:2',3'-c]phenazine against the 
adenocarcinoma A549 cell line.
27 
34 
 
However, in contrast to the well known vanadium(IV)/(V) complexes containing VO
2+
 or VO
3+
 
units,
28
 only very few octahedral nonoxido V
IV
 and V
V
 complexes, the so-called 'bare' 
complexes, have been isolated and structurally characterized.
29
 Amavadin,
30
 a compound 
isolated from the mushroom Amanita muscaria, has been shown to contain an octacoordinated 
V
4+
 ion
31
 without oxido ligands but such nonoxido vanadium species are still scarce.
29
  
 
On the other hand, hydrazones, –NH–N=CRR' (R and R = H, alkyl, aryl), are versatile ligands 
due to their applications in the field of analytical
32
 and medicinal chemistry.
33
 Hydrazone 
moieties are the most important pharmacophoric cores of several anticancer, antiinflammatory, 
antinociceptive, and antiplatelet drugs.
34
 In the context of the present study it is relevant to 
mention that although the chemistry of oxido vanadium(IV)-aroylhydrazone complexes is well 
developed,
35
 far less information is available for model nonoxido complexes,
29a,p
 particularly 
concerning their biological properties. 
 
We have been studying the chemistry of oxido-metal complexes including those of vanadium in 
O–N containing donor environments36 along with electro generation of mixed-valence 
divanadium(IV,V) complexes,
36a,b
 in this chapter we report the syntheses and X–ray crystal 
structures of three nonoxido vanadium(IV) complexes containing aroylhydrazones along with 
special reference to their insulin mimetic and antiproliferative activities. These nonoxido V
IV
 
complexes were fully characterized by various physicochemical techniques like IR, EPR, ESI 
mass, electronic spectroscopy, magnetic susceptibility studies and electrochemical 
investigations. 
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2.2. EXPERIMENTAL SECTION 
 
2.2.1. General Methods and Materials. All chemicals were purchased from commercial 
sources and used without further purification. [VO(acac)2] was prepared as described in the 
literature.
37
 Reagent grade solvents were dried and distilled prior to use. 
 
L6 myoblast cells 
derived from a rat were procured from NCCS, Pune, India. Penicillin, streptomycin, DMEM, 
fetal bovine serum and insulin were purchased from Invitrogen (San Diago, CA, USA), and the 
glucose estimation kit from Randox. MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium) and DAPI (4′,6-diamidino-2-phenylindole dihydrochloride) were purchased 
from Sigma Aldrich (USA). Minimal essential medium (MEM) was purchased from Gibco, 
India. Elemental analyses were performed on a Vario ELcube CHNS Elemental analyzer. IR 
spectra were recorded on a Perkin-Elmer Spectrum RXI spectrophotometer. 
1
H and
 13
C NMR 
spectra were recorded on a Bruker Ultrashield 400 MHz spectrometer using SiMe4 as an internal 
standard. Electronic spectra were recorded on a Lamda25, PerkinElmer spectrophotometer. Mass 
spectra were obtained on a SQ-300 MS instrument operating in ESI mode. DC magnetic 
susceptibility measurements were carried out on a Vibrating Sample magnetometer, PPMS 
(Physical Property Measurement System, Quantum Design, USA) in the temperature range 
2−300 K with an applied field of 1 T. Electrochemical data were collected using a PAR 
electrochemical analyzer and a PC-controlled Potentiostat/Galvanostat (PAR 273A) at 298 K in a 
dry nitrogen atmosphere. Cyclic voltammetry experiments were carried out with Pt working and 
auxiliary electrodes, Ag/AgCl as the reference electrode and TEAP as the supporting electrolyte. 
X-band EPR measurements were performed on a JEOL JES-FA 200 and Bruker EMX EPR 
Spectrometer. 
 
2.2.2. Synthesis of Ligands (H2L
1–3
). Schiff base ligands, anthranylhydrazone of 2-hydroxy-1-
acetonaphthone (H2L
1
), salicylhydrazone of 2-hydroxy-1-acetonaphthone (H2L
2
) and 
benzoylhydrazone of 2-hydroxy-1-acetonaphthone (H2L
3
), were prepared by the condensation of  
2-hydroxy-1-acetonapthone and the respective acidhydrazide in equimolar ratio in ethanol by a 
standard procedure.
38 
The resulting white compounds were filtered, washed with ethanol and 
dried over fused CaCl2. Elemental analysis results, NMR (
1
H and 
13
C) and IR data for all of these 
verified their preparation. 
36 
 
H2L
1
. Yield: 64%. Anal. Calcd. for C19H17N3O2: C, 71.46; H, 5.36; N, 13.16. Found: C, 71.48; 
H, 5.37; N, 13.14. IR (KBr pellet, cm
–1
): 3473 ν(O–H); 3410 ν(NH2)s; 3329 ν(NH2)as; 3221 
ν(NH); 1663 ν(C=O); 1553 ν(C=N). 1H NMR (400 MHz, DMSO-d6): δ 10.35 (s, 1H, naphthyl–
OH), 9.17 (s, 1H, NH), 7.91–6.23 (m, 10H, Aromatic), 6.05 (s, 2H, NH2), 2.35 (s, 3H, CH3). 
13
C 
NMR (100 MHz, DMSO-d6): δ 153.98 (CO–N), 152.47 (N=C(Me)), 152.36–113.59 (16C, 
aromatic), 24.15 (–CH3). 
 
H2L
2
. Yield: 60%. Anal. Calcd. for C19H16N2O3: C, 71.24; H, 5.03; N, 8.74. Found: C, 71.28; H, 
5.01; N, 8.71. IR (KBr pellet, cm
–1
): 3542 ν(O–H); 3113 ν(N–H); 1661 ν(C=O); 1555 ν(C=N). 
1
H NMR (400 MHz, DMSO-d6): δ 10.84 (s, 1H, phenyl–OH), 10.37 (s, 1H, NH), 10.21 (s, 1H, 
naphthyl–OH), 7.94–6.69 (m, 10H, Aromatic), 2.32 (s, 3H, CH3). 
13
C NMR (100 MHz, DMSO-
d6): δ 161.19 (CO–N), 155.89 (N=C(Me)), 152.50–114.52 (16C, aromatic), 24.09 (–CH3). 
 
H2L
3
. Yield: 58%. Anal. Calcd. for C19H16N2O2: C, 74.98; H, 5.29; N, 9.20. Found: C, 74.96; H, 
5.32; N, 9.21. IR (KBr pellet, cm
–1
): 3337 ν(O–H); 3071 ν(N–H); 1659 ν(C=O); 1573 ν(C=N). 
1
H NMR (400 MHz, DMSO-d6): δ 10.31 (s, 1H, naphthyl–OH), 9.55 (s, 1H, NH), 7.91–7.27 (m, 
11H, Aromatic), 2.34 (s, 3H, CH3).
13
C NMR (100 MHz, DMSO-d6): δ 153.71 (CO–N), 152.63 
(N=C(Me)), 152.12–113.74 (16C, aromatic), 24.30 (–CH3). 
 
2.2.3. Synthesis of Complexes [V
IV
(L
1–3
)2] (1–3). A general synthetic procedure taking 
[VO(acac)2] as representative metal precursor is described below: 
[VO(acac)2] (0.5 mmol) was added to a hot solution of appropriate ligand H2L
1-3 
(1.0 mmol) in 
EtOH (20 mL), the color changed instantly to greenish black. After 3 h of stirring, black crystals 
were obtained from reaction mixture, which were filtered off, washed thoroughly with ethanol 
and dried. Some crystals are of diffraction quality and were used directly for X-ray structure 
determination using single crystal X-ray diffractometer. 
 
[V
IV
(L
1
)2] (1). Yield: 66%. Anal. Calcd. for C38H30N6O4V: C, 66.57; H, 4.41; N, 12.26. Found: 
C, 66.55; H, 4.37; N, 12.29. IR (KBr pellet, cm
–1
): 3298 ν(NH2)s; 3043 ν(NH2)as; 1589 ν(C=N); 
1256 ν(C–O)enolic; 1048 ν(N–N). ESI-MS (CH2Cl2): m/z 708.49 (53%, [M + Na]
+
); ESI-MS 
(CH3CN + CH2Cl2) (19:1): m/z 708.12 (100%, [M + Na]
+
); ESI-MS (MeOH + DMF) (19:1): m/z 
708.21 (100%, [M + Na]
+
). 
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[V
IV
(L
2
)2] (2). Yield: 65%. Anal. Calcd. for C38H28N4O6V: C, 66.37; H, 4.10; N, 8.15. Found: C, 
66.40; H, 4.07; N, 8.17. IR (KBr pellet, cm
–1
): 3427 ν(O–H); 1591 ν(C=N); 1250 ν(C–O)enolic; 
1047 ν(N–N). ESI-MS (CH2Cl2): m/z 710.10 (50%, [M + Na]
+
); ESI-MS (CH3CN + CH2Cl2) 
(19:1): m/z 710.10 (100%, [M + Na]
+
); ESI-MS (MeOH + DMF) (19:1): m/z 710.20 (100%, [M 
+ Na]
+
). 
 
[V
IV
(L
3
)2] (3). Yield: 68%. Anal. Calcd. for C38H28N4O4V: C, 69.62; H, 4.30; N, 8.54. Found: C, 
69.58; H, 4.31; N, 8.57. IR (KBr pellet, cm
–1
): 1598 ν(C=N); 1243 ν(C–O)enolic; 1046 ν(N–N). 
ESI-MS (CH2Cl2): m/z 655.25 (90.27%, [M]
+
); ESI-MS (CH3CN + CH2Cl2) (19:1): m/z 678.27 
(100%, [M + Na]
+
); ESI-MS (MeOH + DMF) (19:1): m/z 678.25 (100%, [M + Na]
+
). 
 
Alternatively, these complexes can also be synthesized from the starting materials like VCl3, 
VOSO4 and NH4VO3 as shown in Scheme 2.1. The spectral data matched well with the one 
reported above. 
 
 
X = NH2, OH, H
Nonoxido vanadium(IV) 
complex
V
O
N
O
O
N
O
1.VO(acac)2 / VOSO4
CH3CN
4.NH
4VO3 / CH3CN
5.VCl
3 / EtOHH2L
[VIV(L)2]
X Ligand
NH2
OH
H
H2L
1
H2L
2
H2L
3
[VIV(L1)2]
[VIV(L2)2]
[VIV(L3)2]
Nonoxido vanadium(IV) 
complex
 EtOH
 EtOH, O
2
2.VO(acac)2 / VOSO4
3.VO(acac)2 / VOSO4
(1)
(2)
(3)
H
N
O
N
HO
CH3
X
 
Scheme 2.1. Schematic diagram of various pathways through which the hexacoordinated V
IV
(L)2 
nonoxido vanadium(IV) (1-3) complex were synthesized. 
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2.2.4. X-ray Crystallography. For all three complexes (1–3) the black crystals were obtained 
from reaction mixture. Single crystal X-ray diffraction measurements were performed on a 
Bruker SMART CCD diffractometer employing graphite-monochromated Mo Kα radiation (λ = 
0.71073) so that max = 27.5°. Data collection and reduction were by standard methods,
39
 and 
absorption corrections were applied based on multiple scans.
40
 The structures were solved by 
direct methods
41
 and refined by full-matrix least-squares on F
2
.
41
 All non-hydrogen atoms were 
refined anisotropically, C-bound hydrogen atoms were included in the riding model 
approximation, and O–H and N–H H atoms were refined with the distance constraint 0.82±0.01 
and 0.86±0.01 Å, respectively. In the final cycles of each refinement, a weighting scheme of the 
form w = 1/[2(Fo
2
) + aP
2
], where P = (Fo
2
 + 2Fc
2
)/3, was introduced. The final difference maps 
were featureless. Molecular structure diagrams of 1–3 were drawn with ORTEP-3 for 
Windows
42a
 at the 50% probability level, the overlay diagram of 1–3 was drawn with QMol42b 
while remaining crystallographic diagrams were drawn with DIAMOND.
42c
 A summary of 
crystal data and refinement details for 1–3 is provided in Table 2.1. 
 Crystallographic data in CIF format for the structures have been deposited in the Cambridge 
Crystallographic Data Centre; CCDC 928538 for 1, CCDC 928539 for 2 and CCDC 928540 for 
3.  
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Table 2.1 Crystal data and refinement details for [V
IV
(L
1-3
)2] ( 1–3) 
Parameter 1 2 3 
Formula C38H30N6O4V C38H28N4O6V C38H28N4O4V 
Formula weight 685.62 687.58 655.58 
Crystal habit, color rectangle, red block, red hexagon, dark green 
Crystal size, mm 0.06 x 0.07 x 0.17 0.07 x 0.11 x 0.13 0.05 x 0.16 x 0.26 
Crystal system monoclinic monoclinic monoclinic 
Space group P21/n P21/n P21/c 
a, Å 14.608(6) 14.711(4) 13.807(7) 
b, Å 14.846(6) 14.697(4) 23.851(12) 
c, Å 14.976(6) 15.068(4) 10.249(5) 
, º 97.704(8) 96.590(4) 106.571(10) 
V, Å
3
 3219(2) 3236.3(15) 3235(3) 
Z 4 4 4 
Density, g/cm
3
 (calculated) 1.415 1.411 1.346 
, cm-1 0.361 0.362 0.354 
Reflections collected 36356 35724 26859 
Independent reflections 7362 7419 7320 
Reflecitons with I ≥ 2(I) 3686 3887 2745 
R (observed data) 0.062 0.071 0.074 
a in wghting scheme 0.058 0.065 0.064 
Rw (all data) 0.158 0.174 0.196 
Largest diff. peak and hole e Å
-3
 0.33 and -0.28 0.34 and -0.28 0.30 and -0.38 
CCDC deposition number        928538                    928539                 928540 
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2.2.5. In Vitro Insulin Mimetic Activity. L6 myoblast were cultured in DMEM containing 10% 
FBS, penicillin (100 U/ml) and streptomycin (100 µg/ml) in a humidified 5% CO2 incubator at 
37
◦
C. To differentiate myotubes, the myoblast cells (5x10
4
) were seeded in 24 well plates in 
DMEM containing 2% FBS. The myoblast cells (5x10
4
) were grown for 11 days in 0.4 ml of 2% 
FBS/DMEM to allow the formation of myotubes. The medium was changed every 2 days. On 
the 11
th
 day, the cells were washed and incubated in Kreb‘s bicarbonate buffer (KRBB) for 2 h. 
Myotubes were then further cultured in KRBB containing 25 mM glucose along with 1, 2 and 4 
µM of vanadium complexes (1–3) and VO(acac)2 for 4 h. The insulin (2 µM) was taken as 
positive control.
43
 The residual glucose in the buffer aliquots remaining in each well after 4 h 
was estimated using the hexokiase method by Randox autoanalyser.  
 
2.2.6. Cytotoxic Assay. Human cervical cells HeLa were obtained from National Centre of Cell 
Science (NCCS), Pune, India and were maintained in minimal essential medium supplemented 
with 10% fetal bovine serum, penicillin-streptomycin solution and incubated at 37°C in 5% CO2 
and 95% humidified incubator. HeLa cells were harvested from maintenance cultures in 
logarithmic phase, after counting in a hemocytometer using trypan blue solution. The cell 
concentration was adjusted to 5x10
4
 cells/ml and the cells were plated in a 96 well ﬂat bottom 
culture plate and incubated for 72 h with various concentrations of the test complexes which 
were dissolved in a 90% (v/v) DMF solution. The effect of the drugs on the cancer cell viability 
was studied using MTT dye reduction assay by measuring the optical density at 595 nm using 
micro-plate reader spectrophotometer (Perkin-Elmer 2030).
44
 DMF solutions that was used to 
dissolve the drugs was used in control group treatment. 
 
2.2.7. Nuclear Staining. Nuclear staining using DAPI stain was performed according to the 
method previously described.
45
 Briefly, HeLa cells either treated or untreated with test 
compounds were smeared on a clean glass slide, cells were fixed with 3.7% formaldehyde for 15 
minutes, permeabilized with 0.1% Triton X-100 and stained with 1 μg/ml DAPI for 5 min at 37 
°C. The cells were then washed with PBS and examined by fluorescence microscopy (Olympus 
IX 71) to ascertain any condensation or fragmentation of the nuclei indicating cells undergoing 
apoptosis. 
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2.3. RESULT AND DISSCUSSION 
 
2.3.1. Synthesis. The various pathways through which the nonoxido vanadium(IV) 
hexacoordinated [V
IV
(L)2] complexes were obtained is shown in Scheme 2.1. Reactions of 
aroylhydrazones (H2L
1-3
) with [VO(acac)2] or VOSO4 in acetonitrile or ethanol lead to the 
formation of monomeric bis(tridentate)-vanadium(IV) complexes [V
IV
(L
1-3
)2] (1–3). The 
reactions are clean, affording large quantities of pure crystalline products in good yield (~ 70%). 
These compounds are highly soluble in CH2Cl2, DMF and DMSO and sparingly soluble in 
MeOH, EtOH and CH3CN.  
 
Alternatively, these nonoxido V
IV
 complexes can also be isolated directly by the reaction of 
aroylhydrazones with various oxido vanadium(V), and vanadium(III) compounds as starting 
materials. The formation of [V
IV
(L)2] complexes from oxido vanadium(V), NH4VO3, and 
vanadium(III), VCl3, species probably involves a one step reduction from vanadium(V) to 
vanadium(IV), and a one step oxidation from vanadium(III) to vanadium(IV) in open air, 
respectively, followed by oxido abstraction from the oxido vanadium(IV) species generated in 
situ. It is noteworthy that the entire above synthetic route can be carried out in laboratory grade 
ethanol or acetonitrile under ambient conditions. The reactions do not require dry solvent, the 
presence of base, or an inert atmosphere, which is unusual compared to previous reports.
29c,e,o,x, 46 
 
Complexes 1–3 are highly stable both in the solid state and in solution. For example, a solution 
of 1 in different coordinating or noncoordinating solvents does not give any oxidized product (no 
color change, no oxido-V
IV
, no oxido-V
V
, as confirmed by ESI mass, time dependent UV-Vis 
and EPR spectroscopy) after exposure to aerial oxygen for 3–4 days or even purging oxygen gas 
into its solution, a rather uncommon observation for nonoxido vanadium(IV) complexes. Again, 
to check the stability of these nonoxido vanadium(IV) species, all three complexes (1-3) were 
dissolved and recovered back from solvent mixture (MeOH + DMF) (9:1) after keeping three 
days in solution. The isolated solid products were characterized by different spectroscopic 
techniques (Figures 2.1-2.3). The results matched well regardless of having been recorded using 
original compound or isolated compound from solvent. The absence of vanadium oxido (V=O) 
peak in IR spectrum, no disappearance of low energy transition peaks in UV-Vis spectrum and 
time dependent EPR clearly discard the formation of corresponding V(V) in solution. The 
42 
 
stability of the complexes may be due to the simultaneous removal of the oxido group, complete 
charge neutralization as well as the formation of six strong covalent bonds at the V
4+
 center from 
the hard donor atoms N and O, which possibly precludes the approach of a reagent species 
within the reaction sphere of the well-protected V
4+
 center. Also, the rigidity and steric bulk of 
the ligands do not permit the formation of the square pyramidal pentacoordinated [V
V
OL(OR)] 
complex so familiar in vanadium chemistry, in which the terminal oxygen is in an axial position 
and the tridentate ligand occupies the equatorial plane.  
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Black- IR spectra of Complex 1 (original crystal) 
Blue- IR spectra of Compound 1' isolated from DMF + MeOH  
Figure 2.1. IR spectra of complex 1 and isolated compound 1' in the range 1800–600 cm–1 
{compound 1' is isolated by dissolving complex 1 in solvent mixture (MeOH + DMF) (9:1) after 
keeping for three days}. 
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Figure 2.2. UV-Vis spectra of compound 2' (1.75 X 10
-5
M) in CH2Cl2 as solvent){compound 2' 
is isolated by dissolving complex 2 in solvent mixture (MeOH + DMF) (9:1) after keeping for 
three days}. 
 
 
 
 
 
Figure 2.3. ESI mass spectra of isolated compound 1' in (CH3CN + CH2Cl2 (19:1) {compound 1' 
is isolated by dissolving complex 1 in (MeOH + DMF) (9:1) after keeping for three days}. 
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2.3.2. Structure Description. Crystals were obtained for each of 1–3 and their crystal structures 
determined. Molecular structures are illustrated in Figure 2.4 and selected geometric parameters 
are collected in Table 2.2. In 1, the central V atom is coordinated by two dinegative, NO2 
coordinating hydrazone ligands forming five membered CN2OV and six membered C3NOV 
chelate rings. The five membered rings have envelope conformations with the V atom lying 
0.215(5) and 0.301(5) Å above the plane of the remaining atoms of the O1 and O3 chelate rings 
(r.m.s. deviation = 0.0061 Å for each). Each five membered ring is virtually coplanar to the 
attached benzene ring (dihedral angles between least squares planes = 4.17(16) and 7.04(15)º, 
respectively) which allows for the formation of intramolecular N–H…N hydrogen bonds 
between an amino-H and noncoordinating azo N atoms, Table 2.2. The six membered chelate 
rings exhibit significantly greater deviations from planarity and may to a first approximation be 
described as having an envelope conformation with the V atom lying well out of the plane, i.e., 
0.963(3) Å, defined by the remaining five atoms (r.m.s. deviation = 0.0949 Å); the equivalent 
parameters for the O4 chelate ring are 0.904(3) and 0.1200 Å, respectively. This distortion 
enables the V atom to exist within a N2O4 donor set that approximates a trigonal prism. In this 
description, the two triangular faces are defined by the (O1, O4, N4) and (O2, O3, N2) atoms. 
The dihedral angle between the trigonal faces is 2.67(9)º and the twist of one face relative to the 
other is 13.5º, cf., 0º for an ideal trigonal prism and 60º for an ideal octahedron. The structure of 
2 is isostructural with 1 and presents very similar coordination geometry. 
For the two five membered rings in 2, the V atom lies 0.196(5) and 0.270(5) Å above the plane 
defined by the remaining four atoms (r.m.s. deviation = 0.0033 and 0.0061 Å for the O1 and O3 
rings, respectively). The adjacent benzene ring is approximately coplanar to the respective five 
membered ring forming dihedral angles of 1.81(17) and 4.88(17)º; this arrangement enables 
intramolecular O–H…N hydrogen bonding, Table 2.2. Significant distortions are again evident 
for the six membered chelate rings with the V atom lying 0.960(4) Å out of the plane through the 
remaining five atoms of the O2 chelate ring (r.m.s. deviation = 0.0943 Å); the equivalent values 
for the O4 chelate are 0.926(4) and 0.1181 Å, respectively. In terms of coordination geometry, 
the dihedral angle between the trigonal faces is 2.00(10)º and the twist angle is 10.1º. While not 
isostructural with 1 and 2, the structure of 3 presents all the hallmarks just described with the 
exception of the intramolecular hydrogen bonding. 
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For the five membered rings rings in 3, the V atom lies 0.215(6) and 0.252(7) Å out of the planes 
of the O1 (r.m.s. deviation = 0.0087 Å) and O3 chelate (0.0139 Å) rings, confirming the flattened 
envelope conformations. Despite the lack of an intramolecular hydrogen bond, as for 1 and 2, the 
adjacent five and six membered chelate and benzene rings are coplanar forming dihedral angles 
of 4.9(3) and 10.4(3)º. For the six membered chelate rings, the V atom lies 0.975(4) Å out of the 
plane of the remaining atoms (r.m.s. deviation = 0.1064 Å) for the O2 chelate ring; 0.981(5) and 
0.1064 Å for the O4 chelate ring. Finally, the dihedral angle between the trigonal face is 
2.85(12)º and the twist angle is 10.0º. 
The overlap diagram Figure 2.4d, where the V,O1,O2 atoms have been superimposed highlights 
the similarity in the molecular structures of 1–3, there being only minor differences in the 
orientations of the peripheral substituents. This homogeneity is reflected in the geometric 
parameters collated in Table 2.2, with no significant differences apparent in the bond lengths 
about the three V atoms. In the same way, no trends are discerned from the bond angles 
indicating that the amino (1) and hydroxyl (2) groups do not exert an influence on the molecular 
structure even though they form intramolecular hydrogen bonds with the noncoordinating azo N 
atoms. 
In the crystal structure of 1, no specific intermolecular contacts were identified as being 
significant employing the distance criteria established in PLATON,
47
 implying the second 
amino-H atom does not form a significant intermolecular contact. As shown in Figure 2.5, 
molecules are arranged in rows along the b-axis and are surrounded by molecules forming 
hydrophobic contacts. In isostructural 2, a similar packing is observed but in this case a C–H…, 
edge to face, interaction is formed between methyl-H and the C1-benzene ring of centro 
symmetrically related molecules to form dimeric aggregates, for details see Figure 2.6. As for 1, 
no specific intermolecular interactions are noted in the crystal structure of 3, Figure 2.7. A 
macroscopic difference in the global crystal packing is apparent as molecules in 3 can be 
described as aggregating in the bc-plane with the flat layers stacking along the a-axis. By 
contrast, molecules in each of 1 and 2 aggregate in a zigzag pattern parallel to the ab-plane and 
stack along the c-axis. 
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Table 2.2 Selected geometric parameters (Å, º) for [V
IV
(L
1-3
)2] (1–3) 
Parameter  1  2  3 
Coordination geometry 
V-O1 1.903(2) 1.919(2) 1.903(3) 
V-O2 1.895(2) 1.902(2) 1.906(3) 
V-O3 1.891(2) 1.908(2) 1.894(3) 
V-O4 1.878(2) 1.888(2) 1.900(3) 
V-N2 2.053(3) 2.058(3) 2.073(4) 
V-N4 2.066(3) 2.081(3) 2.065(4) 
O1-V-O2 126.48(10) 127.59(11) 126.66(13) 
O1-V-O3 137.78(10) 136.73(11) 136.77(14) 
O1-V-O4 87.33(10) 87.26(10) 87.06(14) 
O1-V-N2 74.41(10) 74.75(11) 74.22(15) 
O1-V-N4 86.84(10) 87.05(11) 86.86(15) 
O2-V-O3 86.27(10) 86.23(10) 87.22(14) 
O2-V-O4 84.47(9) 83.75(10) 83.87(13) 
O2-V-N2 81.43(10) 81.27(11) 82.11(14) 
O2-V-N4 143.32(10) 141.64(11) 142.77(14) 
O3-V-O4 125.70(10) 126.99(11) 126.80(14) 
O3-V-N2 87.21(10) 86.94(11) 86.92(14) 
O3-V-N4 74.47(10) 74.65(11) 74.24(15) 
O4-V-N2 143.13(10) 141.72(11) 142.62(14) 
O4-V-N4 82.14(10) 81.96(11) 82.14(15) 
N2-V-N4 127.22(10) 129.20(11) 127.47(15) 
Hydrogen bonds 
H…N1 2.03(4) 1.91(4) 
Y…N1 2.710(5) (Y = N5) 2.626(4) (Y = O5) 
H…N3 2.10(4) 1.86(4) 
Y…N3 2.716(4) (Y = N6) 2.628(4) (Y = O6) 
Y-H…N1 135(3) (Y = N5) 147(4) (Y = O5) 
Y-H…N3 128(3) (Y = N6) 153(4) (Y = O6) 
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(a) 
 
(b) 
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(c) 
 
(d) 
 
 
 
Figure 2.4. Molecular structures of  [V
IV
(L
1
)2] (1) (a), [V
IV
(L
2
)2] (2)  (b), [V
IV
(L
3
)2] (3) (c), and 
overlay diagram of of  [V
IV
(L
1
)2] (1) (red image), of  [V
IV
(L
2
)2] (2)  (green) and of  [V
IV
(L
3
)2] (3)  
(blue) drawn so that the V, O1 and O2 atoms are coincident (d). 
50 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. View in projection down the b-axis of the unit cell contents of [V
IV
(L
1
)2] (1). No 
significant intermolecular contacts are apparent. 
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Figure 2.6. View in projection down the b-axis of the unit cell contents of of [V
IV
(L
2
)2] (2). The 
purple dashed lines represent C9–H9c... (C1-C6), edge to face, interactions: H9c...ring 
centroid(C1-C6)
i
 = 3.00 Å, C9...ring centroid(C1-C6)
i
 = 3.907(5) Å, angle at H9c = 159º for 
symmetry operation i: 1-x, -y, 1-z. 
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Figure 2.7. View in projection down the c-axis of the unit cell contents of of  [V
IV
(L
3
)2] (3). No 
significant intermolecular contacts are apparent. 
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2.3.3. Spectral Characteristics 
2.3.3.1 IR Spectroscopy. The IR data of all the ligands, H2L
1–3
 and their corresponding metal 
complexes, 1–3 are given in the experimental section. All the ligands posses a band in the region 
of 3542–3337 cm–1 due to aromatic –OH present in the naphthalene moiety is found absent in the 
corresponding metal complexes due to the coordination. However, the presence of band at 3427 
cm
–1
 in case of complex 2 is due to the –OH group attached to the benzene nucleus of ligand, 
H2L
2
. Disappearance of bands for –NH and –C=O and appearance of bands in the range 1256–
1243 cm
–1
 indicates the enolization of these two groups forming –N=C–O– type of bond. 
Absence of ν(V=O) bands in the range 1035–935 cm–1 clearly indicate the nonoxido nature of 
the complex.
48
  
 
2.3.3.2. UV Spectroscopy. Electronic spectra of the complexes 1–3 were recorded in CH2Cl2, 
DMF, and different mixture solvents like H2O + DMF (19:1) and MeOH + DMF (19:1). In all 
solutions the spectral features are quite similar for all three complexes (Figures 2.8–2.10). The 
spectral data from CH2Cl2 are summarized in Table 2.3 and the representative spectrum is 
shown in Figure 2.11. There are two bands in the 633–501 nm range, among which, the lowest-
energy transition band around 633–614 nm is situated in the d−d transition region, but the 
intensity (εmax, 16174–10273 M
−1
cm
−1
) of this band appears too large for a pure d−d transition, 
for which the intensity is generally very low for vanadium(IV) complexes. The high intensity of 
these two bands (633–501nm) and analogy with other 'bare' vanadium(IV) 
complexes
29a,b,c,e,j,h,o,p,x 
suggest that these transitions are most reasonably assigned as ligand-to-
metal charge transfer in origin. The other bands in the higher energy absorptions (388–229 nm) 
are likely to be due to ligand centered transitions.
36b
 In 1 and 2 the bands are slightly red shifted 
relative to 3, presumably a consequence of the electron-releasing –NH2 and –OH substituent on 
the ligands in 1 and 2, respectively.
29n   
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Table 2.3. Electronic spectra for [V
IV
(L
1-3
)2] ( 1–3) in CH2Cl2 
______________________________________________________________________________ 
Complex                                             wavelength (nm) (εmax (M
−1
cm
−1
)) 
______________________________________________________________________________ 
[V
IV
(L
1
)2], 1    633 (16174), 509 (13278), 368 (52404), 325 (65737), 265 (80382), 229 (99234) 
[V
IV
(L
2
)2], 2    619 (13060), 507 (13770), 388 (48743), 312 (54808), 253 (89508), 229 (109781) 
[V
IV
(L
3
)2], 3    614 (10273), 501 (9508), 361 (29726), 319 (46775), 265 (56666), 229 (72568) 
_____________________________________________________________________________ 
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Figure 2.8. Time dependent UV-Vis spectra of [V
IV
(L
3
)2] (3) (1.83 X 10
-5
M) in DMF as solvent. 
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Figure 2.9. Time dependent UV-Vis spectra of [V
IV
(L
2
)2] (2) (2.18 X 10
-5
M) in solvent mixture 
(H2O + DMF) (19:1). 
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Figure 2.10. Time dependent UV-Vis spectra of [V
IV
(L
3
)2] (3) (2.18 X 10
-5
M) in solvent mixture 
(MeOH + DMF) (19:1). 
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Figure 2.11. UV-Vis spectra of [V
IV
(L
1
)2] (1) (1.83 x 10
-5
 M) in CH2Cl2 . 
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2.3.3.3. NMR Spectroscopy. 
1
H and 
13
C NMR of the ligands (H2L
1–3
) are recorded in DMSO-d6 
and the data are given in the experimental section. The spectra of the free ligands, (H2L
1–3
) 
exhibit a resonance in the range, δ = 10.35–10.21 ppm due to naphthyl –OH, δ = 10.37–9.17 ppm 
due to –NH and δ = 2.35–2.32 ppm due to –CH3 protons respectively. All the aromatic protons 
of the ligands are clearly observed in the expected region, δ = 7.94–6.23 ppm.36a,b  
 
From the 
13
C NMR spectra, it is observed that, signals for (CO–N) and (N=C(Me)) carbon 
resonates in the downfield region in the range, δ = 161.19–153.71 ppm and δ = 155.89–152.47 
ppm respectively whereas the carbon due to the methyl groups (–CH3) are found in the upfield 
region (δ = 24.30–24.09 ppm). Furthermore appearance of signals in the range δ = 152.50–
113.59 ppm due to aromatic carbon confirm the formation of the ligands.
49 
 
2.3.3.4. ESI mass Spectroscopy. ESI mass spectra of the complexes, 1–3 have been recorded in 
dichloromethane solution. Mass spectral analysis for 3 shows the characteristic molecular ion 
peak (M
+
) at m/z 655.25, whereas for compounds 1 and 2, ESI-MS peaks are observed at m/z 
708.49 [(M + Na)
+
] and 710.10 [(M + Na)
+
] respectively. The ESI mass spectra have also been  
recorded from different solvent mixtures like CH3CN + CH2Cl2 (19:1) and MeOH + DMF 
(19:1). The results matched well regardless of having been recorded in solutions with 
coordinating or noncoordinating solvents. The ESI mass data are summarized in experimental 
section.  
 
2.3.4. Electrochemical Properties. The electrochemical properties of 1–3 have been examined 
in CH2Cl2 solution (0.1 M TEAP) by cyclic voltammetry using a Pt working electrode, Pt 
auxiliary electrode, and an Ag/AgCl reference electrode. The voltammogram pattern is similar 
for 1–3, which includes both oxidation and reduction process corresponding to one electron 
transfer. The potential data are listed in Table 2.4 and Figure 2.12 depicts a representative 
voltammogram of 3. In the anodic region, complexes show a quasi reversible single electron 
wave (Figure 2.12a) at E1/2 values within the potential window 1.11 to 1.09 V is assigned to the 
oxidation of the metal, V(IV)/V(V).
50
 In the cathodic region V(IV) is reduced to V(III) showing 
a quasi reversible single electron wave (Figure 2.12b) at E1/2 values within the potential window 
–0.55 to –0.53 V.51 
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Table 2.4. Cyclic voltammetric results for  [V
IV
(L
1-3
)2] ( 1–3) at 298 K 
______________________________________________________________________________ 
Complex                         E
a
1/2 (V)           ΔE
a
P (mV)        E
c
1/2 (V)           ΔE
c
P (mV) 
______________________________________________________________________________ 
[V
IV
(L
1
)2], 1                     1.10             300                – 0.54                240 
[V
IV
(L
2
)2], 2                     1.11                    340                – 0.55                270 
[V
IV
(L
3
)2], 3                     1.09                    280                – 0.53                220 
______________________________________________________________________________ 
 In CH2Cl2 at a scan rate of 100 mV s
–1
. E1/2 = (Epa + Epc)/2, where Epa and Epc are anodic and 
cathodic peak potentials vs. Ag/AgCl, respectively. ΔEP = Epa – Epc. 
 
 
  
Figure 2.12. Cyclic voltammogram of [V
IV
(L
3
)2] (3)  showing (a) oxidation (V(IV) →V(V)) and 
(b) reduction (V(IV) →V(III)) of the vanadium(IV) centre. 
a)                                                                                    b) 
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2.3.5. Magnetic Properties. Magnetic susceptibility data for 1–3 were collected over the 
temperature range 2–300 K in an applied magnetic field of 1 T and a representative temperature 
dependence of the magnetic susceptibility is shown in Figure 2.13. At 300 K 1–3 have effective 
magnetic moments (eff) of 1.64, 1.66 and 1.68 BM, respectively. These results are typical for a 
compound with spin ½ per formula unit, suggesting that complexes are monomeric with no or 
very weak antiferromagnetic interaction between V atoms (intermolecular coupling).
52, 53 
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Figure 2.13. Temperature dependence of the magnetic susceptibility of [V
IV
(L
3
)2] (3)  at 1 Tesla 
between 2 and 300 K. 
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2.3.6. EPR Spectroscopy. X-band EPR spectra of 1–3 were recorded in CH2Cl2 solution in the 
frozen state (77 K). The data are listed in Table 2.5. A representative frozen solution spectrum 
for 3 is shown in Figure 2.14 which reveals well-resolved axial anisotropy with 8-line hyperfine 
structure, characteristic of a mononuclear vanadium complex with nuclear spin (
51
V, I = 7/2).
54 
Corresponding spin-Hamiltonian parameters (g, 1.948−1.945; A, 129.43  10
–4
 cm
–1−126.94 × 
10
–4
 cm
–1
; g, 1.996−1.983; A, 42.4 × 10
–4
 cm
–1−40.8 × 10–4 cm–1) are typical of trigonal 
prismatic oxido vanadium(IV) complexes under comparable ON-containing donor 
environments.
29a,o
 Analysis of the EPR spectra of vanadium(IV) complexes showed that, the 
anisotropic hyperfine parameters of six-coordinate complexes
35g,54 
have significantly lower 
values compared to the corresponding values obtained with the five-coordinated 
complexes,
35e,f,36a,55
 as is observed in the present case. The EPR spectra have also been recorded 
from DMF solution and the results matches well with the original spectrum reported above.    
  
 
Table 2.5. X-band EPR data for [V
IV
(L
1-3
)2] ( 1–3) at 77 K 
_____________________________________________________________________________ 
Complex                                  g                 g               gav             A                A               Aav   
                                                                                                (10
–4
 cm
–1
 )
    
(10
–4
 cm
–1
)  (10
–4
 cm
–1
) 
______________________________________________________________________________ 
 
[V
IV
(L
1
)2], 1                          1.947           1.983        1.971          128.25            41.8           70.61                 
 
[V
IV
(L
2
)2], 2                          1.945          1.991         1.975         129.43             42.4           71.41 
[V
IV
(L
3
)2], 3                          1.948           1.996        1.980          126.94            40.8           69.51 
______________________________________________________________________________ 
 
gav = 
1
/3 (2 g + g). Aav = 
1
/3(2A + A ). 
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Figure 2.14. Frozen solution X-band EPR spectrum (77 K) in CH2Cl2 of complex 3. Instrument 
settings: power, – 0.009 dB; modulation, 100 kHz; sweep centre, 2500 G; sweep time, 120 s; 
sweep width, 2500 G. 
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2.3.7. In Vitro Insulin Mimetic Activity. Vanadium compounds are known to have insulin 
mimetic effect.
56
 In this study 1–3 were tested for their insulin mimetic potential in an in vitro 
glucose uptake assay. In L6 myotubes, a cell line of skeletal muscle origin, glucose uptake in 
response to insulin stimulation plays a key role in the whole body glucose homeostasis. Glucose 
transporter (GLUT) 4 is the major glucose transporter of muscle exquisitely regulated by insulin 
through posttranslational events.
57 
The L6 myotubes differentiated from L6 myoblast have the 
ability to respond to insulin via insulin receptor signaling and translocation of Glut 4 to the 
plasma membrane. The hyperglycemic condition was created in cell culture by incubating the 
cells in 25 mM glucose. In the present experiment, 3 at 4µM had a glucose uptake comparable to 
2µM insulin, taken as the positive control (Figure 2.15). The other two complexes (1 and 2) 
have moderate insulin mimetic activity and VO(acac)2 showed negligible activity at the 
concentrations tested. In case of 3, the enhancement of the insulin mimetic activity, with respect 
to 1 and 2, might be related with their different structural characteristics, specifically, the lack of 
hydrogen bonding functionality in 3. As 3 showed glucose uptake stimulating activity in the 
myotubes comparable to that of insulin, it is likely that 3 mimics insulin action via insulin 
receptor signaling with translocation of Glut 4 to the plasma membrane. 
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Figure 2.15. Effect of [V
IV
(L
1-3
)2] (1-3) on glucose uptake in cultured L6 myotubes under high 
glucose conditions (25mM Glucose). Three concentrations 1µM, 2µM and 4µM were tested for 
each complex.The data is indicated as mean ± SEM (n=3). Student‘s t-Test was used where bars 
with asterisk show a significant difference (*P< .05) with respect to the untreated control 
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2.3.8. Inhibition of Cancer Cell Viability. In the present study antiproliferative efficacy of 1–3 
was assayed by determining the viability of HeLa cells using the MTT assay. The ligands, H2L
1–3 
and VO(acac)2 gave high IC50 values of > 200 μM, whereas 1–3 gave values in the range 41–22 
μM. In contrast, cisplatin, gefitinib, gemcitabine, 5-fluorouracil and vinorelbine, the most 
commonly used chemotherapeutic drugs, are comparably effective in HeLa cells with an IC50 
value of 13, 20, 35, 40 and 48 μM, respectively under similar experimental conditions.58 The 
significant decrease in the inhibitory concentration for the ligand compared to the metal complex 
clearly indicates that incorporation of vanadium in the ligand environment has a marked effect 
on cytotoxicity. A possible explanation is that by coordination the polarity of the ligand and the 
central metal ion are reduced through the charge equilibration, which favors permeation of the 
complexes through the lipid layer of the cell membrane.
59,60
 The present results are consistent 
with the observation that metal complexes can exhibit greater biological activities than the free 
ligand.
20a
 
Comparing the activity of three complexes, the cytotoxicity follows the order 2 > 3 > 1, which is 
reflected from their IC50 values with dose dependency illustrated in Figure 2.16. It is remarkable 
that 2, containing the ortho-hydroxy group, is most active suggesting that the electron 
withdrawing and releasing nature of the ortho-substituent may exert an influence over 
antiproliferative activity. Specifically, 2 was most cytotoxic, a result correlated with the presence 
of the electron withdrawing hydroxyl group. On the other hand, presence of an electron donating 
substituent (–NH2) in the ligand core of 1, diminishes cytotoxicity which is reflected in its IC50 
value. For complex 3 the value is in between because of not having an electron withdrawing nor 
releasing group in the ligand. Very recently the antiproliferative activity of some oxido 
vanadium(IV) compounds has been reported by Yamaguchi et al. using the similar technique 
against U937 cells, and the present results are in accordance with the reported values.
61 
 
2.3.9. Nuclear Staining Assay. To investigate the apoptotic potential of test compounds in HeLa 
cells, DAPI staining was performed. Chromatin condensation during the process of apoptosis 
(type I programmed cell death) is a characterizing marker of nuclear alteration. HeLa cells were 
treated with 35, 20, and 25 μM of 1, 2, and 3, respectively, that is at doses less than their 
respective IC50 values. The cells were incubated for 24 h before DAPI nuclear staining. Cells 
were examined under fluorescent microscope fitted with a DAPI filter. Control cells (treated with 
65 
 
90% DMF) hardly showed any sort of condensation in comparison to the treated cells, see 
Figure 2.17. All images taken in grayscale demonstrate the brightly condensed chromatin bodies 
and the nuclear blebbings as marked by arrows in Figure 2.17. Besides showing nuclear change, 
the treated cells exhibited a shrinking morphology, which is another important hallmark of 
apoptosis. 
 
 
Figure 2.16. Effect of [V
IV
(L
1-3
)2] (1-3) on cell viability and growth: Hela cells were treated with 
different concentrations of the test compound for 72h and then cell viability was measured by 
MTT assay. Data reported as the mean ± S.D. for n = 6 and compared against PBS control by 
using a Student‘s t-test. (*significant compared to PBS control). 
 
                                                                    
Compounds IC50 (µM) 
1 40.38 ± 1.27 
2 21.73 ± 2.89 
3 28.84 ± 1.34 
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Figure 2.17. Study of apoptosis by morphological changes in nuclei of HeLa cells: After 
treatment HeLa cells from control and treated group were fixed with 3.7% formaldehyde for 15 
min, permeabilized with 0.1% Triton X-100 and stained with 1µg/ml DAPI for 5 min at 37 °C. 
The cells were then washed with PBS and examined by fluorescence microscopy (Olympus IX 
71) (200×). Arrows showing the morphological changes in nuclei of HeLa cells observed on 
applying drug (1-3) in comparison to control. 
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2.4. CONCLUSION 
 
The following are the salient observations and findings of this work:  
(a) Three aroylhydrazone ligands, possessing a rigid bulky 2-hydroxy-1-acetonaphthone core and 
a selection of anthranil-, salicyl- and benzoyl- hydrazide arms have been synthesized and utilized 
in the synthesis of the corresponding vanadium complexes. As expected, monomeric, 
hexacoordinated and bis(tridentate)-vanadium(IV) [V
IV
(L)2] complexes were isolated: these do 
not contain an oxido-group. Stability of the complexes are related to the simultaneous oxido 
removal and complete charge neutralization as well as the formation of six strong covalent bonds 
at the V
4+
 center from the hard donor atoms N and O. (b) The importance of the structural and 
electronic effects arising from the incorporation of a bulky 2-hydroxy-1-acetonaphthone group in 
the ketone part of aroylhydrazones that can stabilize six-coordinate nonoxido vanadium(IV) 
complexes has been highlighted, which can be compared with our earlier work on oxido 
vanadium(V) with a ligand containing ONO donor atoms.
36a,b
 (c) Complexes 1–3 are highly 
stable both in the solid state and in solution being resistant to exposure to aerial oxygen for 3–4 
days and even purging oxygen into their solutions, a rather unusual phenomenon for ―bare‖ 
vanadium(IV) or nonoxido vanadium(IV) complexes. (d) EPR and magnetic susceptibility data 
provide reference values for typical V(IV) sites. Electrochemical results suggest that the 
electrochemical oxidations and reductions are not ligand-centered but metal-centered generating 
V
V
 and V
III 
species respectively. (e) All the complexes show in vitro insulin mimetic activity 
against insulin responsive L6 myoblast cells, with complex 3 being the most potent which is 
comparable to insulin at the complex concentration of 4 µM, while the others have moderate 
insulin mimetic activity. In addition, the in vitro antiproliferative activity of complexes 1–3 
against HeLa cell line was assayed. The cytotoxicity of the complexes is affected by the various 
functional groups attached to the benzoylhydrazone derivative and 2 showed considerable 
antiproliferative activity. It is worth noting that although the structure and chemistry of few 
nonoxido vanadium(IV) hydrazone complexes has been recently described,
29a,p
 the suitability of 
these and the related nonoxido vanadium(IV) complexes in the study of vanadium insulin 
mimesis and antiproliferative activity has not been previously described.  
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Chapter 3 
 
Oxido vanadium(V) complexes incorporating tridentate aroylhydrazoneoximes: Synthesis, 
characterizations and antibacterial activity  
ABSTRACT 
_____________________________________________________________________________ 
Some new oxido vanadium(V) complexes [VOL
1–3
(OEt)(EtOH)] (1–3) have been reported 
which are obtained from the reaction of the Schiff bases (H2L
1–3
) (Where H2L
1
= 
salicylhydrazone of diacetyl monoxime; H2L
2
= 4-methoxy salicylhydrazone of diacetyl 
monoxime and H2L
3 
= 4-hydroxy salicylhydrazone of diacetyl monoxime) with VO(acac)2 in 1:1 
molar ratio. Three 4-R-aroylhydrazoneoximes (V) have been used as ligands in the present study, 
differing in the inductive effect of the substituent R (R = H, OCH3 and OH), in order to observe 
their influence, if any, on the redox potentials and biological activity of the complexes. All the 
synthesized ligands and the metal complexes are successfully characterized by elemental 
analysis, IR, UV–Vis and NMR spectroscopy. X-ray diffraction study of [VOL1(OEt)(EtOH)], 1 
reveals that the metal centre is in distorted octahedral O5N coordination spheres where the ONO- 
donor ligand and the ethoxido group constitute a satisfactory O3N basal plane. Cyclic 
voltammetry of the complexes show a quasi-reversible cyclic voltammetric response in the 
potential range of 0.36–0.29V involving single electron V(V)–V(IV) reduction. The complexes 
have also been screened for their antibacterial activity against Escherichia coli, Bacillus, Proteus 
and Klebsiella. Minimum inhibitory concentration of these complexes and antibacterial activity 
indicates the compound 1 as the potential lead molecule for drug designing.  
______________________________________________________________________________ 
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3.1. INTRODUCTION 
 
The chemistry of vanadium has become a fascinating area of research in recent time because of 
the presence of vanadium in metalloenzymes and its medicinal as well as catalytic    
importance.
1–13
 The expanding knowledge of the role of vanadium in biological systems as a 
therapeutic agent, for example in antitumor and anticancer drugs
14,15
 has led to a continuously 
increasing interest in the coordination chemistry and solution chemistry of this element.  
 
Over the years, oximes have been widely used as very efficient complexing agents in analytical 
chemistry for isolation, separation and extraction of different metal ions.
16–26 
The metal 
complexes of oxime have also various interesting features
27,28
 which include short intramolecular 
hydrogen bonding and packing configurations, which give rise to unusual optical properties. 
From the medicinal chemistry, it is found that they served as models for biosystems such as 
vitamin B12
29
 and myocardial perfusion imaging agents.
30 
As a ligand, the oxime moiety is 
potentially ambidentate
16
 and can coordinate either through the nitrogen (I, Chart 3.1)
23–26
 or 
oxygen atom (II).
31
 The vast literature on structural studies of oxime complexes reveals some 
interesting features of its coordination behavior. It may coordinate to one metal ion through the 
nitrogen atom and another metal ion through the oxygen atom (III). Thus it can form a 1,2 (N,O) 
oximato-bridged extended network.
19-22
 In the majority of complexes only the nitrogen atom (I) 
coordinates to the metal center, and the oxygen atom does not take part in coordination. There 
are quite few examples where both the atoms (oximato nitrogen and oxygen, IV) do take part in 
coordination.
32,33
  
 
On the other hand, hydrazones –NH–N=CRR' (R and R = H, alkyl, aryl) are versatile ligands 
due to their applications in the field of analytical
34
 and medicinal chemistry.
35
 Hydrazone 
moieties are the most important pharmacophoric cores of several antiinflammatory, 
antinociceptive and antiplatelet drugs.
36
 It may be relevant to mention here that though the 
chemistry of aroylhydrazones complexes of many transition metals has been extensively 
studied,
37-40
 that of aroylhydrazoneoximes (V) appears to have remained practically 
unexplored.
41,42 
  
 
Keeping this observation in mind and in continuation of our studies on oxido vanadium 
complexes of hydrazone Schiff base ligands,
43–44
 the oxime functionality is incorporated into the 
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ligand moiety. In this chapter we report the syntheses, X-ray structure and physical properties of 
some oxido vanadium(V) complexes of aroylhydrazoneoximes with special reference to their 
antibacterial activity. It is worth mentioning here that, to the best of our knowledge, this report is 
a rare example
31
 of aroylhydrazoneoxime complexes where the oximato oxygen atom 
coordinates to the metal center, while the nitrogen atom does not take part in coordination. 
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Chart 3.1. Structures I-VI 
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3.2. EXPERIMENTAL SECTION 
 
3.2.1. General Methods and Materials. All chemicals were purchased from commercial 
sources and used without further purification. [VO(acac)2] was prepared as described in the 
literature.
45
 Reagent grade solvents were dried and distilled prior to use. All other chemicals 
were reagent grade, available commercially and used as received. Commercially available TBAP 
(tetra butyl ammonium perchlorate) was properly dried and used as a supporting electrolyte for 
recording cyclic voltammograms of the complexes. Elemental analyses were performed on a 
Vario ELcube CHNS Elemental analyzer. IR spectra were recorded on a Perkin-Elmer Spectrum 
RXI spectrometer. 
1
H NMR spectra were recorded with a Bruker Ultrashield 400 MHz 
spectrometer using SiMe4 as an internal standard. Electronic spectra were recorded on a 
Lamda25, PerkinElmer spectrophotometer. Magnetic susceptibility was measured with a 
Sherwood Scintific AUTOMSB sample magnetometer. Electrochemical data were collected 
using a PAR electrochemical analyzer and a PC-controlled Potentiostat/Galvanostat (PAR 273A) 
at 298 K in a dry nitrogen atmosphere. Cyclic voltammetry experiments were carried out with a 
glassy carbon working electrode, platinum counter electrode and Ag/AgCl as reference electrode 
and TBAP as supporting electrolyte. Antibacterial activity was measured with a PerkinElmer 
(2030 VICTOR X3) microtitre plate optical colorimeter (OD600). 
 
3.2.2. Synthesis of Ligands (H2L
1–3
). Schiff base ligands, H2L
1–3 
were prepared in 80-90% yield 
by the condensation of equimolar ratio of 4-substituted salicylhydrazine with diacetyl monoxime 
in methanol media by a standard procedure.
46
 The resulting white compound was filtered, 
washed thoroughly with ethanol and dried over fused CaCl2. 
 
3.2.3. Synthesis of Complexes [VO(L
1–3
)(OEt)(EtOH)] (1-3). To the stirring solution of ligand, 
H2L
1-3 
(1.0 mmol) in 20 mL of ethanol, VO(acac)2 (1.0 mmol) was added. The colour changed to 
brownish red. After 3 h of stirring, the solution was filtered. The filtrate was allowed to stand at 
room temperature for 4 days, during which crystals, suitable for X-ray analysis were isolated. 
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[VO(L
1
)(OEt)(EtOH)] (1). Yield: 58%. Anal. calc. for C15H22N3O6V: C, 46.03; H, 5.62; N, 
10.74. Found: C, 46.07; H, 5.65; N, 10.79. 
1
H NMR (DMSO-d6):  2.63 (s, 3H, CH3C=NN), 
2.52 (s, 3H, CH3C=NO), 7.86 – 6.93 (m, 4H, C6H4), 11.42 (s, 1H, OH). 
51
V NMR (DMSO-d6):  
–513. 
 
[VO(L
2
)(OEt)(EtOH)] (2). Yield: 54%. Anal. calc. for C16H24N3O7V: C, 45.60; H, 5.70; N, 
9.97. Found: C, 45.65; H, 5.73; N, 9.94. 
1
H NMR (DMSO-d6):  2.68 (s, 3H, CH3C=NN), 2.53 
(s, 3H, CH3C=NO), 3.71 (s, 3H, CH3O), 7.94 – 6.83 (m, 3H, C6H4), 11.46 (s, 1H, OH). 
51
V 
NMR (DMSO-d6):  –518.  
 
[VO(L
3
)(OEt)(EtOH)] (3). Yield: 61%.  Anal. calc. for C15H22N3O7V: C, 44.22; H, 5.40; N, 
10.31. Found: C, 44.27; H, 5.36; N, 10.27.
 1
H NMR (DMSO-d6):  2.61 (s, 3H, CH3C=NN), 2.48 
(s, 3H, CH3C=NO), 7.74 – 6.87 (m, 3H, C6H4), 9.76 (s, 1H, p-Ar–OH), 11.48 (s, 1H, o-Ar–OH). 
51
V NMR (DMSO-d6):  –529. 
 
3.2.4. X-ray Crystallography. A Suitable single crystal of 1 was chosen for X-ray diffraction 
studies. This compound crystallized in the monoclinic space group P 121/n1. The diffraction data 
for 1 were collected at 295 K with a Bruker AXS Smart CCD diffractometer using graphite 
monochromated Mo K radiation ( = 0.71073 Å). The following Bruker software packages 
were used: SMART for collecting frames of data, indexing and determination of lattice parameters, 
SAINT for integration of intensity of reflections and scaling, SADABS for absorption correction, and 
SHELXTL for space group and structure determination, and for refinement. The structures were 
solved by direct methods with SHELX-86 and refined by full-matrix least-squares analysis with 
SHELXL-97.
47
 All the hydrogen atoms were added in their calculated positions using riding models 
whereas non-hydrogen atoms were refined with anisotropic thermal parameters. Crystallographic 
data and details of refinement are given in Table 3.1. 
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Table 3.1. Crystallographic data and details of refinement of [VO(L1)(OEt)(EtOH)] (1). 
 
 
Empirical formula  C15H22N3O6V 
Formula weight  391.30 
Temperature  295(2) K 
Wavelength  1.54184 Å 
Crystal system  Monoclinic 
Space group  P 121/n1 
Unit cell dimensions a = 7.06518(10) Å = 90°. 
 b = 21.9429(3) Å = 96.5499(12)°. 
 c = 11.80060(13) Å  = 90°. 
Volume 1817.51(4) Å
3
 
Z 4 
Density (calculated) 1.430 mg/m3 
Absorption coefficient 4.887 mm
–1
 
F(000) 816 
Crystal size 0.54 x 0.24 x 0.17 mm3 
Theta range for data collection 5.52 – 77.38°. 
Index ranges –8 ≤ h ≤ 8, –27 ≤ k ≤ 26, –14 ≤ l ≤ 10 
Reflections collected 8227 
Independent reflections 3776 [Rint = 0.0201] 
Completeness to theta = 67.50° 99.6 %  
Absorption correction semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.19723 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 3776 / 10 / 250 
Goodness-of-fit on F2 1.042 
Final R indices [I>2sigma(I)] R1 = 0.0541, wR2 = 0.1500 
R indices (all data) R1 = 0.0604, wR2 = 0.1563 
Largest diff. peak and hole 0.535 and –0.399 e.Å
–3 
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3.2.5. Antibacterial activity. Antibacterial activity of the compounds (ligands and complexes) 
was studied against Escherichia coli (E. coli), Bacillus, Proteus and Klebsiella by determining 
minimum inhibitory concentration (MIC) following CLSI guidelines of broth micro-dilution 
method.
48
 Briefly, bacterial strains were cultured onto Luria Bertani Agar medium [containing 
0.5% peptone, 0.5% yeast extract, 1% NaCl, 1.5% Agar at pH 7.5±0.2]. The stock solution was 
prepared by dissolving the tested compounds in dimethyl sulfoxide (DMSO). Chloramphenicol, 
a common antibiotic was used as the positive control and DMSO was used as the negative 
control. Bacterial cultures were added to the sterilized Mueller Hinton Broth (MHB) [containing 
30% beef extract, 1.75% casein acid hydrolysate and 0.15% starch, pH 7.4±0.2]. MIC was 
determined by using 2 fold serial dilutions in the medium (MHB) containing 1.95-1000 µg/ml of 
the test compounds. To each well of 96 well microtitre plate, 150µl of medium (MHB) was taken 
in duplicate, to which 10µl of 0.5 McFarland standard (1.5x10
8
 CFU/ml) culture pathogens from 
MHB was added. The inoculated plates were incubated at 37
° 
C for 24h. After incubation, 
bacterial growth was monitored by measuring the turbidity of the culture by a microtitre plate 
optical colorimeter (OD600). The MIC was determined as the lowest concentration of compound 
at which the visible growth of the organisms was completely inhibited. 
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3.3. RESULT AND DISSCUSSION 
 
3.3.1. Synthesis. Three 4-R-aroylhydrazoneoximes (V) have been used in the present study, 
differing in the inductive effect of the substituent R (R = H, OCH3 and OH), in order to observe 
their influence, if any, on the redox potentials and biological activities of the complexes. The 
reactions of the selected aroylhydrazoneoximes (V) with VO(acac)2 proceeded in stirring ethanol 
and each of these reactions afforded reddish black colored products in decent yields. During this 
reaction, vanadium is oxidized from its initial +IV state to the +V state. These compounds are 
highly soluble in aprotic solvents, viz. CH3CN, DMF or DMSO. 
 
3.3.2. Spectral Characteristics. 
 
Spectral characteristics of 1–3 are listed in Table 3.2. 
 
3.3.2.1. IR Spectroscopy. The infrared spectra of the complexes display a broad band centred at 
around 3400 cm
–1
. This band is possibly due to the O–H stretch of the hydrazine fragment of the 
ligand. The C=O stretch (1654 cm
–1
) of the amide functionality
49
 in free ligand is found to be 
absent in the spectra of the complexes, which indicates that the Schiff base is completely 
deprotonated and acts as a dibasic enolate. The strong and sharp peak displayed by the 
complexes in the range 1592–1603 cm–1 is likely to be associated with the C=N–N=C 
moiety.
43,44,50
 The presence of a strong band in the range 976–985 cm–1 is assigned to V=O 
stretching.
43,44
 A representative spectrum of 1 is shown in Figure 3.1. 
 
3.3.2.2. UV Spectroscopy. The electronic spectra of the complexes were recorded using 
acetonitrile solutions. The main features of all the spectra are quite similar. A representative 
spectrum of 1 is shown in Figure 3.2. Three strong absorptions are observed in the wavelength 
range 403–207 nm. The lower energy absorption at around 390 nm is ascribable to the ligand-to-
metal charge transfer transitions where as the higher energy absorptions are likely to be due to 
ligand centred transitions.
43,44
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Table 3.2. Characteristics IR
[a]
 bands (cm
–1
) and electronic spectral
[b]
 data [nm (dm
3
 mol
-1 
cm
-1
)] for the [VO(L
1-3
)(OEt)(EtOH)] (1–3) 
______________________________________________________________________________ 
Complex                                  (OH)     (C=N)    (V=O)                   max () 
______________________________________________________________________________ 
[VO(L
1
)(OEt)(EtOH)] (1)       3434        1592         977       383 (4324); 263 (11190); 221 (14423) 
[VO(L
2
)(OEt)(EtOH)] (2)       3381        1603         985       395 (5212); 278 (13654); 216 (15709) 
[VO(L
3
)(OEt)(EtOH)] (3)       3402        1598         976       403 (4931); 265 (12654); 207 (17809)  
[a] 
In KBr pellet; 
[b] 
In CH3CN 
______________________________________________________________________________ 
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Figure 3.1. IR spectrum of [VO(L
1
)(OEt)(EtOH)] (1) 
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Figure 3.2. UV-Vis spectrum of [VO(L
1
)(OEt)(EtOH)] (1) 
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3.3.2.3. NMR Spectroscopy. The 
1
H NMR spectral data of the free ligands and its 
corresponding oxido vanadium(V) complexes (1–3) were recorded using DMSO-d6. The spectra 
of the free ligands exhibit two close but separate singlets in the range 11.74–11.53 ppm due to 
NH and OH (=N–OH) groups, which are absent in the spectra of complexes indicating 
coordination of these groups to the metal centre. However all the spectra display a singlet in the 
range 11.42–11.48 ppm, which corresponds to the OH (phenolic) group of the ligand fragment 
remained uncoordinated in the complexes. Signals for aromatic protons found as multiplets in the          
7.94–6.83 ppm range.46 The protons of the methyl group of the methoxy substituent in 
[VO(L
2
)(OEt)(EtOH)] (2) resonate as a singlet at 3.71 ppm and the protons of the hydroxyl 
substituent at 4- position in [VO(L
3
)(OEt)(EtOH)] (3) resonate as a singlet at 9.76 ppm.
51
 The 
two methyl groups of the diacetyl monoxime moiety appear as singlets in the range 2.48–2.68 
ppm. 
51
V NMR spectra of 1–3 display a singlet at –513, –518 and –529 ppm, respectively. These 
chemical shifts are usual for complexes containing the monooxido vanadium(V) units.
52 
 
3.3.3. Electrochemical properties. The electrochemical properties of all the oxido vanadium(V) 
complexes, 1–3 have been examined in CH3CN solution (0.1 M TBAP) by cyclic voltammetry. 
All the complexes show a quasi-reversible cyclic voltammetric response in the potential range of 
0.36–0.29 V involving single electron V(V)–V(IV) reduction.44 The one-electron nature of this 
reduction has been tentatively established by comparing its current height with that of standard 
ferrocene/ferrocenium couple under the same experimental condition. The potential data of 1–3 
are listed in Table 3.3, and a selected voltammogram is shown in Figure 3.3. The potential of 
V(V)–V(IV) reduction in the 4-R-aroylhydrazoneoxime complexes (VI) has been found to be 
sensitive to the nature of the substituent R in the aroylhydrazone fragment. The potential 
decreases with increasing electron-releasing character of the substituent R as expected.
53,54
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Table 3.3. Cyclic voltammetric results
a
 for [VO(L
1-3
)(OEt)(EtOH)] (1–3) at 298 K 
__________________________________________________________________________ 
Complex                                              E1/2 (V)                  ΔEP (mV) 
__________________________________________________________________________ 
[VO(L
1
)(OEt)(EtOH)] (1)                   0.36                     91 
[VO(L
2
)(OEt)(EtOH)] (2)                     0.31                                            86                                                    
[VO(L
3
)(OEt)(EtOH)] (3)                     0.29                                            79 
_________________________________________________________________________ 
 
a
 In acetonitrile at a scan rate of 50 mVs
-1
. E1/2 = (Epa + Epc)/2, where Epa and Epc are anodic and 
cathodic peak potentials vs. Ag/AgCl, respectively.  ΔEP = Epa – Epc. 
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Figure 3.3. Cyclic voltammogram of [VO(L
1
)(OEt)(EtOH)] (1), in CH3CN (0.1 M TBAP); scan 
rate 50 mV/s, and potentials recorded vs. Ag/AgCl. 
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3.3.4. Description of Crystal Structure of [VO(L
1
)(OEt)(EtOH)] (1). Alhough the preliminary 
characterization data (microanalytical and spectroscopic) of 1 gave some idea of their 
composition and about the donor points through which the ligands were attached to the oxido 
vanadium(V) center, they could not definitely reveal the actual structures, which could only be 
provided by a structure determination using the single-crystal X-ray diffraction technique. To 
determine the coordination mode of the aroylhydrazoneoxime ligands in these complexes (1–3), 
the structure of a representative member of this family, viz. [VO(L
1
)(OEt)(EtOH)], (1) was 
determined. The molecular structure of 1 is shown in Figure 3.4 and some relevant bond 
parameters are listed in Table 3.4. In the structure the metal centre is in distorted octahedral O5N 
coordination spheres. The O,N,O donor ligand and the ethoxido group constitute a satisfactory 
O3N basal plane and the oxido group occupies the apical position. Essentially the same 
arrangement around vanadium has been seen in related systems.
31,44,54 
The displacement of the 
metal centre from the basal plane toward the apical oxido group is 0.2570 (5) Å though the  
displacement is noticeably small. This small displacement is possibly due to the coordination of 
the ethanol molecule.
54
 The short V–O(4) distance of 1.580(3) Å indicates the presence of a 
vanadium–oxygen double-bond (V=O), which is commonly found in five- and six-coordinated 
octahedral complexes
 
of vanadium(IV) and vanadium(V).
43,44,54–57
 The five V–O bond lengths 
are unequal; the V=O bond being the shortest and the V–O [ethanolic oxygen O(6A)] being the 
longest due to the trans influence of the oxido atom. The V–O bond lengths follow the order V–
O (oxido) < V–O (ethoxide) < V–O (oxime) < V–O (enolate) < V–O (ethanolic). This data 
indicate stronger binding of the alkoxido group compared to those of other bonded oxygen 
atoms. The V–O bond distance (av. 1.908 A˚) is similar to those reported for   V–O bonds in 
somewhat related systems.
54
 The cis bond angles are in the range 74.44(8)–103.71(11)o while the 
trans O=V–O (ethanol) bond angle 175.46(11)o is almost linear as compared to the other two 
trans angles (149.44 (9)
o
 and 160.40 (10)
o
) (Table 3.4). The orientation of the ethoxido ethyl in 
complex 1 is toward the oxido group side perhaps due to steric constrains imposed by the metal 
coordinated ethanol (Figure 3.4).  
The one-dimensional self-assembling of the molecule [VO(L
1
)(OEt)(EtOH)] is shown in    
Figure 3.5. The molecule is found to show both inter and intra molecular hydrogen bonding. 
Two [VO(L
1
)(OEt)(EtOH)] molecules form a dimeric unit via a pair of reciprocal hydrogen 
bonds between the phenolic oxygen of one molecule with the ethanolic proton of other moiety 
91 
 
forming intermolecular hydrogen bonding. Another hydrogen bonding between N(1) and 
phenolic hydrogen, H(1), is also observed constituting an intramolecular hydrogen bond. The H-
bond parameters are listed in Table 3.5. 
Structural characterization of complexes 2 & 3 by X-ray crystallography has not been possible, 
as their single crystals could not be grown. As all three complexes have been synthesized 
similarly and display similar properties, the other two [VO(L
2–3
)(OEt)(EtOH)] (2–3) complexes 
are assumed to have the same structure as [VO(L
1
)(OEt)(EtOH)] (1). The results of the 1H NMR 
in DMSO-d6 and IR in CH2Cl2 solution indicate that the structures of complexes 1–3 in solution 
remain the same as those in the solid state. 
 
 
Table 3.4. Selected bond distances (Å) and angles (º) for [VO(L
1
)(OEt)(EtOH)] (1). The 
estimated standard deviations are shown in parentheses. 
 
V-O(4)                                  1.580(3)                            V-O(2)                                1.984(2) 
V-O(5A)                               1.774(2)                            V-N(2)                                2.116(2) 
V-O(3)                                  1.839(2)                            V-O(6A)                             2.366(2) 
 
O(3)-V-N(2)                         81.08(8)                            N(2)-V-O(6A)                     81.43(9) 
O(3)-V-O(2)                         149.44(9)                          O(2)-V-O(5A)                     94.02(10)  
O(3)-V-O(5A)                      103.71(11)                        O(2)-V-O(4)                        99.68(12) 
O(3)-V-O(4)                         100.03(13)                        O(2)-V-O(6A)                     79.30(10)    
O(3)-V-O(6A)                      79.20(11)                          O(5A)-V-O(3)                     103.71(11) 
N(2)-V-O(2)                          4.44(8)                   O(5A)-V-O(6A)                   80.86(11) 
N(2)-V-O(5A                       160.40(10)                   O(4)-V-O(6A)                     175.46(11) 
N(2)-V-O(4)                         94.04(10)                   O(4)-V-O(5A)                     103.64(12) 
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Table 3.5. Hydrogen bond distances (Å) and angles (
o
) for [VO(L
1
)(OEt)(EtOH)] (1) 
____________________________________________________________________________  
D-H...A d(D-H)             d(H...A)                   d(D...A)                    <(DHA) 
____________________________________________________________________________  
 O(1)-H(1)...N(1) 0.82           1.84                         2.562(3)                     146.3 
 O(6A)-H(6A)...O(1)#1 0.82           2.35                         2.847(3)                     119.8 
____________________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. ORTEP diagram of [VO(L
1
)(OEt)(EtOH)], 1 with atom labeling scheme. 
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Figure 3.5. Hydrogen bonding diagram of [VO(L
1
)(OEt)(EtOH)], 1 with atom labeling scheme. 
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3.3.5. Antimicrobial activity. In the present study, the synthesized compounds (1–3) showed 
potential antibacterial activity against all the pathogens tested (Escherichia coli, Bacillus, 
Proteus and Klebsiella) and in some cases they showed more promising results by giving the 
MIC value lesser than the standard drug examined. The biological data (Table 3.6) of MIC of the 
free ligands showed poor activity (MIC = ~ 15.62–500 µg/mL) which is in agreement with the 
previous results (62.5–250 µg/mL) as reported by Sharma et al.58 following broth micro-dilution 
method. However, the corresponding oxido vandium(V) complexes (1–3) showed much better 
result with respect to the individual ligands. A possible explanation is that by coordination, the 
polarity of the ligand and the central metal ion are reduced through the charge equilibration, 
which favors permeation of the complexes through the lipid layer of the bacterial cell 
membrane.
59,60  
The complex 1 showed the most promising result as compared to the other 
compounds (2 and 3) of this study and similar compounds against same and other pathogens 
reported by Sharma et al.
58
 Antibacterial activity of the similar type compounds has also been 
reported by Chohan et al.
61
 and Tahira et al.
62
 using agar well diffusion technique against E. coli, 
Shigella, Pseudomonas, Salmonella, Staphylococcus and Bacillus and the present results are in 
accordance with the reported values. However, the difference in value may be attributed to the 
nature of compounds synthesized with different ligands.  
Vanadium is a trace element which is essential for higher organisms for their survival where as 
vanadium(V) complexes are known as potential inhibitors of various enzymes.
63 
There are 
reports of vanadium complexes showing antibacterial, antifungal and anti cancerous properties.
58, 
61–63
 Hence, the currently synthesized compounds have the potential to be used as an 
antimicrobial as well as antidiabetic drug. There are also certain draw backs of using vanadium 
complexes as a therapeutic agent as its toxicity varies with the route of administration and 
duration; however, there is no report available about its chronic toxicity.
64
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Table 3.6. Antibacterial activity of all the ligands, H2L
1–3
 and oxido vanadium (V) complexes, 
[VO(L
1–3
)(OEt)(EtOH)] (1–3) in vitro MIC in µg mL–1 
_____________________________________________________________________________________ 
                    E.coli                   Bacillus                  Proteus     Klebsiella 
____________________________________________________________________________________ 
H2L
1    
                 15.62                  31.25                       -  - 
H2L
2    
                 125                       -                           125 500 
H2L
3    
                 125                       -  -                                 125  
[VO(L
1
)(OEt)(EtOH)] (1)              7.81                    15.62                      15.62                           7.81 
[VO(L
2
)(OEt)(EtOH)] (2)              62.50                  62.50                      31.25                           125 
[VO(L
3
)(OEt)(EtOH)] (3)              62.50                  31.25                      125                              62.50 
Chloramphenicol                             2.00                   2.00                        6.00                            16.00 
_____________________________________________________________________________________ 
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3.4. CONCLUSION 
 
The present study shows that the 4-R-aroylhydrazoneoximes ligands (H2L
1–3
, V) can bind 
smoothly to vanadium upon reaction with [VO(acac)2], affording complexes of the type 
[VO(L)(OEt)(EtOH)], where the oxime oxygen atom coordinates to the metal center, and the 
nitrogen atom does not take part in coordination (VI). All the complexes have been characterized 
with the help of various spectroscopic techniques and electrochemical measurements. X-ray 
diffraction measurements of 1, [VO(L
1
)(OEt)(EtOH)] have been carried out. The complexes    
(1–3) have also been screened for their antibacterial activity against E. coli, Bacillus, Proteus 
and Klebsiella. Minimum inhibitory concentration of these complexes and antibacterial activity 
indicates the compound 1 as the potential lead molecule for drug designing. 
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Chapter 4 
 
Study of bio- and catalytic potential of oxidoethoxido vanadium(V) complexes with 
aroylhydrazones of naphthol-derivative: Special focus on their solution behavior 
 
ABSTRACT 
_____________________________________________________________________________ 
Four oxidoalkoxido vanadium(V) [V
V
O(L
1–4
)OEt] (1–4) and one dinuclear oxidoalkoxido 
mixed-ligand vanadium(V) [{VO(L
2
)OEt}2(Q)]{Q = 4,4′-bipyridine}(5), complexes, taking 
potentially tridentate binegative aroylhydrazone ligands are reported [where H2L
1 
= 
anthranylhydrazone of 2-hydroxy-1-napthaldehyde, H2L
2 
= salicylhydrazone of 2-hydroxy-1-
napthaldehyde, H2L
3 
= benzoylhydrazone of 2-hydroxy-1-acetonaphthone, H2L
4 
= 
anthranylhydrazone of 2-hydroxy-1-acetonaphthone]. All the complexes were characterized by 
elemental analysis as well as various spectroscopic techniques. Single crystal X-ray diffraction 
crystallography of 1–4, reveals the metal centre is in distorted square pyramidal geometry with 
O4N coordination spheres, whereas 5 exhibits a distorted octahedral geometry around the metal 
center. The solution behavior of the oxidoethoxido vanadium(V) species, 1–4 was studied, which 
indicates the existence of two species (1:1 ratio) in solution. Catalytic potential of 1–5, was 
tested for the oxidative bromination of styrene, salicylaldehyde and oxidation of methyl phenyl 
sulphide. In addition, all the complexes (1–5) showed good DNA binding and photonuclease 
propensity. Among these, 3 and 4 shows higher binding affinity towards CT-DNA than others.  
______________________________________________________________________________ 
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4.1. INTRODUCTION 
The chemistry of vanadium is currently a subject of extensive research, because of its 
increasingly recognized biochemical importance.
1
 Since the discovery by Henze in 1911 of high 
concentrations of vanadium in the blood of ascidians,
2
 it has been identified as an essential 
element for some important vanadium-containing enzymes, nitrogenase,
3
 haloperoxidase,
4
 nitrate 
reductases,
5
 and Amavadin,
6
 a compound isolated from the mushroom Amanita muscaria, that 
has been shown to contain an octacoordinated V
4+
 ion.
7
 A vanadium protein has also been 
proposed to catalyze the oxidation of NADH.
8
 Moreover, several vanadium compounds have 
been shown to be active as insulin mimetics in vitro and in vivo,
9
 including clinical tests, 
demonstrating the usability of simple inorganic (vanadyl sulfate, vanadate)
10
 and coordination 
compounds [VO(maltolato)2]
11
 for the treatment of diabetes mellitus in humans. The distinct 
preference of this metal center for O- and/or N-coordination environments, as delineated by 
EXAFS
12
 and crystallographic studies
13
 on haloperoxidase, has prompted the synthesis of 
numerous model vanadium compounds containing O- and N- donor ligands, whose solid state 
structure, spectroscopic, magnetic, and redox properties have been widely investigated. In 
contrast, study of solution properties of these, especially the oxidovanadium(V) complexes have 
so far received only limited attention
14
 despite the reported involvement of such species to 
provide the alternative route for the generation of monooxidobridged binuclear vanadium(V,V) 
species of the type (VOL)2O. It may also be noted that such binuclear complexes hold the 
possibility of acting as precursors of mixed-valence V(IV,V) species, which are of current 
interest.
14b
 
Over the past few years, we have been studying the chemistry of oxido-metal complexes 
including those of vanadium, in N,O-donor environments
14b,15a-c 
with electro-generation of 
mixed-valence divanadium(IV,V) complexes,
14b,15a 
and the anti-proliferative, DNA binding,  
photo-induced DNA cleavage and insulin mimetic activity of variable valence oxido and 
nonoxido vanadium complexes.
15d,e
 
In previous work
14b
 our group has described the solution behavior of a mononuclear 
oxidoalkoxido vanadium(V) complex in chloroform, a non coordinating solvent, where the 
transformation of a structurally characterized [VO(L)OEt] (H2L = 2-
hydroxybenzaldehydehydrazone of 2-hydroxybenzoylhydrazine) complex to the corresponding 
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monooxidobridged divanadium(V,V) complex (VOL)2O, and electrogeneration of mixed-
valence divanadium(IV,V) species was reported. 
In this chapter we now report the synthesis, characterization and biological and catalytic 
evaluation of five new oxidoethoxido vanadium(V) complex (1−5) with special emphasis on the 
solution behavior of monomeric oxidoethoxido vanadium(V) compounds, namely,             
[VOL
1–4
(OEt)] (1−4) in presence of a coordinating solvent, DMSO. Here, NMR (1H, 13C and 
51
V), solution IR, and ESI-MS solution studies of 1−4, were reported to obtain a detailed 
understanding of the species existing in solution state, their structure, oxidation states, and their 
redox properties. Solution studies indicate that two species simultaneously exists in solution. All 
the complexes (1−5), were isolated in the solid state and are found to show good catalytic 
potential for the oxidative bromination of styrene, salicylaldehyde and oxidation of methyl 
phenyl sulphide. They also show interesting DNA binding and photoinduced DNA cleavage 
activities.  
 
4.2. EXPERIMENTAL SECTION 
4.2.1. General Methods and Materials. All chemicals were purchased from commercial 
sources and used without further purification. [VO(acac)2] was prepared as described in the 
literature.
16
 Reagent grade solvents were dried and distilled prior to use. 
 
Elemental analyses 
were performed on a Vario ELcube CHNS Elemental analyzer. IR spectra were recorded on a 
Perkin-Elmer Spectrum RXI spectrophotometer. 
1
H and
 13
C NMR spectra were recorded on a 
Bruker Ultrashield 400 MHz spectrometer using SiMe4 as an internal standard. Electronic 
spectra were recorded on a Lamda25, PerkinElmer spectrophotometer. Mass spectra were 
obtained on a SQ-300 MS instrument operating in ESI mode. The supercoiled (SC) pUC19 DNA 
was purified from E. coli cells with the aid of Gene JET Plasmid Isolation Kit (Thermo 
Scientific, USA). Calf thymus (CT) DNA was purchased from SRL (India) (biochemistry grade). 
Agarose (molecular biology grade) was purchased from Sigma Aldrich (USA). A Shimadzu 
2010 plus gas-chromatograph fitted with an Rtx-1 capillary column (30 m × 0.25 mm × 0.25 μm) 
and a FID detector was used to analyze the reaction products and their quantifications were made 
on the basis of the relative peak area of the respective product. The identity of the products was 
confirmed using a GC-MS model Perkin-Elmer, Clarus 500 and comparing the fragments of each 
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product with the library available. The percent conversion of substrate and selectivity of products 
was calculated from GC data using the formulae:  
          
% Conversion of substrate
Peak area of a substrate
Total area of substrate + products
X 100100=
% Selectivity of a product =
Peak area of a product
Total area of products
X 100
 
4.2.2. Synthesis of Ligands (H2L
1–4
). Schiff base ligands, anthranylhydrazone of 2-hydroxy-1-
napthaldehyde (H2L
1
), salicylhydrazone of 2-hydroxy-1-napthaldehyde (H2L
2
), 
benzoylhydrazone of 2-hydroxy-1-acetonaphthone (H2L
3
), and anthranylhydrazone of 2-
hydroxy-1-acetonaphthone (H2L
4
) were prepared by the condensation of 2-hydroxy-1-
napthaldehyde / 2-hydroxy-1-acetonapthone and the respective acidhydrazide in equimolar ratio 
in ethanol by a standard procedure.
15d  
The resulting white compounds were filtered, washed with 
ethanol and dried over fused CaCl2. Elemental analysis results, NMR (
1
H and 
13
C) and IR data 
for all of these verified their preparation. 
H2L
1
. Yield: 62%. Anal. Calcd. for C18H15N3O2: C, 70.81; H, 4.95; N, 13.77. Found: C, 70.77; 
H, 4.98; N, 13.75. IR (KBr pellet, cm
–1
): 3472 ν(O–H); 3367 ν(NH2)s; 3201 ν(NH2)as; 3037 ν(N–
H); 1637 ν(C=O); 1591 ν(C=N). 1H NMR (400 MHz, DMSO-d6):  12.97 (s, 1H, naphthyl-OH), 
12.04 (s, 1H, NH), 9.47 (s, 1H, HC═N), 8.18–6.64 (m, 10H, Aromatic), 6.61 (s, 2H, NH2) ppm. 
13
C NMR (100 MHz, DMSO-d6):  165.12, 158.33, 150.93, 146.33, 133.18, 132.91, 132.07, 
129.45, 128.57, 128.25, 128.16, 123.96, 120.88, 119.42, 117.12, 115.14, 112.62, 109.06. 
  
H2L
2
. Yield: 72%. Anal. Calcd. for C18H14N2O3: C, 70.58; H, 4.61; N, 9.15. Found: C, 70.59; H, 
4.58; N, 9.12. IR (KBr pellet, cm
–1
): 3466 ν(O–H); 3022 ν(N–H); 1621 ν(C=O); 1578 ν(C=N). 
1
H NMR (400 MHz, DMSO-d6):  12.74 (s, 1H, naphthyl-OH), 12.07 (s, 1H, NH), 11.87 (s, 1H, 
OH), 9.54 (s, 1H, HC═N), 8.33–6.62 (m, 10H, Aromatic). 13C NMR (100 MHz, DMSO-d6):  
163.72, 158.51, 157.89, 147.44, 133.78, 132.68, 131.44, 128.69, 128.55, 127.57, 127.50, 123.33, 
120.73, 118.92, 118.65, 117.05, 115.48, 108.36.  
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H2L
3
. Yield: 58%. Anal. Calcd. for C19H16N2O2: C, 74.98; H, 5.29; N, 9.20. Found: C, 74.96; H, 
5.32; N, 9.21. IR (KBr pellet, cm
–1
): 3337 ν(O–H); 3071 ν(N–H); 1659 ν(C=O); 1573 ν(C=N). 
1
H NMR (400 MHz, DMSO-d6): δ 10.31 (s, 1H, naphthyl–OH), 9.55 (s, 1H, NH), 7.91–7.27 (m, 
11H, Aromatic), 2.34 (s, 3H, CH3).
13
C NMR (100 MHz, DMSO-d6): δ 153.71, 152.63, 134.24, 
131.82, 131.51, 130.21, 129.06, 128.76, 128.36, 128.23, 127.86, 127.43, 126.99, 123.67, 123.19, 
118.99, 118.71, 113.74, 24.30. 
H2L
4
. Yield: 64%. Anal. Calcd. for C19H17N3O2: C, 71.46; H, 5.36; N, 13.16. Found: C, 71.48; 
H, 5.37; N, 13.14. IR (KBr pellet, cm
–1
): 3473 ν(O–H); 3410 ν(NH2)s; 3329 ν(NH2)as; 3221 ν(N–
H); 1663 ν(C=O); 1553 ν(C=N). 1H NMR (400 MHz, DMSO-d6): δ 10.35 (s, 1H, naphthyl–OH), 
9.17 (s, 1H, NH), 7.91–6.23 (m, 10H, Aromatic), 6.05 (s, 2H, NH2), 2.35 (s, 3H, CH3). 
13
C NMR 
(100 MHz, DMSO-d6): δ 153.98, 152.47, 152.36, 149.84, 132.47, 131.56, 130.22, 129.09, 
128.34, 127.98, 127.67, 123.78, 123.14, 118.94, 117.04, 115.46, 114.69, 113.59, 24.15. 
4.2.3. Synthesis of Complexes [VO(L
1–4
)OEt] (1–4). A general synthetic procedure taking 
[NH4VO3] as metal precursor is described below: 
[NH4VO3] (1 mmol) was added to a hot solution of appropriate ligand H2L
1–4 
(1 mmol) in EtOH 
(20 mL), the color changed instantly to brownish. After 3 h of refluxing, reaction mixture was 
filtered off, and kept for crystallisation. After 3 to 4 days, crystals of diffraction quality were 
obtained which were used for X-ray structure determination using single crystal X-ray 
diffractometer. 
[VO(L
1
)OEt] (1). Yield: 61%. Anal. Calcd. for C20H18N3O4V: C, 57.84; H, 4.37; N, 10.12. 
Found: C, 57.83; H, 4.39; N, 10.08. IR (KBr pellet, cm
–1
): 3461 ν(NH2)s; 3322 ν(NH2)as; 1595 
ν(C=N); 1255 ν(C–O)enolic; 991 ν(V=O). UV–Vis (CHCl3) [λmax, nm (ε, M
–1
 cm
–1
)]: 434 (15257); 
336 (19651); 286 (26852); 248 (30614). 
[VO(L
2
)OEt] (2). Yield: 65%. Anal. Calcd. for C20H17N2O5V: C, 57.70; H, 4.12; N, 6.73. 
Found: C, 57.72; H, 4.08; N, 6.77. IR (KBr pellet, cm
–1
): 3442 (O–H); 1597 ν(C=N); 1254 ν(C–
O)enolic; 996 ν(V=O). UV–Vis (CHCl3) [λmax, nm (ε, M
–1
 cm
–1
)]: 425 (12649); 339 (20637); 273 
(27392); 245 (27822). 
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[VO(L
3
)OEt] (3). Yield: 66%. Anal. Calcd. for C21H19N2O4V: C, 60.88; H, 4.62; N, 6.76. 
Found: C, 60.86; H, 4.58; N, 6.77. IR (KBr pellet, cm
–1
): 1595 ν(C=N); 1239 ν(C–O)enolic; 999 
ν(V=O). UV–Vis (CHCl3) [λmax, nm (ε, M
–1
 cm
–1
)]: 430 (7003); 343 (14511); 286 (21713); 242 
(25207). 
[VO(L
4
)OEt] (4). Yield: 64%. Anal. Calcd. for C21H20N3O4V: C, 58.75; H, 4.70; N, 9.79. 
Found: C, 58.74; H, 4.73; N, 9.78. IR (KBr pellet, cm
–1
): 1567 ν(C=N); 1238 ν(C–O)enolic; 996 
ν(V=O). UV–Vis (CHCl3) [λmax, nm (ε, M
–1
 cm
–1
)]: 419 (14445); 305 (18634); 277 (24006); 253 
(30231). 
4.2.4. Synthesis of mixed-ligand complex [{VO(L
2
)OEt}2(-4,4' bipy)] (5). To the refluxing 
solution of ligand, H2L
2 
(1 mmol) in 20 mL ethanol, 4,4' bipyridine (0.5 mmol) was added. After 
10 mins, NH4VO3 (1 mmol) was added to the reaction mixture. The colour changed to brown. 
After 3 h, the solution was filtered off, and kept for crystallisation. Slow evaporation of the 
filtrate over 5-6 days, produced crystals of diffraction quality, which were used for X-ray 
structure determination using single crystal X-ray diffractometer. 
[{VO(L
2
)OEt}2(-4,4' bipy)] (5). Yield: 41%. Anal. Calcd. for C50H42N6O10V2: C, 60.73; H, 
4.28; N, 8.49. Found: C, 60.70; H, 4.24; N, 8.52. IR (KBr pellet, cm
-1
): 1599 ν(C=N), 1252 ν(C-
Oenolic), 1049 ν(N-N), 959 ν(V=O). UV–vis (CHCl3) [λ max, nm (ε, M
–1
 cm
–1
)]: 456 (7831); 346 
(14651); 281 (12719); 259 (18603).
 1
H NMR (400 MHz, DMSO-d6): δ 11.59 (s, 1H, OH), 9.89 
(s, 1H, CH), 8.70–6.94. (m, 14H, Aromatic), 5.76 (m, 2H, CH2 (OEt)), 1.62 (t, 3H, CH3 (OEt)). 
13
C NMR (100 MHz, DMSO-d6): δ 170.10, 164.33, 159.01, 150.56, 149.27, 145.10, 135.51, 
133.50, 132.98, 129.41, 129.17, 128.61, 128.45, 124.32, 122.05, 121.74, 119.61, 119.25, 117.10, 
114.69, 111.43, 83.15, 18.60.
 51
V NMR (DMSO-d6):  –553.  
4.2.5. Solution state Characterization of [VO(L
1–4
)OEt] (1–4). 
[VO(L
1
)OEt] (1). IR (CHCl3, cm
–1
): 1002, 977 ν(V=O), 821 ν(V–O–V). 1H NMR (400 MHz, 
DMSO-d6):  9.99 (s, 1H, HC═N), 9.94 (s, 1H, HC═N), 8.59–6.43 (m, 20H, Aromatic), 5.65 (m, 
2H, CH2 (OEt)), 4.32 (s, 2H, NH2), 3.46 (q, 4H, CH2 (EtOH)), 1.59 (t, 3H, CH3 (OEt)), 1.07 (t, 
6H, CH3 (EtOH)). 
13
C NMR (100 MHz, DMSO-d6): δ 171.22, 170.93, 164.64, 164.46, 164.18, 
149.78, 149.65, 148.26, 148.11, 135.71, 135.52, 135.15, 132.91, 132.78, 132. 65, 132.41, 130.97, 
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130.57, 129.44, 129.34, 128.82, 128.54, 128.48, 124.71, 124.35, 122.45, 122.11, 119.90, 119.03, 
116.39, 115.17, 111.82, 111.67, 111.05, 110.36, 81.80, 56.52, 19.03, 18.84.
 51
V NMR (DMSO-
d6):   –548, –576. 
1
H NMR (400 MHz, DMSO-d6 + EtOH):  9.80 (s, 1H, HC═N), 8.49–6.57 
(m, 10H, Aromatic), 5.64 (m, 2H, CH2 (OEt)), 4.33 (s, 20H, NH2), 3.47 (q, 46H, CH2 (EtOH)), 
1.59 (t, 3H, CH3 (OEt)), 1.07 (t, 67H, CH3 (EtOH)).
 13
C NMR (100 MHz, DMSO-d6 + EtOH): δ 
171.06, 164.22, 149.65, 148.15, 135.04, 132.88, 132.27, 130.54, 129.23, 128.54, 128.39, 124.24, 
121.94, 119.79, 116.31, 115.08, 111.65, 111.07, 81.70, 56.54, 18.75, 18.64.
 51
V NMR (DMSO-d6 
+ EtOH):  –551. ESI-MS (DMSO) : m/z 386.16 (100%, [M – CH2CH3]
+
); m/z 756.13 (14%, 
[V2O3(L
1
)2]
+
). 
[VO(L
2
)OEt] (2). IR (CHCl3, cm
–1
): 1006, 980 ν(V=O), 823 ν(V–O–V). 1H NMR (400 MHz, 
DMSO-d6)  11.60 (s, 1H, OH), 11.42 (s, 1H, OH), 10.09 (s, 1H, HC═N), 9.95 (s, 1H, HC═N), 
8.65–6.83 (m, 20H, Aromatic), 5.76 (m, 2H, CH2 (OEt)), 3.44 (q, 4H, CH2 (EtOH)), 1.61 (t, 3H, 
CH3 (OEt)), 1.05 (t, 6H, CH3 (EtOH)). 
13
C NMR (100 MHz, DMSO-d6): δ 169.95, 164.66, 
164.29, 158.96, 158.90, 149.52, 136.06, 135.73, 133.98, 133.80, 133.01, 129.72, 129.51, 129.45, 
129.34, 128.90, 128.62, 124. 85, 124.53, 122.64, 122.29, 119.76, 119.57, 118.90, 117.31, 114.69, 
114.30, 111.62, 111.46, 83.32, 56.50, 19.02, 18.81. 
51
V NMR (DMSO-d6):  –553, –591. 
1
H 
NMR (400 MHz, DMSO-d6 + EtOH,)  11.61 (s, 1H, OH), 9.94 (s, 1H, HC═N), 8.56–6.97 (m, 
10H, Aromatic), 5.76 (m, 2H, CH2 (OEt)), 3.45 (q, 46H, CH2 (EtOH)), 1.62 (t, 3H, CH3 (OEt)), 
1.06 (t, 68H, CH3 (EtOH)).
 13
C NMR (100 MHz, DMSO-d6 + EtOH): δ 170.25, 164.36, 159.04, 
149.04, 135.35, 133.31, 132.92, 129.35, 129.05, 128.61, 128.34, 124.18, 121.80, 119.49, 119.05, 
116.95, 114.67, 111.41, 83.14, 56.57, 18.25. 
51
V NMR (DMSO-d6 + EtOH):  –553. ESI-MS 
(DMSO): m/z 387.06 (100%, [M – CH2CH3]
+
); m/z 758.05 (30%, [V2O3(L
2
)2]
+
). 
[VO(L
3
)OEt] (3). IR (CHCl3, cm
–1
): 1004, 966 ν(V=O), 820 ν(V–O–V). 1H NMR (400 MHz, 
DMSO-d6)  7.98–7.20 (m, 22H, Aromatic), 5.48 (m, 2H, CH2 (OEt)), 3.45 (q, 4H, CH2 (EtOH)), 
2.92 (s, 3H, CH3), 2.84 (s, 3H, CH3), 1.50 (t, 3H, CH3 (OEt)), 1.06 (t, 6H, CH3 (EtOH)).
 13
C 
NMR (100 MHz, DMSO-d6): δ 170.91, 170.36, 166.64, 166.47, 166.16, 160.17, 134.85, 134.75, 
133.89, 132.13, 132.01, 131.82, 131.77, 130.94, 130.66, 130.01, 129.95, 129.56, 129.35, 128.97, 
128.70, 128.61, 128.53, 128.00, 127.58, 126.54, 126.17, 124.99, 124.88, 124.34, 119.50, 118.75, 
118.46, 118.17, 118.03, 117.86, 80.23, 56.51, 24.09, 23.84, 19.01, 18.67. 
51
V NMR (DMSO-d6): 
 –518, –534. 1H NMR (400 MHz, DMSO-d6 + EtOH)  8.09–7.20 (m, 11H, Aromatic), 5.48 (m, 
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2H, CH2 (OEt)), 3.46 (q, 56H, CH2 (EtOH), 2.92 (s, 3H, CH3), 1.51 (t, 3H, CH3 (OEt)), 1.06 (t, 
83H, CH3 (EtOH)).
 13
C NMR (100 MHz, DMSO-d6 + EtOH): δ 170.87, 166.13, 159.73, 133.80, 
131.99, 131.75, 131.69, 129.58, 129.26, 128.86, 128.49, 127.47, 126.10, 124.25, 119.41, 118.16, 
80.20, 56.53, 23.68, 18.77, 18.50. 
51
V NMR (DMSO-d6 + EtOH):  –518. ESI-MS (DMSO): m/z 
385.10 (64%, [M – CH2CH3]
+
); m/z 754.19 (100%, [V2O3(L
3
)2]
+
). 
[VO(L
4
)OEt] (4). IR (CHCl3, cm
–1
): 1004, 969 ν(V=O), 821 ν(V–O–V). 1H NMR (400 MHz, 
DMSO-d6):  8.21–6.31 (m, 20H, Aromatic), 5.50 (m, 2H, CH2 (OEt)), 4.52 (s, 2H, NH2), 3.48 
(q, 4H, CH2 (EtOH)), 2.95 (s, 3H, CH3), 2.87 (s, 3H, CH3), 1.53 (t, 3H, CH3 (OEt)), 1.08 (t, 6H, 
CH3 (EtOH)). 
13
C NMR (100 MHz, DMSO-d6): δ 171.89, 171.39, 166.55, 166.22, 166.03, 
159.23, 158.05, 150.01 149.87, 134.68, 133.78, 132.85, 132.59, 131.98, 131.72, 130.73, 130.61, 
129.93, 129.56, 129.33, 127.99, 127.56, 126.52, 126.16, 124.95, 124.33, 119.51, 118.45, 118. 16, 
117.99, 117.89, 116.40, 115.38, 115.13, 111.26, 110.04, 80.15, 56.57, 24.19, 23.96, 19.03, 18.74. 
51
V NMR (DMSO-d6):  –528, –544. 
1
H NMR (DMSO-d6+ EtOH, 400 MHz):  8.09–6.60 (m, 
10H, Aromatic), 5.49 (m, 2H, CH2 (OEt)), 4.51 (s, 2H, NH2), 3.50 (q, 48H, CH2 (EtOH)), 2.86 (s, 
3H, CH3), 1.54 (t, 3H, CH3 (OEt)), 1.09 (t, 72H, CH3 (EtOH)).
 13
C NMR (100 MHz, DMSO-d6 + 
EtOH): δ 171.97, 165.94, 158.21, 149.79, 133.63, 132.36, 131.91, 130.51, 129.14, 127.34, 
126.02, 124.18, 119.28, 118.09, 116.28, 115.27, 111.23, 80.00, 56.61, 23.64, 18.50, 18.35. 
51
V 
NMR (DMSO-d6+ EtOH):   –529. ESI-MS (DMSO): m/z 400.02 (100%, [M – CH2CH3]
+
); m/z 
784.30 (50%, [V2O3(L
4
)2]
+
). 
4.2.6. X-ray Crystallography. Single crystals of complexes 1–5 were mounted on Stoe IPDS 2 
diffractometer equipped with an Oxford Cryosystem open flow cryostat, equipped with a 
graphite monochromator and a Mo K radiator (λ) 0.71073 Å. Crystallographic data and details 
of refinement are given in Table 4.1. The unit cell dimensions and intensity data were measured 
at 200 (2) K. Absorption correction was partially integrated in the data reduction procedure for 
crystals of 1–5.17 The intensity data were corrected for Lorentz, polarization and absorption 
effects. Absorption corrections were applied using SADABS
18
 and the structures were solved by 
direct methods using the program SHELXS-97
19 
and refined using least squares with the 
SHELXL-97
19
 software program. Hydrogens were either found or placed in calculated positions 
and isotropically refined using a riding model. The non-hydrogen atoms were refined 
anisotropically. 
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Table 4.1. Crystal data and refinement details for 1–5 
 
 
Complex 1 2 3 4 5 
Empirical 
formula 
C20 H18 N3 O4 V C20 H17 N2 O5 V C21 H19 N2 O4 V 
 
C21 H20 N3 O4 V C50 H42 N6 O10 V2 
Formula 
weight 
415.31 
 
416.30 
 
414.32 429.34 
 
988.77 
 
Temperature 293(2) K 293(2) K 293(2) K 200(2) K 293(2) K 
 
Wavelength 0.71073 A 0.71073 A 0.71073 A 0.71073 Å 1.54184 Å 
 
Crystal 
system 
Monoclinic Monoclinic Monoclinic Monoclinic 
 
Tetragonal 
 
Space group P 21/n 
 
P 21/c P 21/n 
 
P 21/n P 4/n 
Unit cell 
dimensions 
 
 
a = 7.5992(7) A                           
b = 12.7639(11) A 
c = 19.5684(17) A 
 = 90 °
 = 90.373(2) ° 
 = 90 ° 
a = 18.249(3) A                           
b = 5.9376(11) A 
c = 18.227(3) A 
 = 90 ° 
 = 110.346(9) ° 
 = 90 ° 
a = 10.109(5) A 
b = 15.079(8) A      
c = 13.002(7) A 
 = 90 ° 
 = 91.424(9) ° 
= 90 ° 
 
a = 10.305(2) Å 
b = 10.502(2) Å 
c = 18.603(3) Å 
= 90° 
= 92.716(16)°. 
 = 90°. 
a = 21.5608(3) Å 
b = 21.5608(3) Å 
c = 10.1344(3) Å 
= 90° 
= 90° 
 = 90° 
Volume 1898.0(3) Å3 
 
1851.8(6) Å3 1981.4(18) Å3 2011.0(6) Å3 4711.16(19) Å3 
 
Z 4 4 4 4 4 
Density 
(calculated) 
1.453 Mg/m3 1.493 Mg/m3 1.389 Mg/m3 1.418 Mg/m3 
 
1.394 Mg/m3 
 
Absorption 
coefficient 
0.554 mm-1 0.571 mm-1 0.529 mm-1 0.526 mm-1 
 
3.872 mm-1 
 
F(000) 856 856 856 888 
 
2040 
 
Theta range 
for data 
collection 
1.90 to 26.00 °. 2.26 to 26.00 °. 2.07 to 26.00 ° 2.192 to 24.995°. 11.203 to 66.586°. 
Reflections 
collected 
19292 26070 19369 25232 12627 
Independent 
reflections 
3732 [R(int) = 
0.0788] 
3645 [R(int) = 
0.0979] 
 
3894 [R(int) = 
0.0399] 
3546 [R(int) = 
0.1343] 
 
4129 [R(int) = 
0.0317] 
 
Completenes
s to theta = 
25.00° 
100.0 % 99.9 % 
 
99.7 % 99.9 % 96.6 % 
 
Refinement 
method 
Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
Full-matrix least-
squares on F2 
 
Full-matrix least-
squares on F2 
 
Data / 
restraints / 
parameters 
3732 / 1 / 262 
 
3645 / 13 / 246 3894 / 13 / 255 
 
3546 / 0 / 267 4129 / 0 / 310 
Goodness-of-
fit on F2 
1.045 1.056 0.884 0.857 1.011 
 
Final R 
indices 
[I>2sigma(I)] 
R1 = 0.0939, 
wR2 = 0.2142 
R1 = 0.0831, 
wR2 = 0.2028 
R1 = 0.0464, 
wR2 = 0.1265 
 
R1 = 0.0489, 
wR2 = 0.1124 
 
R1 = 0.0457, 
wR2 = 0.1263 
 
R indices (all 
data) 
R1 = 0.1668, 
wR2 = 0.2584 
R1 = 0.1296, 
wR2 = 0.2560 
R1 = 0.0718, 
wR2 = 0.1531 
R1 = 0.1224, 
wR2 = 0.1393 
R1 = 0.0532,  
wR2 = 0.1317 
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4.2.7. Catalytic Reactions. 
 
4.2.7.1. Oxidative bromination of styrene. Complexes 1–5, were used as catalyst precursors to 
carry out the oxidative bromination of styrene. In a typical reaction, styrene (1.04 g, 10 mmol) 
was added to an aqueous solution (20 mL) of KBr (3.57 g, 30 mmol), followed by the addition of 
CH3CN (25 mL) and 30% aqueous H2O2 (3.39 g, 30 mmol) in a 100 mL reaction flask. The 
catalyst (0.0005g) and 70% HClO4 (2.86g, 5 mmol) were added, and the reaction mixture was 
stirred at room temperature. Three additional 5 mmol portions of 70% HClO4 were further added 
after every 15 min with continuous stirring. In all batches, the experimental conditions (e.g., 
stirring speed, the size of the magnetic bar and reaction flask) were kept as similar as possible. 
After 1 h, the orange organic layer was separated with a separatory funnel, washed with water 
and dried. The crude mass was redissolved in CH3CN; insoluble material, if any, was removed 
by filtration, and the solvent evaporated. The reaction products were separated by using a silica 
gel column. Elution of the column with 1% CH3CN in n-hexane first separated a mixture of 
bromo derivatives followed by 1-phenylethane-1,2- diol. The two bromo derivatives were finally 
separated from each other with the silica gel column again by eluting with pure n-hexane. The 
identity of all the products was confirmed by GC–MS and 1H NMR spectroscopy. 
 
4.2.7.2. Oxidative bromination of salicylaldehyde. Salicylaldehyde (0.610 g, 5 mmol) was 
added to an aqueous solution (20 mL) of KBr (1.785 g, 15 mmol), followed by addition of 
aqueous 30% H2O2 (1.14 g, 10 mmol) in a 100 mL reaction flask. The catalyst (0.0005 g) and 
70% HClO4 (2.14g, 15 mmol) were added, and the reaction mixture was stirred at room 
temperature (20 °C). The addition of HClO4, however, in four equal portions during the reaction 
in 45 min interval was necessary to improve the conversion of the substrate and to avoid 
decomposition of the catalyst. After 3 h, the separated white products were extracted with 
CH2Cl2 and dried. The crude mass was dissolved in methanol and was subjected to gas 
chromatography. The identity of the products was confirmed as mentioned above. 
 
4.2.7.3. Oxidation of methyl phenyl sulfide. Methylphenyl sulfide (0.620 g, 5 mmol) and 
aqueous 30% H2O2 (1.14 g, 10 mmol) were dissolved in CH3CN (5 mL). After addition of   
0.001 g catalyst (1–5) to the above solution, the reaction mixture was stirred at room temperature 
for 2.5 h. During this period, the reaction products formed were analyzed using gas 
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chromatography by withdrawing small aliquots after fixed time intervals. The identities of the 
reaction products were confirmed by GC-MS. 
 
4.2.8. DNA binding experiments. 
 
4.2.8.1. Absorption spectral studies. Binding of the oxidoalkoxido vanadium(V) complexes (1–
5) to calf thymus DNA (CT-DNA) was studied in 10 mM Tris–HCl buffer (pH 8.0) containing 
10% DMF. UV-Vis absorption titration experiments were performed by using a fixed 
concentration of metal complex (25 M) and varying CT-DNA concentration from 0 to 65 M. 
After each addition of CT-DNA (5 M) to the metal complex, the spectra were recorded after 
equilibration for 5 min using Perkin Elmer Lamda35 spectrophotometer. The data were then fit 
to the following equation to obtain binding constant Kb
20
 
  
[DNA ]
εa − εf
=  
[DNA ]
εb − εf
+  
1
Kb (εb − εf )
 ;                                Eq. 1 
where [DNA] is the concentration of DNA base pairs, εa, εf  and εb correspond to apparent 
extinction co-efficient for the complex i.e. Abs/[complex] in presence of DNA, in absence of 
DNA and to fully bound DNA respectively. A plot of [DNA]/(εa -εf) vs [DNA] gave a slope and 
intercept equal to 1/(εb - εf) and 1/Kb(εb - εf), respectively. Kb is calculated from the ratio of the 
slope to the intercept. 
 
4.2.8.2. Thermal denaturation studies. Thermal denaturation studies of CT-DNA (160 M) in 
the absence and presence of complexes (50 M) were carried out by monitoring the absorbance 
at 260 nm in the temperature range of 30–90 oC with a ramp rate of 1 oC/min in 10 mM Tris-HCl 
buffer (pH 8.0). The experiments were carried out using a Chirascan CD spectropolarimeter 
(Applied Photophysics, UK) in absorbance mode equipped with quantum temperature controller. 
The melting of the double stranded DNA to single stranded DNA was observed with significant 
hyperchromicity of absorbance at 260 nm. The melting temperature (Tm) was determined from 
the derivative plot (dA260/dT vs T) of the melting profile.
21
  
 
4.2.8.3. Circular dichroism studies. The Circular Dichroism (CD) spectroscopy was studied 
using Chirascan CD spectropolarimeter (Applied Photophysics, UK) at 25 
o
C. CD spectra of CT-
DNA (160 M) in absence and presence of complexes (25 M) were obtained in the wavelength 
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range of 240–300 nm in 10 mM Tris-HCl buffer (pH 8.0) using quartz cell with 10 mm path 
length.
21 
 
4.2.9. DNA cleavage experiments. For DNA cleavage experiments, 300 ng supercoiled (SC) 
pUC19 DNA was used and all experiments were carried out in 50 mM Tris-HCl buffer (pH 8.0) 
containing 10% DMF. 
 
4.2.9.1. Chemical-induced DNA cleavage. For chemical nuclease studies, the reactions were 
performed in the dark using hydrogen peroxide (0.5 mM) as the oxidising agent in absence and 
presence of complexes (1 – 500 µM). The solutions were incubated at 37 oC for 3 h and analysed 
for DNA cleaved products by agarose gel electrophoresis. 
 
4.2.9.2. Photo-induced DNA cleavage. The effect of oxidoalkoxido vanadium(V) complexes   
(1 – 500 µM) on the cleavage of supercoiled (SC) pUC19 DNA (300 ng) was studied by agarose 
gel electrophoresis in 50 mM Tris HCl buffer (pH 8.0) containing 10% DMF. DNA photo 
cleavage studies were carried out under illuminated conditions using UVA source at 350 nm 
(Luzchem Photoreactor Model LZC-1, Ontario, Canada) fitted with 14 UVA tubes for 3 h. After 
photo irradiation, each sample was further incubated for 1.0 h at 37 
o
C and analyzed for the 
photo-cleaved products using gel electrophoresis. The samples after incubation were added to the 
loading buffer containing 0.25% bromophenol blue and 30% glycerol (2 µL) and the solution 
was finally loaded on 0.8% agarose gel containing 0.5 µg/mL ethidium bromide (EB). 
Electrophoresis was carried out for 1.0 h at 90 V in TAE (Tris–acetate EDTA) buffer. DNA 
cleavage was indicated by the decrease in the supercoiled pUC19 DNA (Form I) and 
subsequently the formation of nicked circular DNA (Form II) and linearized DNA (Form III). 
Bands were visualized by UV light (302nm) and photographed. The extent of SC DNA cleavage 
was measured from the intensities of the bands using UVP (Gel Doc It
2
) Gel Documentation 
System. Due corrections were made for the low level of nicked circular (NC) form of DNA 
present in the original SC DNA sample and for the low affinity of EB binding to SC compared to 
NC and linear forms of DNA.
22 
The percentage of net DNA cleavage was calculated by the 
following equation: 
Net DNA cleavage % =
Form  IIs +2 ×Form  IIIs
Form  Is+ Form  IIs +2 ×Form  IIIs
−  
Form  IIc +2 ×Form  IIIc
Form  Ic+ Form  IIc +2 ×Form  IIIc
        Eq.2 
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The subscripts ―s‖ and ―c‖ refers to the sample and control respectively.23 Appropriate DNA 
controls were taken to calculate the net DNA cleavage percent. The observed error in measuring 
the band intensities ranged between 3% – 6%.  
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4.3. RESULT AND DISSCUSSION 
 
4.3.1. Synthesis and structure. The four tridentate ligands (H2L
1–4
), used in this work are given 
in Scheme 4.1. The reaction of NH4VO3 with H2L
1–4
 in a ratio of 1:1 in refluxing ethanol in open 
air affords the brown colored complexes of composition [VO(L
1–4
)OEt] (1–4) in excellent yields 
and the same reaction in presence of a co-ligand 4,4'-bipy afford the dimeric product, 
[{VO(L
2
)OEt}2(-4,4'-bipy)] (5). These compounds are highly soluble in CH2Cl2, DMF and 
DMSO and sparingly soluble in MeOH, EtOH and CH3CN. All complexes are diamagnetic and 
nonconducting in solution. The IR spectrum of complexes 1−5, showed a characteristic V=O 
stretching band at ~ 999 cm
-1
.
14b 
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Scheme 4.1. Schematic diagram of various pathways through which the oxido vanadium(V) 
complexes (1−5) were synthesized. 
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4.3.2. Description of the X-ray structure of complexes (1−5). The observed elemental          
(C, H, N) analytical data of all the oxidoethoxido vanadium(V) complexes are consistent with 
their composition. It appears from the formulation of the monomeric complexes that the 
hydrazones are serving as tridentate ligands in them. Although the preliminary characterization 
data (microanalysis and IR) indicated the presence of the ligand, oxido group and ethoxido group 
in the complexes, they could not point to any definite stereochemistry of the complexes, or the 
coordination mode of H2L. In order to authenticate the coordination mode of the hydrazones in 
these complexes, the structure of all the monomeric complexes has been determined by X-ray 
crystallography. The atom numbering scheme for complexes (1−4) are given in Figure 4.1 (a-d) 
with the relevant bond distances and angles collected in Table 4.2. In complexes (1−4), the 
vanadium(V) centre is occupied by O4N coordination sphere, constituting a square pyramidal 
structure. The basal plane is made up by the phenolate oxygen, enolic oxygen, imine nitrogen 
from the ligand and the oxygen from deprotonated alkoxide. The Schiff base ligand forms a six 
membered and a five membered chelate ring at the V(V) accepter centre with O(1)–V(1)–N(1) 
and O(2)–V(1)–N(1) bite angles in the range of 82.5(2)−81.6(2)° and 75.1(1)−74.36(7)° 
respectively. The apical position of square pyramid is occupied by the terminal oxido group 
O(3). The short V(1)−O(3) distance in the range of 1.606(5)−1.574(4)A° indicates the presence 
of vanadium oxygen double bond (V=O), which is commonly found in five and six coordinated 
octahedral complexes
24
 of vanadium(IV) and vanadium(V). For all the complexes, the four V−O 
bond lengths are unequal, the V=O bond being the shortest and V−O (enolate) being the longest. 
The V−O bond length follows the order, V−O(oxido) < V−O(alkoxido) < V−O(phenolate) < 
V−O(enolate). These data indicate the stronger binding of alkoxido group compared to those of 
phenolate and enolate oxygen atom.
24a-b
 
The dinuclear complex, 5 (Figure 4.1(e), Table 4.2) crystallizes in the tetragonal crystal system 
with space group, P4/n with the molecule sitting across a crystallographic center of inversion. 
Each half of the dinuclear complex [{VO(L
2
)OEt}2(-4,4'-bipy)] (5), closely resembles the 
structure of the other half of the complex. The coordination environment around the V(V) center 
is octahedral and highly distorted. The ligand H2L
2
 is dianionic and tridentate, with its 
meridionally situated donor sites O(1), N(1), and O(2) lying in the equatorial plane along with 
the alkoxido oxygen O(4). The chelate bite angles for the five- and six-membered rings have 
values within the expected ranges [O(2)–V(1)–N(1), 74.87(6); O(1)–V(1)–N(1), 82.09(6)]. The 
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bond distances about V(1) reveal the magnitude of the distortions, as can be seen in Table 4.2. 
The V–O distances range from 1.601(2) Å for the oxido ligand O(3), located in an axial position, 
to 1.966(1) Å for the enolate oxygen O(2). The V(1)–O(1) (phenolate) distance is slightly shorter 
at 1.853(1) Å. The second axial position is occupied by a nitrogen atom of the bridging 4,4'-
bipyridine ligand, which is significantly farther from the V center than the other five ligated 
atoms. V(1)–N(3), at 2.377(2) Å, is undoubtedly the weakest of the six V–L bonds and 
consequently the most susceptible to ligand exchange.  
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Table 4.2. Selected bond distances (Å) and angles (
0
) for 1−5.  
 
                                     1                        2                      3                     4                             5 
 
Distances 
V(1)-O(1)               1.834(4)           1.840(4)          1.835(2)            1.812(3)                 1.853(1) 
V(1)-O(2)               1.914(4)           1.936(4)          1.908(2)            1.895(3)                 1.966(1) 
V(1)-O(3)               1.606(5)           1.581(6)          1.587(2)            1.574(4)                 1.601(2) 
V(1)-O(4)               1.730(7)           1.730(5)          1.753(2)            1.711(4)                 1.779(2) 
V(1)-N(1)               2.075(5)           2.095(5)          2.093(2)            2.088(3)                 2.110(2) 
N(1)-N(2)               1.384(6)           1.387(7)          1.395(3)            1.394(5)                 1.393(2) 
V(1)-N(3)                   -                         -                       -                            -                   2.377(2) 
Angles 
O(1)-V(1)-O(3)       106.7(2)          105.3(2)        108.11(8)             107.3(2)               100.89(7) 
O(1)-V(1)-O(4)         99.4(3)            98.6(2)          99.03(8)               96.8(2)               105.17(6) 
O(1)-V(1)-N(1)         82.5(2)            81.6(2)          81.91(7)               82.1(1)                 82.09(6) 
O(2)-V(1)-O(3)       107.1(2)          104.4(2)        111.68(9)             107.1(2)                 97.61(7) 
O(2)-V(1)-O(4)         90.2(3)            90.5(2)          89.39(8)               89.1(2)                 91.29(6) 
O(2)-V(1)-N(1)         74.4(2)            74.7(2)          74.36(7)               75.1(1)                 74.87(6) 
O(3)-V(1)-O(4)       105.1(3)          108.5(3)        105.20(9)             109.6(2)               102.04(7) 
O(3)-V(1)-N(1)         97.0(2)            98.4(2)          97.15(8)               97.4(2)                 96.81(7) 
O(3)-V(1)-N(3)            -                     -                    -                              -                     175.58(7) 
O(1)-V(1)-N(3)            -                     -                    -                              -                       82.12(6) 
O(4)-V(1)-N(3)            -                     -                    -                              -                       80.14(6) 
O(2)-V(1)-N(3)            -                     -                    -                              -                       78.44(6) 
_____________________________________________________________________________ 
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       (a) 
 
         (b) 
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         (c) 
 
          (d) 
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(e) 
Figure 4.1. ORTEP diagram of (a) [VO(L
1
)OEt] (1), (b) [VO(L
2
)OEt] (2), (c) [VO(L
3
)OEt] (3), 
(d) [VO(L
4
)OEt] (4), (e) [{VO(L
2
)OEt}2(-4,4'-bipy)] (5) . 
 
 
 
 
122 
 
4.3.3. IR spectroscopy. The IR data of all the ligands, H2L
1–4
 and their corresponding metal 
complexes, 1–5 are given in the experimental section. The disappearance of characteristic bands 
due to –NH and –C=O in the ligand, and the appearance of new bands in the range 1255–1238 
cm
–1
 in the complexes (1–5), indicates the enolisation of these two groups forming a =C–O bond 
sequence. The strong and sharp peak displayed by the complexes in the range 1599–1567 cm-1 is 
likely to be associated with the –C=N–N=C– moiety.15a,25 The presence of a sharp band in the 
range 999–959 cm-1 is assigned to V=O stretching of an oxidoalkoxido vanadium(V) complex.15a  
4.3.4. Electronic spectra. The electronic spectra of 1–5 were recorded in CHCl3 (1.20 x 10
-4
 M) 
and are quite similar. A representative spectrum of 2 is shown in Figure 4.2. Strong absorptions 
in the range 456–419 nm are assignable to the ligand-to-metal charge transfer transitions whereas 
the bands in the higher energy region (346–242 nm) are likely to be due to ligand centred 
transitions.
15a,14b
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. UV-Vis spectra of [VO(L
2
)OEt] (2) (1.20 x 10
-4
 M) in CHCl3. 
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4.3.5. Study of Solution behavior of Complexes 1−4. The IR spectrum of all the complexes 
(1−4) in chloroform/DMSO shows two V=O stretch bands in the range 1006–1002 cm−1 and 
980–966 cm−1, which suggested that two different V=O groups exist in solution.14b The 
representative spectrum is shown in Figure 4.3. Another new band corresponding to the ν(V–O–
V)
14b,15a
 mode is also observed at around 821 cm
-1
,
 
which were absent in the spectrum of 1−4 in 
the solid state. The IR spectrum in solution pointed to the retention of their mononuclear nature 
which was in the solid state and simultaneous formation of the corresponding dimeric complexes 
as a 2nd species. So, these observations suggest that two species may exist in solution and 
demand proper explanation. 
 
 
Figure 4.3. FTIR spectra of complex [VO(L
3
)OEt] (3): a) in solid state b) in CHCl3 solution. 
The 
1
H NMR spectra of the complexes 1−4 in DMSO-d6 (which contained trace water) yielded 
two close but separate sets of bands in an approximate 1:1 ratio [Figures 4.4 (a) and 4.5 (a)]. 
The set of sharp 
1
H NMR signals denoted by the pink rectangles correspond to the monomeric 
form M of the species [VO(L
1−4
)OEt] (1−4) which were isolated in the solid state and 
structurally characterized. The relatively less sharp signals denoted by the blue rectangles were 
assigned to the other species (let the corresponding 2nd species is a dimer, labeled as D). So, the 
NMR results suggest that two species exist in DMSO solution. The spectrum of 1 and 2 exhibits 
two sets of CH singlets at 9.99−9.94 ppm (1) and 10.09−9.95 ppm (2) respectively. The 
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spectrum of 2 exhibits two sets of OH (phenolic) resonance at 11.60 and 11.42 ppm. The 
spectrum of 3 and 4 exhibits two sets of CH3 (methyl) resonance at 2.92−2.84 ppm (3) and 
2.95−2.87 ppm (4). The spectrum of 1 and 4 exhibits a broad signal for two NH2 group in the 
range 4.52−4.32 ppm. Finally, the aromatic protons of 1, 2 and 4 (a total of 20) and of 3 (a total 
of 22) appear in the range 8.65−6.31 ppm. In addition, all the complexes exhibit separate bands 
corresponding to bound ethoxido in the range, 5.76−5.48 (−CH2) and 1.61−1.50 (−CH3) 
ppm
14a,b,26 
 and the sharp peaks observed in the range 3.48−3.44 (−CH2) and 1.08−1.05 (−CH3) 
ppm were assigned to free, non-ligated ethanol that is most likely to be formed in situ in solution. 
Though the chemical shifts of the methylene and methyl protons of the ethanol are very close to 
those of the free ethanol, the alcoholic proton is not detected may be because of less 
concentration or overlap of the signals. 
 
On addition of few drops of ethanol to the DMSO solution of complexes 1−4, the 2nd set of 
bands (blue) disappeared and a clear spectrum resulted [Figures 4.4 (b) and 4.5 (b)]. The clear 
spectrum exhibits only one OH (phenolic) resonance at 11.61 ppm for 2, one CH proton signal at 
9.80 ppm for 1 and 9.94 ppm for 2, and signals for a total of ten aromatic protons for 1, 2 and 4 
and eleven aromatic protons for 3 in the range 8.56−6.57 ppm. In addition, the coordinated 
ethoxido bands in the range 5.76−5.48 ppm (−CH2) ppm and at ~ 1.62−1.51 (−CH3) ppm
14a,b,26,27 
 
broadened and the free ethanol bands in the range 3.50−3.45 (−CH2) and 1.09−1.06 (−CH3) ppm 
increased.  
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Figure 4.4. Representative 
1
H NMR spectrum (full range) of [VO(L
1
)OEt] (1) in DMSO-d6: a) 
before addition of ethanol. b) after addition of ethanol. 
 
Figure 4.5. Representative 
1
H NMR spectrum (aromatic region) of [VO(L
1
)OEt] (1) in DMSO-
d6: a) before addition of ethanol b) after addition of ethanol. 
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The 
13
C (Figures 4.6 and 4.7) and 
51
V (Figure 4.8) NMR spectra of complexes 1−4, in DMSO 
also showed two sets of bands at an approximate ratio of 1:1 and the 2
nd
 set of band (blue) 
disappeared on addition of small amount of ethanol, as in the case of 
1
H NMR spectrum. 
 
Figure 4.6. Representative
 13
C NMR spectrum (full range) of [VO(L
1
)OEt] (1) in DMSO-d6: a) 
before addition of ethanol b) after addition of ethanol. 
 
Figure 4.7. Representative
 13
C NMR spectrum (aromatic region) of [VO(L
1
)OEt] (1) in DMSO-
d6: a) before addition of ethanol b) after addition of ethanol. 
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Figure 4.8. Representative 
51
V NMR spectrum of [VO(L
1
)OEt] (1) in DMSO-d6: a) before 
addition of ethanol b) after addition of ethanol. 
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Like the solution IR, the NMR (
1
H, 
13
C and
 51
V) results also suggest that two species exist in 
DMSO solution and whatever the 2nd species (D) is, it converts to its monomeric form (M) in 
the presence of a small amount of ethanol. 
Glas et al. reported the solution behavior of octahedral monoalkoxido-bound monooxido 
vanadium(V) complexes with pyrazolylpyridine bidentate chelating ligand and proposed a 
coordination isomerism for their complexes based on the NMR study.
24a
 However, in present 
study, the vanadium ions are coordinated by a chelating tridentate ligand, so the occurrence of a 
coordination isomerism is not plausible. Moon et al. also reported
14a
 a similar solution behavior 
of a mononuclear square pyramidal dialkoxido-bound monooxido vanadium(V) complex with a 
dianionic tridentate chelating ligand and they proposed an intermolecular hydrogen-bonded 
polymeric form of their oxido vanadium(V) complex may present as minor species in solution. 
But, they could not produce any conclusive evidence for the final structure of that minor species, 
so the occurrence of a hydrogen-bonded polymeric structure is excluded.     
    One of the possible structures for the 2nd species is an alkoxido-bridged dimer.
14c,24b
 It is well-
known that alkoxides usually form dimeric complexes. However, we could exclude the 
possibility of an ethoxido-bridged dimer as the 2nd species because there is only one set of bands 
for a coordinated ethoxido group. If the 2nd species is an ethoxido bridged dimer, there should 
be another set of bands for two bridging ethoxido groups and as a six coordinated complex the 
V=O stretching could have been found in lower frequency.
28
 So we could exclude the possibility 
of an alkoxido-bridged dimer as the other (2nd) species. The other possible structure for the 2nd 
species is a chain structure where a phenolate oxygen atom of the neighboring monomeric 
species would link vanadium centers of the monomeric species. We could also exclude the 
possibility of a phenolate-linked chain structure from the evidence that, if phenolate was 
coordinated to the vanadium ion in the minor species, a phenolate ligand to vanadium metal 
charge-transfer band would have had to disappear when a small amount of ethanol was added to 
the chloroform solution of complexes 1−4. However, there were no recognizable changes in the 
UV-Vis spectrum of complexes 1−4 in the chloroform solution were observed after the addition 
of a small amount of ethanol to the solution. Finally, one of the possible structures for the 2nd 
species is a µ-oxido dimer. From the IR results in solution, there was a significant change in the 
V=O stretch of complexes 1−4 in chloroform/DMSO solution compared to that of the 
monomeric species in the solid state and another new band corresponding to the ν(V-O-V)14b,15a 
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mode was observed. This suggests that, with the addition of monomeric species, the 
corresponding divanadium complexes may exist as a µ-oxido dimer (2nd species) in solution.  
To support the above observations, ESI mass spectra of all the complexes (1–4) were recorded in 
DMSO solution. The data are summarized in the experimental section. For complexes 1–4, two 
peaks corresponding to the [M – CH2CH3]
+ 
and [V2O3(L
4
)2]
+
 are observed which correspond to 
the existence of the monomeric and dimeric species respectively. A representative ESI mass 
spectrum of complex 4 is shown in Figure 4.9. 
 
 
  
Figure 4.9. ESI mass spectrum of [VO(L
4
)OEt] (4). 
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On the basis of above results, these solution behavior of 1−4 can be interpreted as by proposing 
the following equilibrium (Chart 4.1) existing in CDCl3 / DMSO-d6 containing a little water, 
which also explains the simultaneous presence of the two species, M (monomer, isolated in the 
solid state and solved by X-ray crystallography) and D (2nd species, µ-oxido dimer) in solution. 
N
O
N
H
O
V
O
OCH2CH3
NH2
N
O
N
H O
V
O
H2N
N
O
N
H
O
V
O
NH2
O
Monomeric form (M), isolated 
in the solid state and solved
by  X-ray crystallography
Dimeric form (D), 2nd species  generated 
insitu in solution
H2O+
2 EtOH+
2
[VO(L1)OEt] (1)
[V2O3 (L
1
2 )]
 
Chart 4.1. Schematic diagram for the inter-conversion of monomeric and dimeric species in 
solution taking [VO(L
1
)OEt] (1) as representative. 
Even though no water molecules were observed in the crystal structure of 1−4, it is assumed that 
the possible water source was either from NMR solvents or from water molecules in the air that 
were probably physisorbed on the surface of the complexes. The role of water as well as the free 
ethanol molecules for the existence of the above equilibrium were inferred from the presence of 
band at ~ 3.73 (br) ppm for H2O and the sharp peaks at ~ 3.47 and ~ 1.07 ppm for the protons of 
free, non-ligated ethanol in DMSO-d6. However, this equilibrium could be shifted more to the 
left by the addition of ethanol into the NMR sample, which was reflected in the change in NMR 
spectrum of [VO(L
1–4
) OEt] (1−4).  
It is concluded that, on addition of few drops of ethanol into the NMR sample in DMSO-d6, 1−4 
retain their structure in which they exist in the solid state and the other (2nd, D) species, which 
were also present in solution, were reconverted into the mononuclear state (M). D exhibits all the 
characteristic signals of a μ-oxido binuclear species, which matches well with the similar results 
reported earlier.
14b
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4.3.6. Catalytic Activity Studies.   
4.3.6.1. Oxidative bromination of Styrene. Model vanadium complexes can act as functional 
models of vanadium-dependent haloperoxidases, in that they catalyse the oxidative bromination 
of organic substrates in the presence of H2O2 and bromide ion.
29-31 
During catalytic reaction, 
vanadium complex reacts with 1 or 2 equivalent of H2O2, generates oxido-monoperoxido, 
[VO(O2)]
+
 or oxido-diperoxido, [VO(O2)2]
-
 species which ultimately oxidizes bromide species 
(to Br2, and/ or HOBr), the bromination of the substrate then proceeds with the liberation of a 
proton. The oxidoalkoxido vanadium(V) complexes reported here satisfactorily catalyse the 
oxidative bromination of styrene. 
Oxidative bromination of styrene using these alkoxido vanadium(V) (1−5) complexes as catalyst 
precursor in the presence of H2O2, KBr and HClO4 gave mainly three products, namely, (a) 1,2-
dibromo-1-phenylethane, (b) 2-bromo-1-phenylethane-1-ol and (c) 1-phenylethane-1,2-diol 
(Scheme 4.2). Some minor products (benzaldehyde, styrene epoxide, benzoic acid and 4-
bromostyrene) were also detected but their overall percentage was approximately very low (7 %) 
of the total of the main products. Addition of HClO4 in four equal portions was required to obtain 
better oxidative bromination. All products were separated/ isolated by column chromatography 
and the content of each fraction was confirmed by 
1
H NMR spectroscopy as well as GC–MS.  
Br
Br
HO
Br
HO
OH
++
H2O2, KBr
HClO4
a b c
 
Scheme 4.2. Main products obtained upon oxidative bromination of styrene. (a) 1,2-dibromo-1-
phenylethane, (b) 2- bromo-1-phenylethane-1-ol and (c) 1-phenylethane-1,2-diol. 
The following parameters were studied to optimize the reaction conditions for the maximum 
oxidative bromination of styrene considering 3, as catalyst precursor: (i) amount of catalyst, (ii) 
amount of KBr (iii) amount of oxidant and (iv) amount of HClO4 while reaction was run at room 
temperature. 
132 
 
Three different amounts of 3 (0.0005, 0.0010 and 0.0015 g) were used as catalyst precursor 
while keeping fixed the amounts of styrene (1.04 g, 10 mmol), KBr (1.19 g, 10 mmol), 30% 
H2O2 (1.14 g, 10 mmol) and aqueous 70% HClO4 (1.43 g, 10 mmol) in a CH3CN/ water (20/5 
mL) (entry no.1 to 3 of Table 4.3). Additions of HClO4 were made in four equal portions, one 
immediately after the catalyst precursor (reaction time = 0) and the three other portions with 15 
min intervals. A maximum of 21% conversion was obtained after 1 h of reaction with 0.0005 g 
of catalyst while 0.0010 and 0.0015 g of catalyst did not improve conversion much and gave 
23% and 27 % conversion, respectively. Therefore, 0.0005 g of 3 was set as optimum (Figure 
4.10a). 
Similarly, three different substrate-to-KBr ratios were used (entry no. 4 to 5). The initial 
conversion of 21 % with substrate-to-KBr ratio of 1:1 improved to 38% upon increasing the 
substrate to KBr ratio to 1:2. This conversion further increased to 69 % at substrate-to-KBr ratio 
of 1:3. Therefore 3.57 g (30 mmol) of KBr was used for optimization of other conditions (Figure 
4.10b). 
The effect of the amount of oxidant, added as an aqueous 30% H2O2 solution, was studied with 
substrate-to-oxidant ratios of 1:2 and 1:3, for the fixed amount of styrene (1.04 g, 10 mmol), 
catalyst (0.0005 g), KBr (3.57 g, 30 mmol) and HClO4 (1.43 g, 10 mmol) in CH3CN/ H2O (25 
mL), and the reaction was monitored at room temperature for 1 h. The conversion increased 
upon increasing the substrate-to-oxidant ratio, and the substrate-to-oxidant ratio of 1:3 gave 53% 
conversion of styrene (entry no.6 to7) (Figure 4.10c). 
To optimize the amount of HClO4, four different amounts of 70% HClO4 were used for fixed 
amounts of styrene (1.04 g, 10 mmol), catalyst precursor (0.0005 g), KBr (3.57 g, 30 mmol), 
30% H2O2 (3.39 g, 30 mmol) and CH3CN/ water (25 mL). Increasing the HClO4 amount from 
1.43 g (10 mmol) to 2.86 g (20 mmol) increased the conversion from 53 to 98%. Only a slight 
improvement in conversion was obtained upon further increasing this amount to 4.29 g (30 
mmol) (entry no. 8 to 9). Therefore, 2.86 g (20 mmol) of 70% HClO4 was considered to be 
adequate to obtain maximum oxidative bromination of styrene (Figure 4.10d). 
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a) b) 
 
 
 
 
 
c)  d)  
 
 
 
 
 
 
Figure 4.10. (a) Effect of catalyst amount on the oxidative bromination of styrene. Reaction 
condition: styrene (1.04g, 10 mmol), 30 % aqueous H2O2 (1.14, 10 mmol), KBr (1.19 g, 10 
mmol) and 70 % aqueous HClO4  (1.43 g, 10 mmol).(b) Effect of KBr amount on the oxidative 
bromination of styrene. Reaction condition: styrene (1.04 g, 10 mmol), 3 (0.0005g), 30 % 
aqueous H2O2 (1.14,10 mmol), and 70 % aqueous HClO4  (1.43 g, 10 mmol). (c) Effect of 
oxidant amount on the oxidative bromination of styrene. Reaction condition: styrene (1.04 g, 10 
mmol), 3 (0.0005g), KBr (3.57 g, 30 mmol) and 70 % aqueous HClO4  (1.43 g, 10 mmol). (d) 
Effect of HClO4 amount on the oxidative bromination of styrene. Reaction condition: styrene 
(1.04 g, 10 mmol), 3 (0.0005g), KBr (3.57 g, 30 mmol) and 30 % aqueous H2O2 (3.39, 30 
mmol).    
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Entry 8 of Table 4.3 presents the optimized reaction conditions for the oxidative bromination of 
10 mmol of styrene, which are: catalyst precursor 3 (0.0005 g), 30% aqueous H2O2 (3.39 g, 30 
mmol), KBr (3.57 g, 30 mmol), 70 % aqueous HClO4 (2.86 g, 20 mmol) (added in four equal 
portions in 15 min intervals), and CH3CN/ H2O (25 mL,) at room temperature for 1 h. Catalytic 
activities of other complexes (1, 2, 4, 5) have also been carried out under similar reaction 
conditions and are presented in Table 4.3 (entry no. 11 to 14).  
 
Table 4.3. Conversion of styrene (1.04 g, 10 mmol) using vanadium complexes (1−5), as 
catalyst in 1 h of reaction time under different reaction conditions 
Entry 
No. 
KBr  
[g 
(mmol)] 
H2O2 
 [g 
(mmol)] 
HClO4  
[g 
(mmol)] 
Catalyst  
[g 
(mmol)] 
TOF  
[h
-1
] 
Conv. 
[%] 
Mono 
Brom
o 
Dibromo Di
ol 
Other 
product 
 1. 1.19 (10) 1.14 (10) 1.43 (10)  0.0005 g 1750 21 14 0 86 0 
2 1.19 (10) 1.14 (10) 
 
1.43 (10)    0.001 g   958 23 25 0 74 1 
3 1.19 (10) 
 
1.14 (10) 
 
1.43 (10)  0.0015 g 750 27 17 0 82 1 
4 2.38 (20 ) 1.14 (10) 
 
1.43 (10)  0.0005 g 3166 38 13 0 86 1 
5 3.57 (30) 1.14 (10) 1.43 (10)  0.0005 g 5750    69 39 0 60 1 
6 3.57 (30) 2.27 (20) 1.43 (10)  0.0005 g 3916 47 9 0 90 1 
7 3.57 (30) 3.39 (30) 1.43 (10)  0.0005 g 4416 53 11 0 88 1 
 
8 3.57 (30) 3.39 (30) 2.86 (20) 0.0005 g 8167 98 30 2 67 1 
9 3.57 (30) 3.39 (30) 4.29 (30) 0.0005 g 8250 99 23 4 69 4 
10 3.57 (30) 3.39 (30) 5.72 (40) 0.0005 g 8250 99 17 8 74 1 
11
a
 3.57 (30) 3.39 (30) 2.86 (20) 0.0005 g 8000 96 28 1.4 69 1.6 
12
b
 3.57 (30) 3.39 (30) 2.86 (20) 0.0005 g 8000 96 28 1.7 67 3.3 
13
c
 3.57 (30) 3.39 (30) 2.86 (20) 0.0005 g 8818 97 23 2.3 74 0.7 
14
d
 3.57 (30) 3.39 (30) 2.86 (20) 0.0005 g 19600 98 33 2.3 63 1.7 
  15 3.57 (30) 3.39 (30) 2.86 (20) blank - 44 45 0 52 3 
 
a = 1, b = 2, c = 4 and d = 5. 
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Their catalytic activities are comparable (Figure 4.11) and indicated that substituents (-H, -NH2 
and -OH) on the benzene ring have no impact on their catalytic activity. Negative control (entry 
no. 15) shows under above conditions only 44 % conversion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Comparison of catalytic efficiency of different catalysts on the oxidative 
bromination of styrene. Reaction condition: styrene (1.04 g, 10 mmol), catalyst (0.0005g), 30 % 
aqueous H2O2 (3.39, 30 mmol), KBr (3.57 g, 30 mmol) and 70 % aqueous HClO4  (2.86 g, 20 
mmol).           
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Figure 4.12 represents the consumption of styrene and the selectivity of the formation of major 
products with time for these experimental conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Plots showing percentage conversion of styrene and the selectivity of the formation 
of different reaction products as a function of time. Reaction condition: styrene (1.04 g, 10 
mmol), 3 (0.0005g), 30 % aqueous H2O2 (3.39, 30 mmol), KBr (3.57 g, 30 mmol) and 70 % 
aqueous HClO4  (2.86 g, 20 mmol). 
 
 
 
 
20 30 40 50 60
0
20
40
60
80
100
%
 C
o
n
v
er
si
o
n
Time/min
 % Conversion
Monobromo
 Dibromo
 Diol
0
20
40
60
80
100
 %
 P
ro
d
u
ct
 S
el
ec
ti
v
it
y
137 
 
4.3.6.2. Oxidative bromination of salicylaldehyde. Vanadium(V) complexes also catalyze the 
oxidative bromination of salicylaldehyde in the presence of H2O2. In the present study, 
complexes 1–5 were used as catalyst precursors with water as solvent. The catalytic oxidative 
bromination of salicylaldehyde gave 5-bromosalicylaldehyde, 3,5-dibromosalicylaldehyde and 
2,4,6-tribromophenol (Scheme 4.3).    
 
     
 
                                                                  
Scheme 4.3. Main products obtained upon oxidative bromination of salicylaldehyde.                                  
(a) 5-bromosalicylaldehyde, (b) 3,5-dibromosalicylaldehyde and (c) 2,4,6- tribromophenol. 
 
After carrying out experiments under different conditions (Table 4.4), the best suited reaction 
conditions concluded for the maximum conversion of salicylaldehyde were: salicylaldehyde 
(0.610 g, 5 mmol), catalyst (0.0005 g), KBr (1.78 g, 15 mmol), aqueous 30% H2O2 (1.14 g, 10 
mmol), aqueous 70 % HClO4 ( 2.14g, 15 mmol) and water (20 mL) (entry no. 7, Table 4.4); the 
addition of HClO4, however, in four equal portions during the reaction  was necessary to 
improve the conversion of the substrate and to avoid decomposition of the catalyst. Under the 
above conditions, a maximum of 99% conversion was achieved with 3 as representative and the 
selectivity of different products follows the order: 5-bromosalicylaldehyde (74%), 2,4,6-
tribromophenol (21%) > 3,5-dibromosalicylaldehyde (5%). Table 4.5 also provides % 
conversion of salicylaldehyde and selectivity of products obtained by other catalysts (1, 2, 4, 5) 
under above reaction conditions and is comparable to 3.  
In the absence of the catalyst, the reaction mixture gave only ca. 37% conversion of 
salicylaldehyde with the selectivity order of products: 5-bromosalicylaldehyde (89%) > 2,4,6-
tribromophenol (10.5%) > 3,5-dibromosalicylaldehyde (0.5 %) 
 
 
OH
Catalyst
KBr/H2O2/HClO4
O
OH
O
OH
O
OH
Br
Br
Br
Br Br
Br
a b c
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Table 4.4. Results of oxidative bromination of salicylaldehyde catalyzed by 3 after 3 h of 
contact time 
Entry 
no. 
Catalyst (g) H2O2 (g, mmol) KBr (g, mmol) HClO4(g, mmol) % Conversion 
1 0.0005 1.14, 10 1.19, 10 1.43,10 63 
2 0.0005 1.14, 10 1.19, 10 2.14, 15 88 
3 0.0005 1.14, 10 1.19, 10 2.86, 20 98 
4 0.0005 0.57, 05 1.19, 10 2.14, 15 65 
5 0.0005 1.71, 15 1.19, 10 2.14, 15 99 
6 0.0005 1.14, 10 0.59, 05 2.14, 15 48 
7 0.0005 1.14, 10 1.78, 15 2.14, 15 99 
8 0.0010 1.14, 10 1.19, 10 1.43,10 68 
9 0.0015 1.14, 10 1.19, 10 1.43,10 73 
 
 
 
Table 4.5. Effect of different catalysts (1-5) on the oxidative bromination of salicyldehyde, 
TOF and product selectivity 
Catalyst (g) TOF 
(h
-1
) 
% Conversion                       % Selectivity  
monobromo Dibromo Tribromo 
      
1 1375 99 71 0.6 28.4 
2 1375 99 68 7 25 
3 1375 99 74 5 21 
4 1500 99 71 0.5 28.5 
                5 3300 99  67 3 30 
 _____________________________________________________________________________ 
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4.3.6.3. Oxidation of methyl phenyl sulfide. Sulfoxides and sulfone, the oxidation product of 
sulfides, are useful precursors for biologically and chemically important compounds.
32,33
 used in 
various chemical reactions. Vanadium dependent haloperoxidases
1a,34
 and model complexes 
catalyse the oxidation of sulfides (thioethers) to sulfoxides and further to sulfones
30,35
 by H2O2. 
Such oxidation of methyl phenyl sulfide was tested using complexes 1–5, as catalyst and 
corresponding oxidation products were obtained as shown in Scheme 4.4. 
 
                
S
CH3 H2O2
Catalyst S
CH3
O
+
S
CH3
OO
 
                                                                             a                            b 
Scheme 4.4. Main products obtained upon oxidation of methyl phenyl sulfide. (a) methyl phenyl 
sulfoxide (b) methyl phenyl sulfone.  
 
The reaction conditions were optimized for the maximum oxidation of methyl phenyl sulfide by 
studying three different parameters viz. catalyst (amount of catalyst per mole of methyl phenyl 
sulfide), the effect of amount of oxidant (moles of H2O2 per mole of methyl phenyl sulfide) and 
and solvent of the reaction mixture in detail. The conversions obtained with all these conditions, 
plotted as a function of time, are presented in [Figure 4.13 (a-c)]. Thus for 5 mmol (0.620 g) of 
methyl phenyl sulfide, the amount of catalyst (0.0005 g, 0.001 g and 0.0015 g), 30% aqueous 
H2O2 (5, 10 and 15 mmol) and solvent (acetonitrile) volume (5, 10 and 15 mL) were varied and 
the reaction was carried out at room temperature. Table 4.6 summarizes all conditions and 
conversion obtained under particular condition taking 3 as the representative catalyst. The 
optimized conditions for highest catalytic activity with 94% conversion of methyl phenyl sulfide 
was concluded as: methyl phenyl sulfide (0.620 g, 5 mmol), 3 (0.001 g), 30% aqueous H2O2 
(1.14 g, 10 mmol) and CH3CN (5 mL) [entry no. 2, Table 4.6]. Effect of different catalyst (1–5) 
on oxidation of methyl phenyl sulfide is presented in Figure 4.13d. 
 
The percent conversion of methyl phenyl sulfide under the optimised reaction conditions and the 
selectivity of reaction products as a function of time is shown in Figure 4.14. It is clear from the 
plot that both the products start to form with the conversion of methyl phenyl sulfide. However, 
the initial selectivity of 96 % for methyl phenyl sulfoxide at 33.6 % conversion of methyl phenyl 
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sulfide in the first half an hour starts to decrease and reaches 65 % after 2.5 h of reaction time. 
Thus, initially formed sulfoxide further reacts with H2O2 present in the reaction mixture to give 
sulfone with 35% selectivity at the end of 2.5 h. 
 
 
 
Figure 4.13. (a) Effect of catalyst amount on the oxidation of methyl phenyl sulfide. Reaction 
conditions: methyl phenyl sulfide (0.620 g, 5 mmol), 30 % H2O2 (1.14 g, 10 mmol) and 
acetonitrile (5 mL). (b) Effect of oxidant amount on the oxidation of methyl phenyl sulfide. 
Reaction conditions: methyl phenyl sulfide (0.620 g, 5 mmol), catalyst (0.001 g) and acetonitrile 
(5 mL). (c) Effect of solvent amount on the oxidation of methyl phenyl sulfide. Reaction 
conditions: methyl phenyl sulfide (0.620 g, 5 mmol), catalyst (0.001 g) and 30 % H2O2 (1.14 g, 
10 mmol). (d) Effect of different catalyst (1–5) on oxidation of methyl phenyl sulfide. 
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Table 4.6. Conversion of methyl phenyl sulfide (0.620 g, 5 mmol) using 3 as catalyst in 2.5 h 
of reaction time under different reaction conditions 
 
Entry No. Catalyst [g] H2O2 [g, mmol] CH3CN [mL] Conv. [%] 
1 
2 
3 
4 
5 
6 
7 
0.0005 
0.0010 
0.0015 
0.0010 
0.0010 
0.0010 
0.0010 
1.14, 10 
1.14, 10 
1.14, 10 
0.57, 05 
1.71, 15 
1.14, 10 
1.14, 10 
5 
5 
5 
5 
5 
10 
15 
66 
94 
98 
67 
99 
34 
17 
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Figure 4.14. Plots showing percentage conversion of methyl phenyl sulfide and the selectivity of 
the formation of methyl phenyl sulfoxide and methyl phenyl sulfone as a function of time under 
optimized conditions using 3 as catalyst.  
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Other catalysts 1, 2, 4 and 5, tested under the above optimized reaction conditions gave maxima 
of 96%, 93%, 96.2% and 98% conversion, respectively. Thus, amongst the other complexes, the 
catalytic efficiency varies in the order: 5 > 4 > 1 > 3 > 2. The selectivity of different products 
along with the conversion and turn over frequency for these catalysts are presented in Table 4.7. 
It is clear from the table that the selectivity of the formation of methyl phenyl sulfoxide is nearly 
same in all cases but always higher than methyl phenyl sulfone.  
 
Table 4.7. Oxidation of methyl phenyl sulfide, conversion, TOF and product selectivity 
using 1–5, as catalyst 
Catalyst TOF [h
–1
]
 [a]
 Conv. [%] Selectivity [%]
[b]
 
mpso mpsn 
1 
 
800 96 63.5 36.5 
2 775 93 66.6 33.4 
3 
 
         783 94          65       35 
4 
 
835    96.2  66.7 33.3 
5 
 
1960 
 
98 66       34 
Blank reaction - 20 79       21 
[a] TOF values calculated at 2.5 h of reaction time. [b] mpso; methyl phenyl sulfoxide; mpsn: 
methyl phenyl sulfone. 
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4.3.7. DNA binding studies 
 
4.3.7.1. Absorption spectroscopic studies. DNA binding is a significant factor for chemical and 
photo-induced DNA cleavage activity of the metal complexes, therefore the binding affinity of 
the complexes (1–5) to CT-DNA was studied using various spectral techniques. UV-Vis titration 
experiments were used to determine the equilibrium binding constant (Kb) of the complexes to 
CT-DNA (Table 4.8). The electronic absorption spectra of 3 and 4  are shown in Figure 4.15. 
Binding of complexes to DNA through intercalation generally leads to hypochromism and 
bathochromism of the absorption band. This shift is observed due to the strong stacking 
interaction between the aromatic chromophore of the ligand and the base pairs of the DNA. 
Minor groove binding of the complexes to DNA results in hyperchromism in absorption 
intensity, resulting in the unwinding of the DNA double helix as well as its unstacking and 
concomitant exposure of the bases.
21
 Therefore the extent of hypochromism or hyperchromism 
observed provides a measure of the strength of intercalative binding or minor groove binding of 
the complexes. All the oxidoalkoxido vanadium(V) complexes 1–5, exhibited an intense 
absorption band in the range of 400 – 440 nm which is attributed to ligand to vanadium (d) 
charge transfer (LMCT).
15a
 On addition of calf thymus DNA to the complexes, they show a 
hypochromic shift in the LMCT absorption band which suggests the binding of CT-DNA to the 
complexes. Interestingly 3 and 4 shows a significant and drastic hypochromism than other 
complexes, which implies that these two complexes have a higher binding affinity towards CT-
DNA than others. Therefore, a decrease in the absorption intensity in the LMCT absorption band 
due to the addition of CT-DNA to the complexes indicates that there is an interaction/binding 
between the complexes and CT-DNA. 
In order to quantify the binding affinity of the interaction between CT-DNA and each of the 
complexes 1–5, the binding constant (Kb) was calculated using Eq. 1 (Experimental Section). 
The Kb values reported in Table 4.8 reveal that 3 and 4 are strongly bound with CT-DNA as 
compared with the others, with binding constant of 7.16  105 and 2.73  105 M-1, respectively. 
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Table 4.8. Thermodynamic data for CT-DNA binding with 1–5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complex  Binding Constant (M
-1
) ∆Tm (
o
C) 
1 2.35  104 -0.27 
2 2.48  104 0.15 
3 7.16  105 -1.46 
4 2.73  105 -1.11 
5 9.29  104 0.66 
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Figure 4.15. Electronic absorption spectra of 3 (a) and 4 (b) (25 M each) upon the titration of 
CT-DNA (0 – 65 M) in 10 mM Tris-HCl buffer (pH 8.0) containing 10% DMF. Arrow shows 
the changes in absorbance with respect to an increase in the CT-DNA concentration. The inset 
shows the linear fit of [DNA]/(εa - εf) vs [DNA] and binding constant (Kb) was calculated using 
Eq.1. 
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4.3.7.2. Thermal denaturation studies. To understand the nature of interaction between CT-
DNA and these complexes, thermal denaturation experiments were performed. The melting 
temperature of CT-DNA in absence of any complex is ~65.7 °C which is in good agreement with 
previous results.
36
 The melting temperature of CT-DNA increased very slightly upon interaction 
with complex 2 and 5 whereas a slight decrease in the melting temperature of CT-DNA was 
observed upon interaction with complex 1 (Figure 4.16, Table 4.8). On the other hand a 
substantial decrease in the melting temperature of CT-DNA was observed when it interacts with 
complex 3 and 4. This significant decrease in the melting temperature of CT-DNA may be due to 
the destabilisation of DNA double helix by these two complexes. A similar kind of property is 
also shown by well known alkylating agents cisplatin and its derivatives.
37,38
 A small shift in the 
DNA melting temperature suggest that the interaction between the complexes and CT-DNA 
follows a groove binding mode. 
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Figure 4.16. Derivative plot of thermal denaturation of CT-DNA (160 M) in absence and 
presence of 1–5 (50 M). The experiment was done in 10 mM Tris-HCl buffer (pH 8.0) 
containing 10% DMF. Inset shows the ∆Tm (
o
C) of the complexes as compared to CT-DNA.  
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4.3.7.3. Circular dichroism studies. The conformational changes in CT-DNA due to interaction 
with the complexes (1–5) were monitored using circular dichroism (CD) spectroscopy.39 The B-
conformation of CT-DNA shows two conservative CD bands in the UV region, a positive band 
at 275 nm due to base stacking and a negative band at 245 nm due to right handed helicity.
39
 
Groove binding and electrostatic interaction of small molecules shows less or no perturbation on 
the base stacking and helicity bands whereas an intercalation mode can induce intensity changes 
of both bands, thus modulating the right handed B-conformation of DNA.
39
 The CD spectra of 
CT-DNA (160 M) in the presence of the complexes (1–5) showed an increase in the negative 
ellipticity at 245 nm as well as an enhanced positive ellipticity at 275 nm (Figure 4.17). 
Therefore, the spectral behavior of the complexes (1–5) with CT-DNA suggests that the binding 
of DNA to the complexes follows a minor groove mode of binding, which is in coherence with 
the results of our absorption studies.  
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Figure 4.17. Circular dichroism spectra of CT-DNA (160 M) in the presence and absence of  1-
5 (25 M) in 10 mM Tris-HCl buffer (pH 8.0). The path length of the cuvette was 10 mm. 
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4.3.8. DNA cleavage studies. 
 
4.3.8.1. Chemical-induced DNA cleavage. The cleavage of supercoiled (SC) pUC19 DNA 
(300ng) by 1–5 (1–500 M) in the dark was done with the aid of hydrogen peroxide as the 
oxidising agent. The complexes do not show any apparent DNA cleavage implying no hydrolytic 
cleavage activity. The lack of chemical nuclease activity may be due to their weak interaction 
and binding with DNA. 
 
4.3.8.2. Photo-induced DNA cleavage. To investigate whether the DNA binding properties of 
the complexes were associated with photonuclease activity, a photo-induced nuclease activity 
assay was performed. Photo-induced DNA nuclease activity of 1–5 was studied using 
supercoiled (SC) pUC19 DNA in 50 mM Tris-HCl buffer (pH 8.0) upon irradiation of UVA light 
of 350 nm with the aid of gel electrophoresis in the presence and absence of the complexes 
(Figure 4.18). The extent of SC DNA cleavage by the complexes was monitored in a 
concentration dependent manner as shown in Figure 4.19. All the oxidoalkoxido vanadium(V) 
complexes showed greater than 10% DNA cleavage activity at a concentration of 50 M (Figure 
4.19, inset). Among all the complexes, 3 showed the highest DNA cleavage activity of ~20% at a 
concentration of 50 M of the complex which correlates well with its DNA binding parameters 
(Table 4.8). Control experiments were suggest that neither DMF (10%) nor the ligands exhibited 
show photo-induced DNA cleavage activity, which implies that ligands or DMF (10%) alone are 
cleavage inactive under the similar conditions (Figure 4.20). 
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Figure 4.18. Gel diagram showing concentration dependent DNA cleavage by 1–5; 300 ng of SC 
pUC19 DNA at different concentrations of the complexes [1–500 µM in 50 mM Tris-HCl buffer 
(pH 8.0) containing 10% DMF] was photo-irradiated with UVA at 350 nm for 3 h. Lanes 1–9: 1, 
2.5, 5.0, 7.5, 10, 50, 75, 100 and 500 µM of 1–5. 
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Figure 4.19. Concentration dependent DNA cleavage by 1–5; 300 ng of SC pUC19 DNA at 
different concentration of the complexes [1–500 µM in 50 mM Tris-HCl buffer (pH 8.0) 
containing 10% DMF] was photo-irradiated with UVA at 350 nm for 3 h. The net DNA cleavage 
percent was calculated using Eq.2. Inset shows a bar diagram representation of the net DNA 
cleavage of different complexes at 50 and 500 µM. 
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Figure 4.20. Effect of DMF (10%) and ligands on the photo-induced cleavage of SC pUC19 
DNA. 300 ng pUC19 DNA with either 10% DMF or various ligands (100 M) was photo-
irradiated with UVA at 350 nm for 3 h. Lane 1, DNA only; Lane 2, DNA in presence of 10% 
DMF; Lane 3, DNA + H2L
1
; Lane 4, DNA + H2L
2
;
 
Lane 5, DNA + H2L
3
; Lane 6, DNA + H2L
4
. 
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4.4. CONCLUSION 
 
The following are the salient observations of the present work:  
a) Four oxidoethoxido vanadium(V) [V
V
O(L
1-4
)OEt] (1–4) and one dinuclear oxidoethoxido 
mixed-ligand vanadium(V) [{VO(L
2
)OEt}2(Q)] {Q = 4,4′-bipyridine}(5), complexes, taking 
potentially tridentate binegative aroylhydrazone ligands are reported. 
b) All the complexes were characterized by various elemental as well as spectroscopic 
techniques. Single crystal X-ray diffraction crystallography of 1–4 reveals that the metal centre is 
in distorted square pyramidal geometry with O4N coordination spheres, whereas 5 exhibits a 
distorted octahedral geometry around the metal center. 
c) The solution behavior of the oxidoethoxido vanadium(V) species, 1–4 was studied, which 
indicates the existence of a new (2
nd
) species generated insitu in solution state. These 2
nd
 species 
were characterized by spectroscopic techniques (IR, NMR, ESI-MS). 
d) Catalytic potential of 1–5 was tested for the oxidative bromination of styrene, salicylaldehyde 
and oxidation of methyl phenyl sulphide and are found to act as efficient catalyst. 
e) Complexes 1–5, showed good DNA binding propensity. Their DNA binding activities were 
investigated using UV-Vis absorption titration, circular dichroism and thermal denaturation 
studies. The experimental results show that the complexes effectively interact with CT-DNA by 
an groove binding mode, with binding constants ranging from 10
4−105 M-1. Among 1–5, 
complex 3 and 4 shows higher binding affinity towards CT-DNA than others. 
f) In all complexes show moderate photo-induced cleavage of pUC19 supercoiled plasmid DNA 
with complex 3 showing the highest photo induced DNA cleavage activity of ~20% at a 
concentration of 50 M.  
 
 
 
 
 
 
 
 
 
 
 
152 
 
 
4.5. REFERENCES 
 
(1) (a) Rehder, D. Bioinorganic Vanadium Chemistry; Wiley: Chichester, UK, 2008. (b) Kustin, 
K.; Pesssoa, J. C.; Crans, D. C.; Eds. Vanadium: The Versatile Metal; ACS Symposium Series 
974; American Chemical Society: Washington, DC, 2007. (c) Tracey, A. S.; Willsky, G. R.; 
Takeuchi, E. S. Vanadium Chemistry, Biochemistry, Pharmacology and Practical Applications; 
CRC Press: Boca Raton, FL, 2007. (d) Crans, D. C.; Smee, J. J.; Gaidamauskas, E.; Yang, L. 
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Chapter 5 
 
Syntheses and structural investigation of some alkali metal ion-mediated LV
V
O2
-
 (L
2-
 = 
Tridentate ONO ligands) species: DNA binding, photo-induced DNA cleavage and 
cytotoxic activities 
 
ABSTRACT 
_____________________________________________________________________________ 
Eight, alkali metal ion-mediated dioxido vanadium(V), [{V
V
O2L
1-6
}A(H2O)n], complexes for A 
= Li
+
, Na
+
, K
+
 and Cs
+
, containing tridentate aroylhydrazonate ligands coordinating via ONO 
donor atoms, are described. All the synthesised ligands and the metal complexes were 
successfully characterised by elemental analysis, IR, UV-Vis and NMR spectroscopy. X-ray 
crystallographic investigation of 3, 5−7 shows the presence of distorted NO4 coordination 
geometries for LVO2
-
 in each case, and varying -oxido and/or -aqua bridging with interesting 
variations correlated with the size of the alkali metal ions: with small Li
+
, no bridging-O is found 
but four ion aggregates are found with Na
+
, chains for K
+
 and finally, layers for Cs
+
. Two (5) or 
three-dimensional (3, 6 and 7) architectures are consolidated by hydrogen bonding. The dioxido 
vanadium(V) complexes were found to exhibit DNA binding activity due to their interaction 
with CT-DNA by the groove binding mode, with binding constants ranging from 10
3 −104 M-1. 
Complexes 1−8 were also tested for DNA nuclease activity against pUC19 plasmid DNA which 
showed that 6 and 7 had the best DNA binding and photonuclease activity; these results support 
their good protein binding and cleavage activity with binding constants ranging from 10
4 −105  
M
-1
. Finally, the in vitro antiproliferative activity of all complexes was assayed against the HeLa 
cell line. Some of the complexes (2, 5, 6 and 7) show considerable activity compared to 
commonly use chemotherapeutic drugs. The variation in cytotoxicity of the complexes is 
influenced by the various functional groups attached to the aroylhydrazone derivative. 
______________________________________________________________________________ 
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5.1. INTRODUCTION 
Metal-based anticancer drug discovery is at the forefront of pharmaceutical research. Metal 
complexes which can efficiently bind and cleave DNA under physiological conditions are 
considered as potential candidates for use as therapeutic agents in medicinal applications and for 
genomic research.
1–6
 Therefore, attempts are being made to replace the most successful anti-
cancer drug cisplatin with suitable alternatives and hence numerous transition metal complexes 
have been synthesised and tested for their anti-cancer activities. Among the transition metals, the 
coordination chemistry of the vanadium attracts increasing interest because of the use of many 
vanadium complexes as models for the biological functions of vanadium,
7–10
 such as 
haloperoxidation,
11
 phosphorylation,
12
 insulin mimicking,
13–17
 nitrogen fixation,
18
 tumour growth 
inhibition and prophylaxis against carcinogenesis.
19
 This bioelement takes part in various DNA 
maintenance reactions and thereby prevents genomic instability which otherwise leads to 
cancer.
20,21
 Vanadium complexes could also suppress the growth and spread of existing tumours 
by inhibiting tumour cell proliferation, inducing apoptosis and limiting the invasion and 
metastatic potential of neoplastic cells. Moreover, it has been found that oxido vanadium 
complexes that efficiently interact with DNA also show antitrypanosomatid activity.
21-23
 Thus, 
the DNA-binding, DNA photocleavage and anti-proliferative activity of oxidometal complexes 
based on vanadium and multifunctional ligands have been of recent interest.
24
 
Additionally, in recent times a new area of research involving the design and synthesis of 
extended frameworks via supramolecular interactions has emerged. Hydrogen bonding 
interactions have been particularly explored in the context of molecular recognition and 
engineering of molecular solids.
25
 Many studies have focused on the use of monovalent alkali 
metals as a source of counter ion for the formation of polymeric aggregates,
26
 featuring channels 
or sheets of metal ions and which may have potential to act as ionic conductors,
27
 charge storage 
materials as well as biomimetic models.
28
 In most of these cases the water molecules are present 
as part of aquated A
+
 ions (A = alkali metal), and play a vital role in holding the components of 
the assembly together through hydrogen bonding networks and thereby enhancing the stability 
through charge neutralisation. In the context of the present study it is relevant to mention that 
although the pharmacological activity of many vanadium-hydrazone complexes has been 
studied
21-23
 and the syntheses and structural investigation of alkali metal ion-mediated LV
V
O2
- 
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complexes have been reported previously,
26b,c,h,i
 the study of pharmacological activity of the 
latter has yet to be explored. 
Hydrazones, –NH–N=CRR' (R and R = H, alkyl, aryl), are versatile ligands and have 
applications in the fields of analytical
29
 and medicinal chemistry.
30
 Hydrazone moieties are 
important pharmacophoric cores of several anti-cancer, anti-inflammatory, anti-nociceptive and 
anti-platelet drugs.
31
 Moreover, the electronic effects of hydrazone complexes are also important 
in the design of complexes with better DNA-binding and cleaving characteristics.
32
 In addition, 
the presence of a rigid aromatic system in the Schiff base structure gives rise to particular 
spectroscopic properties, which makes it a potential probe for nucleic acids. Recently, reports on 
vanadium hydrazone complexes with potential biological properties have appeared.
33
 In this 
context, the utilisation of the intercalating aroylhydrazone moiety when coordinated to vanadium 
might accentuate the biochemical activity of the derived hybrid molecules, which may lead to 
efficient DNA binding and cleavage. As the complexes cause photocleavage of DNA and exhibit 
photocytotoxic properties, these are established as important potential chemotherapeutic 
agents.
23,34
 In short, the new oxido vanadium complexes may prove to be a promising and 
attractive approach in the search for new potential drugs for the treatment of cancer. 
 
For the past few years, we have been studying the chemistry of oxido-metal complexes including 
those of vanadium, in N,O-donor environments
35
 along with electro-generation of mixed-valence 
divanadium(IV,V),
35a,b 
and some highly stable nonoxido vanadium(IV) complexes.
36
 Although 
many hydrazone complexes exhibit good biological activities, their water-solubility is still 
unsatisfactory, which may restrict their application. Hence, it seemed of interest to synthesise 
some new water-soluble dioxido-metal complexes of hydrazones which may have significant 
pharmacological effects. 
 
In previous studies it was found a change in the substituent in the hydrazone moiety changed bio-
activity.
36
 In connection with that, in the present chapter the syntheses, structural investigation 
and pharmacological activities of some water-soluble alkali metal (Li
+
, Na
+
, K
+
 and Cs
+
) ion-
mediated dioxido vanadium(V) hydrazone complexes, with varying substitution, that show 
interesting DNA binding, photo-induced DNA cleavage and cytotoxicity profiles activities, is 
reported. The interaction of these complexes with calf-thymus DNA (CT-DNA) was investigated 
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using UV-Vis absorption titration, circular dichroism and thermal denaturation studies. Their 
photo-cleavage reactions with pUC19 supercoiled plasmid DNA were investigated by gel 
electrophoresis, and for 6 and 7, the protein binding and cleavage activity were also tested. In 
addition, the cytotoxicity of the new complexes against the HeLa cell line was assessed by the 
MTT assay. 
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5.2. EXPERIMENTAL SECTION 
5.2.1. General Methods and Materials. All chemicals were purchased from commercial 
sources and used without further purification. [VO(acac)2] was prepared as described in the 
literature.
37
 MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium) and DAPI (4′,6-
diamidino-2-phenylindole dihydrochloride) were purchased from Sigma Aldrich (USA). 
Minimal essential medium (MEM) was purchased from Gibco, India. Reagent grade solvents 
were dried and distilled prior to use. The supercoiled (SC) pUC19 DNA was purified from E. 
coli cells with the aid of GeneJET Plasmid Isolation Kit (Thermo Scientific, USA). Calf thymus 
(CT) DNA was purchased from SRL (India) (biochemistry grade). Agarose (molecular biology 
grade) and bovine serum albumin (BSA) was purchased from Sigma Aldrich (USA). Elemental 
analyses were performed on a Vario ELcube CHNS Elemental analyzer and IR spectra were 
recorded on a Perkin-Elmer Spectrum RXI spectrophotometer. 
1
H and
 13
C NMR spectra were 
recorded with a Bruker Ultrashield 400 MHz spectrometer using SiMe4 as the internal standard. 
Electronic spectra were recorded on a Perkin-Elmer Lamda25 spectrophotometer. 
 
5.2.2. Synthesis of Ligands (H2L
1–6
). Schiff base ligands, H2L
1-6 
were prepared in good yield by 
the condensation of acid hydrazide with the corresponding carbonyl compound in equimolar 
ratio in ethanol by a standard procedure.
38
 The resulting white compounds were filtered, washed 
with ethanol and dried over fused CaCl2. Elemental analysis results, NMR (
1
H and 
13
C) and IR 
data for all of these verified their preparation. 
 
H2L
1
. Yield: 68%. Anal. Calcd for C15H14N2O3: C, 66.65; H, 5.22; N, 10.36. Found C, 66.63; H, 
5.27; N, 10.38. FTIR (KBr pellet, cm
–1
): 3303 ν(O–H), 3053 ν(N–H), 1627 ν(C=O), 1615 
ν(C=N), 1580 ν(C=C/aromatic). 1H NMR (400 MHz, DMSO-d6): δ 13.18 (s, 1H, OH), 12.10 (s, 
1H, OH), 11.55 (s, 1H, NH), 8.00–6.88 (m, 8H, C6H4), 2.42 (s, 3H, CH3). 
13
C NMR (100 MHz, 
DMSO-d6): δ 162.69, 159.04, 157.11, 156.37, 134.22, 131.73, 131.02, 128.94, 120.23, 119.67, 
119.11, 117.76, 117.66, 117.36, 13.62. 
  
H2L
2
. Yield: 64%. Anal. Calcd for C14H12N2O3: C, 65.61; H, 4.72; N, 10.93. Found C, 65.63; H, 
4.74; N, 10.89. FTIR (KBr pellet, cm
–1
): 3383 ν(O–H), 3102 ν(N–H), 1629 ν(C=O), 1619 
ν(C=N), 1573 ν(C=C/aromatic). 1H NMR (400 MHz, DMSO-d6): δ 12.05 (s, 1H, OH), 11.79 (s, 
1H, OH), 11.22 (s, 1H, NH), 8.68 (s, 1H, CH), 7.91–6.90 (m, 8H, C6H4). 
13
C NMR (100 MHz, 
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DMSO-d6): δ 164.99, 159.50, 157.99, 149.48, 134.44, 132.08, 130.55, 129.95, 129.27, 119.85, 
117.76, 117.33, 116.92, 116.06.  
 
H2L
3
. Yield: 64%. Anal. Calcd for C15H14N2O2: C, 70.85; H, 5.54; N, 11.01. Found C, 70.82; H, 
5.56; N, 11.02. FTIR (KBr pellet, cm
–1
): 3341 ν(O–H), 3216 ν(N–H), 1650 ν(C=O), 1606 
ν(C=N), 1579 ν(C=C/aromatic). 1H NMR (400 MHz, DMSO-d6): δ 13.45 (s, 1H, OH), 11.37 (s, 
1H, NH), 7.99–6.91 (m, 9H, C6H4), 2.46 (s, 3H, CH3). 
13
C NMR (100 MHz, DMSO-d6): δ 
164.92, 159.29, 158.62, 133.47, 132.40, 131.72, 128.94, 128.86, 128.58, 119.91, 118.99, 117.80, 
14.48.  
 
H2L
4
. Yield: 69%. Anal. Calcd for C14H13N3O2: C, 65.87; H, 5.13; N, 16.46. Found C, 65.88; H, 
5.11; N, 16.50. FTIR (KBr pellet, cm
–1
): 3218 ν(O–H), 3099 ν(N–H), 1679 ν(C=O), 1607 
ν(C=N), 1574 ν(C=C/aromatic). 1H NMR (400 MHz, DMSO-d6): δ 13.32 (s, 1H, OH), 11.72 (s, 
1H, NH), 8.20–6.89 (m, 8H, C6H4), 2.42 (s, 3H, CH3). 
13
C NMR (100 MHz, DMSO-d6): δ 
163.40, 160.01, 159.21, 150.56, 140.84, 132.05, 129.19, 122.84, 122.63, 122.43, 119.68, 119.10, 
117.82, 14.78.  
 
H2L
5
. Yield: 62%. Anal. Calcd for C13H11N3O2: C, 64.72; H, 4.59; N, 17.41. Found C, 64.68; H, 
4.58; N, 17.45. FTIR (KBr pellet, cm
–1
): 3167 ν(O–H), 3002 ν(N–H), 1683 ν(C=O), 1612 
ν(C=N), 1567 ν(C=C/aromatic). 1H NMR (400 MHz, DMSO-d6): δ 12.33 (s, 1H, OH), 11.14 (s, 
1H, NH), 8.69 (s, 1H, CH), 8.80–6.89 (m, 8H, C6H4). 
13
C NMR (100 MHz, DMSO-d6): δ 
161.83, 157.96, 150.81, 150.11, 149.56, 140.40, 132.19, 129.76, 123.17, 121.98, 119.88, 119.09, 
116.90.  
 
H2L
6
. Yield: 63%. Anal. Calcd for C15H15N3O2: C 66.90; H, 5.61; N, 15.60. Found C, 66.89; H, 
5.62; N, 15.63. FTIR (KBr pellet, cm
–1
): 3476 ν(O–H), 3364 ν(N–H2)s, 3207 ν(N–H2)as, 3028 
ν(N–H), 1627 ν(C=O), 1611 ν(C=N), 1573 ν(C=C/aromatic). 1H NMR (400 MHz, DMSO-d6): δ 
13.55 (s, 1H, OH), 11.09 (s, 1H, NH), 7.68–6.61 (m, 8H, C6H4), 2.48 (s, 3H, CH3). 
13
C NMR 
(100 MHz, DMSO-d6): δ 166.68, 159.23, 157.52, 150.49, 133.10, 131.54, 129.64, 128.78, 
119.99, 118.95, 117.77, 116.89, 115.30, 113.61, 14.35. 
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5.2.3. Synthesis of complexes [{VO2L
1-6
}A(H2O)n] (1–8). To the (1 mmol) sample of ligand 
H2L
1–6 
in 20 mL of ethanol, alkali metal carbonate (1 mmol) dissolved in 5 mL of water was 
added. The white suspension turned yellowish. The mixture was refluxed for 5 min to give a 
clear yellow solution. Thereafter a sample of [VO(acac)2] (1 mmol) was added under refluxing 
conditions. After 1h, the resulting deep-yellow solution was filtered and slow evaporation of the 
filtrate over 4–5 days produced thin yellow or orange crystals. The crystals were filtered and 
washed with ethanol. Elemental analysis results, NMR (
1
H, 
13
C, 
51
V), UV-Vis and IR data for all 
of these verified their preparation. 
 
[{VO2L
1
}Li(H2O)3] (1). Yield: 63%. Anal. Calcd for C15H18LiN2O8V: C, 43.70; H, 4.40; N, 
6.79. Found: C, 43.67; H, 4.42; N, 6.78. FTIR (KBr pellet, cm
–1
): 3400 ν(O–H), 1603 ν(C=N), 
1261 ν(C–O)enolic, 947, 901 ν(V=O). UV–Vis (DMF) [λmax, nm (ε, M
–1
 cm
–1
)]: 410 (25410), 365 
(33650), 278 (39321).
 1
H NMR (400 MHz, DMSO-d6): δ 12.58 (s, 1H, OH), 7.87–6.83 (m, 8H, 
C6H4), 2.73 (s, 3H, CH3). 
13
C NMR (100 MHz, DMSO-d6): δ 170.16, 164.98, 161.96, 159.42, 
133.23, 132.79, 130.20, 129.43, 122.36, 120.55, 119.15, 118.00, 116.96, 116.16, 17.12.
 51
V 
NMR (DMSO-d6): δ –542. 
 
[{VO2L
1
}K(H2O)2] (2). Yield: 67%. Anal. Calcd for C15H16KN2O7V: C, 42.26; H, 3.78; N, 
6.57. Found C, 42.24; H, 3.81; N, 6.55. FTIR (KBr pellet, cm
–1
): 3590 ν(O–H), 1599 ν(C=N), 
1253 ν(C–O)enolic, 921, 903 ν(V=O). UV–Vis (DMF) [λmax, nm (ε, M
–1
 cm
–1
)]: 408 (23910), 323 
(38209), 265 (43120).
 1
H NMR (400 MHz, DMSO-d6): δ 12.58 (s, 1H, OH), 7.83–6.84 (m, 8H, 
C6H4), 2.73 (s, 3H, CH3). 
13
C NMR (100 MHz, DMSO-d6): δ 170.14, 165.04, 161.90, 159.42, 
133.18, 132.71, 130.18, 129.47, 122.33, 120.61, 119.08, 117.88, 117.66, 116.19, 17.10. 
51
V 
NMR (DMSO-d6): δ –540.  
 
[{VO2L
2
}Li(H2O)4.5] (3). Yield: 63%. Anal. Calcd for C28H38Li2N4O19V2: C, 39.54; H, 4.50; N, 
6.58. Found C, 39.51; H, 4.49; N, 6.60. FTIR (KBr pellet, cm
–1
): 3457 ν(O–H), 1606 ν(C=N), 
1228 ν(C–O)enolic, 929, 905 ν(V=O). UV–Vis (DMF) [λmax, nm (ε, M
–1
 cm
–1
)]: 406 (30600), 336 
(44480), 265 (46680).
 1
H NMR (400 MHz, DMSO-d6): δ 12.21 (s, 1H, OH), 9.09 (s, 1H, CH), 
7.83–6.80 (m, 8H, C6H4).
 13
C NMR (100 MHz, DMSO-d6): δ 170.73, 165.19, 159.03, 156.78, 
134.20, 133.24, 133.15, 129.46, 120.06, 119.16, 117.52, 116.97, 115.94.
 51
V NMR (DMSO-d6): 
δ –539. 
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[{VO2L
2
}Cs(H2O)3] (4). Yield: 69%. Anal. Calcd for C14H16CsN2O8V: C, 32.08; H, 3.07; N, 
5.34. Found C, 32.04; H, 3.10; N, 5.35. FTIR (KBr pellet, cm
–1
): 3488 ν(O–H), 1607 ν(C=N), 
1227 ν(C–O)enolic, 920, 899 ν(V=O). UV–Vis (DMF) [λmax, nm (ε, M
–1
 cm
–1
)]:  403 (24160), 337 
(33200), 266 (35600). 
1
H NMR (400 MHz, DMSO-d6): δ 12.21 (s, 1H, OH), 9.11 (s, 1H, CH), 
7.85–6.81 (m, 8H, C6H4).
 13
C NMR (100 MHz, DMSO-d6): δ 170.74, 165.12, 159.04, 156.83, 
134.23, 133.26, 133.16, 129.50, 120.08, 119.18, 117.61, 116.99, 115.93.
 51
V NMR (DMSO-d6): 
δ –539.  
[{VO2L
3
}Cs(H2O)2] (5). Yield: 61%. Anal. Calcd for C15H14CsN2O5V: C, 37.06; H, 2.90; N, 
5.76. Found C, 37.03; H, 2.91; N, 5.79. FTIR (KBr pellet, cm
–1
): 3562 ν(O–H), 1599 ν(C=N), 
1243 ν(C–O)enolic, 946, 900 ν(V=O). UV–Vis (DMF) [λmax, nm (ε, M
–1
 cm
–1
)]: 390 (11240), 317 
(16200), 266 (19280).
 1
H NMR (400 MHz, DMSO-d6): δ 8.07–6.81 (m, 9H, C6H4), 2.87 (s, 3H, 
CH3).
 13
C NMR (100 MHz, DMSO-d6): δ 168.76, 164.27, 162.11, 133.36, 131.82, 130.60, 
129.60, 128.30, 128.11, 127.92, 122.48, 120.04, 117.39, 16.26.
 51
V NMR (DMSO-d6): δ  –534.  
 
[{VO2L
4
}K(H2O)2] (6). Yield: 63%. Anal. Calcd for C14H15KN3O6V: C, 40.88; H, 3.67; N, 
10.21. Found C, 40.85; H, 3.66; N, 10.24. FTIR (KBr pellet, cm
–1
): 3429 ν(O–H), 1601 ν(C=N), 
1248 ν(C–O)enolic, 943, 907 ν(V=O). UV–Vis (DMF) [λmax, nm (ε, M
–1
 cm
–1
)]: 395 (36920), 322 
(45840), 268 (50760).
 1
H NMR (400 MHz, DMSO-d6): δ 8.71–6.82 (m, 8H, C6H4), 2.89 (s, 3H, 
CH3).
 13
C NMR (100 MHz, DMSO-d6): δ 167.26, 165.01, 164.25, 150.49, 141.19, 132.60, 
130.19, 122.58, 122.15, 120.58, 117.78, 16.68.
 51
V NMR (DMSO-d6): δ –533.  
 
[{VO2L
5
}Na(H2O)4] (7). Yield: 60%. Anal. Calcd for C13H17N3NaO8V: C, 37.42; H, 4.10; N, 
10.07. Found C, 37.47; H, 4.13; N, 10.04. FTIR (KBr pellet, cm
–1
): 3531 ν(O–H), 1614 ν(C=N), 
1223, ν(C–O)enolic, 926, 907 ν(V=O). UV–Vis (DMF) [λmax, nm (ε, M
–1
 cm
–1
)]: 410 (65240), 328 
(77920), 268 (87560).
 1
H NMR (400 MHz, DMSO-d6): δ 9.05 (s, 1H, CH), 8.69–6.78 (m, 8H, 
C6H4).
 13
C NMR (100 MHz, DMSO-d6): δ 168.32, 165.44, 157.83, 150.52, 140.59, 134.15, 
133.34, 122.02, 120.11, 117.33.
 51
V NMR (DMSO-d6): δ –531. 
 
[{VO2L
6
}Cs(H2O)3] (8). Yield: 65%. Anal. Calcd for C15H19CsN3O7V: C, 33.54; H, 3.56; N, 
7.82. Found C, 33.56; H, 3.52; N, 7.85. FTIR (KBr pellet, cm
–1
): 3454 ν(O–H), 3365 ν(NH2)s, 
3237 ν(NH2)as, 1597 ν(C=N), 1253 ν(C–O)enolic, 932, 897 ν(V=O). UV–Vis (DMF) [λmax, nm (ε, 
M
–1
 cm
–1
)]: 398 (15780), 320 (21718). 258 (28242).
 1
H NMR (400 MHz, DMSO-d6): δ 7.83–
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6.84 (m, 8H, C6H4), 2.73 (s, 3H, CH3). 
13
C NMR (100 MHz, DMSO-d6): δ 170.76, 164.81, 
160.67, 149.45, 132.02, 131.60, 129.87, 122.86, 120.44, 117.56, 116.80, 115.19, 114.99, 113.74, 
17.20. 
51
V NMR (DMSO-d6): δ –540.  
 
5.2.4. X-ray Crystallography. Intensity data for 3, 5-7 were collected on a Bruker APEXII 
diffractometer equipped with a CCD area detector and graphite-monochromated Mo K 
radiation ( = 0.71069 Å). Crystal data and refinement details are given in Table 5.1. Data 
reduction and empirical absorption correction, based on the multi-scan method, was by standard 
methods.
39
 The structures were solved by direct methods using SHELXS97
2
 and refinement 
(anisotropic displacement parameters and C-bound hydrogen atoms in idealised positions) of 
each structure was carried out on F
2
 by using full-matrix least-squares procedures.
40
 Based on 
hydrogen bonding considerations, the hydroxyl- and water-H atoms in 3 were included in their 
idealised positions. The water-H atoms in 5 and 7 were located from the respective difference 
Fourier maps and refined with the distance restraint O‒H = 0.84±0.01 Å. The water-H atoms in 6 
were located in the case of the O1w water molecule but not for O2w. For the latter, the H atoms 
were placed based on stereochemical grounds and all refined with the distance restraint O‒H = 
0.84±0.01 Å. While the O1w molecule formed the anticipated hydrogen bonding interactions, the 
same was not true for the O2w water molecule which exists in a pocket, forming O...O 
separations in the range 2.852(4) to 3.364(2) Å with four putative hydrogen bond acceptors as 
detailed in Table 5.2. Therefore, it was concluded that the O2w-bound hydrogen atoms are 
disordered over several positions. Molecular structure diagrams, showing the atom labelling 
schemes, were drawn with 50% (6 and 7) or 70% (3 and 5) displacement ellipsoids using 
ORTEP-3 for Windows,
41
 the overlay diagrams were drawn with QMol
42
 and the remaining 
crystallographic figures were drawn with DIAMOND.
43
 Data manipulation and interpretation 
were accomplished using WinGX
3
 and PLATON.
44 
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Table 5.1. Crystal data and refinement details for 3, 5–7 
    3     5    6    7 
Empirical formula 
Li2, 2(C14H10N2O5V), 
9H2O 
Cs, C15H12N2O4V, 
H2O 
K, C14H11N3O4V, 
2H2O 
Na, C13H9N3O4V, 
4H2O 
Formula weight 850.38 486.13 411.33 417.23 
Crystal size (mm) 0.15  0.15  0.60  0.04  0.07  0.30 
0.03 0.05 
0.32 
0.03  0.04  
0.27 
Crystal 
morphology,   
colour 
Prism, orange Prism, yellow Prism, yellow Prism, yellow 
Temperature (K) 100(2) 100(2)  293(2)  293(2) 
Crystal system Triclinic  Monoclinic Orthorhombic Triclinic 
Space group 
P
_
1 
P21/c Pbca P
_
1 
 a (Å) 6.8227(2) 15.430(2) 11.6880(4)  7.7429(8)  
b (Å) 15.4441(6) 7.1128(10) 8.2858(2) 10.3131(10) 
 c (Å) 18.3454(7) 30.505(4) 34.9484(11)  12.0373(13)  
 (°) 67.969(2) 90 90 109.590(6) 
 (°) 80.954(2) 98.682(8) 90 104.363(5) 
 (°) 89.346(2) 90 90 92.983(5) 
V (Å3) 1767.24(11) 3309.5(8)  3384.56(18)  867.59(15)  
Z 2 8 8 2 
Dx (g cm
–3) 1.598 1.951 1.614 1.597 
 (mm–1) 0.616 2.795 0.868 0.644 
 range (°) 2.2–28.5 1.8–28.4 2.1–30.6 1.9–30.7 
Reflections 
measured 
24488 107431 63472 17852 
Independent 
reflections; Rint 
8797; 0.026 8117; 0.049 5179; 0.070 5283; 0.028 
Reflections with I > 
2(I) 
7372 6866 3225 4107 
Number of 
parameters 
498 447 239 259 
R(F) [I> 2(I) 
reflns] 
0.036 0.028 0.046 0.042 
a, b in wghting 
scheme 
0.054, 0.949 0.019, 5.712 0.040, 1.998 0.057, 0.095 
wR(F2) (all data) 0.102 0.059 0.109 0.111 
max, min (e Å
–3) 0.54, -0.50 0.95, -0.92  0.43, -0.48  0.39, -0.27  
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Table 5.2. Summary of intermolecular interactions (A–H…B; Å, º) operating in the crystal 
structures of 3, 5-7.
a
 
A H B A–H H…B A…B A–H…B Symmetry       operation 
3 
O1 H1O N1 0.84 1.83 2.567(2) 146 x, y, z 
O6 H6O N3 0.84 1.83 2.571(2) 146 x, y, z 
O1W H1W1 O9 0.80 1.93 2.7126(19) 167 x, y, z 
O1W H1W2 O5 0.80 2.01 2.7486(19) 153 x, y, -1+z 
O2W H2W1 O3 0.80 2.09 2.886(2) 173 -1+x, y, -1+z 
O2W H2W2 O8W 0.80 2.04 2.817(2) 165 -1+x, y, z 
O3W H3W1 O7 0.80 2.24 2.972(2) 152 1-x, 1-y, -z 
O3W H3W1 O10 0.80 2.46 3.108(2) 139 1-x, 1-y, -z 
O3W H3W2 O9W 0.80 1.99 2.774(2) 165 x, y, z 
O4W H4W1 O8 0.80 2.06 2.831(2) 163 -1+x, y, z 
O4W H4W2 O7 0.80 2.31 3.088(2) 165 x, y, z 
O5W H5W1 O8W 0.80 1.97 2.736(2) 159 -1+x, y, z 
O5W H5W2 O2 0.80 2.14 2.937(2) 171 1-x, -y, 1-z 
O6W H6W1 O2 0.80 2.06 2.8552(19) 169 x, y, -1+z 
O6W H6W2 O3 0.80 2.39 3.079(2) 145 -1+x, y, -1+z 
O6W H6W2 O4 0.80 2.36 3.0187(19) 140 -1+x, y, -1+z 
O7W H7W1 O4 0.80 1.95 2.744(2) 173 x, y, -1+z 
O7W H7W2 O6W 0.80 2.04 2.825(2) 166 1-x, -y, -z 
O8W H8W1 O8 0.80 2.41 3.073(2) 141 x, y, z 
O8W H8W1 O9 0.80 2.27 2.959(2) 145 x, y, z 
O8W H8W2 O7W 0.80 1.97 2.760(2) 169 x, y, z 
O9W H9W1 O10 0.80 1.97 2.767(2) 178 x, y, z 
O9W H9W2 O2W 0.80 1.99 2.785(2) 171 1+x, y, z 
C8 H8 O6 0.95 2.35 3.274(2) 165 1+x, y, z 
C22 H22 O1 0.95 2.30 3.240(2) 168 x, y, z 
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5 
O1W H1W1 O2 0.84(2) 2.43(3) 3.038(3) 130(2) x, y, z 
O1W H1W1 O4 0.84(2) 2.48(2) 3.274(3) 159(2) x, y, z 
O1W H1W2 O4 0.84(3) 1.89(2) 2.723(3) 170(3) 1-x, 1-y, 1-z 
O2W H2W1 O6 0.85(3) 1.96(3) 2.776(3) 160(3) -x, -1-y, 1-z 
O2W H2W2 O7 0.85(3) 2.15(3) 2.986(3) 171(2) x, -1+y, z 
 
6 
O1W H1W1 O1 0.85(3) 2.11(4) 2.931(3) 162(3) ½-x, ½+y, z 
O1W H1W2 N1 0.837(18) 2.01(2) 2.815(3) 162(4) 1-x, -y, -z 
C5 H5 O4 0.93 2.54 3.439(3) 164 1-x, -y, -z 
C7' H72 Cg1 0.96 2.56 3.477(3) 159 1½-x, - ½+y, z 
O2W H2W2 O3 0.863(14) 2.44(5) 2.852(4) 110(4) ½-x, ½+y, z 
The O2W-water molecule atom lies in a pocket comprising the O3 atom, see above, and the O1W (separation 3.313(2) Å),   O3 
(3.261(2) Å) and O4 (3.364(2) Å) atoms. 
Cg1 is the centroid of the (C8-C13) ring 
7 
O1W H1W1 O1 0.82(3) 2.17(3) 2.975(2) 165(2) x, y, z 
O1W H1W2 O4W 0.83(3) 1.97(3) 2.787(2) 166(3) 1-x, -y, 2-z 
O2W H2W1 O3 0.84(3) 2.08(3) 2.885(2) 162(3) -1+x, y, z 
O2W H2W2 O4W 0.83(3) 1.98(3) 2.809(2) 173(3) x, y, z 
O3W H3W1 O2W 0.83(3) 2.24(3) 3.015(3) 156(3) -x, -y, 2-z 
O3W H3W2 N2 0.83(3) 2.26(3) 2.991(3) 147(3) 1-x, 1-y, 2-z 
O4W H4W1 N1 0.834(13) 1.982(13) 2.808(2) 171(2) -1+x, -1+y, -1+z 
O4W H4W2 O2 0.84(2) 2.06(2) 2.876(2) 166(2) x, y, z 
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5.2.5. DNA binding experiments. 
 
5.2.5.1. Absorption spectral studies. Binding of the dioxido vanadium(V) complexes to calf 
thymus (CT) DNA was studied in 10 mM Tris–HCl buffer (pH 8.0) containing 10% DMF.     
UV-Vis absorption titration experiments were performed with Perkin-Elmer Lamda35 
spectrophotometer using a fixed concentration of metal complex (25 M) but variable nucleotide 
concentrations ranging from 0 to 100 M. After each addition of DNA (10 M) to the metal 
complex, the readings were noted. The data were then fit to the following equation to obtain 
binding constant Kb
45 
  
[DNA ]
εa − εf
=  
[DNA ]
εb − εf
+  
1
Kb (εb − εf )
 ;                                Eq. 1 
where [DNA] is the concentration of DNA base pairs, εa, εf  and εb correspond to apparent 
extinction co-efficient for the complex i.e. Abs/[complex] in presence of DNA, in absence of 
DNA and to fully bound DNA respectively. A plot of [DNA]/(εa - εf) vs [DNA] gave a slope and 
the intercept equal to 1/(εb - εf) and 1/Kb(εb - εf), respectively. The binding constant Kb is 
calculated from the ratio of the slope to the intercept. Binding of ligands to CT-DNA was also 
studied. In order to find out the binding constant (Kb) of ―ligand-DNA interaction‖, a fixed 
concentration of ligand [25 M in 10 mM Tris–HCl buffer (pH 8.0) containing 10% DMF] was 
titrated with variable DNA concentration ranging from 0 to 350 M.  
 
5.2.5.2. Thermal denaturation studies. Thermal denaturation studies of CT-DNA (160 M) in 
the absence and presence of complexes (100 M) were carried out by monitoring the absorbance 
at 260 nm in the temperature range of 30-90 
o
C with a ramp rate of 1 
o
C/min in 10 mM Tris-HCl 
buffer (pH 8.0). The experiments were carried out using a Chirascan CD spectropolarimeter 
(Applied Photophysics, UK) in absorbance mode equipped with quantum temperature controller. 
The melting of the double stranded DNA to single stranded DNA was observed with significant 
hyperchromicity of absorbance at 260 nm. The melting temperature (Tm) was determined from 
the derivative plot (dA260/dT vs T) of the melting profile.
46
  
 
5.2.5.3. Circular dichroism studies. The Circular Dichroism (CD) spectroscopy was studied 
using Chirascan CD spectropolarimeter (Applied Photophysics, UK) at 25 
o
C. CD spectra of CT-
DNA (160 M) in absence and presence of complexes (300 M) were obtained in the 
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wavelength range of 240–400 nm in 10 mM Tris-HCl buffer (pH 8.0) using quartz cell with 2 
mm path length.
46
 
 
5.2.6. DNA cleavage experiments. 
For DNA cleavage experiments, 300 ng supercoiled (SC) pUC19 DNA was used and all 
experiments were carried out in 50 mM Tris-HCl buffer (pH 8.0) containing 10% DMF. The 
photo-induced DNA cleavage experiments were also carried out in 10 mM phosphate buffer (pH 
7.8) containing 1 % DMF or 10 mM Tris-HCl buffer (pH 8.0) containing 1% DMF. 
 
5.2.6.1. Chemical-induced DNA cleavage. For chemical nuclease studies, the reactions were 
performed in the dark using hydrogen peroxide (0.5 mM) as the oxidising agent in absence and 
presence of complexes (1 – 500 µM). The solutions were incubated at 37 oC for 3 h and analysed 
for DNA cleaved products by agarose gel electrophoresis. 
  
5.2.6.2. Photo-induced DNA cleavage. The effect of complexes (1 – 500 µM) on the cleavage 
of supercoiled (SC) pUC19 DNA (300 ng) was studied by agarose gel electrophoresis in 50 mM 
Tris HCl buffer (pH 8.0). DNA photocleavage studies were carried out under illuminated 
conditions using UVA source at 350 nm (Luzchem Photoreactor Model LZC-1, Ontario, Canada) 
fitted with 14 UVA tubes for 3 h. After photo irradiation, each sample was further incubated for 
1.0 h at 37 
o
C and analyzed for the photo-cleaved products using gel electrophoresis. The 
samples after incubation were added to the loading buffer containing 0.25% bromophenol blue 
and 30% glycerol (2 µL) and the solution was finally loaded on 0.8% agarose gel containing 0.5 
µg/mL ethidium bromide (EB). Electrophoresis was carried out for 1.0 h at 90 V in TAE (Tris–
acetate EDTA) buffer. DNA cleavage was indicated by the decrease in the supercoiled pUC19 
DNA (Form I) and subsequently the formation of nicked circular DNA (Form II) and linearised 
DNA (Form III). Bands were visualised by UV light (302nm) and photographed. The extent of 
SC DNA cleavage was measured from the intensities of the bands using UVP (Gel Doc It
2
) Gel 
Documentation System. Due corrections were made for the low level of nicked circular (NC) 
form of DNA present in the original SC DNA sample and for the low affinity of EB binding to 
SC compared to NC and linear forms of DNA.
47 
The percentage of net DNA cleavage was 
calculated by the following equation: 
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Net DNA cleavage % =
Form  IIs +2 ×Form  IIIs
Form  Is+ Form  IIs +2 ×Form  IIIs
−  
Form  IIc +2 ×Form  IIIc
Form  Ic+ Form  IIc +2 ×Form  IIIc
        Eq.2 
 
The subscripts ―s‖ and ―c‖ refers to the sample and control respectively.48 Appropriate DNA 
controls were taken to calculate the   net DNA cleavage percent. The observed error in 
measuring the band intensities ranged between 3% - 6%. The mechanistic studies were done 
using different additives (sodium azide, L-histidine, KI and D-mannitol, each 0.5 mM) prior to 
the addition of the complex. 
 
5.2.7. Protein binding and cleavage experiments. 
 
5.2.7.1. Bovine serum albumin (BSA) interaction studies. The protein binding study was 
performed by tryptophan fluorescence quenching experiments using BSA (2 M) as a substrate 
in 10 mM Tris-HCl buffer (pH 8.0) using Fluoromax 4P spectrofluorimeter (Horiba Jobin 
Mayer, USA). The quenching of the emission intensity of tryptophan residues of BSA at 344 nm 
(excitation at 295 nm) was monitored with increasing complex concentration [0 – 20 M in 10 
mM Tris-HCl buffer (pH 8.0) containing 1% DMF].
49
 Stern-Volmer plots and Scatchard analysis 
were done using corrected fluorescence data taking into account the effect of dilution. Linear fit 
of the data using the Stern-Volmer  
equation, 
F0
F
= 1 +  KSV   Q           Eq.3 
and the Scatchard equation, 
log  
F0− F
F
 = log KBSA +  𝑛 log Q         Eq.4 
where F0 and F are the emission intensity of BSA in absence and in presence of the quencher 
(complexes) concentration [Q] respectively, gave the Stern-Volmer quenching constant (KSV), 
the binding constant (KBSA) and the number of binding sites (n).
45
  
 
5.2.7.2. BSA photo-induced cleavage studies. Freshly prepared solution of BSA in 10 mM 
Tris-HCl buffer (pH 8.0) was used for photochemical protein cleavage studies. BSA (5 M) 
solution in absence and presence of complexes [1 – 500 M in 10 mM Tris-HCl buffer (pH 8.0) 
containing 1% DMF] was photo-irradiated using UVA source at 350 nm (Luzchem Photoreactor 
Model LZC-1, Ontario, Canada) fitted with 14 UVA tubes (84 W) for 90 min. The irradiated 
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samples (20 L) were dissolved in loading buffer (20 L) containing SDS (7% w/v), glycerol 
(4% w/v), Tris-HCl buffer (50 mM, pH 6.8), mercaptoethanol (2% v/v) and bromophenol blue 
(0.01% w/v). The samples were then heat denatured at 100 
o
C for 5 min and loaded onto a 12% 
SDS PAGE separating gel. The gel electrophoresis was done at 60 V until the dye passed into the 
separating gel from the stacking (5 %) gel, and then the voltage was increased to 120 V. The gels 
were run for 2 h, stained with Coomassie Brilliant Blue R-250 solution (acetic acid: methanol: 
water = 1 : 5 : 4 v/v ) and destained with water:methanol:acetic acid mixture (5 : 4 : 1 v/v). The 
gels after destaining, were photographed by using the UVP (Gel Doc It
2
) Gel Documentation 
System. Molecular weight markers were used in each gel to calibrate the molecular weight of 
BSA.
49 
We also studied the BSA cleavage activity in dark as well as  in presence of UV-A light 
(84 W) for all the complexes with a molar ratio of BSA to complex 1:20. 
 
5.2.8. Cytotoxicity Studies 
 
5.2.8.1. MTT assay. Human cervical cells HeLa were obtained from National Centre of Cell 
Science (NCCS), Pune, India, and were maintained in minimal essential medium supplemented 
with 10% fetal bovine serum, penicillin-streptomycin solution and incubated at 37 °C in 5% CO2 
and 95% humidified incubator. HeLa cells were harvested from maintenance cultures in 
logarithmic phase, after counting in a hemocytometer using trypan blue solution. The cell 
concentration was adjusted to 5x10
4
 cells/ml and the cells were plated in a 96 well ﬂat bottom 
culture plate and incubated for 72 h with various concentrations of the test complexes which 
were dissolved in a 10% (v/v) DMF solution. The effect of the drugs on the cancer cell viability 
was studied using MTT dye reduction assay by measuring the optical density at 595 nm using 
micro-plate reader spectrophotometer (Perkin-Elmer 2030).
50
 A 10% (v/v) DMF solution which 
was used to dissolve the drugs was used in the control group treatment. 
 
5.2.8.2. Nuclear Staining. Nuclear staining using DAPI stain was performed according to the 
method previously described.
51
 Briefly, HeLa cells either treated or untreated with test 
compounds were smeared on a clean glass slide, cells were fixed with 3.7% formaldehyde for 15 
min, permeabilised with 0.1% Triton X-100 and stained with 1 μg/ml DAPI for 5 min at 37 °C. 
10% DMF solution which was used to dissolve the drugs was also used in control group 
treatment. The cells were then washed with PBS and examined by fluorescence microscopy 
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(Olympus IX 71) to ascertain any condensation or fragmentation of the nuclei indicating cells 
undergoing apoptosis. 
 
5.3. RESULT AND DISSCUSSION 
 
5.3.1. Synthesis. Eight dioxidovanadium(V) complexes [{V
V
O2L
1-6
}A(H2O)n] (1–8) have been 
prepared (Scheme 5.1) in the present study by taking six different aroyl hydrazones as ligands, 
with varying substitution in their hydrazone moieties, in order to observe their influence on the 
pharmacological activities of the complexes. Reactions of the selected aroylhydrazones with 
VO(acac)2 along with alkali metal carbonate proceed in refluxing ethanol / water afforded yellow 
or orange products in good yields. These compounds are highly soluble in protic, viz. water, 
ethanol and methanol, as well as in aprotic solvents, viz. CH3CN, DMF and DMSO. 
Alternatively, these complexes can also be synthesised using acetonitrile / water as solvent. 
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 Scheme 5.1. Schematic diagram of various pathways through which the dioxido vanadium(V) 
complexes[{V
V
O2L
1-6
}A(H2O)n] (1–8) were synthesised. 
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5.3.2. Spectral Characteristics 
 
The spectral (IR, UV-Vis and NMR) data of all the ligands, H2L
1–6
 and their corresponding 
dioxido vanadium(V) complexes, 1–8, are given in the Experimental Section. 
 
5.3.2.1. IR Spectroscopy. The infrared spectra of all the complexes, display a broad band in the 
range 3590–3400 cm–1, due to the O–H stretch of the coordinated water molecules which form 
extensive hydrogen bonding interactions. The disappearance of characteristic bands due to –NH 
and –C=O in the ligand spectra, and the appearance of new bands in the range 1261–1223 cm–1 
in the complexes indicates the enolisation of these two groups forming a –N=C–O bond 
sequence. The strong and sharp peak displayed by the complexes in the range 1614–1597 cm-1 is 
likely to be associated with the –C=N–N=C– moiety.35a,b,52 The presence of two strong bands in 
the range 947–897 cm-1 is assigned to V=O stretching,26h,i which clearly indicates the dioxido 
nature of the complexes. A representative spectrum of complex 6 is shown in Figure 5.1. 
 
5.3.2.2. UV Spectroscopy. The electronic spectra of the complexes 1–8 were recorded in DMF 
at 25 M concentration, and are quite similar for all eight complexes. A representative spectrum 
of complex 7 is shown in Figure 5.2. The strong absorptions are observed in the wavelength 
range 410–390 nm are assignable to the ligand-to-metal charge transfer transitions whereas the 
other bands in the higher energy region (365–258 nm) are likely to be due to ligand centred 
transitions.
35a,b 
 
5.3.2.3. NMR Spectroscopy. The 
1
H and 
13
C NMR data of the free ligands (H2L
1-6
) and 
corresponding dioxido vanadium(V) complexes (1–8) were recorded using DMSO-d6 and the 
data are given in the Experimental Section. The spectra of all the ligands exhibit resonances in 
the range δ = 13.55–11.79 ppm due to phenyl–OH and δ = 11.72–11.09 ppm due to –NH, which 
disappear in the spectra of the complexes confirming deprotonation and complexation of the 
ligands. The presence of resonances in the range δ = 12.58–12.21 ppm in complexes 1–4 is due 
to the uncoordinated –OH present in the hydrazide part of the ligand. Complexes 3, 4 and 7 
possess a resonance in the range δ = 9.11–9.05 ppm, and complexes 1, 2, 5, 6 and 8 display a 
singlet in the range δ = 2.89–2.73 ppm due to –CH and –CH3 group, respectively. All the 
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aromatic protons of the complexes are clearly observed in the expected region, δ = 8.71–6.78 
ppm.
35a,b
 A representative 
1
H NMR spectrum of complex 6 is shown in Figure 5.3. 
The 
51
V NMR spectra of 1–8 each displays a singlet in the range δ = –542.22 to –531.87 ppm. 
These chemical shifts are usual for complexes containing the dioxido vanadium(V) complexes.
53
 
 
 
 
 
 
   Figure 5.1. FTIR spectra of [{VO2L
4
}K(H2O)2] (6) 
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                  Figure 5.2. Electronic absorption spectra of [{VO2L
5
}Na(H2O)4] (7) in DMF.
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                    Figure 5.3. 
1
H NMR spectra of [{VO2L
4
}K(H2O)2] (6) in DMSO-d6
.
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5.3.3. Description of the X-ray structure of complexes. The crystal and molecular structures of 
3, 5–7 have been determined and reveal a wide variety of structural motifs dependent in the main 
on the type of cation and presence of water (coordinated or lattice). The common feature of the 
structures is the presence of five-coordinate vanadium within NO4 donor sets which define 
coordination geometries between the extremes of square pyramidal and trigonal bipyramidal. 
The asymmetric unit of 3 comprises two complex anions, two Li
+
 cations and nine water 
molecules, Figure 5.4. selected geometric parameters are given in the caption. Seven of the 
water molecules coordinate to Li
+
 cations. The molecular structures of the anions are quite 
similar as seen from the overlay diagram (Figure 5.5) and feature five-coordinate vanadium 
atoms, being coordinated by a dinegative, tridentate ligand and two oxido-O atoms. The status of 
the Schiff base ligand as 2-hydroxy-N-(2-oxidobenzylidene)benzenecarbohydrazonate, i.e. an 
azo ligand, is confirmed by the C=N bond lengths, Figure 5.4. Based on  values of 0.51 (V1-
containing anion) and 0.47 (V2), the resulting NO4 donor set defines a geometry intermediate 
between square pyramidal (ideal value of  = 0.0) and trigonal bipyramidal ( = 1.0).54 The five- 
and six-membered chelate rings are practically planar with r.m.s. deviations of the atoms 
comprising these being 0.013 Å (0.008) and 0.031 Å (0.036), respectively; values for the V2-
containg anion are given in parenthesis. Co-planarity between the five-membered ring and 
attached hydroxyphenyl ring (dihedral angles = 3.48(8) and 1.95(8)º, respectively) is ensured by 
an intramolecular O–H...N hydrogen bond (Table 5.2). This planarity extends throughout the 
anion as seen in the dihedral angles between the terminal rings of 5.37(9) and 2.69(9)º, 
respectively. According to a search of the Cambridge Structural Database (CSD),
55
 the specific 
anion in 3 has been characterised as a variety of vanadium salts and adopt very similar molecular 
conformations.
56
 
The Li
+
 cations are bridged by a water molecule and each of their tetrahedral coordination 
geometries is completed by three additional water molecules. The components of the crystal 
structure are connected into supramolecular layers in the ab-plane by an extensive network of O–
H...O hydrogen bonds involving all but the hydroxyl-O atoms (Figure 5.6a); geometric data 
defining the intermolecular interactions for 3, 5-7 are collated in Table 5.2. The Schiff base 
ligands project to either side of the layers and associate via significant C‒H...O(hydroxyl) 
hydrogen bonds to consolidate the three-dimensional crystal packing (Table 5.2 and Figure 
5.6b). 
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The asymmetric unit of 5 comprises two Cs
+
 cations, two complex anions and two aqua ligands, 
Figure 5.7. By contrast to the other structures described herein, both the five- and six-membered 
rings deviate significantly from planarity, with the former adopting an envelope conformation 
with the V1 or V2 atom being the flap atom. The six-membered rings adopt half-chair 
conformations with the V1 atom lying 0.566(3) Å above the plane of the remaining five atoms 
comprising the chelate ring (r.m.s. deviation = 0.0461 Å); the corresponding values for the V2-
containing anion are 0.840(3) and 0.0487 Å, respectively. The two anions adopt distinct 
conformations (Figure 5.8) with the differences best reflected in the dihedral angles between the 
five-membered and attached phenyl ring of 8.34(13) and 18.54(13)°, respectively. The values of 
 compute to 0.04 and 0.21, consistent with descriptions of the coordination geometry being 
based on a square pyramid.
54
 The same anion as found in 5 has been described in the literature as 
its anhydrous diethylammonium salt.
57
 Underscoring the flexibility of coordination modes 
exhibited by these Schiff base ligands, in the ammonium salt the five-membered ring is very 
close to planar and the six-membered ring has a half-chair conformation with the phenoxide-O 
atom lying above the plane of the remaining atoms.
57 
The Cs1 cation is in a highly distorted eight-coordinate environment whereas the Cs2 cation is in 
a seven-coordinate geometry resembling closely a square anti-prism but with one site vacant.  
The -O bridging leads to a layer in the ab-plane as illustrated in Figure 5.9a. The layers are 
also stabilised by an extensive network of O–H…O hydrogen bonds (Table 5.2) and stack along 
the c-axis with no specific interactions between them (Figure 5.9b). 
For 6, the asymmetric unit comprises a K
+
 cation, a complex anion and two coordinated water 
molecules, Figure 5.10. The introduction of a methyl group into the backbone of the ONO-
coordinating tridentate ligand of 3 introduces a change in the configuration of the six-membered 
chelate ring. Thus, while the five-membered ring is planar (r.m.s. deviation = 0.028 Å), the 
conformation of the six-membered ring is based on a screw-boat. This has the result that overall 
the dianion exhibits a twist as seen in the dihedral angle of 11.12(12)º between the terminal 
rings. The value of  is 0.14, suggesting a coordination geometry approaching square 
pyramidal.
54
 There are no V-containing precedents featuring this Schiff base ligand in the 
crystallographic literature.
55 
The cation in 6 is coordinated by the two water molecules comprising the asymmetric unit, 
Figure 5.10, and direct links between this and the anion are afforded by oxido bridges. The 
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oxido-O4 and phenoxide-O2 atoms also link symmetry related cations, which in turn are bridged 
by two water molecules with the result that the K
+
 cation is eight-coordinate within an O8 donor 
set (range of K‒O bond lengths: 2.7176(17) to 3.107(3) Å). The coordination geometry is based 
on a heavily distorted square anti-prism with each face defined by two oxido- and two water-O 
atoms. The K‒O bridging leads to a supramolecular zigzag chain oriented along the b-axis, 
Figure 5.11. Chains are linked into a three-dimensional architecture by water-O-
H...O(phenoxide), N(pyridyl) hydrogen bonds as well as phenyl-C-H...O(oxido) and methyl-C-
H...(arene) interactions, as illustrated in Figure 5.12; Table 5.2 for parameters. In this scheme, 
the O2w molecule does not form significant hydrogen bonding interactions, most likely as the 
hydrogen atoms are disordered in a pocket defined by four possible hydrogen atom acceptors, 
see Experimental Section and Table 5.2.  It is noted that all four oxygen atoms in the pocket 
belong to a single supramolecular chain indicating that any putative hydrogen bonds formed by 
the O2w molecule would contribute primarily to the stability of the chain. 
The asymmetric unit of 7 comprises a Na
+
 cation, a complex anion, three coordinated water 
molecules and a water molecule of hydration, Figure 5.13. The anion exhibits the similar 
features as described for 3. The r.m.s. deviations for the five- and six-membered chelate rings are 
0.036 and 0.045 Å, respectively. A small twist is noted between the five-membered ring and 
attached pyridyl ring, i.e. 9.33(9)º, so that the ligand is no longer planar; the dihedral angle 
between the terminal rings is 8.42(10)º. The value of  is computed to be 0.41, indicating a 
coordination geometry intermediate between square pyramidal and trigonal pyramidal.
54
 There is 
only one precedent in the crystallographic literature
55
 for a vanadium complex of the Schiff base 
ligand in 7. In this single molecule structure, the charge balance is achieved by protonation at the 
pyridyl-N atom,
58
 i.e. the Schiff base ligand is present as a zwitterion. 
The ions in 7 are connected into a centrosymmetric four-component aggregate via oxido-O 
bridges whereby the O3 atom connects to one Na cation and the O4 atom bridges two Na cations, 
Figure 5.14. In this way, the Na cation achieves a coordination number of six based on an 
octahedral O6 donor set, range of Na‒O bond lengths = 2.2904(18) to 2.7277(19) Å. A 
supramolecular layer in the ab-plane is formed by O‒H...O hydrogen bonds as well as an 
O‒H...N hydrogen bond involving the non-coordinating azo-N3 atom, Figure 5.15a (Table 5.2). 
Layers are connected along the c-axis by water-O‒H...N(pyridyl) hydrogen bonds, Figure 5.15b. 
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Figure 5.4. Perspective view of the components of the crystallographic asymmetric unit of 
[{VO2L
2
}Li(H2O)4.5] (3). V1‒O2 2.0028(12), V1‒O3 1.9119(13), V1‒O4 1.6330(13), V1‒O5 
1.6238(13), V1‒N2 2.1121(14), N1‒N2 1.3994(19), N1‒C7 1.302(2), N2‒C8 1.298(2), V2‒O7 
1.9771(12), V2‒O8 1.9109(13), V2‒O9 1.6284(13), V2‒O10 1.6343(13), V2‒N4 2.1163(14), 
N3‒N4 1.3975(19), N3‒C21 1.301(2), N4‒C22 1.297(2) Å; O2‒V1‒O3 157.54(5), O7‒V2‒O8 
156.95(5)º. 
 
 
 
 
Figure 5.5. Overlay diagram of the two independent complex anions in [{VO2L
2
}Li(H2O)4.5] (3). 
Molecules have been superimposed so that the five-membered chelate rings involving the V1 (red 
image) and V2 (blue image) atoms are superimposed. 
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(a) 
 
(b) 
Figure 5.6. (a) A view of the supramolecular layer in the ab-plane in [{VO2L
2
}Li(H2O)4.5] (3) 
sustained by an extensive network of O‒H...O hydrogen bonds shown as orange dashed lines. 
For clarity, only the chelate rings of the anions are illustrated, and (b) Unit cell contents for 3 
viewed in projection down the b-axis. The O‒H...O and C‒H...O(hydroxy) hydrogen bonds are 
shown as orange and blue dashed lines, respectively. 
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Figure 5.7. Perspective view of the components of the crystallographic asymmetric unit of 
[{VO2L
3
}Cs(H2O)2] (5). Selected geometric parameters: V1‒O1 1.892(2), V1‒O2 1.9656(19), 
V1‒O3 1.6352(19), V1‒O4 1.634(2), V1‒N1 2.149(2), N1‒N2 1.399(3), N1‒C7 1.305(4), 
N2‒C9 1.298(4), V2‒O5 1.883(2), V2‒O6 1.9631(19), V2‒O7 1.6534(19), V2‒O8 1.618(2), 
V2‒N3 2.162(2), N3‒N4 1.402(3), N3‒C22 1.299(3), N4‒C24 1.295(4), O3…Cs1 2.923(2), 
O4…Cs1i 3.302(2), O7…Cs1 3.019(2), O3…Cs2i 3.014(2), O7…Cs2 2.9900(19), O8 …Cs2i 
3.292(2) and O8…Cs2ii 3.473(2) Å.  Symmetry operation i: x, 1+y, z, and ii: -x, -y, 1-z. 
 
 
Figure 5.8. Overlay diagram of the two independent complex anions in [{VO2L
3
}Cs(H2O)2] 
(5). Molecules have been superimposed so that the C1-C6 ring (red image) and C16-C21 ring 
(blue image) are superimposed. 
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(a) 
 
(b) 
Figure 5.9. (a) Crystal packing in [{VO2L
3
}Cs(H2O)2] (5): Layer in the ab-plane mediated by 
-O bridges. For clarity, only the chelate rings of the anions are illustrated, and (b) Unit cell 
contents for 5 viewed in projection down the b-axis. The O‒H...O hydrogen bonds are shown as 
orange dashed lines. 
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Figure 5.10. Perspective view of the components of the crystallographic asymmetric unit of 
[{VO2L
4
}K(H2O)2] (6). Selected geometric parameters: V1‒O1 1.9668(16), V1‒O2 
1.8926(16), V1‒O3 1.6174(17), V1‒O4 1.6350(16), V1‒N3 2.1552(19), N2‒N3 1.409(2), 
N2‒C6 1.291(3), N3‒C7 1.306(3), O3…K 2.9383(19), O4…K 2.8330(18) and O4i…K 
2.7178(17) Å. Symmetry operation i: ½-x, -½+y, z. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11. Crystal packing in [{VO2L
4
}K(H2O)2] (6): Zigzag chain along the b-axis mediated 
by -O bridging. For clarity, only the chelate rings of the anions are illustrated. 
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Figure 5.12. Crystal packing in [{VO2L
4
}K(H2O)2] (6): View in projection down the b-axis 
showing the unit cell contents. The O‒H...O, O‒H...N, C‒H...O and C‒H... interactions are 
shown as orange, blue, green and purple dashed lines, respectively. 
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Figure 5.13. Perspective view of the components of the crystallographic asymmetric unit of 
[{VO2L
5
}Na(H2O)4] (7). Selected geometric parameters: V1‒O1 1.9884(12), V1‒O2 
1.9027(13), V1‒O3 1.6183(14), V1‒O4 1.6263(14), V1‒N3 2.1236(14), N2‒N3 1.4067(18), 
N2‒C6 1.291(2), N3‒C7 1.293(2), O4…Na 2.3889(16), O3…Nai 2.7274(19) and O4…Nai 
2.5576(18) Å.  Symmetry operation i: 1-x, -y, 2-z. 
 
 
 
 
Figure 5.14. Crystal packing in [{VO2L
5
}Na(H2O)4] (7): Centrosymmetric four-ion aggregate 
mediated by -O bridging. 
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(a) 
 
(b) 
Figure 5.15. Crystal packing in [{VO2L
5
}Na(H2O)4] (7): (a) Layer in the ab-plane sustained by 
O‒H...O and O‒H...N hydrogen bonds shown as orange and blue dashed lines, respectively. For 
clarity, only the chelate rings of the anions are illustrated, and (b) Unit cell contents viewed in 
projection down the b-axis. 
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5.3.4. DNA binding studies 
 
5.3.4.1. Absorption spectroscopic studies. DNA binding is an important parameter for 
chemical- and photo-induced DNA cleavage activity of the metal complexes, therefore the 
binding affinity of the complexes 1–8 to CT-DNA was studied using various spectral techniques. 
UV-Vis titration experiments were carried out to determine the equilibrium binding constant (Kb) 
of the complexes to CT-DNA (Table 5.3). The electronic absorption spectra of 6  and 7  are 
shown in Figure 5.16. Binding of complexes to DNA through intercalation generally leads to 
hypochromism and bathochromism of the absorption band. This shift is observed due to the 
strong stacking interaction between the aromatic chromophore of the ligand and the base pairs of 
the DNA. Minor groove binding of the complexes to DNA results in hyperchromism in 
absorption intensity, resulting in the unwinding of the DNA double helix as well as its 
unstacking and concomitant exposure of the bases.
46
 Therefore the extent of hypochromism or 
hyperchromism observed provides a measure of the strength of intercalative binding or minor 
groove binding of the complexes. The UV-Vis spectra of the complexes in the absence and 
presence of CT-DNA (at a constant complex concentration of 25 M) exhibited a hypochromic 
shift around ~260 nm (Figure 5.16), which indicates that there is an interaction/binding between 
the complexes and CT-DNA. 
In order to quantify the binding affinity of the interaction between CT-DNA and each of 1–8, the 
binding constant (Kb) was calculated using Eq. 1 (Experimental Section). The Kb values were 
reported in Table 5.3.  Complexes 6 and 7 showed higher Kb values among all the complexes, 
i.e. 3.34 × 10
4
 and 6.88 × 10
4
 M
-1
, respectively. The binding propensities of ligands to CT-DNA 
were also estimated. All the ligands showed DNA binding affinity yielding Kb values 10
3
 M
-1
 
(Table 5.4). 
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         Table 5.3. Thermodynamic data for CT-DNA binding with [{V
V
O2L
1-6
}A(H2O)n] (1–8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
DNA binding constant by UV-vis spectral method. 
b
 Change in the melting temperature of    
CT- DNA 
 
 
       Table 5.4. Binding Constant (Kb) values for the interaction of CT-DNA with ligands 
 
 
 
 
 
 
 
 
              a
DNA binding constant by UV-vis spectral method. 
 
 
 
Complex  Binding Constant (Kb) 
a
 (M
-1
) ∆Tm 
b
 (
o
C) 
1 1.23  104 0.75 
2 5.5  103 1.30 
3 1.67  104 1.63 
4 2.41  104 1.31 
5 7.6  103 1.15 
6 3.34  104 1.95 
7 6.88  104  2.09 
8 1.11  104 1.03 
Complex  Binding Constant (Kb) 
a
 (M
-1
) 
H2L
1
 1.29  103 
H2L
2
 7.74  103 
H2L
3
 8.79  103 
H2L
4
 3.82  103 
H2L
5
 1.09  103 
H2L
6
 4.57  103 
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Figure 5.16.  Electronic absorption spectra of 6 (a) and 7 (b) (25 M each) upon the titration of 
CT-DNA (0 – 100 M) in 10 mM Tris-HCl buffer (pH 8.0) containing 10% DMF. Arrow shows 
the changes in absorbance with respect to an increase in the CT-DNA concentration. The inset 
shows the linear fit of [DNA]/(εa - εf) vs [DNA] and binding constant (Kb) was calculated using 
Eq.1. 
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5.3.4.2. Thermal denaturation studies. To understand the nature of interaction between CT-
DNA and these complexes, thermal denaturation experiments were performed.
46
 The melting 
temperature of CT-DNA (Tm) increased very slightly upon interaction with complexes 1-8 
(Table 5.3, Figure 5.17). The shift of DNA melting temperature (ΔTm) for the interaction 
between CT-DNA and complexes 6 and 7 was greater among eight synthesised dioxido 
vanadium complexes i.e ~ 2 
0
C. The low ΔTm values for 1-8 suggests groove binding of the 
complexes to CT-DNA rather than an intercalative mode of binding to DNA which usually gives 
a large positive ΔTm value.
59,60
 
 
5.3.4.3. Circular dichroism studies. The conformational changes in CT-DNA due to interaction 
with the complexes were monitored using circular dichroism (CD) spectroscopy.
61
 The B-
conformation of CT-DNA shows two conservative CD bands in the UV region, a positive band 
at 275 nm due to base stacking and a negative band at 245 nm due to right handed helicity.
61
 
Groove binding and electrostatic interaction of small molecules shows less or no perturbation on 
the base stacking and helicity bands whereas an intercalation mode can induce intensity changes 
of both bands, thus modulating the right handed B-conformation of DNA.
61
 The CD spectra of 
CT-DNA (160 M) in the presence of the complexes showed very marginal changes, with a 
slight increase in the negative ellipticity at 245 nm for all the complexes except for 8 which 
exhibited a slight decrease in negative ellipticity.  (Figure 5.18). The positive band at 275 nm 
did not show any significant change in intensity. The results of CD spectra indicate that there is 
an interaction between complexes with CT-DNA. 
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Figure 5.17. Derivative plot of thermal denaturation of CT-DNA (160 M) in absence and 
presence of 1–8 (100 M). The experiment was done in 10 mM Tris-HCl buffer (pH 8.0) 
containing 10% DMF. Inset shows the thermal denaturation derivate plot for 6 and 7 which 
showed ~ 2 
o
C shift in Tm as compared to CT-DNA.  
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Figure 5.18. Circular dichroism spectra of CT-DNA (160 M) in the presence and absence of 7 
(a) and 8 (b) in 10 mM Tris-HCl buffer (pH 8.0). The path length of the cuvette was 2 mm. 
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5.3.5. DNA cleavage studies. 
 
5.3.5.1. Chemical-induced DNA cleavage. The cleavage of supercoiled (SC) pUC19 DNA 
(300ng) by 1–8 (1–500 M) in the dark using hydrogen peroxide as the oxidising agent was 
studied. The complexes do not show any apparent DNA cleavage implying no hydrolytic 
cleavage activity. The lack of chemical nuclease activity may be due to their weak interaction 
and binding with DNA. 
 
5.3.5.2. Photo-induced DNA cleavage. To investigate whether the DNA binding properties of 
the complexes were associated with photonuclease activity, a photo-induced nuclease activity 
assay was performed. Photo-induced DNA nuclease activity of 1–8 was studied using 
supercoiled (SC) pUC19 DNA in 50 mM Tris-HCl buffer (pH 8.0) upon irradiation of UVA light 
of 350 nm with the aid of gel electrophoresis in the presence and absence of the complexes   
(Figure 5.19). The extent of SC DNA cleavage by the complexes was monitored in a 
concentration-dependent manner as shown in (Figure 5.20). All of the complexes (except 3) 
exhibited more than 10% enhanced photo-induced DNA cleavage activity at a complex 
concentration of 10 M (Figure 5.20, inset). The cleavage activity is saturated for each of the 
complexes at a concentration of 100 M and the highest nuclease activity of 33 and 39 %, at a 
100 M complex concentration, was conferred by 6 and 7, respectively, which correlates well 
with their DNA binding parameters (Figure 5.20, inset and Table 5.3). All the complexes 
exhibited almost similar cleavage even in solutions having low DMF concentrations, i.e. 1% 
DMF (v/v). Butenko et al reported that organic buffers such as tris, MOPS, HEPES, etc. 
suppressed the nuclease activity of some vanadium complexes.
62
 In the same paper, they 
demonstrated that these complexes exhibited more nuclease activity in phosphate buffer 
compared to that of organic buffers listed above. Thus, we also performed the photo-induced 
DNA cleavage activity of 1–8 in 10 mM phosphate buffer (pH 7.8) containing 1% DMF . We 
found that buffer had no effect on the photo-nuclease activity of these complexes. They exhibited 
almost similar activity even when we used phosphate buffer instead of tris buffer. Since, we 
worked with buffer solutions having basic pH (>7.5), this may be ruled out the influence of tris 
buffer on the photo-nuclease activity of these dioxidovanadium complexes. Control experiments 
suggest that neither DMF (10%) nor the ligands show any photo-induced DNA cleavage activity, 
which implies that, the ligands or DMF alone are cleavage inactive under similar conditions. 
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 In order to understand the mechanistic pathway involved in the DNA cleavage reactions, we 
systematically investigated the photo-induced DNA cleavage activity in presence of various 
additives. The DNA cleavage reaction involving molecular oxygen can proceed in two 
mechanistic pathways, namely, a type-II process involving singlet oxygen species (
1
O2) or by a 
photo-redox pathway involving reactive hydroxyl radicals (OH).
49
 For the present mechanistic 
studies NaN3 and L–histidine were used as singlet oxygen quenchers, and KI and D-mannitol 
were employed as hydroxyl radical quenchers. The addition of singlet oxygen quenchers like 
NaN3 partially inhibited the DNA cleavage activity of 6 and 7 among the series, whereas the 
other singlet oxygen quencher L-histidine did not inhibit DNA cleavage activity of any complex. 
Similarly, the hydroxyl radical scavenger KI showed moderate inhibition of photo-induced DNA 
cleavage activity for 6 and 7, whereas the other hydroxyl radical scavenger, D-mannitol did not 
inhibit the DNA cleavage activity of any complex (Figure 5.21). These results suggest that 6 and 
7 exhibit photo-induced DNA cleavage activity via both singlet oxygen and hydroxyl radical 
pathways. Although the other complexes showed slight inhibition of DNA cleavage activity in 
presence of various additives, the mechanistic pathway followed could not be stated with 
certainty. 
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Figure 5.19. Gel diagram showing concentration dependent DNA cleavage by 1–8; 300 ng of SC 
pUC19 DNA at different concentrations of the complexes [1–500 µM in 50 mM Tris-HCl buffer 
(pH 8.0) containing 10% DMF] was photo-irradiated with UVA at 350 nm for 3 h. Lanes 1–9: 1, 
2.5, 5.0, 7.5, 10, 50, 75, 100 and 500 µM of 1–8. . 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20. Concentration dependent DNA cleavage by 1–8; 300 ng of SC pUC19 DNA at 
different concentration of the complexes [1–500 µM in 50 mM Tris-HCl buffer (pH 8.0) 
containing 10% DMF] was photo-irradiated with UVA at 350 nm for 3 h. The net DNA cleavage 
percent was calculated using Eq.2. Inset shows a bar diagram representation of the net DNA 
cleavage of different complexes at 10 and 100 µM. 
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Figure 5.21. Cleavage of SC pUC19 DNA by 1–4 (a) and 5–8 (b) in presence of various 
additives in 50mM Tris-HCl buffer (pH 8.0) containing 10% DMF. SC pUC19 DNA (300 ng) in 
the presence of various additives was photo-irradiated at 350 nm for 3 h with 1-8 (100 µM). The 
additive concentrations were: sodium azide (0.5 mM), L-histidine (0.5 mM), KI (0.5 mM) and 
D-mannitol (0.5 mM). 
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5.3.6. Protein binding and cleavage experiments. 
 
5.3.6.1. Bovine Serum Albumin (BSA) binding studies. As 6 and 7 revealed good binding 
propensities towards CT-DNA and showed better photo-induced DNA cleavage activity, the 
investigation of the interaction of these two complexes with bovine serum albumin (BSA) was 
undertaken. Qualitative analysis of the interaction of the complexes with BSA was studied by 
examining the quenching of tryptophan fluorescence emission spectra of BSA in presence of 6 
and 7. The fluorescence of the protein is specifically caused by three amino acid residues namely 
tryptophan, tyrosine and phenylalanine. The sequence analysis of BSA reveals the presence of 
two tryptophan residues and exhibits tryptophan fluorescence at an excitation of 295 nm with an 
emission maximum at 344 nm. The interaction with BSA was followed by monitoring the 
quenching of tryptophan fluorescence upon the addition of 6 and 7. The effect of increasing 
concentration of 6 and 7 on the fluorescence emission of BSA is shown in Figure 5.22. The 
intrinsic tryptophan fluorescence intensity of BSA is found to quench gradually on increasing the 
complex concentration (Figure 5.22). The Stern-Volmer quenching constant (KSV) was 
calculated using Eq. 3 (Experimental Section). The quenching constants for 6 and 7 are 2.52 
 and 2.72 , respectively, (Table 5.5) which reveals that 7, has 10 fold greater 
quenching ability than 6. The extent of quenching of the fluorescence intensity confers a measure 
of association of the complex with BSA. Small molecules bind independently to a set of sites in a 
protein molecule and the equilibrium between the free and the bound molecule is given by the 
Scatchard equation
45
 (Eq. 4). The binding constant (KBSA) and the number of binding sites (n) 
were obtained from the plot of log  
F0− F
F
  vs log [Q] (Table 5.5). Both complexes interact with 
BSA in a 1:1 stoichiometry, although the binding affinity of complex 7 towards BSA is greater 
than for complex 6. 
 
5.3.6.2. BSA cleavage activity. Since both the complexes exhibited good binding affinity 
towards BSA, their protein cleavage activity by photo-induced BSA cleavage assay was 
investigated. The photo-induced BSA cleavage activity of these two complexes in UVA light of 
350 nm was carried out using 5 M of BSA in 10 mM Tris-HCl buffer (pH 8.0) monitored by 
SDS-PAGE gel electrophoresis in the presence and absence of 6 and 7. A 100 M solution of 6 
and 7 showed more than 75% cleavage of BSA (5 M) with a photo-irradiation of 90 min 
(Figure 5.23 (a, b), lane 8) which suggests that both the complexes have similar photo-induced 
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BSA cleavage activity. At this same molar ratio of BSA to complex, all other complexes also 
exhibited similar kind of photo-induced BSA cleavage activity, whereas all the complexes (1−8) 
failed to show any cleavage of BSA in the dark. Moreover, the densitometry analysis of photo-
induced BSA cleavage experiments revealed that  33-36% BSA cleavage occurred even at 1:1 
molar ratio of BSA to complex (Figure 5.23c). 
 
 
 
Table 5.5. BSA Binding parameters of 6 and 7 
Complex 
Stern Volmer 
Constant (KSV) 
( 
Binding Constant 
(KBSA)  
( 
Number of Binding 
Sites (n) 
6 2.52 ± 0.11 
 3.12 ± 0.13  0.81 ± 0.11  
7 2.72 ± 0.15  4.12 ± 0.18   1.04 ± 0.07 
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Figure 5.22. Intrinsic tryptophan fluorescence spectra of BSA (2 µM) in presence of complex 6 
(a) and 7 (b) (0–20M in 10 mM Tris-HCl buffer (pH 8.0) containing 1% DMF). Tryptophan 
fluorescence spectra were recorded in the range 310–400 nm at 25 °C. The excitation wavelength 
was 295 nm. Arrow indicates the effect of increasing concentration of complexes on the 
tryptophan fluorescence emission of BSA. The inset shows the linear fit of F0/F vs [complex] and 
Stern-Volmer quenching constant (KSV) was calculated using Eq.3. 
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Figure 5.23. SDS-PAGE profile of concentration dependent photo-induced cleavage of BSA (5 
M) in UVA light of 350 nm by 6 (a) and 7 (b) in 10 mM Tris-HCl buffer (pH 8.0) containing 
1% DMF. Lane 1, Molecular marker; Lane 2, BSA only; Lane 3, BSA + complex (1 M); Lane 
4, BSA + complex (2.5 M); Lane 5, BSA + complex (5 M); Lane 6, BSA + complex (10 M); 
Lane 7, BSA + complex (50 M); Lane 8, BSA + complex (100 M); Lane 9, BSA + complex 
(300 M); Lane 10, BSA + complex (500 M). (c) Net BSA cleavage percent of concentration 
dependent photo-induced cleavage of BSA (5 M) in UVA light of 350 nm (84 W) by 6 and 7. 
 
 
b a 
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5.3.7. Cytotoxicity Studies 
 
5.3.7.1. MTT assay. In the present study, antiproliferative efficacy of 1–8 was assayed by 
determining the viability of HeLa cells using the MTT assay. The ligands, H2L
1–6 
and VO(acac)2 
gave high IC50 values of > 200 μM, whereas 1–8 gave values in the range 45–17 μM (Table 5.6). 
By contrast, cisplatin, gefitinib, gemcitabine, 5-fluorouracil and vinorelbine, commonly used 
chemotherapeutic drugs, are comparably effective in HeLa cells with an IC50 value of 13, 20, 35, 
40 and 48 μM, respectively, under the same experimental conditions.63 The significant decrease 
in the inhibitory ability of the ligands as well as their lower binding affinity to CT-DNA 
compared to their metal complexes clearly indicates that incorporation of vanadium has a 
marked effect on cytotoxicity. A possible explanation is that by coordination, the polarity of the 
ligand and the central metal ion are reduced through the charge equilibration, which favours 
permeation of the complexes through the lipid layer of the cell membrane.
64,65
 The results of 
DNA binding/cleavage ability for the ligands have been considered and are consistent with the 
observation that metal complexes can exhibit greater biological activities than the free ligands.
66
 
     Within the series 1–8, the cytotoxicities of 2, 5, 6 and 7 are almost similar whereas those of 6 
and 7 are greater as reflected from their IC50 values, Table 5.6, with their dose dependency 
illustrated in Figure 5.24. The variation in results of cytotoxicity of the complexes may be 
affected by the various functional groups attached to the aroylhydrazone derivative. Very 
recently, the antiproliferative activity of some vanadium compounds reported by Yamaguchi et 
al.
67
 and us
36
 using U937 cells and HeLa cells, respectively, and the present results are in 
accordance with the reported values. 
  
5.3.7.2. Nuclear Staining Assay. To investigate the apoptotic potential of test compounds in 
HeLa cells, DAPI staining was performed. Chromatin condensation during the process of 
apoptosis (type I programmed cell death) is a characterising marker of nuclear alteration. HeLa 
cells were treated with 40, 15, 20, 30, 18, 15, 12 and 30 μM of complexes 1–8, respectively. The 
cells were incubated for 24 h before DAPI nuclear staining. Cells were examined under 
fluorescent microscope fitted with a DAPI filter. Control cells (treated with 10% (v/v) DMF) 
hardly showed any sort of condensation in comparison to the treated cells, as shown in Figure 
5.25. All images taken in grayscale demonstrate the brightly condensed chromatin bodies and the 
nuclear blebbings as marked by arrows in Figure 5.25. Besides showing nuclear change, the 
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treated cells exhibited a shrinking morphology, which is another important hallmark of 
apoptosis. 
 
 
Table 5.6. Cytotoxic scores for 1–8 in HeLa cancer cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complex IC50 (µM) 
1 44.96±3.98 
2 20.56±4.58 
3 24.25±3.74 
4 33.25±2.9 
5 23.18±3.66 
6 18.96±4.09 
7 17.23±3.24 
8 37.45±4.26 
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Figure 5.24. Effect of 1–8 on cell viability and growth: HeLa cells were treated with different 
concentrations of the test compound for 72 h and then cell viability was measured by MTT 
assay. Data reported as the mean ± S.D. for n = 6 and compared against 10% (v/v) DMF treated 
control by using a Student‘s t-test. (*significant compared to control). 
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Figure 5.25. Study of apoptosis by morphological changes in nuclei of HeLa cells: HeLa cells, 
from control and treated groups, were fixed with 3.7% formaldehyde for 15 min, permeabilised 
with 0.1% Triton X-100 and stained with 1 µg/ml DAPI for 5 min at 37 °C. The cells were then 
washed with PBS and examined by fluorescence microscopy (Olympus IX 71) (200×). HeLa 
cells were treated with 40, 15, 20, 30, 18, 15, 12 and 30 μM of complexes 1–8, respectively. 
Arrows showing the morphological changes in nuclei of HeLa cells observed on applying 1–8 in 
comparison to the control group treated with 10% (v/v) DMF. 
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5.4. CONCLUSION 
 
The following are the salient observations of the present work: A series of dioxido vanadium(V) 
complexes (1−8) with tridentate aroylhydrazonates containing ONO donor atom form polymeric 
extended structures incorporating various alkali metal ion. The vanadium anions in 3, 5–7 have 
been shown by X-ray crystallography to be five-coordinated within NO4 donor sets tending 
towards square pyramidal. The primary influence of the cations is related to size so that with 
small Li
+
, no bridging-O is found between the constituent ions but four-ion aggregates are found 
with Na
+
, chains for K
+
 and finally, layers for Cs
+
. Strong electrostatic and hydrogen bonding 
interactions play the central role in stabilizing these extended structures in the solid-state.  
          Complexes 1–8 demonstrated moderate DNA binding propensity. Their DNA binding 
activities were investigated using UV-Vis absorption titration, circular dichroism and thermal 
denaturation studies. The experimental results show the complexes moderately interact with CT-
DNA probably by groove binding mode, with binding constants ranging from 10
3−104 M-1. All 
complexes also show efficient photo-induced cleavage of pUC19 supercoiled plasmid DNA. 
Among 1–8, complexes 6 and 7 showed the best CT-DNA binding properties. Moreover, these 
two complexes exhibited greater cleavage activity of pUC19 DNA under photolytic conditions 
probably via both singlet oxygen and hydroxyl radical pathways. Complexes 6 and 7 also exhibit 
good binding affinity in the range of 10
4−105 M-1 towards BSA. Both complexes also showed 
efficient photo-induced BSA cleavage activity. The results obtained are significant in the context 
that vanadium complexes showing only DNA photo-cleavage activity but no chemical nuclease 
activity are sparse. The in vitro antiproliferative activity of complexes 1−8 against HeLa cell line 
was assayed. Among the complexes, 2, 5, 6 and 7 show considerable activity compared to 
commonly used chemotherapeutic drugs and the variation of cytotoxicity of the complexes may 
be affected by the various functional groups attached to the aroylhydrazone derivative whereby it 
may be globally stated that 6 and 7 are more potent against the HeLa cell line. The results of 
DNA binding, photo-induced DNA cleavage and antiproliferative activity of the new 
dioxidovanadium(V) complexes of aroylhydrazones reported in this paper reveals that the 
pharmacological activities of these complexes can be fine-tuned by changing the substituent on 
the hydrazone residue. It is important to mention that the alkali metal ions variation in 1−8 may 
have some influence on the results of pharmacological activity but their precise role remains 
unknown. Further work is in progress to identify the reasons. The results obtained from the 
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present dioxidovanadium(V) complexes are of importance for the development of metal-based 
agents for anti-cancer applications. Further work is in progress to better identify the mechanism 
of action and to prepare more potent related compounds for the treatment of cancer. 
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Chapter 6 
 
Oxido vanadium(V) complexes of aroylhydrazones containing bioactive heterocycles: 
Synthesis, characterisation and study of DNA binding, photo-induced DNA cleavage and 
cytotoxic activities 
 
ABSTRACT 
_____________________________________________________________________________ 
Four neutral oxido vanadium(V) complexes [VO2L
1
] (1), [VO2L
2
] (2), [VOL
3
(OEt)] (3) and 
[VOL
4
(OEt)EtOH] (4) [where HL
1
= 2-thiophenoylhydrazone of 2-acetylpyridine, HL
2
= 2-amino 
benzoylhydrazone of 2-benzoyl pyridine, H2L
3
= isonicotinoylhydrazone of 2-hydroxy 
acetophenone, H2L
4
= 2-furoylhydrazone of 2-hydroxy-1-napthaldehyde] with a bioactive 
hydrazone scaffold containing furan, thiophene and pyridine-residues have been synthesised. All 
complexes were thoroughly characterised by various spectroscopic (IR, UV-Vis, NMR and ESI-
MS) and single crystal X-ray diffraction techniques. Crystallography establishes five-coordinate 
geometries, distorted toward square pyramidal for each of 1 and 2, based on a tridentate-ONN 
coordinating anion and two oxido-O atoms. The dianion in 3 is tetradentate, coordinating one V 
atom as for 1 and 2, and bridging another via the pyridyl-N atom, and the N2O4 octahedral 
coordination geometry is completed by oxido- and ethanolate-O atoms. The result of the V–N 
bridging is a helical coordination polymer. An NO5 octahedral geometry is found in 4 defined by 
a tridentate-ONO anion, as well as oxido-, ethanolate- and ethanol-O atoms. Biological studies 
reveal that 1–4 have DNA binding propensity and show these to interact with CT-DNA by a 
minor groove binding mode, with binding constants ranging from 10
3−105 M-1. All complexes 
show good photo-induced cleavage of pUC19 supercoiled plasmid DNA with 3 showing the 
highest photo-induced DNA cleavage activity of ~ 65%. Additionally, 1–4 are cytotoxic against 
the human cervical cancer cell line (HeLa) following the order 4 > 2 > 3 > 1 with IC50 values 
ranging from 10 to 20 M. 
______________________________________________________________________________ 
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6.1. INTRODUCTION 
 
Metal complexes bearing a heterocyclic moiety open a new era of pharmaceutical research since 
their presence moderates not only physicochemical properties but also enhances medicinal 
properties.
1–4 
Isoxazoles, pyrroles, and pyrazoles are well-known examples of heteroaromatic 
organic compounds associated with diverse biological properties. Hence, it is not surprising there 
are several reports in the literature where metal complexes have had their physicochemical and 
pharmacological properties influenced by the presence of biologically active heterocycles 
containing nitrogen.
5–7
 In this context, thiophene,
8
 furan,
9
 and pyridine
10
 moieties are especially 
regarded as desirable, due to their widespread use as a scaffold in medicinal chemistry. 
 
Metal coordination is one of the most efficient strategies in the design of repository, slow-release 
or long-acting drugs.
11
It was the discovery of cisplatin that gave momentum to metal-based drug 
research.
12
 Despite its tremendous success as an anti-cancer drug, its use is restricted due to 
serious side-effects, general toxicity, and acquired drug resistance.
13–16
 Therefore, considerable 
effort is being made to synthesise new metal-based drugs that effectively and specifically target 
cancer cells while minimising toxic side effects. Among transition metals, vanadium complexes 
have attracted significant attention owing to their diversified applications as models for the 
biological functions of vanadium,
17–20 
such as haloperoxidation,
21
 phosphorylation,
22
 insulin 
mimicking,
23–26
 nitrogen fixation,
27
 tumour growth inhibition and prophylaxis against 
carcinogenesis.
28
 These complexes have also numerous applications in DNA binding, cleavage 
and have shown the ability to act as anti-proliferative agents.
29–32
 
 
Hydrazones, –NH–N=CRR' (R and R = H, alkyl, aryl), are versatile ligands and have 
applications in the fields of analytical
33
 and medicinal chemistry.
34
 Hydrazone moieties are 
important pharmacophoric cores of several anticancer, anti-inflammatory, anti-nociceptive and 
anti-platelet drugs.
35
 Moreover, the electronic properties of hydrazone complexes are also 
important in the design of complexes with better DNA-binding and cleavage characteristics.
36
 
Hydrazones in combination to heterocycles display a broad range of biological activity.
37–39
 
Examples of hydrazide and hydrazone derivatives containing bioactive heterocycles 
demonstrating medicinal properties are presented in Chart 6.1.
40–44
 There are a handful reports 
in the literature on metal complexes having hydrazone ligands where a heterocyclic moiety 
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enhances the pharmacological activity of these complexes.
45
 However, to date, analogous 
vanadium complexes, and especially the study of their pharmacological activity, is still scarce 
and needs to be explored.
46
 
 
Considering the interesting pharmacological properties of ligand systems containing bioactive 
heterocycles and as a part of our studies on design and synthesis of novel vanadium complexes 
with potential pharmaceutical activities,
32,47
 in this chapter we now focus our attention on the 
synthesis of some new oxido vanadium complexes with a bioactive hydrazone scaffold 
containing furan, thiophene and pyridine residues. These show interesting DNA binding, photo-
induced DNA cleavage and cytotoxicity profiles. The interaction of the complexes with calf-
thymus DNA (CT-DNA) was also investigated using UV-Vis absorption titration and thermal 
denaturation studies. Their photo-cleavage reactions with pUC19 supercoiled plasmid DNA were 
investigated by gel electrophoresis. In addition, the cytotoxicity of the complexes against the 
cervical cancer cell line (HeLa) was assessed by the MTT assay. 
 
 
 
 
Chart 6.1. Chemical structures of some hydrazide and hydrazone derivatives demonstrating 
pharmacological activities. 
 
N
H
N
H O NO2
O
HO
Nifuroxazide
N
N
O
NH2
H
Isoniazid
N
N
NH
H2N
H2N N
H
N
O
O
NO2
Furacilin
N
H
N
N
O
OH
O
Ftivazide
Hydralazine
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6.2. EXPERIMENTAL SECTION 
6.2.1. General Methods and Materials. All chemicals were purchased from commercial 
sources and used without further purification. The VO(acac)2 complex was prepared as described 
in the literature.
48
 MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium) and DAPI (4′,6-
diamidino-2-phenylindole dihydrochloride) were purchased from Sigma Aldrich (USA). 
Minimal essential medium (MEM) was purchased from Gibco, India. Reagent grade solvents 
were dried and distilled prior to use. The supercoiled (SC) pUC19 DNA was purified from E. 
coli cells with the aid of GeneJET Plasmid Isolation Kit (Thermo Scientific, USA). Biochemistry 
grade calf thymus (CT) DNA was purchased from SRL (India). Molecular biology grade agarose 
was purchased from Sigma Aldrich (USA). Elemental analyses were performed on a Vario 
ELcube CHNS Elemental analyser and IR spectra were recorded on a Perkin-Elmer Spectrum 
RXI spectrophotometer. 
1
H and
 13
C NMR spectra were recorded with a Bruker Ultrashield 400 
MHz spectrometer using SiMe4 as the internal standard. Electronic spectra were recorded on a 
Perkin-Elmer Lamda25 spectrophotometer. 
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6.2.2. Synthesis of Ligands (HL
1-2
, H2L
3–4
) Schiff base ligands, HL
1 
and H2L
3–4
, were prepared 
by condensation of acid hydrazides (10 mmol) and the corresponding carbonyl compound (10 
mmol) in stirring ethanol (15 mL) for 3 h following a standard procedure.
47
 HL
2 
was prepared by 
condensation of 2-amino benzoylhydrazide with 2-benzoyl pyridine in refluxing methanol for 5 
h. The resulting white compound was filtered, washed with ethanol and dried over fused CaCl2. 
The synthesised ligands are shown in Scheme 6.1. 
 
 
   Scheme 6.1. Schematic diagram of ligand molecules and composition of the complexes. 
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HL
1
. Yield: 74%. Anal. Calcd for C12H11N3OS: C, 58.76; H, 4.52; N, 17.13; S, 13.07. Found: C, 
58.79; H, 4.48; N, 17.11; S, 13.05. IR (KBr pellet, cm
–1
): 3164 ν(N–H), 1647 ν(C=O), 1572 
ν(C=N). 1H NMR (400 MHz, DMSO-d6): δ 11.09 (s, 1H, NH), 8.61–7.20 (m, 7H, aromatic), 
2.45 (s, 3H, CH3). 
13
C NMR (100 MHz, DMSO-d6): δ 162.55, 155.32, 150.79, 149.12, 137.10, 
135.59, 133.33, 127.16, 125.23, 124.45, 121.25, 12.88. 
 
HL
2
. Yield: 78%. Anal. Calcd for C19H16N4O: C, 72.14; H, 5.10; N, 17.71. Found: C, 72.15; H, 
5.11; N, 17.69. IR (KBr pellet, cm
–1
): 3472 (NH2)sym, 3354 ν(NH2)asym, 3048 ν(N–H), 1654 
ν(C=O), 1576 ν(C=N). 1H NMR (400 MHz, DMSO-d6): δ 14.50 (s, 1H, NH), 8.91–6.63 (m, 
13H, aromatic), 6.56 (s, 2H, NH2). 
13
C NMR (100 MHz, DMSO-d6): δ 157.07, 155.75, 153.94, 
153.81, 152.27, 143.60, 142.78, 141.95, 138.00, 134.30, 134.12, 134.05, 133.64, 132.51, 131.38, 
130.09, 122.24, 120.67, 117.91. 
 
H2L
3
. Yield: 69%. Anal. Calcd for C14H13N3O2: C, 65.87; H, 5.13; N, 16.46. Found: C, 65.88; H, 
5.11; N, 16.50. IR (KBr pellet, cm
–1
): 3368 ν(O–H), 3151 ν(N–H), 1678 ν(C=O), 1607 ν(C=N). 
1
H NMR (400 MHz, DMSO-d6): δ 13.32 (s, 1H, OH), 11.72 (s, 1H, NH), 8.20–6.89 (m, 8H, 
aromatic), 2.42 (s, 3H, CH3). 
13
C NMR (100 MHz, DMSO-d6): δ 163.40, 160.01, 159.21, 150.56, 
140.84, 132.05, 129.19, 122.84, 122.63, 122.43, 119.68, 119.10, 117.82, 14.78. 
 
H2L
4
. Yield: 71%. Anal. Calcd. for C16H12N2O3: C, 68.57; H, 4.32; N, 9.99. Found: C, 68.59; H, 
4.34; N, 9.96. IR (KBr pellet, cm
–1
): 3445 ν(O–H), 3172 ν(N–H), 1640 ν(C=O), 1603 ν(C=N). 
1
H NMR (400 MHz, DMSO-d6): δ 12.72 (s, 1H, OH), 12.26 (s, 1H, NH), 9.51 (s, 1H, CH), 8.21–
6.71 (m, 9H, aroamtic). 
13
C NMR (100 MHz, DMSO-d6): δ 158.43, 154.24, 147.54, 146.70, 
146.50, 133.20, 132.10, 129.37, 128.26, 128.16, 123.96, 121.04, 119.29, 115.95, 112.75, 109.00. 
 
6.2.3. Synthesis of complexes (1–4).  
 
6.2.3.1. Synthesis of [VO2L
1
] (1). To a hot solution of HL
1
 (1 mmol) in methanol (30 mL), 
VO(acac)2 (1 mmol) in DMF (5 mL) was added, the colour changed instantly to green-brown. 
After 6 h of reflux, the solution was cooled, filtered and kept for crystallisation. Slow 
evaporation of the filtrate over 4 days produced yellow crystals. 
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[VO2L
1
] (1). Yield: 63%. Anal. Calcd for C12H10N3O3SV: C, 44.05; H, 3.08; N, 12.84; S, 9.80. 
Found: C, 44.06; H, 3.05; N, 12.83; S, 9.81. IR (KBr pellet, cm
–1
): 1600 ν(C=N), 1255 ν(C–
O)enolic, 1036 ν(N–N), 946 ν(V=O). UV–Vis (DMF) [λmax, nm (ε, M
–1
 cm
–1
)]: 399 (14121), 277 
(8371). 
1
H NMR (400 MHz, DMSO-d6): δ 8.81–7.22 (m, 7H, aromatic), 2.72 (s, 3H, CH3). 
13
C 
NMR (100 MHz, DMSO-d6): δ 171.54, 165.30, 159.69, 152.14, 148.11, 145.19, 144.33, 132.16, 
127.23, 126.40, 124.22, 13.48. 
51
V NMR (DMSO-d6): δ –507. 
 
6.2.3.2. Synthesis of [VO2L
2
] (2). To a hot solution of HL
2
 (1 mmol) in ethanol (30 mL), 
VO(acac)2 (1 mmol) was added, the colour changed instantly to orange. After 5 h of reflux, the 
solution was cooled, filtered off and kept for crystallisation. Slow evaporation of the filtrate over 
4 days produced orange crystals. 
 
[VO2L
2
] (2). Yield: 68%. Anal. Calcd for C19H15N4O3V: C, 57.30; H, 3.80; N, 14.07. Found: C, 
57.31; H, 3.84; N, 14.08. IR (KBr pellet, cm
–1
): 3393 ν(NH2)sym, 3284 ν(NH2)asym, 1594 ν(C=N), 
1255 ν(C–O)enolic, 1028 ν(N–N), 943 ν(V=O). UV–Vis (DMF) [λmax, nm (ε, M
–1
 cm
–1
)]: 460 
(8945), 298 (11114), 258 (12770). 
1
H NMR (400 MHz, DMSO-d6): δ 8.93–6.53 (m, 13H, 
aromatic), 6.73 (s, 2H, NH2). 
13
C NMR (100 MHz, DMSO-d6): δ 178.68, 158.22, 155.08, 
154.13, 150.71, 143.56, 134.04, 131.61, 130.99, 129.96, 129.32, 129.21, 127.12, 116.69, 115.45, 
110.75. 
51
V NMR (DMSO-d6): δ –512. 
 
6.2.3.3. Synthesis of [VOL
3
(OEt)] (3). To the (1 mmol) sample of ligand H2L
3 
in ethanol (20 
mL), VO(acac)2 (1 mmol) was added under refluxing conditions. After 3 h, the resulting deep-
brown solution was filtered and slow evaporation of the filtrate over 4–5 days produced brown 
crystals. The crystals were filtered and washed with ethanol. 
 
[VOL
3
(OEt)] (3). Yield: 64%. Anal. Calcd for C16H16N3O4V: C, 52.61; H, 4.42; N, 11.50. 
Found: C, 52.63; H, 4.44; N, 11.48. IR (KBr pellet, cm
–1
): 1601 ν(C=N), 1239 ν(C–O)enolic, 1037 
ν(N–N), 964 ν(V=O). UV–Vis (DMF) [λmax, nm (ε, M
–1
 cm
–1
)]: 399 (7783), 326 (18601), 267 
(22547). 
1
H NMR (400 MHz, DMSO-d6): δ 8.75–6.92 (m, 8H, aromatic), 5.59 (m, 2H, 
CH2(OEt)), 1.54 (t, 3H, CH3(OEt)), 2.93 (s, 3H, CH3). 
13
C NMR (100 MHz, DMSO-d6): δ 
167.52, 164.69, 164.32, 161.80, 150.22, 140.15, 133.79, 130.69, 123.00, 122.51, 120.72, 117.00, 
82.18, 56.50, 18.98, 17.32. 
51
V NMR (DMSO-d6): δ –541. 
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6.2.3.4. Synthesis of [VOL
4
(OEt)EtOH)] (4). Complex 4 was prepared similarly to 3, replacing 
H2L
3
 by H2L
4
. 
 
[VOL
4
(OEt)EtOH)] (4). Yield: 69%. Anal. Calcd for C20H21N2O6V: C, 55.05; H, 4.85; N, 6.42. 
Found: C, 55.02; H, 4.86; N, 6.38. IR (KBr pellet, cm
–1
): 1611 ν(C=N), 1238 ν(C–O)enolic, 1052 
ν(N–N), 998 ν(V=O). UV–Vis (DMF) [λmax, nm (ε, M
–1
 cm
–1
)]: 436 (7621), 326 (8168), 284 
(11506), 260 (13128). 
1
H NMR (400 MHz, DMSO-d6): δ 9.61(s, 1H, CH), 8.40–6.65 (m, 9H, 
aromatic), 5.67 (m, 2H, CH2(OEt)), 3.45 (q, 2H, CH2(EtOH)), 1.55 (t, 3H, CH3(OEt)), 1.06 (t, 
3H, CH3(EtOH)). 
13
C NMR (100 MHz, DMSO-d6): δ 164.45, 163.24, 148.60, 146.19, 145.88, 
135.40, 132.74, 129.24, 128.70, 128.61, 124.43, 121.75, 119.55, 115.27, 112.53, 111.50, 74.38, 
56.61, 48.94, 18.57. 
51
V NMR (DMSO-d6): δ –537. 
 
6.2.4. X-ray Crystallography. Intensity data for 1, 2 and 4 were collected on a Bruker APEXII 
diffractometer equipped with a CCD area detector and graphite-monochromated Mo K 
radiation ( = 0.71069 Å), and those for 3 were measured on an Oxford Difftaction Xcalibur 
Ruby Gemini system employing graphite-monochromated Cu K radiation ( = 1.54178 Å). 
Data reduction and empirical absorption correction, based on the multi-scan method, was by 
standard methods.
49,50
 The structures were solved by direct methods using SHELXS97
51
 through 
the WinGX Interface
52
 and refinement (anisotropic displacement parameters, C-bound hydrogen 
atoms in idealised positions and a weighting scheme of the form w = 1/[2(Fo
2
) + aP
2
 + bP] 
where P = (Fo
2
 + 2Fc
2
)/3) of each structure was carried out on F
2
 by full-matrix least-squares 
procedures.
51
 The amine-H atoms in 2 were located from a difference Fourier map and refined 
with the distance restraint N‒H = 0.88±0.01 Å. The thienyl ring in 1 was found to be disordered 
over two coplanar dispositions of opposite orientation: the major component refined to a site 
occupancy factor of 0.836(2).  For 1, the maximum and minimum residual electron density peaks 
of 1.03 and 0.41 e Å
-3
, respectively, were located 0.78 and 0.51 Å, respectively, from the V 
atom. The absolute structure of 3 was determined on the basis of 539 Friedel pairs included in 
the data set; the value of the Flack parameter
53
 was 0.012(6).  Crystal data and refinement details 
are given in Table 6.1. The molecular structures shown in Figures 6.1, 6.2, 6.4,6.5 were drawn 
with 70% (35% for 2) displacement ellipsoids.
52
 The overlay diagrams shown in the were drawn 
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with QMol,
54
 and the crystal packing diagrams with DIAMOND.
55
 Data interpretation was 
accomplished using PLATON.
56
 
 
Table 6.1. Crystallographic and refinement details for 1–4. 
Compound                              1                            2     3                               4 
Formula                              C12H10N3O3SV             C19H15N4O3V     C16H16N3O4V            C20H21N2O6V 
Formula weight                   327.23                         398.29    365.26                       436.33 
Crystal colour/habit             Orange prism               Dark-red prism    Black prism               Red needle 
Crystal dimensions/mm       0.11 x 0.15 x 0.20        0.14 x 0.17 x 0.34    0.06 x 0.11 x 0.25      0.03 x 0.07 x 0.40 
Temperature/K                    100                          100    293                             293 
Crystal system                      monoclinic                    triclinic    orthorhombic             monoclinic 
Space group                          P21/c                           P1¯    Pna21                         C2/c 
a/Å                                        7.1876(3)                      7.2745(2)   12.4265(2)                  41.893(4) 
b/Å                                        10.6882(4)                   14.3309(3)   10.8273(2)                   8.7854(10) 
c/Å                                        16.6167(6)                    16.7694(4)   12.0750(2)                   21.729(2) 
a/°                                          90                           87.92(10)   90                                 90 
β/°                                          92.567(2)                     80.07(10)   90                                 98.017(5) 
/°                                           90                           83.41(10)   90                                 90 
V/Å
3
                                       1275.26(9)                   1710.41(7)   1624.64(5)                   7919.2(14) 
Z                                             4                           4    4                                  16 
Dc/g cm
-3
                                1.704                           1.547   1.493                            1.464 
F(000)                                    664                           816   752                               3616 
μ/mm-1                                   0.951                           0.609   5.339                            0.541 
Measured data                       43228                           29305   4415                             114454 
 range/°                                2.3–27.5                       1.9–27.5   5.4–77.5                       1.9–25.6 
Unique data                           2933                           7826   2329                             7421 
Observed data [I  2.0ζ(I)]   2760                           6698   2119                             5085 
R, obs. data; all data              0.028; 0.030                 0.033; 0.040   0.030; 0.033                 0.045; 0.80 
a, b in weighting scheme      0.035, 1.109                  0.046, 0.865   0.061, 0                        0.052, 15.124 
Rw, obs. data; all data            0.075; 0.076                  0.086; 0.091   0.081; 0.082                 0.106, 0.130 
Residual electron density 
peaks/e Å
3 
                            1.03, -0.41                     0.39, -0.42    0.22, -0.22                   0.65, -0.39 
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6.2.5. DNA binding experiments. 
 
6.2.5.1. Absorption spectral studies. Binding of the oxido vanadium(V) complexes to calf 
thymus (CT) DNA was carried out as previously described.
47
 The UV-Vis titration experiments 
were performed using a fixed concentration of metal complex (25 M) but variable CT-DNA 
concentrations ranging from 0 to 70 M in 10 mM Tris–HCl buffer (pH 8.0) containing 1% 
DMF. Binding of ligands to CT-DNA was also studied. For this, a fixed concentration of ligand 
[25 M in 10 mM Tris–HCl buffer (pH 8.0) containing 1% DMF] was titrated with variable 
DNA concentration ranging from 0 to 350 M. 
 
6.2.5.2. Thermal denaturation studies. Thermal denaturation studies of CT-DNA (160 M) in 
the absence and presence of complexes (150 M) were carried out by monitoring the absorbance 
at 260 nm in the temperature range of 30–90 oC with a ramp rate of 1 oC/min in 10 mM Tris-HCl 
buffer (pH 8.0) containing 1% DMF. The experiments were carried out using a Chirascan CD 
spectropolarimeter (Applied Photophysics, UK) in absorbance mode equipped with peltier 
temperature controller. The melting temperature (Tm) was determined from the derivative plot 
(dA260/dT vs T) of the melting profile.
57 
 
6.2.6. DNA cleavage experiments. 
For DNA cleavage experiments, 300 ng supercoiled (SC) pUC19 DNA was used and all 
experiments were carried out in 50 mM Tris-HCl buffer (pH 8.0) containing 1% DMF and 10 
mM phosphate buffer (pH 7.8) containing 1% DMF. 
 
6.2.6.1. Chemical-induced DNA cleavage. For chemical nuclease studies, the reactions were 
performed in the dark using hydrogen peroxide (0.5 mM) as the oxidising agent in the absence 
and presence of complexes (1-500 µM). The solutions were incubated at 37 ºC for 3 h and 
analysed for DNA cleaved products by agarose gel electrophoresis. 
 
6.2.6.2. Photo-induced DNA cleavage. The photo-induced DNA cleavage activity was done as 
described previously.
47
 The photolytic DNA cleavage experiments were carried out on 
supercoiled (SC) pUC19 DNA (300 ng) with complexes (1-500 µM) in 50 mM Tris HCl buffer 
(pH 8.0) containing 1% DMF and in 10 mM phosphate buffer (pH 7.8) containing 1% DMF. The 
extent of DNA cleavage was measured from the intensities of the bands using UVP Gel 
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Documentation System. The observed error in measuring the band intensities ranged between 3-
6%. The mechanistic studies were performed using four different additives: two are singlet 
oxygen quenchers (sodium azide and L-histidine) and two are hydroxyl radical quenchers (KI 
and D-mannitol) prior to the addition of the complex. The concentration of each additive was 0.5 
mM. 
 
6.2.7. Cytotoxicity Studies 
 
6.2.7.1. MTT assay. Human cervical cancer cells (HeLa) were obtained from National Centre of 
Cell Science (NCCS), Pune, India, and were maintained in minimal essential medium 
supplemented with 10% fetal bovine serum, penicillin-streptomycin solution and incubated at 37 
°C in 5% CO2 and 95% humidified incubator. HeLa cells were harvested from maintenance 
cultures in logarithmic phase, after counting in a hemocytometer using trypan blue solution. The 
cell concentration was adjusted to 5x10
4
 cells/ml and the cells were plated in a 96 well ﬂat 
bottom culture plate and incubated for 72 h with various concentrations of the test complexes 
which were dissolved in a 10% (v/v) DMF solution. The effect of the drugs on the cancer cell 
viability was studied using MTT dye reduction assay by measuring the optical density at 595 nm 
using microplate reader spectrophotometer (Perkin-Elmer 2030).
58
 A 10% (v/v) DMF solution 
which was used to dissolve the drugs was used in the control group treatment. 
 
6.2.7.2. Nuclear Staining. Nuclear staining using DAPI stain was performed according to the 
method previously described.
59
 Briefly, HeLa cells either treated or untreated with test 
compounds were smeared on a clean glass slide, cells were fixed with 3.7% formaldehyde for 15 
min, permeabilised with 0.1% Triton X-100 and stained with 1 μg/ml DAPI for 5 min at 37 °C. 
10% DMF solution which was used to dissolve the drugs was also used in control group 
treatment. The cells were then washed with PBS and examined by fluorescence microscopy 
(Olympus IX 71) to ascertain any condensation or fragmentation of the nuclei indicating cells 
undergoing apoptosis. 
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6.3. RESULT AND DISSCUSSION 
 
6.3.1. Synthesis. Four oxido vanadium(V) complexes (1–4) have been prepared using different 
aroylhydrazones as ligands (Scheme 6.1), i.e. with varying heterocycle-derivatives in their 
hydrazone moieties, in order to observe their influence on the pharmacological activities of the 
resultant complexes. Reactions of the selected aroylhydrazones with VO(acac)2 proceed in 
refluxing ethanol / DMF+MeOH to afford crystalline products in good yields. These complexes 
are highly soluble in aprotic solvents, viz. DMF and DMSO. 
 
6.3.2. Spectral Characteristics. The spectral (IR, UV-Vis and NMR) data of HL
1–2
, H2L
3–4 
and 
their corresponding oxido vanadium(V) complexes (1–4) are given in the Experimental Section. 
 
6.3.2.1. IR Spectroscopy. The disappearance of characteristic bands due –NH and –C=O in the 
respective ligand spectra, and the appearance of new bands in the range 1255–1238 cm–1 in the 
spectra of the resulting complexes indicates the enolisation of these two groups to form a –N=C–
O bond sequence. The strong and sharp peak displayed by the complexes in the range 1611–1594 
cm
-1
 is likely to be associated with the –C=N–N=C– moiety.60,61 The presence of  broad bands at 
946 and 943 cm
-1 
for 1 and 2, respectively, is assigned to V=O stretching,
47,62
 which indicates the 
presence of dioxido group in the complexes whereas a sharp band in the range 998–964 cm-1 is 
assigned to V=O stretching of a oxidoalkoxido vanadium(V) complex, as for 3 and 4.
60a 
 
6.3.2.2. UV Spectroscopy. The electronic spectra of 1–4 were recorded in DMF (1.48 x 10-4 M) 
and are similar. Strong absorptions in the range 460–399 nm are assignable to the ligand-to-
metal charge transfer transitions whereas the bands in the higher energy region (326–258 nm) are 
likely to be due to ligand centred transitions.
60a,b 
 
6.3.2.3. NMR Spectroscopy. The 
1
H and 
13
C NMR data of HL
1–2
, H2L
3–4
 and 1–4 were recorded 
in DMSO-d6. The spectra of HL
1–2
 and H2L
3–4
 exhibit resonances due to –NH in the range 
14.50–11.09 ppm. These disappear in the spectra of the complexes confirming enolisation of the 
ligands. For 3 and 4, the absence of signals in the range 13.32–12.72 ppm indicates 
deprotonation of the –OH groups and its coordination to the vanadium centre after metallation. 
Complexes 1 and 3 each displays a singlet in the range δ = 2.93–2.72 ppm due to –CH3 protons. 
Complexes 3 and 4 exhibit separate resonances corresponding to bound ethanolate at 5.59 and 
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5.67 ppm due to –CH2 and 1.54 and 1.55 ppm due to –CH3, respectively.
60b,63,64
 In addition, 4, 
exhibits a quartet at 3.45 ppm due to –CH2 and a triplet at 1.06 ppm due to –CH3, respectively 
which indicates the presence of the coordinated ethanol group. Finally, 4 displays a resonance at 
δ = 9.61 ppm ascribed to –CH. 
 
The 
51
V NMR spectra of 1–4 each displays a singlet in the range δ= –541 to –507 ppm. These 
chemical shifts are usual for complexes containing oxido vanadium(V) species.
65 
 
6.3.3. Description of the X-ray structure of complexes 1-4. 
 
6.3.3.1. Structural commentary. Crystal structures were obtained for each of 1–4 and these are 
discussed in turn below. The selected geometric parameters are listed in Table 6.2. 
 
6.3.3.2. Molecular structures. In [VO2L
1
] (1), Figure 6.1, the penta-coordinated vanadium 
atom is bound by a tridentate uninegative anion, coordinating via enolate-O, azo-N and pyridyl-
N atoms, and two oxido-O atoms. Confirmation that the multidentate ligand is functioning as a 
2-acetylpyridine 2-thiophenoylhydrazone is found in the magnitudes of the two C=N bond 
lengths, Table 6.2; a similar mode of coordination for this specific anion toward vanadium was 
found in a seven-coordinated species where one oxido-O atom is replaced by peroxo- and 
methanol-O atoms.
66
 The resulting N2O3 donor set in 1 is distorted toward square pyramidal 
based on a  value of 0.30 which compares to ideal values of 0.0 and 1.0 for square pyramidal 
and trigonal bipyramidal geometries, respectively.
67
 Each five-membered chelate ring is planar 
with r.m.s. deviations of 0.021 and 0.023 Å for the (V1,O1,N2,N3,C7) and (V1,N1,N2,C1,C6) 
rings, respectively, and the dihedral angle between them is 1.91(6)º. The dihedral angle between 
the terminal pyridyl and thienyl (major component) rings is 4.96(19)º suggesting that the entire 
ligand is approximately planar. The overall molecular structure in 1 matches closely to the most 
relevant structure available for comparison, namely the furanyl derivative, which exhibits 
crystallographically imposed mirror symmetry with the tridentate ligand lying on the plane.
68
 
The molecular structures of the two independent molecules comprising the asymmetric unit of 
[VO2L
2
] (2) are shown in Figure 6.2 and Figure 6.3a, and these are similar to that just described 
for 1 except that the methyl and thienyl groups in 1 have been substituted by phenyl and anilinyl 
groups, respectively. The uninegative, tridentate ligand adopts a similar mode of coordination as 
just described for 1 in each molecule of 2. The independent molecules differ most notably in the 
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relative orientations of the phenyl and anilinyl substituents as highlighted in the overlay diagram, 
Figure 6.3b, and quantified in the dihedral angles formed between the pyridyl and each of the 
phenyl and anilinyl rings of 54.39(8) and 23.36(8)º, respectively, for the first independent 
molecule in 2, and 47.77(7) and 6.18(8)º for the second molecule. From these data, the tridentate 
ligand in the second molecule adopts a more planar conformation cf. the first independent 
molecule.  The five-membered chelate rings in each molecule are almost planar with the r.m.s. 
deviations for (V1,O1,N2,N3,C7) and (V1,N1,N2,C1,C6) rings being 0.046 and 0.009 Å for the 
first molecule, respectively, and 0.044 and 0.028 Å for the second molecule, respectively. The 
values of  calculated for the two independent molecules are 0.35 and 0.28, respectively, again 
indicating a distortion toward a square pyramidal geometry.  Each molecule features an 
intramolecular N–H...N hydrogen bond which closes an S(6) loop.69 The analogous ligand where 
the phenyl group has been substituted for a methyl group has been characterised in two crystal 
structures, i.e. mononuclear cobalt
70
 and uranium
71
 complexes, each with a nearly planar 
conformation of the tridentate ligand. 
 
An increase in coordination number at vanadium in [VOL
3
(OEt)] (3), Figure 6.4, is evident 
owing to the formation of intermolecular V–N1(pyridyl) bonds. The vanadium atom is 
coordinated by the enolate-O1, phenoxide-O2 and azo-N2 atoms of the dinegative ligand, as well 
as oxido-O3, ethanolate-O4 and bridging pyridyl-N1 atoms; the dianion is therefore, tetradentate. 
The result of the V–N bridging is the formation of a supramolecular helical chain along the c-
axis, Figure. 6.4b. The N2O4 donor set defines a distorted octahedral geometry with the twist 
angle between the trigonal faces defined by the O1,O4,N1 atoms and the O2,O3,N2 atoms being 
approximately 51º, cf. 60º for an ideal octahedron and 0º for an ideal trigonal prism. While the 
five-membered chelate ring is essentially planar, r.m.s. deviation = 0.033 Å, the six-membered 
chelate ring is best described as being based on a half-chair conformation with the vanadium 
atom lying 0.812(3) Å out of the plane defined by the remaining chelate atoms, i.e. 
O2,N2,C1,C6,C7, which have a r.m.s. deviation of 0.0787 Å from their least-squares plane. 
There are no literature precedents for crystal structures containing the ligand as found in 3. 
 
The fourth structure, [VOL
4
(OEt)EtOH)] (4), is illustrated in Figure 6.5 and Figure 6.6a, as the 
asymmetric unit comprises two independent complex molecules; for the second independent 
molecule, the ethanol molecule is statistically disordered over two positions (Figure 6.6a). The 
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overlay diagram of the two independent molecules with the moleculeis shown in Figure 6.6b. 
The coordination geometry is based on an octahedral NO5 donor set defined by enolate-O1, azo-
N2 and naphthyl-oxide-O2 atoms of the tridentate dinegative anion, as well as oxido-O4, 
ethanolate-O5 and ethanol-O6 atoms. The V=O4 bond lengths in 4 are the shortest across the 
series owing to the trans disposition of the oxido-O to the relatively weakly bound ethanol 
molecules. Each five-membered chelate ring is planar but the six-membered rings are best 
described as having half-chair conformations with the O2 atom lying 0.454(3) Å out of the plane 
defined by the remaining five atoms (r.m.s. deviation = 0.1037 Å); the equivalent values for the 
V2-molecule are 0.348(3) and 0.0826 Å, respectively.  The dihedral angle between the chelate 
rings for the V1-containing molecule is 6.88(18)º, and this opens up to 10.06(12)º for the species 
with V2. Overall, the multidentate ligand exhibits a small twist as seen in the dihedral angles 
formed between the outermost ring of the naphthalyl system and furanyl group of 13.90(19)º 
(V1) and 10.42(18)º (V2). A search of the Cambridge Structural Database
72
 revealed 42 
vanadium-containing structures with an NO5 donor set defined by the same donor atoms as for 4. 
In each structure there was a trans arrangement of oxido-O and ethanol-O atoms as well as 
between ethanolate-O and nitrogen donor atoms.  The most closely related structure is one where 
the furanyl group has been replaced by a 3-pyridyl ring and the N1-imine C atom carries a 
methyl group.
73
 In the latter, the tridentate ligand has a decidedly curved conformation with the 
dihedral angle between the terminal rings being 34.56(7)°. 
 
6.3.3.3. Supramolecular features. In the absence of functional groups capable of hydrogen 
bonding, the most significant intermolecular interactions operating in the structure of 1 are of the 
type … and C–H…O. The former connect molecules into centrosymmetric dimers via 
interactions involving the thienyl and pyridyl rings. These are connected into a three-dimensional 
architecture via pyridyl-C–H interacting with a bifurcated oxido-O3 atom. A view of the unit cell 
contents for 1 is given in Figure 6.7 and full geometric details describing the aforementioned 
interactions are collected in the figure caption. 
 
The most prominent feature of the crystal packing in [VO2L
2
] (2) is the formation of N–H…O 
hydrogen bonds between the amino-H and oxido-O atoms so that supramolecular chains aligned 
along [101] are formed comprising alternating V1- and V2-containing molecules, Figure 6.8a. 
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These are linked by a network of C–H…O interactions involving anilinyl-, methyl-, phenyl- and 
pyridyl-H as donors and oxido-O as acceptors, see Figure 6.8b for geometric data. 
 
In the crystal structure of [VOL
3
(OEt)] (3), the coordination polymers are connected into a 
supramolecular layer in the ac-plane with the links being of the type C–H…(chelate) ring with 
the latter comprising the (V,O1,N2,N3,C8) atoms of the five-membered ring, see Figure 6.9a. 
for geometric data. Such C–H…(chelate) ring interactions are relatively rare, or more likely not 
always recognised, but are increasingly attracting attention in the crystallographic literature.
74–76
 
The layers stack along the b-axis in an ...ABA... pattern with no specific interactions between 
them, see Figure 6.9b. 
 
Finally, in the crystal packing of [VOL
4
(OEt)EtOH)] (4), each of the two independent molecules 
comprising the asymmetric unit self-associate via methanol-O–H...N1(imine) hydrogen bonds to 
form two-molecule aggregates and 10-membered {...HOVN2}2 supramolecular synthons, see             
Figure 6.10 (a,b). Within the dimeric aggregates there are also ... interactions between the 
thienyl and inner ring of the naphthalyl group. The dimers stack into columns aligned along the 
b-axis, so that layers of alternating V1- and V2-containg molecules stack along the a-axis. In the 
layers comprising V2-containing molecules, naphthalyl-C–H...O(naphthalyl) interactions 
stabilise the architecture but there are no specific interactions between V1-containing dimers or 
between layers, Figure 6.10c. 
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Table 6.2. Selected bond lengths and angles (Å, º) for 1–4. 
________________________________________________________________________________________ 
Complex 1 2a 2b 3
a
 4a 4b
b
 
________________________________________________________________________________________ 
Parameter 
V–O1 1.9684(11) 1.9458(12) 1.9604(12) 1.969(2) 1.958(2) 1.938(2) 
V–O2 1.6213(12) 1.6196(13) 1.6203(12) 1.859(2) 1.856(2) 1.848(2) 
V–O3 1.6196(13) 1.6206(13) 1.6171(12) 1.594(2) – – 
V–O4 – – – 1.777(2) 1.577(2) 1.575(3) 
V–O5 – – – – 1.775(2) 1.753(2) 
V–O6 – – – – 2.325(2) 2.46(3) 
V–N1 2.1112(13) 2.0939(15) 2.1015(14) 2.434(2) – – 
V–N2 2.1200(13) 2.1067(14) 2.1200(14) 2.141(2) 2.111(2) 2.109(2) 
V–N3 – – – – – – 
N2–N3 1.3840(18) 1.381(2) 1.3786(19) 1.400(3) 1.392(3) 1.395(3) 
C=N1 – – – – 1.299(4) 1.297(4) 
C=N2 1.291(2) 1.303(2) 1.304(2) 1.298(4) 1.285(4) 1.283(4) 
C=N3 1.312(2) 1.324(2) 1.325(2) 1.297(4) – – 
O1–V–O2 102.55(6) 103.92(6) 101.83(6) 149.59(9) 150.57(9) 151.97(10) 
O1–V–O3 102.16(6) 104.12(6) 102.57(6) 100.86(11) – – 
O2–V–O3 109.99(7) 109.89(7) 109.15(7) 99.62(11) – – 
O4–V–O6 – – – – 177.03(10) 171.5(6) 
O1–V–N1 146.50(5) 147.47(6) 146.72(5) 79.19(9) – – 
O3–V–N1 97.60(6) 95.25(6) 97.00(6) 178.81(11) – – 
O4–V–N2 – – – 163.35(9) 93.61(11) 96.30(11) 
O5–V–N2 – – – – 163.36(11) 157.32(12) 
N1–V–N2 73.08(5) 73.32(6) 72.94(5) 85.55(9) – – 
___________________________________________________________________________ 
a The N1 atom in 3 is related by the symmetry operation 2-x, 2-y, ½+z. 
b For the second component of the disordered ethanol molecule in 4, the V2–O6b bond length is 
2.52(3) Å and the O4a–V2–O6b bond angle is 174.8(6)º. 
  
231 
 
 
 
 
Figure 6.1. The molecular structure of [VO2L
1
] (1), showing the atom-labelling scheme and 70% 
displacement ellipsoids. Only the major component of the disordered thienyl ring is shown. 
 
 
 
 
 
 
 
Figure 6.2. The molecular structure of one of the two independent molecules comprising the 
asymmetric unit of [VO2L
2
] (2), showing atom-labelling scheme and 70% displacement 
ellipsoids 
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(a) 
 
(b) 
Figure 6.3. (a) The molecular structure of the second of the two independent molecules 
comprising the asymmetric unit of [VO2L
2
] (2) showing the atom-labelling scheme and 70% 
displacement ellipsoids.  Atoms are further designated with a suffix ―a‖; and (b) overlay diagram 
of the two independent molecules with the molecule containing the V1 atom shown in red. The 
molecules have been overlapped so that the V(=O)2 units are superimposed. 
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(a) 
 
(b) 
Figure 6.4. (a) The asymmetric unit in [VOL
3
(OEt)] (3), showing the atom-labelling scheme and 
35% displacement ellipsoids. The coordination geometry of the vanadium atom has been 
extended to indicate the V‒N1 bonds that generate the helical polymer along the c-axis, shown in 
(b). 
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Figure 6.5. The molecular structure of one of the two independent molecules comprising the 
asymmetric unit of [VOL
4
(OEt)EtOH)] (4), showing atom-labelling scheme and 70% 
displacement ellipsoids. 
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(a) 
 
(b) 
Figure 6.6. (a) The molecular structure of the second of the two independent molecules 
comprising the asymmetric unit of [VOL
4
(OEt)EtOH)] (4) showing the atom-labelling scheme 
and 70% displacement ellipsoids.  Atoms are further designated with a suffix ―a‖. The 
coordinated ethanol molecule is statistically disordered over two positions. The atoms 
comprising the second orientation of the disordered ethanol molecule are additionally labelled 
with a suffix ―b‖ and are highlighted with dashed bonds; and (b) overlay diagram of the two 
independent molecules with the molecule containing the V1 atom shown in red; the inverted V2-
containing molecule is shown for a better match. The molecules have been overlapped so that the 
V, O4 and N2 atoms are superimposed. 
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Figure 6.7. A view of the unit cell contents for [VO2L
1
] (1) in projection down the b-axis. The 
C–H…O [C2–H2...O3i = 2.57 Å, C2...O3i = 3.413(2) Å, angle at H2 = 147° for symmetry 
operation i: x, ½-y, -½+z; and C4–H4...O3ii = 2.53 Å, C4...O3ii = 3.183(2) Å, angle at H4 = 126° 
for ii: 2-x, 1-y, -z] and … interactions [Cg(S1,C8-C11)…Cg(N1,C1-C5)iii = 3.625(2) Å, angle 
of inclination = 4.96(19)° for iii: 1-x, -y, -z] are shown as orange and purple dashed lines, 
respectively. The 2-thienyl ring is disordered over two co-planar conformations and the 
complementary Cg(S1b,C8b-C11b)…Cg(N1,C1-C5)iii separation is 3.666(12) Å and the angle of 
inclination is 4.3(12)º. 
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(a) 
 
 
 
 
 
(b) 
 
Figure 6.8. Crystal packing in [VO2L
2
] (2): (a) a view of the supramolecular chain comprising 
alternating V1- and V2-containing molecules sustained by N–H…O hydrogen bonding [N4–
H1n...O2a
i
 = 2.406(19) Å, N4...O2a
i
 = 3.063(2) Å, with angle at H1n = 132.1(18)° for symmetry 
operation i: 1-x, 1-y, -z; N4a–H3n...O3ii = 2.259(14) Å, N4a...O3ii = 3.033(2) Å, with angle at 
H3n = 148.6(19) for symmetry operation ii: -x, 1-y, 1-z], shown as blue dashed lines; and (b) a 
view of the unit cell contents in projection down the a-axis.  The C–H…O [C4a–H4a3...O3aiii = 
2.50 Å, C4a...O3a
iii
 = 3.149(2) Å, angle at H4a3 = 126° for symmetry operation iii: 1-x, -y, -z; 
C5a–H5a...O3ai = 2.55 Å, C5a...O3ai = 3.178(2) Å, angle at H5a = 124°; C10a–H10a...O2ii = 
2.47 Å, C10a...O2
ii
 = 3.283(2) Å, angle at H10a = 143°; and C15a–H15a...O3 = 2.57 Å, 
C15a...O3 = 3.235(2) Å, angle at H15a = 127°] interactions are shown as orange dashed lines. 
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    (a) 
 
 
 
 
 
 
 
 
        (b) 
Figure 6.9. Crystal packing in [VOL
3
(OEt)] (3): (a) a view of the supramolecular layer in the ac-
plane whereby the supramolecular chains are linked C–H…(chelate) ring interactions [C4–
H4...(V,O1,N2,N3,C8)i = 2.68 Å, C4...(V,O1,N2,N3,C8)i = 3.582(4) Å, with angle at H4 = 
164° for symmetry operation i: 1-x, 2-y, ½+z] shown as purple dashed lines, and (b) a view of 
the unit cell contents in projection down the a-axis showing the ...ABA... pattern of 
supramolecular layers stacked along the b-axis. 
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     (a)                                                                               
 
 
 
 
 
 
 
 
     (b) 
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(c) 
Figure 6.10. Crystal packing in [VOL
4
(OEt)EtOH)] (4): (a) a view of the two-molecule 
aggregate whereby centro symmetrically related V1-containing molecules are linked by ethanol-
O–H…N hydrogen bonds, (b) equivalent dimer formed by the V2-containing molecule; second 
orientation of the disordered ethanol molecule and all non-participating hydrogen atoms removed 
for clarity [O6–H6o...N1i = 2.12 Å, O6...N1i = 2.873(3) Å, with angle at H6o = 149° for 
symmetry operation i: -x, 1-y, 1-z; O6a–H6oa...N1aii = 2.31 Å, O6a...N1aii = 2.95(2) Å, with 
angle at H6oa = 136° for symmetry operation ii: ½-x, ½-y, -z; for the second disordered 
conformation: O6b–H6ob...N1aii = 2.20 Å, O6b...N1aii = 2.99(2) Å, with angle at H6ob = 164°] 
shown as orange dashed lines, and (c) a view of the unit cell contents in projection down the b-
axis showing the stacking of alternating layers of V1- and V2-containing molecules along the a-
axis.  The C–H…O [C8a–H8a...O2aiii = 2.57 Å, C8a...O2aiii = 3.398(4) Å, with angle at H8a = 
149° for symmetry operation iii: ½-x, ½+y, ½-z] and ... [Cg(O3,C13-C16)…Cg(C1,C2,C7-
C10)
i
 = 3.702(2) Å, angle of inclination = 13.45(19)°; Cg(O3a,C13a-C16a)…Cg(C1a,C2a,C7a-
C10a)
ii
 = 3.641(2) Å, angle of inclination = 8.64(18)°] interactions are shown as blue and purple 
dashed lines, respectively. 
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6.3.4. DNA binding studies. 
 
6.3.4.1. Absorption spectroscopic studies. The binding propensity of 1–4 to CT-DNA was 
studied using different spectroscopic techniques. Complexes 1–4 show absorption bands in the 
regions 440–400 and 340–300 nm which are attributed to L–V(d) LMCT and intra-ligand 
transitions, respectively.
60a
 UV-Vis titration experiments were carried out to determine the 
equilibrium binding constant (Kb) of the complexes to CT-DNA (Table 6.3 and Figure 6.11). 
Upon addition of CT-DNA the UV-Vis absorption bands in the region 340–300 nm showed a 
hypochromic shift for 1 whereas 2–4 exhibited hyperchromism (Figure 6.11), indicating 
interaction between each complex and CT-DNA. The binding affinity of the interaction between 
CT-DNA and each of 1–4 is indicated by the binding constant, Kb, which was calculated using 
the following equation
36e
:  
 
[DNA ]
εa −εf
=  
[DNA ]
εb −εf
+  
1
Kb (εb −εf )
                                 Eq. 1 
 
where [DNA] is the concentration of DNA base pairs, εa, εf, and εb correspond to apparent 
extinction coefficient for the complex i.e. Abs/[complex] in presence of DNA, in absence of 
DNA and to fully bound DNA, respectively. A plot of [DNA]/(εa -εf) vs [DNA] gave a slope and 
intercept equal to 1/(εb - εf) and 1/Kb(εb - εf), respectively; Kb is calculated from the ratio of the 
slope to the intercept. The data reported in Table 6.3 reveal Kb has values for 1–4 from 1.13 × 
10
5
 to 5.03 × 10
3
 M
−1
 with the order of DNA binding strength being 2 > 1 > 3 > 4. These results 
suggest that 1–4 binds CT-DNA through the groove binding mode. The binding affinity of the 
ligands to CT-DNA were also estimated and gave values lower than their corresponding 
complexes (Table 6.4). 
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     Table 6.3. DNA binding parameters for 1–4. 
 
 
 
 
 
 
 
 
a
 DNA binding constants were determined by the UV-Vis spectral method. 
b
 Change in the melting temperature of CT-DNA. 
 
 
 
       Table 6.4. DNA binding parameters for Ligands. 
 
 
 
 
 
 
 
a
 The DNA binding constant was determined by the UV-Vis spectral method. 
 
 
 
 
 
Complex  Binding constant (Kb)
a
 (M
-1
) ∆Tm
b
 (
o
C) 
1 8.56  104 +1.31 
2 1.13  10
5
 +1.83 
3 4.95  10
4
 +1.32 
4 5.03  10
3
 -1.70 
Ligand  Binding constant (Kb) (M
-1
) 
HL
1
 7.42  103 
HL
2
 3.88  10
3
 
H2L
3
 2.91  10
4 
H2L
4
 2.48  10
3
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Figure 6.11. Electronic absorption spectra of 1 (a), 2 (b), 3 (c), and 4 (d) (25 M each) upon the 
titration of CT-DNA (0 – 70 M) in 10 mM Tris-HCl buffer (pH 8.0) containing 1% DMF. 
Arrow shows the changes in absorbance with respect to an increase in the CT-DNA 
concentration. The inset shows the linear fit of [DNA]/(εa - εf) vs [DNA] and the binding 
constant (Kb) was calculated using Eq. 1. 
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6.3.4.2. Thermal denaturation studies. To investigate whether the stability of DNA alters upon 
interaction with the complexes, DNA melting experiments were performed in the absence and 
presence of 1–4.57 The midpoint transition temperature or melting temperature (Tm) of CT-DNA 
in absence of any complex is ~65.7 °C. The Tm increased very slightly (~1.3–1.8 °C) upon 
interaction with 1–3 whereas 4 showed a slight decrease (1.7 °C) in the thermal melting of CT-
DNA (Figure 6.12. and Table 6.3). The low ΔTm values for 1–3 primarily suggest groove 
binding of the complexes to CT-DNA rather than an intercalative mode of binding to DNA 
which usually gives a large positive ΔTm value.
77,78
 The slight negative ∆Tm value of -1.70 °C for 
4 (Figure 6.12. and Table 6.3) may be due to the destabilisation of the DNA double helix by this 
complex.
79
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Figure 6.12. Derivative plot of thermal denaturation of CT-DNA (160 M) in the absence and 
presence of 1–4 (150 M). The experiment was done in 10 mM Tris-HCl buffer (pH 8.0) 
containing 1% DMF. Inset shows the ∆Tm (
o
C) of the complexes as compared to CT-DNA. 
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6.3.5. DNA cleavage studies. 
 
6.3.5.1. Chemical-induced DNA cleavage. The DNA cleavage activity of the complexes 1–4 
(1-500 μM) was studied in the dark in the presence of hydrogen peroxide (500 μM) as the 
oxidising agent using supercoiled pUC19 DNA (300 ng) in 50 mM Tris-HCl buffer (pH 8.0) 
containing 1% DMF. The complexes do not show any chemical-induced DNA cleavage activity . 
 
6.3.5.2. Photo-induced DNA cleavage. To investigate whether the DNA binding properties of 
the complexes were accompanied with photo-nuclease activity, a photo-induced DNA cleavage 
activity assay was performed. Photo-induced DNA nuclease activity of 1–4 was studied using 
supercoiled (SC) pUC19 DNA in 50 mM Tris-HCl buffer (pH 8.0) containing 1% DMF, upon 
irradiation of UVA light of 350 nm in the presence and absence of the complexes (Figure 6.13). 
The percentage of net DNA cleavage by the complexes was estimated using the following 
equation: 
 
Net DNA cleavage % =
Form  IIs +2 ×Form  IIIs
Form  Is+ Form  IIs +2 ×Form  IIIs
−
Form  IIc +2 ×Form  IIIc
Form  Ic+ Form  IIc +2 ×Form  IIIc
        Eq. 2 
 
The subscripts ―s‖ and ―c‖ refers to the sample and control, respectively.80 The net DNA 
cleavage by 1–4 was plotted in a concentration dependent manner (Figure 6.14). Approximately 
10% DNA cleavage was observed in the presence of 10 M of 1–4 (Figure 6.14, inset). The 
cleavage activity was saturated for each of the complexes at a concentration of 100 M. At this 
concentration, the photo-nuclease activity of 1, 2, 3 and 4 was 50, 33, 65 and 45%, respectively, 
indicating that 3 has the highest photo-nuclease activity over the series. The photo-induced DNA 
cleavage experiments were also carried out with phosphate buffer returning similar activity as for 
the experiments in tris buffer, an observation in accord with previous studies with dioxido 
vanadium complexes.
47
 Control experiments revealed that neither DMF (1%) nor the ligand 
molecules showed any photo-induced DNA cleavage activity, implying that DMF and the 
ligands are cleavage inactive under similar conditions. 
 
In order to understand the mechanistic pathways involved in the photo-cleavage reactions, the 
photo-induced DNA cleavage activity of 1–4 was investigated in the presence of various 
additives. The DNA cleavage reaction involving molecular oxygen can proceed in two 
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mechanistic pathways: (a) a type-II process involving singlet oxygen species (
1
O2), or (b) by a 
photo-redox pathway involving reactive hydroxyl radicals (OH).
81
 The addition of NaN3 (singlet 
oxygen quencher) inhibited the DNA cleavage activity of 1, 3 and 4 by 8, 14 and 10 %, 
respectively (Figure 6.15). By contrast, the other singlet oxygen quencher (L-histidine) slightly 
inhibited the photo-induced DNA cleavage activity of complexes 1, 3 and 4. Surprisingly, it was 
observed that the DNA cleavage activity of 2 did not alter in the presence of these two additives. 
The hydroxyl radical scavenger, KI, inhibited the photo-nuclease activity of 1, 3 and 4 by 10, 15 
and 13 %, respectively, whereas the other hydroxyl radical scavenger D-mannitol inhibited the 
DNA cleavage activity of these three complexes moderately. However it is to mention that no 
inhibition of DNA cleavage was observed for 2 in the presence of these two additives        
(Figure 6.15). Therefore, it is concluded that 1, 3 and 4 exhibit photo-induced DNA cleavage 
activity via both singlet oxygen and hydroxyl radical pathways, while the mechanistic pathways 
involved in the photo-induced DNA cleavage by 2 cannot be stated with certainty. 
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Figure 6.13. Gel diagram showing concentration dependent DNA cleavage by 1–4; 300 ng of SC 
pUC19 DNA at different concentrations of the complexes [1–500 µM in 50 mM Tris-HCl buffer 
(pH 8.0) containing 1% DMF] was photo-irradiated with UVA at 350 nm for 3 h. Lanes 1–9: 1, 
2.5, 5.0, 7.5, 10, 50, 75, 100 and 500 µM of 1–4. 
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Figure 6.14. Concentration dependent DNA cleavage by 1–4; 300 ng of SC pUC19 DNA at 
different concentration of the complexes [1–500 µM in 50 mM Tris-HCl buffer (pH 8.0) 
containing 1% DMF] was photo-irradiated with UVA at 350 nm for 3 h. The net DNA cleavage 
percent was calculated using Eq. 2. Inset shows a bar diagram representation of the net DNA 
cleavage of different complexes at 10 and 100 µM. 
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Figure 6.15. DNA cleavage of SC pUC19 DNA by 1–4 in presence of various additives in 50 
mM Tris-HCl buffer (pH 8.0) containing 1% DMF. SC pUC19 DNA (300 ng) in the presence of 
various additives was photo-irradiated at 350 nm for 3 h with 1–4 (100 µM). The additive 
concentrations were: sodium azide (0.5 mM), L-histidine (0.5 mM), KI (0.5 mM) and D-mannitol 
(0.5 mM). 
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6.3.6. Cytotoxicity studies. 
 
6.3.6.1. MTT assay. The in vitro cytotoxicities of 1–4 were evaluated by the MTT assay against 
the cervical cancer cell line HeLa; the IC50 values are presented in Table 6.5. The species HL
1–2
, 
H2L
3–4
 and VO(acac)2 gave high IC50 values of > 200 μM, whereas 1–4 gave values in the range 
10–20 μM. Under the same experimental conditions, the commonly used chemotherapeutic drugs 
cisplatin, gefitinib, gemcitabine, 5-fluorouracil and vinorelbine are comparably effective in HeLa 
cells with IC50 values of 13, 20, 35, 40 and 48 μM, respectively.
82
 The significant decrease in the 
inhibitory ability of the ligand molecules as well as their lower binding affinity to CT-DNA 
compared to their metal complexes clearly indicates that incorporation of vanadium has a 
marked effect on cytotoxicity. A possible explanation is that by coordination, the polarity of the 
ligand and the central metal ion are reduced through charge equilibration which favours 
permeation of the complexes through the lipid layer of the cell membrane.
83,84
 The results of 
DNA binding/cleavage ability for the ligands have been considered and are consistent with the 
observation that metal complexes can exhibit greater biological activities than the free ligands.
85
 
 
Within the series 1–4, the cytotoxicities of 1, 2 and 3 are approximately similar whereas 4 is 
more potent, Table 6.5. Their dose dependencies are illustrated in Figure 6.16. The variation in 
cytotoxicity may be affected by the various functional groups attached to the aroylhydrazone 
derivative. Very recently, the anti-proliferative activity of some vanadium complexes were 
reported by Yamaguchi et al.
86
 and us
32,47
 using U937 cells and HeLa cells, respectively. The 
present results are in accord with these results. 
 
6.3.6.2. Nuclear Staining Assay. To investigate the apoptotic potential of the test complexes in 
HeLa cells, DAPI staining was performed. Chromatin condensation during the process of 
apoptosis (type I programmed cell death) is a characterising marker of nuclear alteration. HeLa 
cells were treated with 18, 15, 16, and 5μM of 1–4, respectively. The cells were incubated for 24 
h before DAPI nuclear staining and were examined under a fluorescent microscope fitted with a 
DAPI filter. As shown in Figure 6.17, control cells (treated with 10% (v/v) DMF) hardly showed 
any sort of condensation in comparison to the treated cells. All images, taken in gray-scale, 
demonstrate the brightly condensed chromatin bodies and the nuclear blebbings as marked by 
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arrows in Figure 6.17. Besides showing nuclear change, the treated cells exhibited a shrinking 
morphology which is another important hallmark of apoptosis. 
 
 
 
 
Table 6.5. Cytotoxic scores in HeLa cancer cells for 1–4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complex IC50 (µM) 
1 20±4.52 
2 18±3.38 
3 19.5±3.54 
4 9.9±3.18 
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Figure 6.16. Effect of 1–4 on cell viability and growth: HeLa cells were treated with different 
concentrations of the test compound for 72 h and then cell viability was measured by MTT 
assay. Data are reported as the mean ± S.D. for n = 6 and compared against 10% (v/v) DMF 
treated control by using a Student‘s t-test. (*significant compared to control). 
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Figure 6.17. Study of apoptosis by morphological changes in nuclei of HeLa cells: HeLa cells, 
from control and treated groups, were fixed with 3.7% formaldehyde for 15 min, permeabilised 
with 0.1% Triton X-100 and stained with 1 µg/ml DAPI for 5 min at 37 °C. The cells were then 
washed with PBS and examined by fluorescence microscopy (Olympus IX 71) (200×). HeLa 
cells were treated with 18, 15, 16, and 5 μM of complexes 1–4, respectively. Arrows showing the 
morphological changes in nuclei of HeLa cells observed on application of 1–4 in comparison to 
the control group treated with 10% (v/v) DMF. 
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6.4. CONCLUSION 
 
The synthesis and characterisation of four neutral oxido vanadium(V) complexes (1−4) with 
bioactive hydrazone scaffolds containing furan, thiophene and pyridine residues has been 
achieved. X-ray crystallography confirm the spectroscopic analyses and show N2O3 five-
coordinate geometries, distorted toward square pyramidal, for each of 1 and 2. The dianion in 3 
is tetradentate as the pyridyl-N atom also bridges a second V atom leading to a helical 
coordination polymer and an N2O4 octahedral geometry. A NO5 octahedral geometry is found in 
mononuclear 4. Biological studies reveal that the oxido vanadium(V) complexes (1–4) show 
considerable DNA binding propensity. DNA binding activities were investigated using UV-Vis 
absorption titration and thermal denaturation studies, and shows that the complexes interact with 
CT-DNA by a minor groove binding mode, with binding constants ranging from 10
3−105 M-1. 
All complexes show good photo-induced cleavage of pUC19 supercoiled plasmid DNA with 3 
showing the highest photo-induced DNA cleavage activity of ~65%. The results from the 
mechanistic study suggested that the photolytic DNA cleavage of 1, 3 and 4 preceded possibly 
via both singlet oxygen and hydroxyl radical pathways. Additionally, the cytotoxic activities of 
1–4 were evaluated against human cervical cancer cell lines (HeLa). All are appreciably 
cytotoxic compared with standard drugs (cisplatin, gefitinib, gemcitabine, 5-fluorouracil and 
vinorelbine) with IC50 values ranging from 10 to 20 µM. This potency correlates with the 
presence of a bioactive heterocycle attached to the hydrazone moiety. Despite having a lower 
binding affinity, the higher cytotoxicity of 4 may be due to the destabilising interaction between 
the complex and the DNA as evidenced from the thermal denaturation data. The results reported 
herein will inspire further work on oxido vanadium(V) complexes for the development of metal-
based agents for anti-cancer applications. 
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ABSTRACT 
_____________________________________________________________________________ 
In this chapter, series of mononuclear nonoxido vanadium(IV) [V
IV
(L
1-4
)2] (1–4), oxidoethoxido 
vanadium(V) [V
V
O(L
1-4
)OEt] (5–8), and binuclear μ-oxido vanadium(V) [VV2O3(L
1
)2]
 
(9) 
complexes, taking potentially tridentate binegative aroylhydrazone ligands are reported [where 
H2L
1 
= 2-furoyl hydrazone of 2-hydroxy-1-acetonaphthone, H2L
2 
=2-thiophenoylhydrazone 
hydrazone of 2-hydroxy-1-acetonaphthone, H2L
3 
=1-napthoyl hydrazone of 2-hydroxy-1-
acetonaphthone, H2L
4 
=3-hydroxy-2-napthoyl hydrazone of 2-hydroxy-1-acetonaphthone]. All 
the mononuclear complexes were characterized by elemental analysis as well as by various 
spectroscopic techniques. The nonoxido vanadium(IV) complexes are quite stable in open air as 
well as in solution. The solution study of the oxidoethoxido vanadium(V) species (5-8) were 
carried out which indicates the existence of two different species in solution. The new species, a 
μ-oxido divanadium complex, [V2O3(L
1
)2]
 
(9) is generated in situ in solution state from 
corresponding mononuclear complex [V
V
O(L
1
)OEt] (5), successfully isolated in solid state and 
fully characterized by several physicochemical techniques. Single crystal X-ray diffraction 
crystallography of nonoxido vanadium (IV) (2) showed the N2O4 donor set to define a trigonal 
prismatic geometry and that of oxido vanadium (V) (5 & 6) and μ-oxido divanadium(V) (9) 
reveals that the metal centre is in distorted square pyramidal geometry with O4N coordination 
spheres. 
______________________________________________________________________________ 
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7.1. INTRODUCTION 
 
Hydrazones, –NH–N=CRR' (R and R = H, alkyl, aryl), are versatile ligands and the study of 
complexes with these is of unabated interest to inorganic chemists because of their relevance to 
apparently dissimilar fields, like bioinorganic chemistry,
1
 and catalysis.
2
 The phenolic- 
hydrazone ligands with good π-donor atoms are expected to stabilize higher oxidation states with 
highly covalent M–O(phenolate) bonds. On the other hand, the diversified roles of vanadium 
among others in biological systems
3,4
 are primarily responsible for stimulating a recent 
increasing interest in vanadium coordination chemistry. However, in contrast to the well known 
vanadium(IV)/(V) complexes containing VO
2+
 or VO
3+
 units,
5
 only very few octahedral 
nonoxido (V
IV
 and V
V
) complexes, the so-called 'bare' complexes, have been isolated and 
structurally characterized.
6
 This type of nonoxido V
IV
 centers
7
 have been found in amavadin,
8
 a 
compound isolated from the mushroom Amanita muscaria and such class of vanadium species 
are still scarce.
6
  
 
We have been exploring the feasibility of using tridentate aroylhydrazone ligands, which 
comprise the three donor atoms [ONO] for generating novel transition metal complexes. Thus, 
we reported several oxido-, nonoxido-, µ-oxido divanadium complexes of general formula, 
[V
V
O(L)OEt], [V
IV
(L)2] and [V
V
2O3(L)2] with potentially tridentate binegative aroylhydrzone 
ligands.
9
 Here, we extend our studies to a potentially tridentate hydrazone ligand with an aim to 
scrutinize the effect of the sterically hindered/bulky naphthoyl- derivative and bioactive hetero 
aromatic thiophenoyl and furoyl-derivative arm on these types of ligands, which are expected to 
yield homoleptic bis (tridentate) nonoxido vanadium(IV) complexes and mono ligand, oxido 
alkoxido vanadium(V), whose relevance to solution chemistry has been mentioned quite often in 
the literature.
10
  
 
This work forms part of a study on the synthesis, characterization, of a series of nonoxido 
vanadium(IV) and oxido alkoxido vanadium(V) complexes incorporating oxygen and nitrogen 
donor ligands.
9
 Herein we explore the binding of some new dibasic tridentate ligands (Scheme 
7.1), abbreviated H2L where we wanted to see, if the change in ligand environment by varying 
the steric bulk of the aroylhydrazones can control the coordination number of the vanadium in 
these complexes. Here mononuclear nonoxido vanadium(IV) (1-4) and oxido vanadium(V) (5-8) 
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species have been isolated, structurally characterized, and scanned for solution study. Solution 
study results (IR and NMR) of oxido vanadium(V) complexes (5-8) indicate that two species 
simultaneously exists in solution, the monomeric complexes and as well as their corresponding 
μ-oxido dimeric species. One of these μ-oxido bridged trioxido binuclear vanadium(V) species 
(9) is now successfully isolated in the solid state, characterized by spectroscopic techniques and 
the molecular structure is solved by X-ray crystallography. 
  
7.2. EXPERIMENTAL SECTION 
 
7.2.1. General Methods and Materials. [VO(acac)2] was prepared as described in the 
literature.
11
 Reagent grade solvents were dried and distilled prior to use. 
 
Elemental analyses 
were performed on a Vario ELcube CHNS Elemental analyzer. IR spectra were recorded on a 
Perkin-Elmer Spectrum RXI spectrophotometer. 
1
H and
 13
C NMR spectra were recorded on a 
Bruker Ultrashield 400 MHz spectrometer using SiMe4 as an internal standard. Electronic 
spectra were recorded on a Lamda25, PerkinElmer spectrophotometer. Cyclic voltammograms 
were recorded in DMF solutions, containing 0.1 M TEAP (Tetraethyl ammonium perchlorate) as 
supporting electrolyte, using a CH1120A potentiostat, with Pt disc/glassy carbon working 
electrode, Pt wire as counter electrode and Ag, AgCl/saturated KCl as reference electrode. X-
band EPR measurements were performed on JEOL, Model: JES-FA200 ESR Spectrometer.  
 
7.2.2. Synthesis of Ligands (H2L
1–4
). Schiff base ligands, 2-furoyl hydrazone of 2-hydroxy-1-
acetonaphthone (H2L
1
), 2-thiophenoylhydrazone hydrazone of 2-hydroxy-1-acetonaphthone 
(H2L
2
), 1-napthoyl hydrazone of 2-hydroxy-1-acetonaphthone (H2L
3
), and 3-hydroxy-2-napthoyl 
hydrazone of 2-hydroxy-1-acetonaphthone (H2L
4
) were prepared by the condensation of 2-
hydroxy-1-acetonapthone and the respective acidhydrazide in equimolar ratio in ethanol by a 
standard procedure.
9d 
The resulting white compounds were filtered, washed with ethanol and 
dried over fused CaCl2. Elemental analysis results, NMR (
1
H and 
13
C) and IR data for all of these 
verified their preparation. 
 
H2L
1
. Yield: 74%. Anal. Calcd. for C17H14N2O3: C, 69.38; H, 4.79; N, 9.52. Found: C, 69.35; H, 
4.78; N, 9.50. IR (KBr pellet, cm
–1
): 3331 ν(O–H); 3102 ν(N–H); 1652 ν(C=O); 1622 ν(C=N). 
1
H NMR (400 MHz, DMSO-d6): δ 10.51 (s, 1H, OH), 9.09 (s, 1H, NH), 7.96–6.51 (m, 9H, 
Aromatic), 2.33 (s, 3H, CH3).
13
C NMR (100 MHz, DMSO-d6): δ 163.29, 152.34, 146.10, 135.11, 
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134.67, 134.23, 131.87, 130.17, 129.13, 128.32, 128.18, 127.43, 123.92, 122.85, 118.83, 112.65, 
24.19.  
 
H2L
2
. Yield: 71%. Anal. Calcd. for C17H14N2O2S: C, 65.79; H, 4.55; N, 9.03. Found: C, 65.77; 
H, 4.56; N, 9.07. IR (KBr pellet, cm
–1
): 3353 ν(O–H); 3108 ν(N–H); 1658 ν(C=O); 1621 
ν(C=N). 1H NMR (400 MHz, DMSO-d6): δ 10.31 (s, 1H, OH), 9.56 (s, 1H, NH), 8.08–7.20 (m, 
9H, Aromatic), 2.38 (s, 3H, CH3).
13
C NMR (100 MHz, DMSO-d6): δ 161.48, 152.83, 149.48, 
135.52, 135.18, 134.23, 131.45, 130.42, 129.05, 128.44, 127.85, 127.08, 123.59, 123.00, 119.03, 
113.62, 24.03. 
 
H2L
3
. Yield: 69%. Anal. Calcd. for C23H18N2O2: C, 77.95; H, 5.12; N, 7.90. Found C, 77.91; H, 
5.14; N, 7.88. IR (KBr pellet, cm
–1
): 3448 ν(O–H); 3113 ν(N–H); 1661 ν(C=O); 1611 ν(C=N). 
1
H NMR (400 MHz, DMSO-d6): δ 10.32 (s, 1H, OH), 10.08 (s, 1H, NH), 8.02–7.30 (m, 13H, 
Aromatic), 2.40 (s, 3H, CH3). 
13
C NMR (100 MHz, DMSO-d6): δ 165.05, 154.35, 153.00, 
152.73, 133.77, 133.37, 131.17, 130.40, 130.36, 130.17, 128.95, 128.60, 128.32, 127.70,125.86, 
125.41, 125.24, 123.53, 123.36, 118.98, 114.47, 24.43. 
 
H2L
4
. Yield: 64%. Anal. Calcd. for C23H18N2O3: C, 74.58; H, 4.90; N, 7.56. Found: C, 74.57; H, 
4.88; N, 7.58. IR (KBr pellet, cm
–1
): 3648 ν(O–H); 3188 ν(N–H); 1652 ν(C=O); 1622 ν(C=N). 
1
H NMR (400 MHz, DMSO-d6): δ 11.87 (s, 1H, OH), 11.67 (s, 1H, naphthoyl hydrazide–OH), 
10.15 (s, 1H, NH), 8.68–7.24 (m, 12H, Aromatic), 2.38 (s, 3H, CH3). 
13
C NMR (100 MHz, 
DMSO-d6): δ 166.82, 154.89, 153.33, 153.01, 136.33, 132.81, 130.22, 129.43, 128.79, 128.20, 
127.68, 127.12, 126.24, 124.41, 124.35, 124.17, 123.25, 121.09, 119.91, 118.74, 111.19, 111.04, 
24.15. 
 
7.2.3. Synthesis of nonoxido vanadium(IV) complexes [V
IV
(L
1–4
)2] (1–4). [VO(acac)2] (0.5 
mmol) was added to a hot solution of appropriate ligand H2L
1-4 
(1.0 mmol) in CH3CN (20 mL), 
the color changed instantly to greenish black. After 3 h of reflux, black crystals were obtained 
from reaction mixture, which were filtered off, washed thoroughly with ethanol and dried. Some 
crystals are of diffraction quality and were used directly for X-ray structure determination using 
single crystal X-ray diffractometer. 
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[V
IV
(L
1
)2] (1). Yield: 68%. Anal. Calcd. for C34H24N4O6V: C, 64.26; H, 3.81; N, 8.82. Found: C, 
64.24; H, 3.82; N, 8.79. IR (KBr pellet, cm
–1
): 1608 ν(C=N); 1243 ν(C–O)enolic; 1043 ν(N–N). 
UV–Vis (CHCl3) [λmax, nm (ε, M
–1
 cm
–1
)]: 624 (20115), 514 (18381), 369 (79017), 317 
(129132), 232 (211098). 
 
[V
IV
(L
2
)2] (2). Yield: 60%. Anal. Calcd. for C34H24N4O4S2V: C, 61.67; H, 3.62; N, 8.39. Found: 
C, 61.65; H, 3.61; N, 8.43. IR (KBr pellet, cm
–1
): 1611 ν(C=N); 1242 ν(C–O)enolic; 1044 ν(N–N). 
UV–Vis (CHCl3) [λmax, nm (ε, M
–1
 cm
–1
)]: 627 (23006), 511 (21387), 371 (78555), 324 
(121850), 261 (122081), 229 (130231). 
 
[V
IV
(L
3
)2] (3). Yield: 61%. Anal. Calcd. for C47H34Cl2N4O4V: C, 67.15; H, 4.08; N, 6.66. Found: 
C, 67.16; H, 4.07; N, 6.67. IR (KBr pellet, cm
–1
): 1591 ν(C=N); 1244 ν(C–O)enolic; 1045 ν(N–N). 
UV–Vis (CHCl3) [λmax, nm (ε, M
–1
 cm
–1
)]: 616 (19132), 515 (20289), 374(70635), 329 (104277), 
232 (180057). 
 
[V
IV
(L
4
)2] (4). Yield: 66%. Anal. Calcd. for C46H32N4O6V: C, 70.14; H, 4.09; N, 7.11. Found: C, 
70.15; H, 4.08; N, 7.13. IR (KBr pellet, cm
–1
): 3362 ν(O–H); 1609 ν(C=N); 1239 ν(C–O)enolic; 
1022 ν(N–N). UV–Vis (CHCl3) [λmax, nm (ε, M
–1
 cm
–1
)]: 623 (18092), 514 (15606), 377(76242), 
322 (121676), 234 (204913). 
 
7.2.4. Synthesis of oxidoethoxido vanadium(V) complexes [V
V
O(L
1–4
)OEt] (5–8). A general 
synthetic procedure taking [VO(acac)2] as metal precursor is described below: 
[VO(acac)2] (1.0 mmol) was added to a hot solution of appropriate ligand H2L
1–4 
(1.0 mmol) in 
EtOH (20 mL), the color changed instantly to brownish. After 3 h of refluxing, reaction mixture 
was filtered off, and kept for crystallisation. After 3 to 4 days, crystals of diffraction quality were 
obtained which were used for X-ray structure determination using single crystal X-ray 
diffractometer. 
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7.2.4.1. Solid state characterization of 5-8. 
 
[V
V
O(L
1
)OEt] (5). Yield: 66%. Anal. Calcd. for C19H17N2O5V: C, 56.45; H, 4.24; N, 6.93. 
Found: C, 56.46; H, 4.22; N, 6.92. IR (KBr pellet, cm
–1
): 1604 ν(C=N); 1241 ν(C–O)enolic; 1034 
ν(N–N); 994 ν(V=O). UV–Vis (CHCl3) [λmax, nm (ε, M
–1
 cm
–1
)]: 427 (14509), 338 (29884), 247 
(48266). 
 
[V
V
O(L
2
)OEt] (6). Yield: 66%. Anal. Calcd. for C19H17N2O4VS: C, 54.29; H, 4.08; N, 6.66. 
Found: C, 54.27; H, 4.04; N, 6.67. IR (KBr pellet, cm
–1
): 1612 ν(C=N); 1238 ν(C–O)enolic; 1037 
ν(N–N); 999 ν(V=O). UV–Vis (CHCl3) [λmax, nm (ε, M
–1
 cm
–1
)]: 431 (40405), 335 (83006), 
232(122775). 
 
[V
V
O(L
3
)OEt] (7). Yield: 66%. Anal. Calcd. for C25H21N2O4V: C, 64.66; H, 4.56; N, 6.03. 
Found: C, 64.63; H, 4.54; N, 6.06. IR (KBr pellet, cm
–1
): 1593 ν(C=N); 1241 ν(C–O)enolic; 1037 
ν(N–N); 998 ν(V=O). UV–Vis (CHCl3) [λmax, nm (ε, M
–1
 cm
–1
)]: 431 (34046), 329 (74508), 231 
(158497). 
 
[V
V
O(L
4
)OEt] (8). Yield: 66%. Anal. Calcd. for C25H21N2O5V: C, 62.51; H, 4.41; N, 5.83. 
Found: C, 62.48; H, 4.40; N, 5.82. IR (KBr pellet, cm
–1
): 3156 ν(O–H); 1571 ν(C=N); 1239 ν(C–
O)enolic; 1035 ν(N–N); 1001 ν(V=O). UV–Vis (CHCl3) [λmax, nm (ε, M
–1
 cm
–1
)]: 432 (30057), 
342 (60635), 313 (69826), 234 (148843).   
                                                 
7.2.4.2. Solution state characterization of 5-8. 
 
[V
V
O(L
1
)OEt] (5). IR (KBr pellet, cm
–1
): 1009, 966 ν(V=O); 820 ν(V–O–V). 1H NMR (400 
MHz, DMSO-d6):  8.20–6.63 (m, 18H, Aromatic), 5.51–5.46 (m, 2H, CH2 (OEt)), 3.47–3.42 (q, 
4H, CH2 (EtOH)), 2.92 (s, 3H, CH3), 2.86 (s, 3H, CH3), 1.49–1.46 (t, 3H, CH3 (OEt)), 1.08–1.04 
(t, 6H, CH3 (EtOH)).
 13
C NMR (100 MHz, DMSO-d6): δ 166.53, 166.03, 163.73, 163.53, 159.72, 
159.49, 146.81, 146.47, 146.25, 145.45, 134.53, 133.81, 131.95, 131.74, 129.92, 129.49, 129.33, 
128.82, 127.93, 127.55, 126.43, 126.13, 124.83, 124.33, 123.93, 119.42, 118.69, 118.24, 118.11, 
116.30, 115.51, 112.62, 80.80, 56.52, 23.89, 19.00, 18.63. 
51
V NMR (DMSO-d6):  –542, –522. 
1
H NMR (400 MHz, DMSO-d6 + EtOH):  8.09–6.67 (m, 9H, Aromatic), 5.50–5.48 (m, 2H, CH2 
(OEt)), 3.48–3.43 (q, 27H, CH2 (EtOH)), 2.86 (s, 3H, CH3), 1.49–1.46 (t, 3H, CH3 (OEt)), 1.08–
1.04 (t, 38H, CH3 (EtOH)).
 13
C NMR (100 MHz, DMSO-d6 + EtOH): δ 166.01, 163.73, 159.48, 
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146.38, 147.27, 133.74, 131.95, 129.56, 129.28, 127.49, 126.09, 124.27, 119.38, 118.24, 115.43, 
112.53, 80.80, 56.52, 23.81, 18.88, 18.55. 
51
V NMR (DMSO-d6 + EtOH):  –522. 
 
[V
V
O(L
2
)OEt] (6). IR (KBr pellet, cm
–1
): 1005, 965 ν(V=O); 817 ν(V–O–V).  1H NMR (400 
MHz, DMSO-d6)  8.20–7.08 (m, 18H, Aromatic), 5.49–5.48 (m, 2H, CH2 (OEt)), 3.46–3.43 (q, 
4H, CH2 (EtOH)), 2.92 (s, 3H, CH3), 2.86 (s, 3H, CH3), 1.50–1.48 (t, 3H, CH3 (OEt)), 1.08–1.05 
(t, 6H, CH3 (EtOH)).
 13
C NMR (100 MHz, DMSO-d6): δ 167.33, 166.50, 166.03, 158.91, 134.83, 
133.77, 133.60, 131.97, 131.75, 131.54, 130.95, 129.96, 129.59, 129.50, 129.32, 128.55, 127.95, 
127.55, 126.43, 126.15, 124.82, 124.32, 119.38, 118.18, 80.67, 56.53, 23.71, 19.00, 18.59. 
51
V 
NMR (DMSO-d6):  –537, –519. 
1
H NMR (400 MHz, DMSO-d6 + EtOH)  8.08–7.17 (m, 9H, 
Aromatic), 5.49–5.48 (m, 2H, CH2 (OEt)), 3.48–3.43 (q, 62H, CH2 (EtOH)), 2.85 (s, 3H, CH3), 
1.51–1.48 (t, 3H, CH3 (OEt)), 1.08–1.04 (t, 95H, CH3 (EtOH)).
 13
C NMR (100 MHz, DMSO-d6 + 
EtOH): δ 167.33, 165.97, 158.89, 134.83, 133.59, 131.94, 131.22, 130.76, 129.58, 129.18, 
128.28, 127.38, 126.03, 124.16, 119.26, 118.16, 80.68, 56.55, 23.48, 18.65, 18.27. 
51
V NMR 
(DMSO-d6 + EtOH):  –520. 
 
[V
V
O(L
3
)OEt] (7). IR (KBr pellet, cm
–1
): 1004, 965 ν(V=O); 818 ν(V–O–V). 1H NMR (400 
MHz, DMSO-d6)  9.30–7.25 (m, 26H, Aromatic), 5.52–5.44 (m, 2H, CH2 (OEt)), 3.47–3.42 (q, 
4H, CH2 (EtOH)), 3.03 (s, 3H, CH3), 2.95 (s, 3H, CH3), 1.49–1.45 (t, 3H, CH3 (OEt)), 1.07–1.04 
(t, 6H, CH3 (EtOH)).
 13
C NMR (100 MHz, DMSO-d6): δ 172.46, 171.75, 171.35, 166.78, 166.66, 
166.32, 160.65, 160.14, 134.91, 134.01, 132.63, 132.20, 132.06, 131.85, 131.22, 130.97, 130.89, 
130.27, 129.95, 129.57, 129.37, 129.21, 129.16, 129.02, 128.96, 128.01, 127.90, 127.61, 127.43, 
127.34, 127.30, 126.57, 126.21, 125.59, 125.31, 124.91, 124.36, 119.58, 118.85, 118.60, 118.17, 
118.02, 117.87, 80.05, 56.50, 24.12, 19.02, 18.75. 
51
V NMR (DMSO-d6):  –540, –521. 
1
H NMR 
(400 MHz, DMSO-d6 + EtOH):  9.16–7.24 (m, 13H, Aromatic), 5.56–5.42 (m, 2H, CH2 (OEt)), 
3.48–3.43 (q, 92H, CH2 (EtOH)), 2.95 (s, 3H, CH3), 1.50–1.47 (t, 3H, CH3 (OEt)), 1.08–1.04 (t, 
136H, CH3 (EtOH)).
 13
C NMR (100 MHz, DMSO-d6 + EtOH): δ 172.45, 166.29, 160.15, 134.02, 
133.92, 132.05, 131.79, 131.24, 129.59, 129.27, 129.15, 128.85, 127.49, 127.29, 127.21, 126.43, 
126.13, 125.45, 124.25, 119.50, 118.16, 80.03, 56.51, 23.97, 18.78, 18.55. 
51
V NMR (DMSO-d6 
+ EtOH):  –522. 
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[V
V
O(L
4
)OEt] (8). IR (KBr pellet, cm
–1
): 1009, 970 ν(V=O); 822 ν(V–O–V). 1H NMR (400 
MHz, DMSO-d6):  11.78 (s, 1H, OH), 11.42 (s, 1H, OH), 8.54–7.10 (m, 24H, Aromatic), 5.72–
5.67 (m, 2H, CH2 (OEt)), 3.47–3.42 (q, 4H, CH2 (EtOH)), 3.01 (s, 3H, CH3), 2.91 (s, 3H, CH3), 
1.61–1.58 (t, 3H, CH3 (OEt)), 1.07–1.04 (t, 6H, CH3 (EtOH)). 
13
C NMR (100 MHz, DMSO-d6): 
δ 170.65, 164.19, 159.74, 155.19, 136.79, 134.39, 131.93, 131.06, 129.97, 129.63, 129.40, 
129.34, 129.06, 128.83, 128.32, 128.14, 127.79, 127.36, 127.24, 126.42, 126.17, 125.96, 124.91, 
124.54, 124.09, 123.70, 122.91, 119.43, 118.79, 117.86, 117.31, 111.01, 110.74, 82.36, 56.51, 
23.56, 19.00, 18.84. 
51
V NMR (DMSO-d6):  –564, –529. 
1
H NMR (400 MHz, DMSO-d6 + 
EtOH):  11.77 (s, 1H, OH), 8.53–7.22 (m, 12H, Aromatic), 5.70–5.69 (m, 2H, CH2 (OEt)), 
3.47–3.42 (q, 47H, CH2 (EtOH)), 2.91 (s, 3H, CH3), 1.61–1.58 (t, 3H, CH3 (OEt)), 1.07–1.04 (t, 
72H, CH3 (EtOH)).
 13
C NMR (100 MHz, DMSO-d6 + EtOH): δ 170.66, 166.17, 159.69, 155.22, 
136.79, 134.32, 131.92, 131.02, 129.63, 129.35, 129.27, 128.74, 127.72, 127.35, 126.37, 126.12, 
124.47, 124.02, 119.38, 117.85, 117.30, 110.97, 82.36, 56.51, 23.48, 18.88. 
51
V NMR (DMSO-
d6 + EtOH):  –532. 
 
7.2.5. Synthesis of μ-oxido divanadium(V) complexes [VV2O3(L
1
)2] (9). Complex 5 was made 
soluble in CH2Cl2 and layered with CH3CN. The above mixture was kept for recrystallisation. 
After seven days X-ray quality crystals obtained, which were filtered off, washed thoroughly 
with CH3CN and dried. Some crystals are of diffraction quality and were used directly for X-ray 
structure determination using single crystal X-ray diffractometer. 
 
[V
V
2O3(L
1
)2] (9). Yield: 66%. Anal. Calcd. for C34H24N4O9V2C0.5HCl: C, 53.29; H, 3.22; N, 
7.21. Found: C, 53.31; H, 3.21; N, 7.24. IR (KBr pellet, cm
–1
): 1608 ν(C=N); 1237 ν(C–O)enolic; 
1040 ν(N–N); 999, 963 ν(V=O), 823 ν(V–O–V). UV–Vis (CHCl3) [λmax, nm (ε, M
–1
 cm
–1
)]: 425 
(21618), 336 (40982), 246 (61040).
 1
H NMR (400 MHz, DMSO-d6)  8.20–6.63 (m, 9H, 
Aromatic), 2.92 (s, 3H, CH3).
13
C NMR (100 MHz, DMSO-d6 ): δ 166.52, 163.51, 163.17, 
159.97, 159.70, 146.82, 146.13, 145.53, 145.41, 134.52, 131.73, 130.18, 129.92, 129.50, 129.13, 
128.21, 127.93, 127.04, 126.43, 124.83, 122.87, 118.69, 118.55, 118.11, 117.98, 116.30, 116.13, 
112.69, 24.22, 24.10. 
51
V NMR (DMSO-d6 ):  –544. 
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7.2.6. X-ray Crystallography. Crystals suitable for X-ray diffraction study were obtained at 
room temperature by slow evaporation from a CH2Cl2 solution. The X-ray diffraction data for (2, 
5, 6, 9) were collected at 100(2) K on SuperNova diffractometer (Agilent) with a CCD detector 
and Mo-Kα radiation. A summary of crystal data and refinement details for 2, 5, 6 and 9 is 
provided in Table 7.1. The crystal data were processed with CrysAlisPro (data collection, cell 
refinement and data reduction).
12
 The crystal structure was solved using direct methods with 
SHELXD and refined with SHELXL.
13
 All hydrogen atoms were initially located in electron-
density difference maps and were constrained to idealized positions, with C-H = 0.95-0.99 Å and 
with Uiso(H) = 1.5Ueq(C) for methyl hydrogen atoms and Uiso(H) = 1.2Ueq(C) for others. The 
non-hydrogen atoms were refined anisotropically..PLATON software
14
 was used to validate the 
crystallographic data 
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     Table 7.1. Crystal data and refinement details for 2, 5, 6, 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Complex              2             5              6              9 
Empirical 
formula 
C34H24N4O4S2V C19 H17 N2 O5 V C19H17N2O4SV C34H24N4O9V2C0.5HCl 
Formula weight 667.63 404.29  420.35 776.92 
Temperature 100(2) K 100(2) K 100(2) K 100(2) K 
Crystal system monoclinic Triclinic monoclinic Triclinic 
Space group P21/c P-1 P21/n P-1 
Unit cell 
dimensions 
 
 
a =13.03105(9) A  
b= 23.24945 (14) A  
c = 10.37682 (9) A  
α = 90° 
= 104.2945 (8)° 
γ = 90° 
a = 8.3450(6) A 
b = 10.1037(7)A 
c = 10.5931(7)A 
α = 79.973(3)° 
 = 81.273(2)° 
γ  = 78.461(2)° 
a = 9.75757(9) A                           
b = 15.62094(14) A 
c = 11.92282(11) A 
α = 90 ° 
 = 91.8964(8)° 
γ = 90 ° 
a =10.39154 (19)Å  
b= 12.21149 (18) Å 
c = 13.8273 (2)Å, 
α = 99.9444 (13) 
= 108.6135 (16) 
γ =103.0069 (14) 
      Volume 3046.48 (4) Å3 
 
855.39(10) Å3 
 
1816.31(3) Å3 1562.34 (4) Å3 
Z 4 2 4 2 
Density 
(calculated) 
1.456 gcm-3 1.570 mgm-3 1.537 gcm-3 1.651gcm-3 
Absorption 
coefficient 
4.39 mm-1 0.615 mm-1 0.69 mm-1 6.37mm-1 
F(000) 1372 416 864 790 
Crystal size 
0.21  0.19  0.02 
mm3 
0.32 x 0.16 x 0.12 
mm3 
0.23 0.14 0.07  
mm3 
0.21  0.19  0.02 
mm3   
Theta range for 
data collection 
3.5 to 67.2 2.64 to 28.00 °. 3.0 to 37.0°. 3.5 to 72.9 
Independent 
reflections 
5304 4113  
9244  
 
6187 
Final R indices 
[I>2sigma(I)] 
R1  = 0.034  
wR2=0.095 
R1 = 0.0302 
wR2 = 0.0790 
R1 = 0.031 
wR2 = 0.091 
R1  = 0.045 
wR2 =0.119 
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7.3. RESULT AND DISSCUSSION 
 
7.3.1. Mononuclear nonoxido vanadium(IV) [V
IV
(L
1-4
)2] (1–4) and oxidoethoxido 
vanadium(V) [V
V
O(L
1-4
)OEt] (5–8) complexes. 
 
7.3.1.1. Synthesis. Scheme 7.1 represents the various pathways through which the nonoxido 
vanadium(IV), oxidoethoxido vanadium(V) and μ-oxido divanadium(V) complexes were 
obtained. Monomeric nonoxido bis(tridentate)-vanadium(IV) complexes [V(L
1–4
)2] (1–4) have 
been synthesized by the reactions of aroylhydrazones (H2L
1–4
) with [VO(acac)2] in CH3CN. The 
same reaction in ethanol lead to the formation of monomeric oxido vanadium(V) [VO(L
1-4
)OEt] 
(5–8). The reactions are clean, affording large quantities of pure crystalline products in good 
yield (~ 70%). These compounds are highly soluble in CH2Cl2, DMF and DMSO and sparingly 
soluble in MeOH, EtOH and CH3CN. 
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Scheme 7.1. Schematic diagram of various pathways through which the mononuclear nonoxido 
vanadium(IV) [V
IV
(L)2], oxido vanadium(V) [V
V
O(L)OEt] and binuclear μ-oxido vanadium(V) 
[V
V
2O3(L
1
)2] complexes were synthesized. 
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7.3.1.2. Description of the X-ray structure of complexes (2, 5 and 6). The observed elemental 
(C, H, N) analytical data of all the nonoxido vanadium(IV) and oxidoethoxido vanadium(V) are 
consistent with their composition. It appears from the formulation of all these above complexes 
that the hydrazones are serving as tridentate ligands in them. Although the preliminary 
characterization data (microanalysis and IR) gives idea about the presence of various 
functionality in the complexes, they could not point to any definite stereochemistry of the 
complexes, or the coordination mode of H2L. In order to authenticate the coordination mode of 
the hydrazones in these complexes, the structure of all the complexes has been determined by X-
ray crystallography. The atom numbering scheme for these complexes are given in Figure 7.1 
with the relevant bond distances and angles collected in Table 7.2−7.3.  
 
Nonoxido vanadium(IV) [V
IV
(L
2
)2] (2). Molecular structure of 2, one of the four nonoxido 
vanadium(IV) complexes has been determined by single crystal X-ray crystallography. The 
details of the structure of [V
IV
(L
2
)2] (2) is shown in Figure 7.1a and selected geometric 
parameters are collected in Table 7.2. The remarkable feature of the structure is the trigonal 
prismatic co-ordination of the d
l
 V
IV
 ion. In complexes 2, the vanadium(IV) centre is coordinated 
to two ligands forming a N2O4 coordination sphere, constituting the rare trigonal prism 
structure.
6a
 The central V atom is coordinated by two dinegative, NO2 coordinating hydrazone 
ligands forming five membered CN2OV and six membered C3NOV chelate rings. The bite angle 
for the two five membered ring around the vanadium centre, O(2)−V(1)−N(1) and 
O(4)−V(1)−N(3) found in the range 74.43(5)−74.37(5)°  and similarly for the six membered ring 
O(1)−V(1)−N(1) and O(3)−V(1)−N(3) it is in the range 82.54(6)−82.33(5)°. The four V−O 
bonds around the central vanadium atoms are in the range 1.912(1) to 1.900(1) Å, among which, 
the V−O bond length follows the order V−O(phenolate) < V−O(enolate). The other distances and 
angles made by the donor atoms are in the expected range as previously reported for compounds 
containing the [V
IV
(ONO)2] moiety.
9d,6x
  
 
Oxidoethoxido vanadium(V) [V
V
O(L
1–2
)OEt] (5 & 6). In complexes [VOL
1-2
(OEt)] (5 and 6), 
the vanadium(V) centre is occupied by O4N coordination sphere, constituting a square pyramidal 
structure (Figure 7.1b,c). The details of the selected geometric parameters are collected in  
Table 7.3. The basal plane is made up by the phenolate oxygen, enolate oxygen, imine nitrogen 
from the ligand and the oxygen from deprotonated alkoxide. The Schiff base ligand forms a six 
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membered and a five membered chelate ring at the V(V) accepter centre with O(1)–V(1)–N(1) 
and O(2)–V(1)–N(1) bite angles in the range of 81.28(3)−80.87(5)° and 75.03(4)−74.96(3)° 
respectively. The apical position of square pyramid is occupied by the terminal oxido group 
O(3). The short V(1)−O(3) distance in the range of 1.592(7)−1.587(1)A° indicates the presence 
of vanadium oxygen double bond (V=O), which is commonly found in five and six coordinated 
octahedral complexes
15
 of vanadium(IV) and vanadium(V). For all the complexes, the four V−O 
bond lengths are unequal, the V=O bond being the shortest and V−O (enolate) being the longest. 
The V−O bond length follows the order, V−O(oxido) < V−O(alkoxido) < V−O(phenolate) < 
V−O(enolate). These data indicate the stronger binding of alkoxido group compared to those of 
phenolate and enolate oxygen atom.
15 
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  Table 7.2. Selected bond distances (Å) and angles (
0
) for 2 
 __________________________________________________________________                                            
 Distances 
V(1)-O(1)                 1.905(1)                                      V(1)-N(1)                 2.076(2)       
V(1)-O(2)                 1.909(1)                                      V(1)-N(3)                 2.069(1)                                    
V(1)-O(3)                 1.900(1)                                      N(1)-N(2)                 1.400(2)                                    
V(1)-O(4)                 1.912(1)                                      N(3)-N(4)                 1.389(2)  
                       
Angles 
O(1)-V(1)-N(1)         82.33(5)                                     O(2)-V(1)-O(3)        86.05(5)   
O(1)-V(1)-O(2)         127.04(5)                                   O(1)-V(1)-O(4)        86.49(5)      
O(2)-V(1)-N(1)         74.37(5)                                     O(3)-V(1)-O(4)        127.51(5)    
O(3)-V(1)-N(3)         82.54(6)                                     O(2)-V(1)-O(4)        137.26(5)    
O(4)-V(1)-N(3)         74.43(5)                                     O(1)-V(1)-O(3)        84.23(5)    
_________________________________________________________________________ 
 
 
 
 
 
Table 7.3. Selected bond distances (Å) and angles (
0
) for 5 and 6  
____________________________________________________________________          
                                                           5                                              6 
____________________________________________________________________ 
Distances 
V(1)-O(1)                                    1.885(1)                 1.8385(7) 
V(1)-O(2)                                    1.926(1)                 1.9123(7) 
V(1)-O(3)                                    1.587(1)                 1.592(7) 
V(1)-O(4)                                    1.771(1)                 1.7826(7) 
V(1)-N(1)                                    2.126(1)                 2.0994(8) 
N(1)-N(2)                                    1.392(2)                 1.391(1)     
  
Angles 
O(1)-V(1)-N(1)                            80.87(5)                 81.28(3) 
O(1)-V(1)-O(3)                            102.78(5)                 110.63(3) 
O(1)-V(1)-O(2)                            143.72(4)                 132.38(3) 
O(2)-V(1)-O(4)                            95.26(5)                 90.48(3) 
O(2)-V(1)-O(3)                            105.67(5)                 112.21(3) 
O(2)-V(1)-N(1)                            75.03(4)                 74.96(3) 
O(3)-V(1)-O(4)                            102.80(5)                         104.72(3) 
O(3)-V(1)-N(1)                            94.28(5)                         95.48(3) 
O(4)-V(1)-N(1)                            162.19(5)                                 158.53(3)                                                             
__________________________________________________________________________ 
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a) 
 
b) 
276 
 
 
c) 
 
Figure 7.1. ORTEP diagram of (a) [V(L
2
)2] (2), (b) [VO(L
1
)OEt] (5), (c) [VO(L
2
)OEt] (6) 
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7.3.1.3. IR Spectroscopy. The IR data of all the ligands, H2L
1–4
 and their corresponding metal 
complexes, 1–8 are given in the experimental section. All the ligands possess a band in the 
region of 3648–3331 cm–1 due to the –OH present in the ketone part, which is found to be absent 
in the corresponding metal complexes due to the coordination. However, the presence of band in 
the range 3362–3156cm–1 in case of complex 4 and 8 is due to the pending –OH group attached 
to the hydrazide nucleus of ligand (H2L
4
) that does not take part in metallation. Disappearance of 
bands for –NH and –C=O and appearance of new bands in the range 1244–1238 cm–1 indicates 
the enolization of these two groups forming –N=C–O– type of bond. For 5–8, presence of sharp 
band in the range 1001–994 cm-1 is assigned to V=O stretching of a penta coordinated oxido 
vanadium(V) complex
9a
 whereas absence of ν(V=O) bands in the range 1035–935 cm–1 clearly 
indicate the nonoxido nature of the complexes (1–4).16 
 
7.3.1.4. UV Spectroscopy. Electronic spectra of complexes, 1–8 were recorded in CHCl3. The 
spectral data are summarized in experimental section. Complexes, 1−4 possess similar 
characteristic spectral features. A representative spectrum of 2 is shown in Figure 7.2. There are 
two bands in the 627–511 nm range, among which, the lowest-energy transition band around 
627–616 nm is situated in the d−d transition region, but the intensity (εmax, 23006–18092 
M
−1
cm
−1
) of this band appears too large for a pure d−d transition, for which the intensity is 
generally very low for vanadium(IV) complexes. The high intensity of these two bands (627–
511nm) and analogy with other 'bare' vanadium(IV) complexes
6a,b,c,e,j,h,o,p,x 
suggest that these 
transitions are most reasonably assigned as ligand-to-metal charge transfer in origin. The other 
bands in the higher energy absorptions (377–229 nm) are likely to be due to ligand centered 
transitions.
10b 
For oxido vanadium(V) complexes (5–8), the spectral features are similar and the 
representative spectrum of 8 is shown in Figure 7.3. The strong absorptions observed in the 
wavelength range 432–427 nm are assignable to the ligand-to-metal charge transfer transitions 
whereas the other bands in the higher energy region (342–231 nm) are likely to be due to ligand 
centred transitions.
9a,10b 
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Figure 7.2. UV-Vis spectra of 2 (1.83 x 10
-5
 M) in CHCl3. 
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Figure 7.3. UV-Vis spectra of 8 (1.83 x 10
-5
 M) in CHCl3.  
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7.3.1.5. NMR Spectroscopy. 
1
H and 
13
C NMR of the ligands (H2L
1–4
) were recorded in DMSO-
d6 and the data are given in the experimental section. The spectra of the free ligands, (H2L
1–4
) 
exhibit a resonance in the range, δ = 11.87–10.31 ppm due to –OH, δ = 10.15–9.09 ppm due to   
–NH and δ = 2.40–2.33 ppm due to –CH3 protons. In H2L
4 an extra peak at δ = 11.67 ppm is 
observed which is due to the –OH group attached to the hydrazide nucleus. All the aromatic 
protons of the ligands are clearly observed in the expected region, δ = 8.68–6.51 ppm.10b  
 
From the 
13
C NMR spectra, it is observed that, signals for (CO–N) and [N=C(Me)] carbon 
resonate in the downfield region in the range, δ = 166.82–161.48 ppm and δ = 154.89–152.34 
ppm respectively whereas the carbon due to the methyl groups (–CH3) are found in the upfield 
region (δ = 24.43–24.03 ppm). Furthermore appearance of signals in the range δ = 153.33–
111.04 ppm due to aromatic carbon confirm the formation of the ligands.
2a 
 
Results of NMR spectra for
 
complexes 5–8 are summarized in the solution study part  
 
 
7.3.1.6. Electrochemical properties of nonoxido vanadium(IV) complexes [V
IV
(L
1-4
)2] (1–4). 
The electrochemical properties of 1–4, have been examined in CH2Cl2 solution (0.1 M TEAP) by 
cyclic voltammetry using a Pt working electrode, Pt counter electrode, and an Ag/AgCl reference 
electrode. The voltammogram pattern is similar for 1–4, which includes both oxidation and 
reduction process corresponding to one electron transfer. The potential data are listed in Table 
7.4 and Figure 7.4 depicts a representative voltammogram of 2. In the cathodic region V(IV) is 
reduced to V(III) showing a quasi-reversible single electron wave (Figure 7.4a) at E1/2 values 
within the potential window –0.53 to –0.40 V.17 In the anodic region, complexes show a quasi- 
reversible single electron wave (Figure 7.4b) at E1/2 values within the potential window 1.20 to 
1.05 V is assigned to the oxidation of the metal, V(IV)/V(V).
18
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Table 7.4. Cyclic voltammetric results for 1–4 at 298 K 
_______________________________________________________________________ 
Complex                         E
c
1/2 (V)               ΔE
c
P (mV)        E
a
1/2 (V)           ΔE
a
P (mV) 
_______________________________________________________________________ 
[V
IV
(L
1
)2] (1)                     – 0.53                    98                  1.13                    120 
[V
IV
(L
2
)2] (2)                     – 0.40                    96                  1.10                    100 
[V
IV
(L
3
)2] (3)                     – 0.50                    95                  1.05                    108 
[V
IV
(L
4
)2] (4)                     – 0.52                   102                 1.20                    124 
_______________________________________________________________________ 
 In CH2Cl2 at a scan rate of 100 mV s
–1
. E1/2 = (Epa + Epc)/2, where Epa and Epc are anodic and 
cathodic peak potentials vs. Ag/AgCl, respectively. ΔEP = Epa – Epc. 
 
 
(a)                                                                              (b) 
 
 
 
 
 
Figure 7.4. Cyclic voltammogram of 2 showing (a) reduction (V(IV) →V(III)) and (b) oxidation 
(V(IV) →V(V)) of the vanadium(IV) centre.  
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7.3.1.7. EPR Spectroscopy of nonoxido vanadium(IV) complexes, 1–4. X-band EPR spectra 
of 1–4 were recorded in CH2Cl2 solution at 300 K. The data are listed in Table 7.5. A 
representative spectrum for 2 is shown in Figure 7.5. which reveals well-resolved axial 
anisotropy with 8-line hyperfine structure, characteristic of a mononuclear vanadium complex 
with nuclear spin (
51
V, I = 7/2).
19 
Corresponding spin-Hamiltonian parameters (g, 1.948−1.941; 
A, 46.47 × 10
–4
 cm
–1−45.59 × 10–4 cm–1) are typical of trigonal prismatic oxido vanadium(IV) 
complexes under comparable ON-containing donor environments.
6a
 Analysis of the EPR spectra 
of vanadium(IV) complexes showed that, the anisotropic hyperfine parameters of six-coordinate 
complexes
19 
have significantly lower values compared to the corresponding values obtained with 
the five-coordinated complexes,
10b,20
 as is observed in the present case.  
 
Table 7.5. X-band EPR data for complexes 1–4 at 300 K 
___________________________________________________________________ 
Complex                                    g                                             A                               
                                                                                                 (10
–4
 cm
–1
 )
    
  
___________________________________________________________________ 
 
[V
IV
(L
1
)2], 1                          1.947                                          46.47 
[V
IV
(L
2
)2], 2                          1.948                                          45.59   
[V
IV
(L
3
)2], 3                          1.941                                          45.86 
[V
IV
(L
4
)2], 4                          1.943                                          46.11 
___________________________________________________________________ 
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                     Figure 7.5. X-band EPR spectrum (300 K) in CH2Cl2 of complex 2. 
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7.3.1.8. Study of solution behavior of oxidoethoxido vanadium(V) complexes (5–8). Study of 
solution behavior of all the oxidoethoxido vanadium(V) complexes (5–8) were carried out in 
DMSO/CHCl3. The IR spectrum of all the complexes (5−8) in DMSO/CHCl3 shows two V=O 
stretch bands in the range 1009–1004 cm−1and 970–965 cm−1, which suggests that two different 
V=O groups exist in solution.
10a
 Another new band corresponding to the ν(V–O–V) 10b,9a mode 
was also observed in the range 822−817 cm−1, which was absent in the spectrum of 5−8 in the 
solid state. The IR spectrum in solution pointed to the retention of their mononuclear nature what 
was in the solid state and simultaneous formation of the corresponding dimeric complexes as a 
2nd species. So, these observations suggest that two species may exist in solution and demand 
proper explanation. 
 
The 
1
H NMR spectra of 5−8 in DMSO-d6 (which contained trace water) yielded two close but 
separate sets of bands in an approximate 1:1 ratio. A representative spectrum of 7 is shown in 
Figures 7.6a. The set of sharp 
1
H NMR signals correspond to the monomeric form of the species 
[VO(L
1−4
)OEt] (5−8) which are isolated in the solid state and structurally characterized. The 
relatively less sharp signals were assigned to the other species (let the corresponding 2nd 
species). So, like our previous report (chapter 4) the NMR results suggest that two species exist 
in DMSO solution. The spectrum of 5–8 exhibits two sets of singlets corresponding to the –CH3 
group in the range 3.03–2.86 ppm and that of 8 exhibits two sets of OH resonance at 11.78 and 
11.42 ppm. The aromatic protons of 5 and 6 (a total of 18), of 7 (a total of 26) and 8 (a total of 
24) appear in the range 9.30−6.63 ppm. In addition, all the complexes exhibit separate bands 
corresponding to bound ethoxido group in the range 5.72–5.44 (–CH2) and 1.61–1.45 (–CH3) 
ppm
10a,b,21 
 and the sharp peaks observed in the range 3.47–3.42 (–CH2) and 1.08–1.04 (–CH3) 
ppm were assigned to free, non-ligated ethanol that is most likely to be formed in situ in solution. 
Though the chemical shifts of the methylene and methyl protons of the ethanol are very close to 
those of the free ethanol, the alcoholic proton is not detected may be because of less 
concentration or overlap of the signals. 
 
On addition of few drops of ethanol to the DMSO-d6 solution of complexes 5−8, the 2nd set of 
bands disappeared and a clear spectrum resulted (Figures 7.6b). The clear spectrum exhibits 
only one OH resonance at 11.77 ppm for 8, one –CH3 proton signal in the range 2.95–2.85 ppm 
for 5–8, and signals for a total of nine aromatic protons for 5 and 6, thirteen for 7 and twelve for 
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8 in the range 9.16−6.67 ppm. In addition, the coordinated ethoxido bands in the range 5.70–5.42 
ppm (–CH2) and 1.61–1.46 (–CH3) ppm
10a,b,21,22 
broadened and the intensity of free ethanol 
bands in the range 3.48–3.42 ppm due to (–CH2) and 1.08–1.04 ppm due to (–CH3) ppm 
increased.  
 
Like above, the 
51
V NMR spectrum of complexes 5−8 in DMSO-d6 display two sets of bands at 
an approximate ratio of 1:1 in the range –564 to –519 ppm (Figures 7.7a) and the 2nd set of band 
disappeared on addition of small amount of ethanol (Figures 7.7b). Similar observations were 
also obtained from 
13
C NMR data (Figure 7.8). 
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a) 
 
b) 
Figure 7.6. 1H NMR spectrum of complex 7 in DMSO-d6: a) before addition of ethanol b) after addition 
of ethanol.  
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a) 
 
b) 
Figure 7.7. Representative 51V NMR spectrum of complex 5 in DMSO-d6: a) before addition of 
ethanol b) after addition of ethanol.  
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a) 
 
b) 
Figure 7.8. Representative 13C NMR spectrum of complex 5 in DMSO-d6: a) before addition of ethanol 
b) after addition of ethanol.  
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So, the NMR results also support the existence of a second species in the solution state and it 
must be the corresponding dimeric species as it is evidenced form the IR as well as NMR 
spectroscopy.  
 
On the basis of the explanation described in our previous results (chapter 4) containing similar 
type complexes, these solution behavior of 5−8 can be interpreted as by proposing the following 
equilibrium (Chart 7.1) existing in DMSO/CHCl3 containing a little water, which also explains 
the simultaneous presence of the two species, M (monomer, isolated in the solid state and solved 
by X-ray crystallography) and D (2nd species, generated in situ as µ-oxido dimer) in solution. 
N
O
N
CH3
O
V
O
OCH2CH3
N
O
N
H3C O
V
O
N
O
N
CH3
O
V
OO
Monomeric form (M), isolated 
in the solid state and solved
by  x-ray crystallography
Dimeric form (D), 2nd species in solution
H2O+
2EtOH+2
O
O
O
[VO(L1)OEt] (5) [V2O3(L
1)2]
 
Chart 7.1. Schematic diagram for the inter-conversion of monomeric and dimeric species in 
solution taking Complex 5. 
The confirmation of the second species as µ-oxido dioxido divanadium(V) was further evidenced 
by the isolation of this complex in solid state. The details of synthesis and full characterization of 
this dimeric complex are described in next section.  
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7.3.1.9. Electrochemical properties of oxido vanadium(V) complexes (5–8). Electrochemical 
properties of all the mono- and dioxido vanadium(V) complexes have been studied by cyclic 
voltammetry in dichloromethane solution (0.1 M TEAP). Voltammetric data are given in Table 
7.6. All the monooxido ethoxido vanadium(V) complexes (5–8) show one reversible oxidative 
response on the positive side of Ag/AgCl and two quasi-reversible reductive responses on the 
negative side. A representative voltammogram is displayed in Figure 7.9 In positive side the 
complexes display a well-defined cyclic voltammetric response at platinum electrode due to the 
VO
3+−VO2+ couple16b,23 at the range E1/2 = 0.35 − 0.31V (EP = 166 − 157 mV), eqs 1, whereas 
in negative side the voltammogram is found to undergo two successive one electron reductions at 
the range E1/2 = − 0.67 V (EP = 279 mV) to – 0.74 (EP = 287 mV) and E1/2 = − 1.34 V (EP = 
278 mV) to E1/2 = − 1.37 V (EP = 280 mV) which are assigned to V
V
V
V
/V
IV
V
V
 and 
V
IV
V
V
/V
IV
V
IV
 couples,
9a
 eqs 2. 
 
                    [VO(ONO)(OEt)] + e
-
                      [VO(ONO)(OEt)]
-
     ……………………(1) 
                     
                    V
V
2O3L2 + 2e
-
                                   V
IV
V
IV
O3L2
2-
 …………………... ………(2) 
 
The above results clearly supports that there were two species present in the solution state, one is 
the monooxido ethoxido vanadium(V) monomer isolated in the solid state and the other is the     
corresponding μ-oxido bridged dioxido divanadium(V) species generated in situ in the solution.  
 
 
Table 7.6. Cyclic voltammetric results for 5–9 at 298 K  
______________________________________________________________________________ 
Complex                         E
a
1/2 (ΔE
a
P) / V(mV)       E
c
1/2 (ΔE
c
P) / V(mV) 
____________________________________________________________________________ 
[V
V
O(L
1
)OEt] (5)             0.35 (166)                               –0.74 (287),  –1.37 (280) 
[V
V
O(L
2
)OEt] (6)             0.31 (157)                               –0.69 (289),  –1.34 (278) 
[V
V
O(L
3
)OEt] (7)             0.32 (164)                               –0.71 (285),  –1.36 (277)   
[V
V
O(L
4
)OEt] (8)             0.31 (162)                               –0.67 (279),  –1.36 (245) 
[V
V
2O3(L
1
)2]   (9)             0.34 (167)                               –0.72 (254),  –1.37 (211) 
______________________________________________________________________________ 
 In CH2Cl2 at a scan rate of 100 mV s
–1
. E1/2 = (Epa + Epc)/2, where Epa and Epc are anodic and 
cathodic peak potentials vs. Ag/AgCl, respectively. ΔEP = Epa – Epc. 
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Figure 7.9. Cyclic voltammogram of complex 5 in CH2Cl2. 
 
 
 
 
The confirmation of the second species as µ-oxido divanadium(V) was further evidenced by the 
isolation of this complex in solid state. The details of synthesis and full characterization of this 
dimeric complex are described in next section.  
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7.3.2. μ-oxido dioxido divanadium(V) complex, [VV2O3(L
1
)2]
 
(9). 
 
7.3.2.1. Synthesis. The μ-oxido dioxido divanadium(V) complex [V2O3(L
1
)2] (9) was obtained 
(Scheme 7.1) by the areial oxidation of [VO(L
1
)OEt] (5) in DCM and CH3CN mixture. The 
reactions are clean, affording large quantities of pure crystalline products in good yield (~ 70%). 
The compound 9 is highly soluble in CH2Cl2, DMF and DMSO and sparingly soluble in MeOH, 
EtOH and CH3CN. 
 
7.3.2.2. Spectroscopy. The spectral (IR, UV-Vis and NMR) data of 9 are summarized in the 
experimental section. In the IR spectrum (Figure 7.10), a pair of sharp band were observed at 
999 and 963 cm
-1 
because of terminal V=O stretching along with a moderately strong band due 
to V–O–V asymmetric bridge vibration is located at 823 cm–1.22  
 
For divanadium(V) complex (9), the UV-Vis spectral feature is similar like mononuclear oxido 
vanadium(V) complexes (5-8). The strong absorptions observed at 425 nm are assignable to the 
ligand-to-metal charge transfer transitions whereas the other bands in the higher energy region 
(336 – 246 nm) are likely to be due to ligand centred transitions.9a,10b 
 
The NMR spectrum of 9 shows a multiplet in the range 8.20–6.63 ppm for nine aromatic protons 
and a singlet at 2.92 ppm due to –CH3 group attached in the ligand fragment. Comparision of the 
1
H NMR spectrum of complex 5 and 9 in DMSO-d6 indicates the presence of 9 in the solution 
state of 5. When a drop of ethanol was added all peaks corresponding to complex 9 get 
disappered and a clear spectrum was observed which corresponds to the mononuclear oxido 
vanadium(V) complex, [V
V
O(L
1
)OEt] (5) and that is the compound isolated in the solid state. 
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Figure 7.10. IR spectrum of [V
V
2O3(L
1
)2] (9). 
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7.3.2.3. Electrochemical property of µ-oxido dioxido divanadium(V) complex, [V
V
2O3(L
1
)2]
 
(9). The electrochemical property of 9 has been examined in CH2Cl2 solution (0.1 M TEAP) by 
cyclic voltammetry (CV) using a Pt working electrode, Pt counter electrode, and an Ag/AgCl 
reference electrode. The voltammogram pattern of 9 is almost similar and the result matches well 
with the voltammogram of corresponding monomeric oxido vanadium(V) complex, 5, discussed 
earlier. Thus, the CV result also suggests that the dimeric complex may converts to the 
corresponding monomeric species in solution state. The cyclic voltammogram of 9 is shown in 
Figure 7.11 and data are given in Table 7.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.11. Cyclic voltammogram of complex 9 in CH2Cl2. 
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7.3.2.4. Description of X-ray structure of μ-oxido dioxido divanadium(V) [VV2O3(L
1
)2]
 
(9). 
 
The divanadium(V) complex (9) afforded good crystals as the solvate V2O3L2∙CH2Cl2. The 
lattice consist of CH2Cl2 molecules which are not bonded to the metal atom in any way. A view 
of the binuclear complex is shown in Figure 7.12, and selected bond parameters are listed in 
Table 7.7. The geometry of the metal atom is similar to that in [VOL
1-2
(OEt)] (5 & 6), but here 
the pyramidal base is constituted of ONO of L
2-
 and the bridging oxygen atom O(4). Both the 
metal atoms have distorted square pyramidal geometry
9a,24 
of coordination type VO4N. The two 
coordination pyramids are metrically distinct. The basal positions are occupied by the donor 
atoms O(1)/O(5), N(1)/N(3), O(2)/O(6) and O4, contributed by the tridentate ligand (L)
2-
, 
together with the bridging oxygen atom. The apical positions are taken up by the terminal 
oxygen atom O3 and O7. The terminal V−O distances 1.586(2) Å [V(1)−O(3)] and 1.585(1) Å 
[V(2)−O(7)] are typical of a vanadium-oxygen double bond. 9a,24 In 9, the trans angles in the 
basal plane O(1)−V(1)−O(2) 147.41(7)° and N(1)−V(1)−O(4) 149.08(7) (corresponding angles 
in V(1) center) and O(5)−V(2)−O(6) 146.55(7)° and N(3)−V(2)−O(4) 149.44(7)° (corresponding 
angles in V(2) center) are much short of linearity, giving indications of distortions in the 
meridian plane. The angles at the vanadium centers subtended by the terminal and bridging 
oxido-atoms, that is, O(3)−V(1)−O(4) [106.52(7)°] and O(7)−V(2)−O(4) [105.97(7)°] are in the 
ranges, as expected for a nearly ideal square pyramidal geometry around V(1) and V(2), 
respectively. The bridge angles V(1)−O(4)−V(2) for 9 have value of 109.81(8)°, in-between 
those expected for asymmetric divanadium(V) compounds with square pyramidal vanadium 
centers.
 9a,24,25 
The other distances and angles made by the donor atoms in the equatorial plane at 
V(1) and V(2) (Table 7.7) are in the expected range as previously reported for compounds 
containing the [V2O3(ONO)2] moiety.
 9a,24 
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Table 7.7. Selected bond distances (Å) and angles (
0
) for 9  
 __________________________________________________________________                                            
Distances 
V(1)-O(1)                    1.833(2)                                V(2)-O(5)                  1.811(2) 
V(1)-O(2)                    1.971(1)                                V(2)-O(6)                  1.961(2) 
V(1)-O(3)                    1.586(2)                                V(2)-O(7)                  1.585(1)   
V(1)-O(4)                    1.798(2)                                V(2)-O(4)                  1.824(2) 
V(1)-N(1)                    2.082(2)                                V(2)-N(3)                  2.090(2)         
N(1)-N(2)                    1.397(2)                                N(3)-N(4)                  1.399(3) 
                       
Angles 
O(1)-V(1)-O(3)           102.11(7)                              O(5)-V(2)-O(7)          104.21(7) 
O(1)-V(1)-O(4)           106.45(7)                              O(5)-V(2)-O(4)          105.97(7)     
O(1)-V(1)-N(1)           82.88(7)                                O(5)-V(2)-N(3)          82.97(7)  
O(2)-V(1)-N(1)           74.53(7)                                O(6)-V(2)-N(3)          75.14(7) 
O(2)-V(1)-O(4)           83.38(7)                                O(6)-V(2)-O(4)          82.67(7) 
O(3)-V(1)-O(4)           106.52(7)                              O(7)-V(2)-O(4)          105.97(7) 
O(1)-V(1)-O(2)           147.41(7)                              O(5)-V(2)-O(6)          146.55(7) 
O(4)-V(1)-N(1)           149.08(7)                              O(4)-V(2)-N(3)          149.44(7)  
V(1)-O(4)-V(2)           109.81 (8) 
___________________________________________________________________________ 
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Figure 7.12. ORTEP diagram of [V2O3(L
1
)2] (9). 
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From the successful isolation of divanadium(V) complex, 9 in the solid state and the solution 
study results (UV-Vis, NMR and CV) of mononuclear as well as dinuclear oxidovanadium(V) 
complexes, it is concluded that, both the mononuclear oxido vanadium(V) complexes (5−8) and 
binuclear divanadium(V) complexes exist in the solution. On addition of few drops of ethanol 
these dimeric species, reconverted into the mononuclear state. The binuclear species exhibits all 
the characteristic signals of a μ-oxido bridged dioxido vanadium(V) species, which matches well 
with the similar results reported earlier.
10b
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7.4. CONCLUSION 
 
The following are the salient observations and findings of this work:  
 
a) Four aroylhydrazone ligands, possessing a rigid bulky 2-hydroxy-1-acetonaphthone core and a 
selection of sterically hindered/bulky naphthoyl- derivative have been synthesized and utilized in 
the synthesis of the corresponding variable valance mononuclear nonoxido vanadium [V
IV
(L)2], 
oxidoalkoxido vanadium [V
V
O(L)OEt], and dimeric -oxido divanadium [VV2O3(L)2] 
complexes. 
 
b) The monomeric, hexacoordinated and bis(tridentate)-vanadium(IV) [V
IV
(L)2] complexes 
isolated, do not contain any oxido-group and are structurally characterized with tridentate 
aroylhydrazonates containing ONO- donor atoms. X-ray crystallography of 2 showed the N2O4 
donor set to define a trigonal prismatic geometry in each case. EPR data provide reference values 
for typical V(IV) sites. Cyclic voltammogram result suggests that the electrochemical oxidations 
and reductions are not ligand-centered but metal-centered generating V
V
 and V
III 
species 
respectively. All the nonoxido vanadium(IV) complexes (1–4) are highly stable both in the solid 
state and in solution.  
 
c) The new oxido vanadium(V) complexes [V
V
O(L
1-4
)OEt] (5–8) reported were successfully 
synthesized and characterized through various spectroscopic techniques. X-ray diffraction study 
of 5 and 6, reveals that the metal centre is in distorted square pyramidal geometry O4N 
coordination spheres where the O,N,O donor ligand and the ethoxido group constitute a 
satisfactory O3N basal plane. 
 
d) The solution behavior of 5–8 was also examined. Where there is an indication of generation of 
a new dimeric -oxido species (9) in solution. 
  
e) One of the dimeric species [V2O3(L
1
)2] (9), is successfully isolated in the solid state and 
characterized through various spectroscopic techniques and finally structurally characterized by 
single crystal X-ray technique. 
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A Brief Resume of the Work Embodied in this Dissertation and Concluding 
Remark  
The aim of this dissertation was to explore in depth certain aspects of the chemistry of a series of 
mono- and binuclear nonoxido vanadium(IV) and oxido vanadium(V) complexes of some 
selected multidentate ONO- and ONN- donor ligands. Major emphasis was given to the 
structural and spectroscopic characterization of the synthesized complexes as well as their study 
of chemical, electrochemical, pharmacological and catalytic activity. Works described in 
chapter 2-7 reveal the results of the attempts taken to fulfill all the objectives. The following 
chapter-wise summary of the work presented in this dissertation reveals the extent to which the 
above-mentioned objectives are fulfilled. 
 
 Chapter 2 deals with the synthesis, X-ray structure and characterization of three highly stable, 
hexacoordinated nonoxido vanadium(IV), V
IV
(L)2, complexes with tridentate aroylhydrazonates 
containing ONO- donor ligands. All the complexes are stable in open air in the solid state as well 
as in solution, a phenomenon rarely observed in nonoxido vanadium(IV) complexes. The 
complexes have good solubility in organic solvents, permitting electrochemical and various 
spectroscopic investigations. The existence of nonoxido vanadium(IV) complexes was confirmed 
by elemental analysis, ESI mass spectroscopy, cyclic voltammetry, EPR and magnetic 
susceptibility measurements. X-ray crystallography showed the N2O4 donor set to define a 
trigonal prismatic geometry in each case. All the complexes show in vitro insulin mimetic 
activity against insulin responsive L6 myoblast cells. In addition, the in vitro antiproliferative 
activity of all the complexes against HeLa cell line was assayed, where the complexes found to 
show good cytotoxic activity.  
    
In Chapter 3 the chemistry of some new oxido vanadium(V) complexes [VOL
1-3
(OEt)(EtOH)] 
(1-3) have been reported which were obtained from the reaction of the Schiff bases (H2L
1-3 
) 
(Where H2L
1
= salicylhydrazone of diacetyl monoxime; H2L
2
= 4-methoxy salicylhydrazone of 
diacetyl monoxime and H2L
3 
= 4-hydroxy salicylhydrazone of diacetyl monoxime) with 
VO(acac)2 in 1:1 molar ratio. Three 4-R- aroylhydrazoneoximes have been used as ligands in the 
present study, differing in the inductive effect of the substituent R (R = H, OCH3 and OH), in 
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order to observe their influence, if any, on the redox potentials and biological activity of the 
complexes. All the synthesized ligands and the metal complexes were successfully characterized 
by elemental analysis, IR, UV-Vis and NMR spectroscopy. X-ray diffraction study of 
[VOL
1
(OEt)(EtOH)], 1 reveals that the metal centre is in distorted octahedral O5N coordination 
spheres where the ONO- donor ligand and the ethoxo group constitute a satisfactory O3N basal 
plane. Cyclic voltammetry of the complexes show a quasi-reversible cyclic voltammetric 
response in the potential range of 0.29−0.36 V involving single electron V(V)−V(IV) reduction. 
The complexes have also been screened for their antibacterial activity against Escherichia coli, 
Bacillus, Proteus and Klebsiella. Minimum inhibitory concentration of these complexes and 
antibacterial activity indicates the compound 1 as the potential lead molecule for drug designing.  
    
Chapter 4 describes the report of four oxidoethoxido vanadium(V) [V
V
O(L
1-4
)OEt] (1–4) and 
one dinuclear oxidoalkoxido mixed-ligand vanadium(V) [{VO(L
2
)OEt}2(Q)]{Q = 4,4'-
bipyridine}(5), complexes, taking potentially tridentate binegative aroylhydrazone ligands 
[where H2L
1 
= anthranylhydrazone of 2-hydroxy-1-napthaldehyde, H2L
2 
= salicylhydrazone of 2-
hydroxy-1-napthaldehyde, H2L
3 
= benzoylhydrazone of 2-hydroxy-1-acetonaphthone, H2L
4 
= 
anthranylhydrazone of 2-hydroxy-1-acetonaphthone]. All the complexes were characterized by 
various physicochemical techniques. Single crystal X-ray crystallography of 1–4 reveals that the 
metal centre is in distorted square pyramidal geometry with O4N coordination spheres, where as 
5 exhibits a distorted octahedral geometry around the metal center. The solution behavior of the 
oxidoethoxido vanadium(V) species was studied, which indicates the existence of two species 
(1:1 ratio ) in solution. Catalytic potential of these complexes was tested for the oxidative 
bromination of styrene, salicylaldehyde and oxidation of methyl phenyl sulphide. All the 
complexes (1–5) showed good DNA binding and photo-nuclease propensity. Among these, 3 and 
4 show high binding affinity towards CT-DNA than others.  
    
In chapter 5 eight alkali metal ion-mediated dioxido vanadium(V), [{V
V
O2L
1–6
}A(H2O)n](1-8), 
complexes for A = Li
+
, Na
+
, K
+
 and Cs
+
, containing tridentate ONO- donor aroylhydrazonate 
ligands are described. All the synthesised ligands and the metal complexes were successfully 
characterised by elemental analysis, IR, UV-Vis and NMR spectroscopy. X-ray crystallographic 
investigation of 3, 5−7 shows the presence of distorted NO4 coordination geometry. The 
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dioxidovanadium(V) complexes were found to exhibit DNA binding activity due to their 
interaction with CT-DNA by the groove binding mode, with binding constants ranging from 10
3 
−104 M-1. Complexes 1−8 were also tested for DNA nuclease activity against pUC19 plasmid 
DNA which showed that 6 and 7 had the best DNA binding and photonuclease activity; these 
results support their good protein binding and cleavage activity with binding constants ranging 
from 10
4 −105 M-1. Finally, the in vitro antiproliferative activity of all complexes was assayed 
against the HeLa cell line. Some of the complexes (2, 5, 6 and 7) show considerable activity 
compared to commonly use chemotherapeutic drugs.  
    
In this chapter (6), four neutral oxido vanadium(V) complexes [VO2L
1
](1), [VO2L
2
](2), 
[VOL
3
(OEt)](3), [VOL
4
(OEt)EtOH](4) [where HL
1
= 2-thiophenoylhydrazone of 2-
acetylpyridine, HL
2
= 2-amino benzoylhydrazone of 2-benzoyl pyridine, H2L
3
= 
isonicotinoylhydrazone of 2-hydroxy acetophenone, H2L
4
= 2-furoylhydrazone of 2-hydroxy-1-
napthaldehyde] with a bioactive hydrazone scaffold containing furan, thiophene and pyridine-
residues have been synthesized. All complexes were thoroughly characterized by various 
spectroscopic (IR, UV-Vis, NMR and ESI-MS) and single crystal X-ray diffraction techniques. 
Biological studies reveal that, 1–4 show good DNA binding propensity and interact with         
CT-DNA by a minor groove binding mode, with binding constants ranging from 10
3−105 M-1. 
All complexes show good photo-induced cleavage of pUC19 supercoiled plasmid DNA with 3 
showing the highest photo-induced DNA cleavage activity of ~ 65%. Additionally, 1–4 show 
satisfactory cytotoxic activity against the human cervical cancer cell line (HeLa) following the 
order 4 > 2 > 3 > 1 with IC50 values ranging from 10 to 20 µM. 
    
The essence of the work presented in chapter 7 is the detailed account of a series of  nonoxido 
vanadium(IV) [V
IV
(L
1-4
)2] (1–4), oxidoethoxido vanadium(V) [V
V
O(L
1-4
)OEt] (5–8), and μ-
oxido divanadium(V) [V
V
2O3(L
1
)2]
 
(9) complexes, taking potentially tridentate dibasic 
aroylhydrazone ligands [where H2L
1 
= 2-furoyl hydrazone of 2-hydroxy-1-acetonaphthone, H2L
2 
=2-thiophenoylhydrazone hydrazone of 2-hydroxy-1-acetonaphthone, H2L
3 
=1-napthoyl 
hydrazone of 2-hydroxy-1-acetonaphthone, H2L
4 
=3-hydroxy-2-napthoyl hydrazone of 2-
hydroxy-1-acetonaphthone]. All the complexes were characterized by elemental analysis as well 
as various spectroscopic techniques. Most of the complexes (2, 3, 5, 6 and 8) were also 
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characterized by single crystal X-ray crystallography. The nonoxido vanadium(IV) complexes 
are quite stable in open air as well as in solution. The solution chemistry of the oxidoethoxido 
vanadium(V) complexes were reported. This indicates the existence of two different species in 
solution. The new species, a μ-oxido divanadium(V) complex, [V2O3(L
1
)2]
 
(9), is successfully 
isolated in solid state and fully characterized by several physicochemical techniques & single 
crystal X-ray crystallography. 
 
The author is very much aware of the fact that some portions of the work described in the present 
dissertation left scope for future work especially the pharmacological and catalytic studies. All 
the reported complexes can be used for the study of several other catalytic and bio activities. 
This dissertation also left scope for further qualitative improvement by the utilization of some 
relevant instrumental data, which could have been really helpful in arriving at completely 
unambiguous conclusions. As those instrumental facilities were not available to us, we were 
rather helpless. However, the above discussion on the entire work presented in chapter 2-7 
reveals that the aims and objectives of the present dissertation are mostly fulfilled.  
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